## ABSTRACT

This material provides documentation for users of the public use micro-data files of the 2006 National Hospital Ambulatory Medical Care Survey (NHAMCS). The NHAMCS is a national probability sample survey of visits to hospital outpatient and emergency departments, conducted by the National Center for Health Statistics, Centers for Disease Control and Prevention. The survey is a component of the National Health Care Survey, which measures health care utilization across a variety of health care providers. There are two micro-data files produced from the NHAMCS, one for outpatient department records and one for emergency department records. Section I of this documentation, "Description of the National Hospital Ambulatory Medical Care Survey," includes information on the scope of the survey, the sample, field activities, data collection procedures, medical coding procedures, and population estimates. Section II provides detailed descriptions of the contents of each file's data record by location. Section III contains marginal data for selected items on each file. The appendixes contain sampling errors, instructions and definitions for completing the Patient Record forms, and lists of codes used in the survey.

# SUMMARY OF CHANGES FOR 2006

The 2006 NHAMCS Emergency Department and Outpatient Department public use micro-data files contains many of the same items as the 2005 files, but also reflect a number of changes made to the 2006 Patient Record forms and induction interview forms. There are also new items that were created during data processing using recoded data collected on the Patient Record form.

## Emergency Department Public Use File

## 1. New/Modified Items

a. Diagnostic/Screening Services -- The addition of a write-in field for the percentage value associated with PULSE OXIMETRY was added. In the past, PULSE OXIMETRY was simply a yes/no checkbox.

The next 10 items were collected at the Hospital Induction Interview and added to the visit records for each emergency department in 2006. Similar items were added to the 2006 National Ambulatory Medical Care Survey (NAMCS) and NHAMCS-Outpatient Department component.

- b. Does your ED's electronic medical record system includes computerized orders for prescriptions, are there warnings of drug interactions or contraindications provided?
- c. If your ED's electronic medical record system includes computerized orders for prescriptions, are prescriptions sent electronically to the pharmacy?
- d. If your ED's electronic medical record system includes computerized orders for tests, are orders sent electronically?
- e. If your ED's electronic medical record system includes lab results, are out of range levels highlighted?
- f. If your ED's electronic medical record system includes imaging results, are electronic images returned?
- g. If your ED's electronic medical record system includes clinical notes, do they include medical history and follow-up notes?
- h. If your ED's electronic medical record system includes clinical notes, do they include reminders for guideline-based interentions and/or screening tests?
- i. If your ED's electronic medical record system includes public health reporting, are notifiable diseases sent electronically?
- j. If your ED's electronic medical record system includes public health reporting, are notifiable diseases sent electronically?
- k. Are there plans for installing a new EMR system or replacing the current system within the next 3 years?

The following items are based on the patient's ZIP code of residence (which is not available on the public use file). ZIP code was used in conjunction with the NCHS Urban-Rural Classification Scheme for Counties (http://www.cdc.gov/nchs/r&d/rdc\_urbanrural.htm) to determine the urban-rural status of the patient's residence. ZIP was used with data from the 2000 U.S. Census to determine education, income, and poverty measures. Cut-points for education and income were developed based on population quartiles (using ZIP code as the level of aggregation) for which the area measure fell. Poverty groupings were based on cut-points consistent with the "Public Health Geocoding Disparities Project" (American Journal of Epidemiol 2002;156(5):471-82.) Category 4, 20% or greater poverty, also corresponds to the Federal designation of a high poverty area established in the 1990 Census. See "Poverty Areas", Economics and Statistics Administration, U.S. Department of Commerce, June 1995. http://www.census.gov/population/socdemo/statbriefs/povarea.html.

I. Percent of poverty in patient's ZIP code

m. Median household income in patient's ZIP code

n. Percentage of adults with a Bachelor's Degree or higher in patient's ZIP code o. Urban-rural classification of the patient's ZIP code

The following section describes changes to the drug characteristics data.

p. One other change involves switching from the Food and Drug Administration's (FDA) National Drug Code Directory (NDC) to Lexicon Plus<sup>®</sup>, a proprietary database of Cerner Multum, Inc., to code characteristics of drugs listed on the Patient Record. This switch was necessitated because the NDC was no longer being maintained by the FDA. The switch to Multum means that the NCHS generic codes (GEN1-GEN8) are no longer used to code NAMCS data. Instead, Multum codes for the generic composition of drugs have been adopted (see new items DRUGID1-DRUGID8). Each drug can have multiple therapeutic classes (termed drug categories in Multum) assigned to it; the public use file lists up to four categories for each drug.

Because each Multum code reflects all of a drug's ingredients, the separate ingredient fields for multi-ingredient drugs are no longer included on the public use file. The therapeutic classes (drug categories) included on the file for each drug will describe that drug, but for multi-ingredient drugs, one can not determine directly from the public use file the association between a particular ingredient and the therapeutic class. Therefore, a separate file for drug ingredients and their specific therapeutic classes is also available for downloading and merging with the public use data file, should users need this information. For a detailed description of the drug data changes on the public use file, please see page 18.

2. Deleted Items

None.

#### **Outpatient Department Public Use File**

- 1. New/Modified Items
  - **a.** Does the patient now have: The cancer checkbox for this item now has 5 checkboxes under it to indicate the stage.
  - b. Diagnostic/Screening Services New checkboxes were added for pap test conventional; pap test – liquid-based; and pap test – unspecified. These replace the former single checkbox for pap test/cervical cytology. Also, a new checkbox for HPV DNA test was added.
  - c. Non-Medication Treatment A radiation therapy checkbox was added.

The next 10 items were collected at the Hospital Induction Interview and added to the visit records for each outpatient department in 2006. Similar items were added to the 2006 NAMCS and NHAMCS-Emergency Department component.

- d. If your OPD's electronic medical record system includes computerized orders for prescriptions, are there warnings of drug interactions or contraindications provided?
- e. If your OPD's electronic medical record system includes computerized orders for prescriptions, are prescriptions sent electronically to the pharmacy?
- f. If your OPD's electronic medical record system includes computerized orders for tests, are orders sent electronically?
- g. If your OPD's electronic medical record system includes lab results, are out of range levels highlighted?

- h. If your OPD's electronic medical record system includes imaging results, are electronic images returned?
- i. If your OPD's electronic medical record system includes clinical notes, do they include medical history and follow-up notes?
- j. If your OPD's electronic medical record system includes clinical notes, do they include reminders for guideline-based interentions and/or screening tests?
- k. If your OPD's electronic medical record system includes public health reporting, are notifiable diseases sent electronically?
- I. If your OPD's electronic medical record system includes public health reporting, are notifiable diseases sent electronically?
- m. Are there plans for installing a new EMR system or replacing the current system within the next 3 years?
- n. Does this clinic offer any type of cervical cancer screening?

The following four items are based on the patient's ZIP code of residence (which is not available on the public use file). They were added to both the emergency and outpatient department files, as well as to the 2006 NAMCS public use file. See description of these items on page 2.

- o. Percent of poverty in patient's ZIP code
- p Median household income in patient's ZIP code
- q. Percentage of adults with a Bachelor's Degree or higher in patient's ZIP code
- r. Urban-rural classification of the patient's ZIP code

The following section describes changes to the drug characteristics data.

s. One other change involves switching from the Food and Drug Administration's (FDA) National Drug Code Directory (NDC) to Lexicon Plus<sup>®</sup>, a proprietary database of Cerner Multum, Inc., to code characteristics of drugs listed on the Patient Record. This switch was necessitated because the NDC was no longer being maintained by the FDA. The switch to Multum means that the NCHS generic codes (GEN1-GEN8) are no longer used to code NAMCS data. Instead, Multum codes for the generic composition of drugs have been adopted (see new items DRUGID1-DRUGID8). Each drug can have multiple therapeutic classes (termed drug categories in Multum) assigned to it; the public use file lists up to four categories for each drug.

Because each Multum code reflects all of a drug's ingredients, the separate ingredient fields for multi-ingredient drugs are no longer included on the public use file. The therapeutic classes (drug categories) included on the file for each drug will describe that drug, but for multi-ingredient drugs, one can not determine directly from the public use file the association between a particular ingredient and the therapeutic class. Therefore, a separate file for drug ingredients and their specific therapeutic classes is also available for downloading and merging with the public use data file, should users need this information. For a detailed description of the drug data changes on the public use file, please see page 18.

2. Deleted Items

None.

## Table of Contents

## Page

Abstract	1
Summary of Changes for 2006	
I. Description of the National Hospital Ambulatory Medical Care Survey	
A. Introduction	7
B. Sample design	
C. Data collection procedures	
D. Field quality control	
E. Confidentiality	
F. Data processing	
G. Medical coding	
H. Estimation procedures	
I. Patient visit weight	
J. Hospital code and patient code	
K. Clinic type code L. Use of the ED and OPD weights	Z3
M. Population figures	
References	
II Record Formats	
A. Format of Emergency Department Micro-Data File	33
B. Format of Outpatient Department Micro-Data File	
III Marginal Data	
A. Emergency department patient visits	
B. Emergency department drug mentions	
C. Emergency departments	111
D. Outpatient department patient visits	112
E. Outpatient department drug mentions	
F. Outpatient departments	116
Appendixes	
Appendix I	
A. Relative standard errors	
B. Instructions for completing Patient Record forms	
C. Definitions of certain terms used in the survey	143
Appendix II	450
A. Reason for Visit Classification - summary of codes	
B. Reason for Visit Classification - tabular listing	
Appondix III	
Appendix III	407
A. Generic codes and names in numeric order	١٥٢
B. Drug entry codes and names in numeric order	
C. Multum End-User License Agreement	
D. Multum Classification of Therapeutic Classes (Drug Categories)	241

# Table of Contents (cont.)

# Page

## List of Tables and Figures

Table I. U	J.S. population estimates used in computing annual visit rates for the National Ambulatory Medical Care Survey and the National Hospital Ambulatory Medical Care Survey, by selected characteristics: July 1, 2006	26
Table II.	U.S. population estimates used in computing annual visit rates for the National Ambulatory Medical Care Survey and the National Hospital Ambulatory Medical Care Survey, by ethnicity, age, race, and sex: July 1, 2006	28
Table III.	Coefficients appropriate for determining approximate relative standard errors of estimates by type of estimate and setting: National Hospital Ambulatory Medical Care Survey, 20061	20
Figure 1.	Emergency Department Patient Record Form	14
Figure 2.	Outpatient Department Patient Record form	15

## I. DESCRIPTION OF THE NATIONAL HOSPITAL AMBULATORY MEDICAL CARE SURVEY

## A. INTRODUCTION

The National Hospital Ambulatory Medical Care Survey (NHAMCS) was initiated to learn more about the ambulatory care rendered in hospital emergency and outpatient departments in the United States. Ambulatory medical care is the predominant method of providing health care services in the United States (1). Since 1973, data on ambulatory patient visits to physicians' offices have been collected through the National Ambulatory Medical Care Survey (NAMCS). However, visits to hospital emergency and outpatient departments, which represent a significant portion of total ambulatory medical care, are not included in the NAMCS (2). Furthermore, hospital ambulatory patients are known to differ from office patients in their demographic characteristics and medical aspects (3). Therefore, the omission of hospital ambulatory care from the ambulatory medical care database leaves a significant gap in coverage and limits the utility of the current NAMCS data. The NHAMCS fills this data gap.

The NHAMCS is endorsed by the Emergency Nurses Association, the Society for Emergency Academic Medicine, the American College of Emergency Physicians, and the American College of Osteopathic Emergency Physicians. A complete description of the NHAMCS is contained in the publication entitled, "Plan and Operation of the National Hospital Ambulatory Medical Care Survey" (4).

These micro-data files comprise the data collected by the NHAMCS in 2006. The NHAMCS is conducted by the Ambulatory and Hospital Care Statistics Branch of the National Center for Health Statistics, Centers for Disease Control and Prevention. The NHAMCS provides data from samples of patient records selected from the emergency departments (EDs) and outpatient departments (OPDs) of a national sample of hospitals. The national estimates produced from these studies describe the utilization of hospital ambulatory medical care services in the United States. In 2006, there were 35,849 Patient Record forms provided by EDs and 35,105 Patient Record forms provided by OPDs that participated in the survey. Both data files, ED and OPD, are included in this product. Reports summarizing data from the 2006 NHAMCS will be available (5, 6).

Please note the following important points concerning analysis of NHAMCS data on this micro-data file:

## ► PATIENT VISIT WEIGHT

Micro-data file users should be fully aware of the importance of the "patient visit weight" and how it must be used. Information about the patient visit weight is presented on page 23. If more information is needed, the staff of the Ambulatory and Hospital Care Statistics Branch can be consulted by calling (301) 458-4600 during regular working hours.

## ► RELIABILITY OF ESTIMATES

Users should also be aware of the reliability or unreliability of certain estimates, particularly the smaller estimates. The National Center for Health Statistics considers an estimate to be reliable if it has a relative standard error of 30 percent or less (i.e., the standard error is no more than 30 percent of the estimate). Therefore, it is important to know the value of the lowest possible estimate in this survey that is considered reliable, so as not to present data in a journal article or paper that may be unreliable. Most data file users can obtain an adequate working knowledge of relative standard errors from the information presented in Appendix I. It should be noted that estimates based on fewer than 30 records are also considered unreliable, regardless of the magnitude of the relative standard error. If you would like more information, do not hesitate to consult the staff of the Ambulatory and Hospital Care Statistics Branch.

#### **B. SAMPLE DESIGN**

The 2006 NHAMCS was a national probability sample of visits to the emergency and outpatient departments of noninstitutional general and short-stay hospitals, exclusive of Federal, military, and Veterans Administration hospitals, located in the 50 states and the District of Columbia. The NHAMCS was designed to provide estimates based on the following priority of survey objectives: United States; region; emergency and outpatient departments; and type of ownership. The NHAMCS used a four-stage probability design with samples of primary sampling units (PSUs), hospitals within PSUs, clinics/emergency service areas within outpatient/emergency departments, and patient visits within clinics/emergency service areas. Each stage of sampling is described below.

## 1. Primary Sampling Units (PSUs)

A PSU consists of a county, a group of counties, county equivalents (such as parishes and independent cities), towns, townships, minor civil divisions (for some PSUs in New England), or a metropolitan statistical area (MSA). MSAs were defined by the U.S. Office of Management and Budget on the basis of the 1980 Census. The first-stage sample consisted of 112 PSUs that comprised a probability subsample of the PSUs used in the 1985-94 National Health Interview Survey (NHIS). The NHAMCS PSU sample included with certainty the 26 NHIS PSUs with the largest populations. In addition, the NHAMCS sample included one-half of the next 26 largest PSUs, and one PSU from each of the 73 PSU strata formed from the remaining PSUs for the NHIS sample.

The NHIS PSU sample was selected from approximately 1,900 geographically defined PSUs that covered the 50 States and the District of Columbia. The 1,900 PSUs were stratified by socioeconomic and demographic variables and then selected with a probability proportional to their size. Stratification was done within four geographical regions by MSA or non-MSA status. A detailed description of the 1985-94 NHIS PSU sample design is available (7).

#### 2. Hospitals

The sampling frame for the 2006 NHAMCS was constructed from products of Verispan L.L.C., specifically "Healthcare Market Index, Updated May 15, 2003" and "Hospital Market Profiling Solution, Second Quarter, 2003." These products were formerly known as the SMG Hospital Database.

The original sample frame was compiled as follows. Hospitals with an average length of stay for all patients of less than 30 days (short-stay) or hospitals whose specialty was general (medical or surgical) or children's general were eligible for the NHAMCS. Excluded were Federal hospitals, hospital units of institutions, and hospitals with less than six beds staffed for patient use. In 1991, the SMG Hospital Database contained 6,249 hospitals that met these eligibility criteria. Of the eligible hospitals, 5,582 (89 percent) had emergency departments (EDs) and 5,654 (90 percent) had outpatient departments (OPDs). Hospitals were defined to have an ED if the hospital file indicated the presence of such a unit or if the file indicated a non-zero number of visits to such a unit. A similar rule was used to define the presence of an OPD. Hospitals were classified into four groups: those with only an ED; those with an ED and an OPD; those with only an OPD; and those with neither an ED nor an OPD. Hospitals in the last class were considered as a separate stratum and a small sample (50 hospitals) was selected from this stratum to allow for estimation to the total universe of eligible hospitals and the opening and closing of EDs and OPDs in the sample hospitals.

All hospitals in non-certainty PSUs with five or fewer hospitals were selected with certainty. There were 149 hospitals in 55 PSUs in this category. In non-certainty PSUs with more than five hospitals, hospitals were stratified by hospital class; type of ownership (not-for-profit, non-Federal government, and for-profit); and hospital size. Hospital size was measured by the combined volume of ED and OPD visits. From the stratified hospital list, five hospitals were selected in each PSU with probability proportional to the number of ED and OPD patient visits. A total of 161 hospitals was selected from this group. In the certainty PSUs, hospitals were stratified by region, hospital class, ownership, and size. From the stratified hospital list, 240 hospitals were selected based on probability proportional to size. A sample of 50 hospitals was selected from the 427 hospitals that had neither an ED nor an OPD.

The hospital selections were made so that each hospital would be chosen only once to avoid multiple inclusions of very large hospitals. A fixed panel of 600 hospitals was selected for the NHAMCS sample; 550 hospitals had an ED and/or an OPD and 50 hospitals had neither an ED nor an OPD. To preclude hospitals participating during the same time period each year, the sample of 600 hospitals was randomly divided into 16 subsets of approximately equal size. Each subset was assigned to 1 of the 16 4-week reporting periods, beginning December 2, 1991, which continues to rotate across each survey year. Therefore, the entire sample does not participate in a given year, and each hospital is inducted approximately once every 15 months.

The 2006 NHAMCS was conducted from January 2, 2006 through December 31, 2006, and consisted of a sample of 486 hospitals. Of the sampled hospitals, 57 were found to be ineligible due to closing or other reasons. Of the 429 hospitals that were in scope (eligible) for the survey, 389 participated, for an unweighted hospital sampling response rate of 90.7 percent.

For 2006, the four-stage probability sample was combined with a supplemental three-stage probability sample of children's general hospitals. The three-stage children's hospital supplement sampled children's hospitals regardless of PSU, but the design of the sample within hospitals was identical to that for the four-stage design.

#### 3. Outpatient Clinics and Emergency Service Areas

Within each hospital, either all outpatient clinics and emergency service areas (ESAs) or a sample of such units were selected. Clinics were in scope if ambulatory medical care was provided under the supervision of a physician and under the auspices of the hospital. Clinics were required to be "organized" in the sense that services were offered at established locations and schedules. Clinics where only ancillary services were provided or other settings in which physician services were not typically provided were out of scope. In addition, freestanding clinics were out of scope since they are included in the NAMCS, and ambulatory surgery centers, whether in hospitals or freestanding, were out of scope since they were included in the National Survey of Ambulatory Surgery which was conducted between 1994-96. A list of in scope and out of scope clinics is provided in Appendix I (Definition of certain terms used in the survey). The OPD clinic definition excluded the "hospital as landlord" arrangement in which the hospital only rented space to a physician group and was not otherwise involved in the delivery of services. These physicians are considered office-based and are currently included in the NAMCS. Emergency services provided under the "hospital as landlord" arrangement, however, were eligible for the study. An emergency department was in scope if it was staffed 24 hours a day. If an in-scope emergency department had an emergency service area that was open less than 24 hours a day, then it was included under the emergency department. If a hospital had an emergency department that was staffed less than 24 hours a day, then it was considered an outpatient clinic.

Hospitals may define the term "separate clinic" differently, for example, by physical location within the hospital, by staff providing the services, by specialty or subspecialty, by schedules, or by patients' source of payment. Because of these differences, "separate clinics" in the NHAMCS were defined as the smallest administrative units for which the hospital kept patient volume statistics.

During the visit by a field representative to induct a hospital into the survey, a list of all emergency service areas and outpatient clinics was obtained from the sample hospital. Each outpatient department clinic's function, specialty, and expected number of visits during the assigned reporting period were also collected. If there were five or fewer clinics, then all were included in the sample. If an outpatient department had more than five clinics, the clinics were assigned into one of six specialty groups: general medicine, surgery, pediatrics, obstetrics/gynecology, substance abuse, and other. Within these specialty groups, clinics were grouped into clinic sampling units (SUs). A clinic sampling unit was generally one clinic, except when a clinic expected fewer than 30 visits. In that case, it was grouped with one or more other clinics to form a clinic SU. If the grouped SU was selected, all clinics included in that SU were included in the sample. Prior to 2001, a sample of generally five clinic SUs was selected per hospital based on probability proportional to the total expected number of patient visits to the clinic during the assigned 4-week reporting period. Starting in 2001, clinic sampling within each hospital was stratified. If an OPD had more than five clinics, two clinic sample units were selected from each of the six specialty

groups with a probability proportional to the total expected number of visits to the clinic. The change was to ensure that at least two SUs were sampled from each of the specialty group strata.

The emergency department was treated as a separate stratum, and all emergency service areas were selected with certainty. In the rare instance that a sample hospital had more than five emergency service areas, a sample of five emergency service areas was selected with probability proportional to the expected number of visits to each emergency service area during the assigned 4-week reporting period.

A total of 486 hospitals was selected for the 2006 NHAMCS, of which 414 were in scope and had eligible EDs. Of these, 362 participated, yielding an unweighted ED response rate of 87.4 percent. A sample of 492 emergency services areas (ESAs) was selected from the EDs. Of these, 464 responded fully or adequately by providing forms for at least half of their expected visits based on the total number or visits during the reporting period, and 5 responded minimally (i.e. they provided fewer than half of their expected forms). In all, 35,849 Patient Record forms (PRFs) were submitted. The resulting unweighted ESA sample response rate was 94.3 percent, and the overall unweighted two stage sampling response rate was 82.5 percent. Response rates have been adjusted to exclude minimal participants.

Of the 486 sample hospitals in the 2006 NHAMCS, 278 were in scope and had eligible OPDs. Of these, 236 OPDs participated, yielding an unweighted OPD response rate of 85.6 percent. A sample of 1,223 clinics was selected from the OPDs. Of these, 1,038 responded fully or adequately (i.e. provided at least one-half of the number of PRFs expected, based on the total number of visits seen during the reporting period), and 20 responded minimally by completing less than half of their expected forms. In all, 31,505 PRFs were submitted. The resulting unweighted clinic sample response was 84.9 percent, and the overall unweighted two stage sampling response rate was 72.7 percent. Response rates have been adjusted to exclude minimal participants.

#### 4. Visits

The basic sampling unit for the NHAMCS is the patient visit or encounter. Only visits made in the United States by patients to EDs and OPDs of non-Federal, short-stay, or general hospitals were included in the 2006 NHAMCS. Within emergency service areas or outpatient department clinics, patient visits were systematically selected over a randomly assigned 4-week reporting period. A visit was defined as a direct, personal exchange between a patient and a physician, or a staff member acting under a physician's direction, for the purpose of seeking care and rendering health services. Visits solely for administrative purposes, such as payment of a bill, and visits in which no medical care was provided, such as visits to deliver a specimen, were out of scope.

The target numbers of PRFs to be completed for EDs and OPDs in each hospital were 100 and 200, respectively. In clinics with volumes higher than these desired figures, visits were sampled by a systematic procedure which selected every nth visit after a random start. Visit sampling rates were determined from the expected number of patients to be seen during the reporting period and the desired number of completed PRFs. During the 2006 NHAMCS, PRFs were completed for 35,849 ED visits and 35,105 OPD visits.

#### C. DATA COLLECTION PROCEDURES

#### 1. Field Training

The U.S. Bureau of the Census was the data collection agent for the 2006 NHAMCS. Census Headquarters staff were responsible for overseeing the data collection process, training the Census Regional Office staff, and writing the field manual. Regional Office staff were responsible for training the field representatives and monitoring hospital data collection activities. Field representative training included approximately four hours of self-study and two days of classroom training. Field representatives inducted the hospitals and trained the hospital staff on visit sampling and completion of the Patient Record forms.

#### 2. Hospital Induction

Approximately three months prior to the hospital's assigned reporting period, NCHS sent a personally signed introductory letter from the Director of NCHS to the hospital administrator or chief executive officer of each sampled hospital. The names of the hospital officials were obtained from the American Hospital Association (AHA) Guide to Health Care. In addition to the introductory letter, NCHS also enclosed endorsement letters from the Emergency Nurses Association, the Society for Emergency Academic Medicine, the American College of Emergency Physicians, the American College of Osteopathic Emergency Physicians, and the U.S. Surgeon General to emphasize the importance of the study to the medical community.

Approximately one week after the mailing of the introductory letter, the Census field representative called the hospital administrator to arrange for an appointment to further explain the study and to verify hospital eligibility for the survey. Earlier studies indicated that the three-month lead time was necessary to obtain a meeting with the administrator, gain hospital approval, collect the required information about the hospital's ambulatory care services, develop the sampling plan, and train participating hospital staff (8, 9).

#### 3. Outpatient Clinic and Emergency Service Area Induction

After the initial visit and the development of the sampling plan, the field representative contacted the hospital coordinator to arrange for induction of the sample emergency service areas and outpatient clinics and for instruction of the hospital staff. At these visits, the field representative described the purpose and use of the survey data, explained the data collection process, including the visit sampling procedures, and presented the Patient Record forms.

#### 4. Data Collection

The actual visit sampling and data collection for the NHAMCS was primarily the responsibility of hospital staff. This procedure was chosen for several reasons. First, the lack of a standard form or record coversheet in hospitals and the individuality of the hospital record keeping made field representative training difficult. Second, for confidentiality reasons, numerous hospitals did not want the field representatives to review patient logs or see actual medical records. Third, hospital staffs were better qualified to abstract data since they were familiar with the medical terms and coding, knew the record keeping systems, and could complete the data collection forms (PRFs) at or near the time of the visit when the information was the most complete and easiest to retrieve.

Hospital staff responsible for completing the PRFs were instructed in how to complete each item by the field representatives. Separate instruction booklets for emergency service areas and outpatient department clinics were prepared and provided to guide hospital staff in this task. These booklets provided an overview of the survey, sampling instructions, instructions for completing the PRFs, and definitions.

A brief, one page Patient Record form consisting of two sections was completed for each sample visit. To account for the differences in emergency and outpatient care, different Patient Record forms were developed for each of these settings. The top section of each PRF, which contains the patient's name and record number, was separated from the bottom section by a perforation running across the page. The top section remained attached to the bottom until the entire PRF was completed. To ensure confidentiality, before collecting the completed PRFs, the top section was detached and given to the hospital staff. The field representatives instructed hospital staff to keep this portion for a period of four weeks, in case it was necessary to retrieve missing information or clarify information that had been recorded.

The PRFs were patterned after those developed for the NAMCS and can be completed in 5 minutes. The OPD PRF most closely resembles the NAMCS PRF, while the ED PRF has been designed to reflect the type of care provided in that setting. The ED and OPD Patient Record forms were each printed on one side of an 8 x 14 inch sheet (Figures 1, 2). The ED PRF has an additional section on the reverse side.

Terms and definitions relating to the Patient Record forms are included in Appendix I. In 2006, 35 percent of ED records and 36 percent of OPD records required Census abstraction.

The 2006 NHAMCS included two supplements. The Emergency Pediatric Services and Equipment Supplement (EPSES) was used in 2002, 2003, and again in 2006. It was sponsored by the Health Resources and Services Administration (HRSA) and assessed how well hospitals were prepared to provide emergency pediatric services. NCHS is using the data collected to evaluate emergency pediatric preparedness at a national level. The Cervical Cancer Screening Supplement is the result of a joint effort by CDC's National Center for Health Statistics and National Center for Chronic Disease Prevention and Health Promotion to collect information on the screening of cervical cancer at hospital-based outpatient departments in the United States. It was introduced in 2006, continued in 2007 and is currently part of the 2008 data collection. Data from these supplements, as well as previous supplements on Staff Capacity and Ambulance Diversion, and Bioterrorism and Casualty Preparedness, will not be released to the general public because of confidentiality requirements, but it may be possible to gain access through the NCHS Research Data Center. Researchers may contact the Ambulatory and Hospital Care Statistics Branch at 301-458-4600 for more information.

## D. FIELD QUALITY CONTROL

The field representative visited the sampled emergency service areas and clinics each week during the data collection period and maintained telephone contact with the hospital staff involved in the data collection effort. The field representative reviewed the log or other records used for visit sampling to determine if any cases were missing and also edited completed forms for missing data. Attempts were made to retrieve both missing cases and missing data on specific cases, either by consulting with the appropriate hospital staff or by reviewing the pertinent medical records.

On the final visit, the field representative collected the remaining Patient Record forms and obtained or verified the total count of visits occurring during the reporting period by reviewing the log used for sample selection or by obtaining counts directly from hospital staff. Because this information was critical to the estimation process, extensive effort was made to ensure the accuracy of this number.

At the end of the hospital's reporting period the field representative sent the administrator a personalized "Thank You" letter.

## E. CONFIDENTIALITY

In April 2003, the Privacy Rule of the Health Insurance Portability and Accountability Act (HIPAA) was implemented to establish minimum Federal standards for safeguarding the privacy of individually identifiable health information. No personally identifying information, such as patient's name or address or Social Security number, is collected in the NHAMCS. Data collection is authorized by Section 306 of the Public Health Service Act (Title 42, U.S. Code, 242k). All information collected is held in the strictest confidence according to law [Section 308(d) of the Public Health Service Act (42, U.S. Code, 242m(d))] and the Confidential Information Protection and Statistical Efficiency Act (Title 5 of PL 107-347). The NHAMCS protocol has been approved by the NCHS Research Ethics Review Board annually since February 2003. Waivers of the requirements to obtain informed consent of patients and patient authorization for release of patient medical record data by health care providers have been granted.

In the Spring of 2003, the NHAMCS implemented additional data collection procedures to help providers assure patient confidentiality. Census Bureau Field Representatives were trained on how the Privacy Rule allows hospitals to make disclosures of protected health information without patient authorization for public health purposes and for research that has been approved by a Research Ethics Review Board. Hospitals were encouraged to accept a data use agreement between themselves and NCHS/CDC, since the Privacy Rule allows hospitals to disclose limited data sets (i.e., data sets with no direct patient identifiers) for research and public health purposes if such an agreement exists.

Assurance of confidentiality was provided to all hospitals according to Section 308 (d) of the Public Health Service Act (42 USC 242m). Strict procedures were utilized to prevent disclosure of NHAMCS data. All information which could identify the hospital or its facilities was confidential and was seen only by persons engaged in the NHAMCS, and was not disclosed or released to others for any other purpose. Names or other identifying information for individual patients were not removed from the hospitals or individual

facilities. Data users are advised that for some hospitals, selected characteristics may have been masked to minimize the potential for disclosure.

#### F. DATA PROCESSING

## 1. Edits

In addition to follow-ups for missing and inconsistent data made by the field staff, numerous clerical edits were performed on data received for central data processing. Detailed editing instructions were provided to manually review the patient records and to reclassify or recode "other" entries. Computer edits for code ranges and inconsistencies were also performed.

#### 2. Quality control

All medical and drug coding and keying operations were subject to quality control procedures. Quality control for the medical and drug coding operation, as well as straight-key items, involved a two-way 10-percent independent verification procedure. As an additional quality control, all Patient Record forms with differences between coders or with illegible entries for the reason for visit, diagnostic and therapeutic procedures, diagnosis, E-code (cause of injury), and medication items were reviewed and adjudicated at NCHS. The average keying error rate for non-medical items was 0.3 percent for both ED and OPD PRFs. For items that required medical coding, discrepancy rates ranged between 0.4 and 0.9 percent (ED) and 0.4 and 1.1 percent (OPD).

#### 3. Adjustment for item nonresponse

Unweighted item nonresponse rates were 5.0 percent or less for ED data items with the following exceptions: waiting time to see physician (20.8 percent), length of visit (7.0 percent); race (12.2 percent); ethnicity (16.3 percent); primary expected source of payment for visit (5.4 percent); initial temperature (6.8 percent); initial pulse (5.8 percent); initial blood pressure, systolic and diastolic (13.6 and 13.8 percent, respectively), oriented x 3 (18.9 percent); presenting level of pain (23.9 percent); is this visit work related (7.) percent); has patient been seen in this ED within the last 72 hours (11.5 percent); has patient been discharged from any hospital within the last 7 days (24.4 percent); intentionality of injury (15.8 percent of injury-related visits); cause of injury (17.0 percent of injury-related visits); was medication #5 given in ED or Rx at discharge (5.1 percent); was medication #6 given in ED or Rx at discharge (5.8 percent); was medication #7 given in ED or Rx at discharge (7.6 percent); was medication #8 given in ED or Rx at discharge (8.0 percent); for visits where patient was admitted to ED's hospital: type of unit admitted to (13.4 percent); length of stay in hospital (9.5 percent); has your hospital received any funding for bioterror hospital preparedness from your state or municipal health department within the last 2 years (24.8 percent), did your hospital receive any Medicaid Disproportionate Share Program funds in 2005 (38.7 percent); does your ED's electronic medical record system include: warnings of drug interactions or contraindications (20.8 percent), prescriptions sent electronically to the pharmacy (18.2 percent), test orders sent electronically (18.5 percent), out of range levels for lab results sent electronically (22.0 percent), imaging results (12.4 percent), electronic images returned (31.5 percent), clinical notes (8.1 percent), medical history and follow-up notes (14.8 percent), reminders for guideline-based interventions and/or screening tests (25.9 percent), public health reporting (21.1 percent), notifiable diseases sent electronically (72,7); in the last two years, has ED increased the number of standard treatment spaces (6,4 percent); plans to expand ED's physical space within the next two years (18.8 percent), who completed the Patient Record forms (8.0 percent). Missing or invalid ZIP code data led to the following nonresponse rates: median household income in patient's ZIP code (5.2 percent), percent of adults 25 years and over with Bachelor's Degree or higher in patient's ZIP code (5.3 percent), and percent of poverty in patient's ZIP code (5.2 percent).

## [Figure 1 omitted]

Please note: Figure 1 has been omitted from this version of the documentation in order to minimize file size and download time. You may view or download the 2006 NHAMCS Emergency Department Patient Record form from this web address:

http://www.cdc.gov/nchs/about/major/ahcd/surinst.htm#Survey Instrument NHAMCS

## [Figure 2 omitted]

Please note: Figure 2 has been omitted from this version of the documentation in order to minimize file size and download time. You may view or download the 2006 NHAMCS Outpatient Department Patient Record form from this web address:

http://www.cdc.gov/nchs/about/major/ahcd/surinst.htm#Survey Instrument NHAMCS

Unweighted item nonresponse rates were 5.0 percent or less for OPD data items with the following exceptions: patient race (13.3 percent); patient ethnicity (16.5 percent); is female patient pregnant (25.8 percent of females ages 10-54 years), week of gestation (24.2 percent of visits by pregnant females), does patient use tobacco (38.2 percent); for "not current" tobacco use: never or former (15.0 percent); are you the patient's primary care physician (6.4 percent); was patient referred for this visit (23.9 percent); is visit related to injury/poisoning/adverse effect (11.5 percent); stage of patient's cancer (52.3 percent), status of patient enrollment in disease management program for listed chronic conditions (51.3 percent), has your hospital received any funding for bioterror hospital preparedness from your state or municipal health department within the last 2 years (30.3 percent), did your hospital receive any Medicaid Disproportionate Share Program funds in 2004 (35.4 percent); does clinic offer any type of cervical cancer screening (11.6 percent of general medicine and ob-gyn clinics), does your OPD's electronic medical record system include: computerized orders for prescriptions (5.2 percent), warnings of drug interactions or contraindications (29.8 percent), prescriptions sent electronically to the pharmacy (24.5 percent), computerized orders for tests (6.8 percent), orders sent electronically (18.3 percent), lab results (7.9 percent), out of range levels highlighted (18.7 percent), imaging results (11.4 percent), electronic images returned (40.6 percent), clinical notes (5.7 percent), medical history and follow-up notes (23.1 percent), reminders for guideline based interventions and/or screening tests (35.2 percent), public health reporting (33.3 percent), and notifiable diseases sent electronically (92.1 percent); plans for installing a new EMR system or replacing current system within the next 3 years (22.5 percent), and who completed the Patient Record forms (7.0 percent). Missing or invalid ZIP code data led to the following nonresponse rates: percent of poverty in patient's ZIP code (6.0 percent), median household income in patient's ZIP code (6.0 percent), and percent of adults 25 years and over with Bachelor's Degree or higher in patient ZIP's code (6.1 percent).

Denominators used to compute item nonresponse rates were adjusted to account for skip patterns on the Patient Record forms. For example, hospital staff were instructed to answer the sub-item on number of past visits in the last 12 months for established patients only; therefore, visits by new patients were excluded when calculating the nonresponse rate for number of past visits.

For some items, missing values were imputed by randomly assigning a value from a Patient Record form with similar characteristics. On the ED file, five items were imputed: birth year (0.8 percent), sex (1.5 percent), ethnicity (17.3 percent), race (11.5 percent), and immediacy with which patient should be seen (3.1 percent). For birth year, sex, and race, imputation was based on ED volume, geographic region, immediacy with which patient should be seen, and 3-digit ICD-9-CM code for primary diagnosis. For ethnicity, imputation was based on ED volume, state, immediacy with which patient should be seen, and 3-digit ICD-9-CM code for primary diagnosis. For the variable "immediacy with which patient should be seen," imputation was based on ED volume, geographic region, and 3-digit ICD-9-CM code for primary diagnosis.

On the OPD file, birth year (1.0 percent), sex (0.9 percent), ethnicity (16.5 percent), race (13.3 percent), has patient been seen in this clinic before (2.2 percent) and if yes, number of past visits in last 12 months (8.5 percent) were imputed. The imputation for birth year, sex, race, seen before, and number of past visits was based on geographic region, OPD volume by clinic type, and 3-digit code for primary diagnosis. The imputation for ethnicity was based on OPD volume by clinic type, state, and 3-digit ICD-9-CM code for primary diagnosis. Race imputation was required for some records for disclosure avoidance purposes.

#### **G. MEDICAL CODING**

The Patient Record form contains several medical items requiring three separate coding systems. The three coding systems are described briefly below. Quality control for the NHAMCS medical and drug coding operations involved a 10-percent independent coding and verification procedure. A dependent

verification procedure was used to review and adjudicate all records with coding discrepancies. Definitions of the medical items can be found in Appendix I.

**1.** Patient's Complaint(s), Symptoms(s) or Other Reason(s) for this Visit: Information collected in item 4 of the ED and item 3 of the OPD Patient Record forms was coded according to <u>A Reason</u> for Visit Classification for Ambulatory Care (RVC) (10). The updated classification is available (11), and the list of codes is shown in Appendix II. The classification was updated to incorporate several new codes as well as changes to existing codes. The system continues to utilize a modular structure. The digits 1 through 8 precede the 3-digit RVC codes to identify the various modules as follows:

<u>Prefix</u>	Module
---------------	--------

- "1" = Symptom module
- "2" = Disease module
- "3" = Diagnostic, screening, and preventive module
- "4" = Treatment module
- "5" = Injuries and adverse effects module
- "6" = Test results module
- "7" = Administrative module
- "8" = Uncodable entries
- "9" = Special code = blank

Up to three reasons for visit were coded from the Patient Record forms in sequence; coding instructions for this item are contained in the Reason for Visit Classification and Coding Manual (11).

**2.** <u>Cause of Injury/Poisoning/Adverse Effect</u>: Up to three causes of injury, poisoning, or adverse effect were coded from responses to item 5 on the ED Patient Record forms. Causes were coded using the Supplementary Classification of External Causes of Injury and Poisoning (E-codes), International Classification of Diseases, 9<sup>th</sup> Revision, Clinical Modification (ICD-9-CM) (12). In the

classification, E-codes range from E800-E999, and many, but not all, codes have an additional fourth digit to provide greater specificity. For the NHAMCS ED public use file, the 'E' has been dropped.

There is an implied decimal between the third and fourth digits; inapplicable fourth digits have a dash inserted.

Examples: 895- = E895 = Accident caused by controlled fire in private dwelling 9056 = E905.6 = Venomous marine animals and plants as the cause of poisoning and toxic reactions

In addition to these character codes, we have also provided numeric recodes for the cause of injury fields at the end of the record format. Please see page 67 in the Record Format section for more information on using the numeric recodes.

**3.** <u>Physician's Diagnoses</u>: Diagnostic information in item 6 of the ED and item 5 of the OPD Patient Record forms was coded according to the <u>International Classification of Diseases</u>, 9<sup>th</sup> <u>Revision, Clinical Modification</u> (ICD-9-CM) (12).

For 2006, the ICD-9-CM codes are provided in two formats, the true ICD-9-CM code in character format, and a numeric recode found at the end of the record format. Please see page 67 in the Record format section for information on the background, purpose, and appearance of the numeric recodes. The rest of this paragraph describes the format of the true ICD-9-CM codes.

The true ICD-9-CM codes are not prefixed or zerofilled on the public use file. For example, 38100 = 381.00 = Acute nonsuppurative otitis media, unspecified. There is an implied decimal between the

third and fourth digits. For inapplicable fourth or fifth digits, a dash has been inserted.

For example, 4011- = 401.1 = Essential hypertension, benign.

True supplementary classification codes are not prefixed or zerofilled. For example, V700- = V70.0 = Routine general medical examination at a health care facility.

In addition to the diagnostic codes from the ICD-9-CM the following unique codes in the diagnostic fields were developed by NHAMCS staff:

- V990- = noncodable diagnosis, insufficient information for coding, illegible diagnosis
- V991- = left before being seen, patient walked out, not seen by doctor, left against medical advice
- V992- = transferred to another facility, sent to see specialist
- V993- = HMO will not authorize treatment
- V997- = entry of "none," "no diagnosis," "no disease," "healthy"
- 0000 = blank

A maximum of three diagnoses were coded in sequence. Coding instructions concerning diagnoses are contained in the NHAMCS Coding Requirements Manual (13).

**4.** <u>Diagnostic/Screening Services and Non-Medication Treatment</u>: Open-ended responses for "Scope procedure" and "Other test/service" from item 7 on the OPD Patient Record form (Diagnostic/Screening Services) as well as open-ended responses for "Procedures" from OPD Patient Record Form item 9 (Non-Medication Treatment) were coded according to the International Classification of Diseases (ICD-9-CM) using the procedure codes in Volume III. Up to 2 scope procedures, 2 other diagnostic/screening tests/services, and up to 4 procedures in the nonmedication treatment item could be coded for each outpatient department visit.</u>

Character format codes have an implied decimal between the second and third position and do not use prefixes or zerofills. Codes without an applicable 4th digit have a dash inserted. Please note that, as with the diagnosis codes described above, the file also contains numeric recodes for procedures at the end of the record format. These are described in the OPD Record Format section. It should be noted that some respondents reported procedures in item 7 (OPD), while others may have reported the same procedure in item 9 (OPD). For this reason, when analyzing procedures, it is recommended that all of the possible procedure fields be taken into account regardless of item location.

**5.** <u>Medications/Injections</u>: The NHAMCS drug data collected in item 9 (ED and item 10 (OPD) have been classified and coded using the entry name (the entry made on the Patient Record form) according to a unique classification scheme developed at NCHS (14). The medical classification system of drugs by entry name uses a five-digit coding scheme which is updated regularly to include new products. It includes the following special codes:

90000 = blank 99980 = unknown entry, other 99999 = illegible entry

Up to 8 medications could be recorded for each visit. A list of drug codes by entry name is included in Appendix III.

In addition to drugs coded by entry name, this file contains the following drug information:

**a. Generic drug code**: Beginning with the 2006 data release, NHAMCS no longer uses the NCHS 5-digit code which had been assigned to each official generic name assigned to every drug entity by the United States Pharmacopeia or other responsible authority. Instead, drugs are coded in terms of their generic components and therapeutic classifications using Lexicon Plus<sup>®</sup>, a proprietary database of Cerner Multum, Inc., also used by the National Health and Nutrition Examination Survey, NCHS. The Lexicon Plus is a comprehensive database of all prescription and some nonprescription drug products available in the U.S. drug market.

In accordance with the license agreement, NCHS publications, tabulations, and software applications should cite the Multum Lexicon as the source and basis for the coding and classification of NHAMCS drug data. For additional information on the Multum Lexicon Drug Database, please refer to the following Web site: <u>http://www.multum.com/Lexicon.htm</u>.

Starting with the 2006 data release, all drug codes based on entry name (using NCHS' classification system as cited above) were also assigned a unique generic drug code from Multum's Lexicon Drug Database where possible. The structure of the Multum database is such that multiple ingredient drugs are assigned a single generic drug code encompassing all of a drug's ingredients rather than being assigned generic drug codes for each ingredient, as in past years of NHAMCS drug data.

For example, prior to 2006, if Tylenol No. 3 was reported in the NHAMCS, it was assigned a drug entry code of 32920 to reflect the entry of Tylenol No. 3. Using the NCHS generic classification, it was also given a code of 51380 in the generic code field to represent a combination product, and then received separate ingredient codes for acetaminophen and codeine. Under Multum, there is a single generic code that reflects the combination of acetaminophen with codeine.

The format of the generic drug code (now called DRUGID rather than GEN) has also changed from previous years. Rather than a 5 digit numeric code, the generic drug code is 6 digits, beginning with the letters "a", "c" or "d". All Multum codes begin with the letter "d", but there were some drug names reported by NHAMCS participants that were not found in the Lexicon Drug Database. These have been assigned unique drug codes beginning with an "a" where a drug's ingredients could be determined, or a "c" in the case where a drug's ingredients could not be determined. The variables DRUGID1 through DRUGID8 reflect the generic codes for each drug reported.

**b. Prescription status code**: A code designed to identify the legal status (prescription or nonprescription) of the drug entry.

**c.** Controlled substance status code: A code used to denote the degree of potential abuse and federal control of a drug entry.

**d. Composition status code**: A code used to distinguish between single-ingredient and combination drugs.

**e. Therapeutic category code**: In data years prior to 2006, a 4-digit code was used to identify up to three therapeutic classes to which the drug entry might belong. (Prior to 2002 only a single therapeutic class was listed, but additional classes can be added for those years using tools available at the NHAMCS website.) These were based on the standard drug classifications used in the National Drug Code Directory, 1995 edition (15).

However, beginning with the 2006 data year, Multum's therapeutic classification system is being used. The Multum Lexicon provides a 3-level nested category system that assigns a therapeutic classification to each drug and each ingredient of the drug (e.g., for naproxen: the broadest category is central nervous system agents [level 1]; the more detailed category is analgesics [level 2]; and the most detailed category is nonsteroidal anti-inflammatory agents [level 3]). Not all drugs have three classification levels; some may only have two [e.g. for digoxin: cardiovascular agents [level 1]; inotropic agents [level 2]), others only have one. See Appendix III for the complete Multum category scheme.

Each drug may have up to four therapeutic categories on the public use file. The variables RX1CAT1 through RX8CAT4 reflect the unique Multum drug categories for a particular drug; these are character values with codes from '001' through '341'. This variable will always show the most detailed therapeutic level available of a particular drug. For example, psychotherapeutic agents in Multum are further classified into a second more detailed level as antidepressants or antipsychotics. Antidepressants are further classified into seven subcategories (miscellaneous antidepressants, SSRI antidepressants, tricyclic antidepressants, monoamine oxidase inhibitors, phenylpiperazine

antidepressants, tetracyclic antidepressants, and SSNRI antidepressants); antipsychotics are further classified into five subcategories. For a drug categorized as a tricyclic antidepressant, it would have a drug category code of '307', reflecting the Level 3 code.

Other drugs may have only two levels available, such as immunologic agents. There are seven level 2 categories of immunologic agents, and no further breakdowns into a third level in the Multum system. Therefore, RX1CAT1 would reflect only a second level code in that case. So, using RX1CAT1-RX8CAT4 will allow one to identify the most specific level of a drug, but will not, by itself, identify whether that code reflects the first, second, or third level.

In order to understand each level in terms of the Multum hierarchy, we have also placed on the file additional variables that show the full first, second, and third levels, if applicable, for each drug category for each drug. For example, in the case of the tricyclic antidepressant mentioned earlier, RX1CAT1='307'. But there are three additional variables corresponding to that drug's first therapeutic category. RX1V1C1 (meaning Drug 1, Level 1 of Therapeutic Category 1) would be '242' (psychotherapeutic agents), RX1V2C1 (Drug 1, Level 2 of Therapeutic Category 1) would be '249' (antidepressants), and RX1V3C1 (Drug 1, Level 3 of Therapeutic Category 1) would be '307' (tricyclic antidepressants). If there were no second or third level for a particular category, the entry would be blank (' '). This is repeated for each of the drug's maximum of four therapeutic categories. The three levels can easily be concatenated by data users if they wish to obtain a complete code showing the full level structure applicable to each drug's therapeutic categories. An advantage of having separate levels is that it allows data users to aggregate drugs at any level desired. SAS code is provided at the website for micro-data users who wish to group therapeutic categories in various ways.

All drugs were coded using Multum drug categories, even those drugs not found in Multum's drug database. "Unspecified" drugs were assigned to their respective therapeutic category (e.g., hormones – unspecified: category id=97, category name=hormones). Drugs that could not be assigned to any drug entry name (MED1-8 = 99980, 99999) were not assigned a therapeutic drug category. In some cases, NCHS was able to categorize a drug's therapeutic class at the first or second Multum level, but not at the more detailed level. When this occurred, the undetermined levels are designated as '999' in the data.

Multum uses a "combination" category for some multiple ingredient drugs. These include antihypertensive combinations, antiasthmatic combinations, upper respiratory combinations, psychotherapeutic combinations, bronchodilator combinations, sex hormone combinations, skeletal muscle relaxant combinations, and narcotic analgesic combinations. This categorization may be sufficient for certain analyses but not for others because it lacks information about the therapeutic effect of the individual ingredients that make up the combination. For example, the drug HYDROCHLOROTHIAZIDE; LOSARTAN is identified as an antihypertensive combination. Therefore, we know that this drug has an antihypertensive drug effect. However, based on this combination category we do not know that the drug's single ingredients have the therapeutic effects of a diuretic and angiotensin II inhibitor, which is relevant for some analyses.

As a result, NCHS decided that, in addition to assigning therapeutic categories to each drug, a separate file would be provided listing the ingredients for each drug along with the therapeutic classes for each ingredient. In the case of single ingredient drugs, the ingredient therapeutic categories would be the same as the drug therapeutic categories. This separate downloadable file (INGRED-2006) can be matched to the main file using the DRUGID code. For each DRUGID on the main file, the supplemental file contains up to 5 ingredients and up to 3 therapeutic category codes for each ingredient. In past years, codes used to identify the active generic ingredients of combination drugs were included on the public use file.

**IMPORTANT**: In 2006, we have continued to update and revise the drug characteristics in our ambulatory care drug database, which underwent substantial revision in 2002. In 2002, many drugs had ingredient lists reviewed, and non-active ingredients were removed. Duplicate codes caused by misspellings or

#### 2006 NHAMCS MICRO-DATA FILE DOCUMENTATION

other variant entries were eliminated, and incorrect codes (for example, for non-medications) were removed. From 2002-2005, each drug entry had up to three therapeutic classes associated with it, compared with a single therapeutic class in prior years. These factors made trend analysis more problematic, and the solution was to provide researchers with our Drug Characteristics file, which is updated annually, at our Ambulatory Health Care Data website. The characteristics from this file could be applied by matching on drug codes to previous years of data in order to get the most accurate results when doing analysis of drug trends. A SAS program for applying drug characteristics from the current drug database to previous years of public use data was also available for downloading.

For 2006, however, with the adoption of the Multum Lexicon for coding drugs according to generic ingredients and therapeutic categories, a new solution for trend analysis was necessary. Therefore, for the 2006 data release, we are also providing a separate downloadable mapping file (DRUGMAP-06), which will allow data users to match all of the drug codes used in previous years (for example, MED1-MED8 in 2005) with the corresponding Multum DRUGID code for generic composition of the drug and its corresponding therapeutic categories. Once that is accomplished, users can also if they wish match to the drug ingredient file as described above.

For users who are interested in analyzing drug data, one method involves the isolation of those records with drugs, or drug mentions, and the creation of a separate data file of drug mentions. Each Patient Record form for 2006 can have up to eight drug mentions recorded, so whatever file is created would need to include all of them. This method can be used for obtaining estimates of drug mentions, but is not recommended for variance estimation. Rather, the structure of the visit file should be kept intact when estimating variance. In order to do this, estimates of drug mentions can be obtained by creating a new weight variable (called DRUGWT in this example). This variable is created by multiplying PATWT (the patient visit weight) by NUMMED (the number of medications recorded at the sampled visit) or DRUGWT=PATWT\*NUMMED. DRUGWT can then be used in place of PATWT to weight one's data; it produces the estimated number of drug mentions rather than visits. (See Record Format for more on PATWT and NUMMED.)

This documentation contains some marginal data for drug mentions. Should the data user need additional assistance in analyzing data on drug mentions, the staff of the Ambulatory and Hospital Care Statistics Branch is available by calling (301) 458-4600. Our website can be accessed at: <a href="http://www.cdc.gov/nchs/nhamcs.htm">http://www.cdc.gov/nchs/nhamcs.htm</a>

## **H. ESTIMATION PROCEDURES**

Statistics from the NHAMCS were derived by a multistage estimation procedure that produces essentially unbiased estimates. The estimation procedure has three basic components: 1) inflation by reciprocals of the sampling selection probabilities; 2) adjustment for nonresponse; and 3) a population weighting ratio adjustment. Beginning with 1997 data, the population weighting ratio adjustment for OPD estimates was replaced by an adjustment which controls for effects of rotating hospital sample panels into and out of the sample each year. (The full NHAMCS hospital sample is partitioned into 16 panels which are rotated into the sample over 16 periods of four weeks each so that only 13 panels are used in each year.)

#### 1. Inflation by reciprocals of selection probabilities

There is one probability for each sampling stage: a) the probability of selecting the PSU; b) the probability of selecting the hospital; c) the probability of selecting the emergency service area (ESA) or OPD clinic from within the hospital; and d) the probability of selecting the visit within the ESA or clinic. The last probability is calculated to be the sample size from the ESA or clinic divided by the total number of visits occurring in that unit during that unit's data collection period. The overall probability of selection is the product of the probabilities at each stage. The inverse of the overall selection probability is the basic inflation weight. Beginning with the 1997 data, the overall selection probabilities of some OPDs were permanently trimmed to prevent individual OPDs from contributing too much of their region's total to OPD visit estimates.

#### 2. Adjustment for nonresponse

NHAMCS data are adjusted to account for two types of nonresponse. The first type of nonresponse occurred when a sample hospital refused to provide information about its ED(s) and/or OPD(s) which were publicly known to exist. In this case, the weights of visits to hospitals similar to the nonrespondent hospitals were inflated to account for visits represented by the nonrespondent hospitals where hospitals were judged to be similar if they were in the same region, ownership control group (government, non-Federal; voluntary non-profit; or proprietary), and had the same metropolitan statistical area (MSA) status (that is, whether they were located in an MSA or not in an MSA). This adjustment was made separately by department type.

The second type of nonresponse occurred when a sample ESA or OPD clinic within a respondent hospital failed to provide completed Patient Record forms for a sample of its patient visits. The weights of visits to ESAs/OPD clinics similar to the nonrespondent ESAs/OPD clinics were inflated to account for visits represented by the nonrespondent ESAs/OPD clinics where ESAs/OPD clinics were judged to be similar if they were in the same region, ownership control group, MSA status group and ESA/OPD clinic group. For this purpose, there were six OPD clinic groups: general medicine, pediatrics, surgery, OB/GYN, alcohol and/or substance abuse, and "other."

Beginning with 2004 data, changes were made to the nonresponse adjustment factor to account for the seasonality of the reporting period. Extra weights for nonresponding hospital outpatient departments and emergency departments were shifted to responding outpatient and emergency departments in reporting periods within the same quarter of the year. The shift in nonresponse adjustment did not significantly affect any of the overall annual estimates.

#### 3. Ratio adjustments

Adjustments were made within hospital strata defined by region and by hospital ownership control groups. Within the Northeast, the Midwest and the South, the adjustment strata were further defined by MSA status. These adjustments were made separately for emergency and outpatient departments. For EDs, the adjustment was a multiplicative factor that had as its numerator the sum of annual visit volumes reported to EDs in sampling frame hospitals in the stratum and as its denominator the estimated number of those visits for that stratum. Through the 1996 NHAMCS, the adjustment for visits to OPDs was a multiplicative factor which had as its numerator the number of OPDs reported in sampling frame hospitals in the stratum and as its denominator the data for the numerator and denominator of both adjustments were based on figures recorded for the data year in the Verispan Hospital Database.

Beginning with the 1997 NHAMCS, the adjustment for OPD estimates was replaced by a ratio which had as its numerator the weighted OPD visit volumes of hospitals in the full NHAMCS sample (16 hospital panels) and as its denominator the weighted OPD visit volumes of hospitals in the 13 hospital panels included in that year's sample. This adjustment used visit volumes that were based on the most recent survey data collected from hospitals that had participated in the NHAMCS for at least one year. For hospitals which had never participated, visit volumes were obtained by phone, from Verispan data, or by using the average of visit volumes for refusal hospitals which had converted to respondent status in the 2002 survey.

## I. PATIENT VISIT WEIGHT

The "patient visit weight" is a vital component in the process of producing national estimates from sample data and its use should be clearly understood by all data file users. The statistics contained on the data file reflect only a sample of patient visits-- not a complete count of all the visits that occurred in the United States. Each record on the ED file represents one visit in the sample of 35,849 visits, and each record on the OPD file represents one visit in the sample of 35,105 visits. In order to obtain national estimates from the two samples, each record is assigned an inflation factor called the "patient visit weight."

By aggregating the "patient visit weights" on the 35,849 sample records for 2006 the user can obtain the total of 119,191,311 estimated visits made by all patients to EDs in the United States. Also, by aggregating the "patient visit weights" on the 31,505 OPD sample records for 2006 the user can obtain the total of 102,208,188 estimated visits made by all patients to OPDs in the United States.

**IMPORTANT:** Data users should note that estimates produced from the 2006 ED and OPD public use files may differ very slightly with estimates produced from NCHS in-house files. This is due to adjustments that were required for the public use data as part of the disclosure avoidance process.

The marginal tables in Section III contain data on numbers of records for selected variables as well as the corresponding national estimated number of visits and drug mentions obtained by aggregating the "patient visit weights" on those records.

## J. HOSPITAL CODE and PATIENT CODE

The purpose of these codes is to allow for greater analytical depth by permitting the user to link individual Patient Record forms on the public use file with individual hospitals. This linkage will enable users to conduct more comprehensive analysis without violating the confidentiality of patients or hospitals. Hospital codes are randomly assigned each year and may be different on the OPD and ED files.

To uniquely identify a record, both the hospital code and the patient code must be used. Patient codes are merely a sequential numbering of the visits recorded by the hospital and alone will not uniquely identify visit records. In order to do so, both the unique 3-digit hospital code and the 3-digit patient code must be used.

## K. CLINIC TYPE CODE (For OPDs only)

The purpose of this code is similar to that of the hospital code. It allows the user to identify all records from a particular type of outpatient clinic.

#### L. USE OF THE ED and OPD WEIGHTS

An emergency department weight (EDWT) and an outpatient department weight (OPDWT) were first added to the 2005 ED and OPD public use files, respectively. These weights enable data users to calculate department-level estimates. There is one weight for each emergency department which appears on the first visit record only for that department. Likewise, there is one weight for each outpatient department, which appears only on the FIRST visit record for that department. When running an analysis of facility-level characteristics using EDWT, it is recommended to select only those records where EDWT is greater than 0. The same principle applies to the OPDWT. This will result in correct sample counts of variables, which is useful for assessing reliability. Weighted estimates will be correct either way, because of the one weight per department format.

Items on the ED file which are appropriate for department-level estimates include the following: Hospital ownership [OWNER], has your hospital received any funding for bioterror hospital preparedness from your state or municipal health department within the last 2 years [BIOTER], did your hospital receive any Medicaid Disproportionate Share Program funds in 2005 [MDSP], does emergency department use electronic medical records (not including billing records) [EMRED], does EMR system include: patient demographics [EDEMOGE], computerized prescription orders [ECPOEE], warnings of drug interactions/contraindications provided [EWARNE], prescriptions sent electronically to pharmacy [ESCRIPE], computerized test orders [ECTOEE], orders sent electronically [EORDERE], lab results [ERESULTE], out of range values highlighted [ERANGEE], imaging results [EIMGRESE], electronic images returned [EIMAGEE], clinical notes [ENNOTESE], medical history/follow-up notes [EHXFUE], reminders for guideline-based interventions and/or screening tests [EREMINDE], public health reporting [EPUBHTHE], notifiable diseases sent electronically [ENOTDISE]; plans for installing a new EMR system or replacing current system within three years [EMRNEWE], in last two years has ED increased the standard number of treatment spaces [INCSHS], in last two years has ED's physical space been expanded [INCPHYS], plans to expand ED's physical space within the next two years [EXPSPACE], [geographic region [REGION], and metropolitan statistical area [MSA]. These variables all pertain to the department's characteristics. Also see the Marginal Data section which includes some marginal tables of emergency-department-level estimates. Appendix I ("Relative Standard Errors") provides further information.

Items on the OPD file which are appropriate for department-level estimates include the following: Hospital ownership [OWNER], has your hospital received any funding for bioterror hospital preparedness from your state or municipal health department within the last 2 years [BIOTER], did your hospital receive any Medicaid Disproportionate Share Program funds in 2005 [MDSP], does outpatient department use electronic medical records (not including billing records) [EMROPD], does EMR system include: patient demographics [EDEMOGO], computerized prescription orders [ECPOEO], computerized test orders [ECTOEO], warnings of drug interactions/contraindications provided [EWARNO], prescriptions sent electronically to pharmacy [ESCRIPO], computerized test orders [ECTOEO], orders sent electronically [EORDERO], lab results [ERESULTO], out of range values highlighted [ERANGEO], imaging results [EIMGRESO], electronic images returned [EIMAGEO], clinical notes [ENNOTESO], medical history/followup notes [EHXFUO], reminders for guideline-based interventions and/or screening tests [EREMINDO], public health reporting [EPUBHTHO], notifiable diseases sent electronically [ENOTDISO]; plans for installing a new EMR system or replacing current system within three years [EMRNEWO]; does clinic offer cervical cancer screening [CCS], geographic region [REGION], and metropolitan statistical area [MSA]. These variables all pertain to the department's characteristics. Also see the Marginal Data section which includes some marginal tables of outpatient department-level estimates.

In addition to producing estimates of department-level characteristics, it is possible to compute means of visit characteristics at the department level, for example, average waiting time to see a physician in the ED. This is a more complicated process, and is described with sample SAS code at the Ambulatory Health Care Data website (<a href="http://www.cdc.gov/nchs/nhamcs.htm">www.cdc.gov/nchs/nhamcs.htm</a>). For more information, contact the Ambulatory and Hospital Care Statistics Branch at 301-458-4600.

## **M. POPULATION FIGURES**

The base population used in computing annual visit rates is presented in Table I and Table II. The estimates of age, sex, race, ethnicity, and geographic region for the civilian noninstitutionalized population of the U.S. are from special tabulations developed by the Population Division, U.S. Census Bureau using the July 1, 2006 set of state population estimates, and reflect Census 2000 data. More information may be obtained from the Census website at <u>www.census.gov.</u>

The 2006 MSA population estimates are based on data from the 2006 National Health Interview Survey (NHIS), National Center for Health Statistics, adjusted to the U.S. Census Bureau definition of core-based statistical areas as of November 2004. See <a href="https://www.census.gov/population/www/estimates/metrodef.html">www.census.gov/population/www/estimates/metrodef.html</a> for more about MSA definitions.

Estimates of visit rates for MSAs and non-MSAs beginning with 2003 may differ somewhat from those derived from 2002 and previous data years because of methodological differences in how the denominators were calculated. In survey years 1992-2002, the NHIS used a 1992 definition of MSAs and non-MSAs, and also used 1990-based Census estimates as controls. Because the NHAMCS used Census 2000-based population estimates beginning in 2001, adjustments needed to be made to the MSA figures obtained from the NHIS in 2001 and 2002. For 2006, special tabulations were obtained from the Office of Analysis and Epidemiology, NCHS, where 2006 NHIS data were matched to the November 2004 U.S. Census Bureau definition of core-based statistical areas. The estimates were further adjusted based on the 2006 population estimates obtained from the Census Bureau.

#### 2006 NHAMCS MICRO-DATA FILE DOCUMENTATION

Population estimates for race groups in the 2006 NHAMCS are based on data from the 2000 U.S. Census in which respondents were able to indicate more than one race category. The multiple race indicator was adopted starting in the 1999 NHAMCS but the population estimates that were available for calculating rates in 1999 and 2000 were based on estimates from the 1990 census, which used only single response race categories. The NHAMCS had very few records for multiple race persons in those years, so rates for single race groups were calculated by dividing estimates by denominators that included some unidentifiable number of multiple race persons. Starting with 2001, the denominators used for calculating race-specific visit rates in NHAMCS reports reflect the transition to multiple-race reporting. Specific race denominators reflect persons with a single race identification, and a separate denominator is now available for persons with more than one race designation.

Data indicate that multiple races are recorded for a patient less frequently in medical records compared to their numbers in the general population. The 2006 population estimates indicate that about 1.6 percent of the total population identify themselves as being of multiple races. In contrast, multiple race patients account for 0.3 percent of ED visits but, in 2006, 1.4 percent of OPD visits (weighted). Differences may exist because hospital staff are less likely to know and record the multiple race preferences of the patient, and not because, after age-adjusting, persons with multiple races make fewer visits to EDs and OPDs. This implies that the ED visit rates by race populations calculated for 2006 are probably slight overestimates for the single race categories and underestimates for the multiple race category.

Table II. U.S. population estimates used in computing annual visit rates for the National Ambulatory
Medical Care Survey and the National Hospital Ambulatory Medical Care Survey, by selected
characteristics: July 1, 2006

			Age in years			
Race and sex	All ages	Under 1	1-4	5-14	15-24	25-34
All races	294,180,154	4,126,516	16,284,756	40,292,354	41,429,759	39,302,445
Male	143,993,599	2,111,047	8,327,334	20,608,619	20,964,790	19,584,180
Female	150,186,555	2,015,469	7,957,422	19,683,735	20,464,969	19,718,265
White Only	236,072,127	3,129,024	12,415,782	30,737,173	32,125,713	30,703,091
Male	116,526,447	1,601,742	6,358,240	15,763,747	16,379,104	15,573,907
Female	119,545,680	1,527,282	6,057,542	14,973,426	15,746,609	15,129,184
Black Only	36,980,547	627,030	2,444,703	6,198,567	6,129,859	5,128,689
Male	17,178,374	319,673	1,240,853	3,142,448	2,983,394	2,312,052
Female	19,802,173	307,357	1,203,850	3,056,119	3,146,465	2,816,637
Asian Only	13,090,211	181,344	708,130	1,620,370	1,704,371	2,362,275
Male	6,327,472	93,021	362,851	821,280	866,622	1,150,045
Female	6,762,739	88,323	345,279	799,090	837,749	1,212,230
NHOPI* Only	519,943	8,098	29,937	85,406	89,632	93,614
Male	261,965	4,187	15,599	43,725	45,575	48,423
Female	257,978	3,911	14,338	41,681	44,057	45,191
AIAN* Only	2,849,566	41,620	161,111	477,327	521,555	429,836
Male	1,412,234	21,274	81,774	242,546	262,684	219,482
Female	1,437,332	20,346	79,337	234,781	258,871	210,354
Multiple Races	4,667,760	139,400	525,093	1,173,511	858,629	584,940
Male	2,287,107	71,150	268,017	594,873	427,411	280,271
Female	2,380,653	68,250	257,076	578,638	431,218	304,669
*NHOPI is Native	e Hawaiian/Othe	r Pacific Island	der. AIAN is A	merican Indiar	n/Alaska Native	ə.
Geographic Reg	ion totals		Metro	opolitan Statis	tical Area total	S
Northeast	53 024 831			MSD	244 770 063	

Geographic Region totals		Metropolitan Statis	stical Area totals
Northeast	53,924,831	MSA	244,770,063
Midwest	65,204,235	Non-MSA	49,410,091
South	106,797,883		
West	68,253,205		

SOURCE: These are U.S. Bureau of the Census postcensal estimates of the civilian noninstitutionalized population of the United States as of July 1, 2006. The estimates of age, sex, race and region are from special tabulations developed by the Population Division, U.S. Census Bureau using the July 1, 2006 set of state population estimates, and reflect data from the 2000 U.S. Census. More information may be obtained from the Census website at <u>www.census.gov</u>. The 2006 MSA population estimates are based on data from the 2006 National Health Interview Survey (NHIS), National Center for Health Statistics, adjusted to the U.S. Census Bureau definition of core-based statistical areas as of November 2004. See <u>www.census.gov/population/www/estimates/metrodef.html</u> for more about MSA definitions.

Table II. U.S. population estimates used in computing annual visit rates for the National Ambulatory Medical Care Survey and the National Hospital Ambulatory Medical Care Survey, by selected characteristics: July 1, 2006 - con.

\_\_\_\_\_

	Age in years						
					75 and		
Race and sex	35-44	45-54	55-64	65-74	over		
All races	42,773,272	42,927,829	31,423,419	18,672,985	16,946,819		
Male	21,071,307	20,997,919	15,114,947	8,557,918	6,655,538		
Female	21,701,965	21,929,910	16,308,472	10,115,067	10,291,281		
White Only	34,222,908	35,236,749	26,525,466	15,980,009	14,996,212		
Male	17,131,444	17,463,418	12,906,932	7,404,991	5,942,922		
Female	17,091,464	17,773,331	13,618,534	8,575,018	9,053,290		
Black Only	5,295,305	5,001,397	3,138,649	1,740,688	1,275,660		
Male	2,361,718	2,264,397	1,389,767	721,144	442,928		
Female	2,933,587	2,737,000	1,748,882	1,019,544	832,732		
Asian Only	2,292,584	1,837,102	1,220,043	679,097	484,895		
Male	1,109,864	861,231	562,410	305,837	194,311		
Female	1,182,720	975,871	657,633	373,260	290,584		
NHOPI* Only	79,566	63,149	38,390	19,856	12,295		
Male	39,737	31,412	18,856	9,386	5,065		
Female	39,829	31,737	19,534	10,470	7,230		
AIAN* Only	409,845	375,573	235,730	118,449	78,520		
Male	202,985	181,098	113,607	54,951	31,833		
Female	206,860	194,475	122,123	63,498	46,687		
Multiple Races	473,064	413,859	265,141	134,886	99,237		
Male	225,559	196,363	123,375	61,609	38,479		
Female	247,505	217,496	141,766	73,277	60,758		

Table III. U.S. population estimates used in computing annual visit rates for the National Ambulatory	
Medical Care Survey and the National Hospital Ambulatory Medical Care Survey, by ethnicity, age, race,	
and sex: July 1, 2006	

HISPANIC			Age in years			
Race and sex	All ages	Under 1	1-4	5-14	15-24	25-34
All races	43,796,437	970,373	3,733,162	8,026,491	7,220,233	7,924,872
Male	22,476,295	495,851	1,905,539	4,105,028	3,767,211	4,304,136
Female	21,320,142	474,522	1,827,623	3,921,463	3,453,022	3,620,736
White Only	40,532,363	897,245	3,488,705	7,343,490	6,629,587	7,364,586
Male	20,858,151	458,487	1,780,805	3,758,345	3,468,693	4,020,948
Female	19,674,212	438,758	1,707,900	3,585,145	3,160,894	3,343,638
Black Only	1,615,034	38,701	118,008	323,504	280,542	277,634
Male	780,702	19,818	60,317	164,198	140,360	133,000
Female	834,332	18,883	57,691	159,306	140,182	144,634
Asian Only	274,325	6,551	20,704	55,851	47,809	47,792
Male	135,014	3,322	10,445	28,459	24,217	23,85
Female	139,311	3,229	10,259	27,392	23,592	23,94
NHOPI* Only	115,188	2,519	7,923	22,876	21,310	22,978
Male	60,236	1,294	4,111	11,717	11,152	12,98
Female	54,952	1,225	3,812	11,159	10,158	9,992
AIAN* Only	637,600	5,583	21,588	120,055	127,372	123,459
Male	334,670	2,859	10,956	61,175	65,958	69,528
Female	302,930	2,724	10,632	58,880	61,414	53,93
Multiple Races	621,927	19,774	76,234	160,715	113,613	88,423
Male	307,522	10,071	38,905	81,134	56,831	43,823
Female	314,405	9,703	37,329	79,581	56,782	44,600

SOURCE: These are U.S. Bureau of the Census postcensal estimates of the civilian noninstitutionalized population of the United States as of July 1, 2006. They were developed by the Population Division, U.S. Census Bureau using the July 1, 2006 set of state population estimates, and reflect 2000 U.S. Census data. More information may be obtained from the Census website at <u>www.census.gov.</u>

## 2006 NHAMCS MICRO-DATA FILE DOCUMENTATION

Table III. U.S. population estimates used in computing annual visit rates for the National Ambulatory Medical Care Survey and the National Hospital Ambulatory Medical Care Survey, by ethnicity, age, race, and sex: July 1, 2006 - con.

HISPANIC		A	ge in years			
					75 and	
Race and sex	35-44	45-54	55-64	65-74	over	
All races	6,555,986	4,480,738	2,527,506	1,364,347	992,729	
Male	3,432,138	2,254,164	1,207,463	610,087	394,678	
Female	3,123,848	2,226,574	1,320,043	754,260	598,051	
White Only	6,089,875	4,152,245	2,350,918	1,278,766	936,946	
Male	3,204,521	2,095,712	1,124,686	572,613	373,341	
Female	2,885,354	2,056,533	1,226,232	706,153	563,605	
Black Only	237,175	167,545	92,366	47,914	31,645	
Male	110,472	78,184	42,243	20,540	11,570	
Female	126,703	89,361	50,123	27,374	20,075	
Asian Only	40,115	28,769	15,221	7,089	4,424	
Male	19,230	13,681	7,030	3,122	1,657	
Female	20,885	15,088	8,191	3,967	2,767	
NHOPI* Only	17,318	10,718	5,410	2,522	1,614	
Male	9,070	5,461	2,633	1,137	675	
Female	8,248	5,257	2,777	1,385	939	
AIAN* Only	102,291	73,532	37,126	16,365	10,229	
Male	55,098	38,532	18,699	7,555	4,310	
Female	47,193	35,000	18,427	8,810	5,919	
Multiple Races	69,212	47,929	26,465	11,691	7,871	
Male	33,747	22,594	12,172	5,120	3,125	
Female	35,465	25,335	14,293	6,571	4,746	

NON- HISPANIC			Age in years			
Race and sex	All ages	Under 1	1-4	5-14	15-24	25-34
All races	250,383,717	3,156,143	12,551,594	32,265,863	34,209,526	31,377,57
Male	121,517,304	1,615,196	6,421,795	16,503,591	17,197,579	15,280,04
emale	128,866,413	1,540,947	6,129,799	15,762,272	17,011,947	16,097,52
Vhite Only	195,539,764	2,231,779	8,927,077	23,393,683	25,496,126	23,338,50
/lale	95,668,296	1,143,255	4,577,435	12,005,402	12,910,411	11,552,95
emale	99,871,468	1,088,524	4,349,642	11,388,281	12,585,715	11,785,54
Black Only	35,365,513	588,329	2,326,695	5,875,063	5,849,317	4,851,05
/ale	16,397,672	299,855	1,180,536	2,978,250	2,843,034	2,179,05
emale	18,967,841	288,474	1,146,159	2,896,813	3,006,283	2,672,00
sian Only	12,815,886	174,793	687,426	1,564,519	1,656,562	2,314,48
Vale	6,192,458	89,699	352,406	792,821	842,405	1,126,19
emale	6,623,428	85,094	335,020	771,698	814,157	1,188,28
NHOPI* Only	404,755	5,579	22,014	62,530	68,322	70,63
/lale	201,729	2,893	11,488	32,008	34,423	35,43
emale	203,026	2,686	10,526	30,522	33,899	35,19
AAN* Only	2,211,966	36,037	139,523	357,272	394,183	306,37
/ale	1,077,564	18,415	70,818	181,371	196,726	149,95
emale	1,134,402	17,622	68,705	175,901	197,457	156,42
/ultiple Races	4,045,833	119,626	448,859	1,012,796	745,016	496,51
/lale	1,979,585	61,079	229,112	513,739	370,580	236,44
emale	2,066,248	58,547	219,747	499,057	374,436	260,06

Table III. U.S. population estimates used in computing annual visit rates for the National Ambulatory Medical Care Survey and the National Hospital Ambulatory Medical Care Survey, by ethnicity, age, race, and sex: July 1, 2006 – con.

## 2006 NHAMCS MICRO-DATA FILE DOCUMENTATION

Table III. U.S. population estimates used in computing annual visit rates for the National Ambulatory Medical Care Survey and the National Hospital Ambulatory Medical Care Survey, by ethnicity, age, race, and sex: July 1, 2006 - con.

 NON-						
HISPANIC		Δ	ge in years			
					75 and	
Race and sex	35-44	45-54	55-64	65-74	over	
All races	36,217,286	38,447,091	28,895,913	17,308,638	15,954,090	
Male	17,639,169	18,743,755	13,907,484	7,947,831	6,260,860	
Female	18,578,117	19,703,336	14,988,429	9,360,807	9,693,230	
White Only	28,133,033	31,084,504	24,174,548	14,701,243	14,059,266	
Male	13,926,923	15,367,706	11,782,246	6,832,378	5,569,581	
Female	14,206,110	15,716,798	12,392,302	7,868,865	8,489,685	
Black Only	5,058,130	4,833,852	3,046,283	1,692,774	1,244,015	
Male	2,251,246	2,186,213	1,347,524	700,604	431,358	
Female	2,806,884	2,647,639	1,698,759	992,170	812,657	
Asian Only	2,252,469	1,808,333	1,204,822	672,008	480,471	
Male	1,090,634	847,550	555,380	302,715	192,654	
Female	1,161,835	960,783	649,442	369,293	287,817	
NHOPI* Only	62,248	52,431	32,980	17,334	10,681	
Male	30,667	25,951	16,223	8,249	4,390	
Female	31,581	26,480	16,757	9,085	6,291	
AIAN* Only	307,554	302,041	198,604	102,084	68,291	
Male	147,887	142,566	94,908	47,396	27,523	
Female	159,667	159,475	103,696	54,688	40,768	
Multiple Races	403,852	365,930	238,676	123,195	91,366	
Male	191,812	173,769	111,203	56,489	35,354	
Female	212,040	192,161	127,473	66,706	56,012	

#### REFERENCES

1. National Center for Health Statistics. Health, United States, 2006, With Chartbook on Trends in the Health of Americans With Special Feature on Pain. Hyattsville, Maryland: 2006.

2. Tenney JB, White KL, Williamson JW. National Ambulatory Medical Care Survey: Background and Methodology. National Center for Health Statistics. Vital Health Stat 2(61). 1974.

3. Schappert SM, Rechtsteiner E. Ambulatory Care Visits to Physician Offices, Hospital Outpatient Departments and Emergency Departments: United States, 2006. National Health Statistics Reports, no. 8. Hyattsville, Maryland: National Center for Health Statistics. 2008.

4. McCaig LF, McLemore T. Plan and Operation of the National Hospital Ambulatory Medical Care Survey. National Center for Health Statistics. Vital and Health Statistics 1(34). 1994.

5. Pitts S, Niska R, Xu, J. National Hospital Ambulatory Medical Care Survey: 2006 Emergency Department Summary. Advance data from vital and health statistics. no. 7. Hyattsville, Maryland. National Center for Health Statistics. 2008.

6. Hing E., Hall M, Xu, J. National Hospital Ambulatory Medical Care Survey: 2006 Outpatient Department Summary. National Health Statistics Reports. no. 4. Hyattsville, Maryland. National Center for Health Statistics. 2008.

7. Massey JT, Moore TF, Parsons VL, Tadros W. Design and estimation for the National Health Interview Survey, 1985-94. National Center for Health Statistics. Vital and Health Statistics 2(110).1989.

8. Methodological Report on the Hospital Ambulatory Medical Care Evaluation Study. Contract No. 282-82-2111. Chicago, Illinois. National Opinion Research Center. 1984.

9. Final Report - Survey of Hospital Emergency and Outpatient Departments. Contract No. 200-88-7017. Rockville, Maryland. Westat. 1990.

10. Schneider D, Appleton L, McLemore T. A Reason for Visit Classification for Ambulatory Care. National Center for Health Statistics. Vital and Health Statistics 2(78). 1979.

11.National Ambulatory Medical Care Survey and National Hospital Ambulatory Medical Care Survey Reason for Visit Classification and Coding Manual (updated annually). Ambulatory and Hospital Care Statistics Branch, Division of Health Care Statistics, National Center for Health Statistics.

12. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, Health Care Financing Administration. International Classification of Diseases, 9th Revision, Clinical Modification. Sixth Edition. October 2006.

13. National Hospital Ambulatory Medical Care Survey: Coding Requirements (updated annually). Ambulatory and Hospital Care Statistics Branch, Division of Health Care Statistics, National Center for Health Statistics.

14. Koch H, Campbell W. The Collection and Processing of Drug Information. National Ambulatory Medical Care Survey, 1980. National Center for Health Statistics. Vital and Health Statistics 2 (90). 1982.

15. Food and Drug Administration. National Drug Code Directory, 1995 Edition. Washington: Public Health Service. 1995.

Information concerning additional reports using NHAMCS data that have been published or are scheduled for publication through NCHS may be obtained from the Ambulatory and Hospital Care Statistics Branch.

## II. A. RECORD FORMAT OF EMERGENCY DEPARTMENT MICRO-DATA FILE

Number of records = 35,849

This section consists of a detailed breakdown of each data record. For each item on the record, the user is provided with a sequential item number, field length, file location, and brief description of the item, along with valid codes. Unless otherwise stated in the "item description" column, the data are derived from the Emergency Department Patient Record form. The hospital induction interview and the Verispan, L.L.C. products, "Healthcare Market Index" and "Hospital Market Profiling Solution" (formerly known as the SMG Hospital Market Database) are other sources of information, and some data are derived by recoding selected items.

ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
1			DATE OF VISIT (from PRF Q1.a)
1.1	2	1-2	[VMONTH] MONTH OF VISIT 01-12: January-December
1.2	4	3-6	[VYEAR] YEAR OF VISIT 2006 (Survey dates were 1/2/2006-12/31/2006)
2	1	7	[VDAYR] DAY OF WEEK OF VISIT 1=Sunday 2=Monday 3=Tuesday 4=Wednesday 5=Thursday 6=Friday 7=Saturday
3	3	8-10	[AGE] PATIENT AGE (IN YEARS; DERIVED FROM DATE OF BIRTH) (from PRF Q1.c) 000 = Under 1 year 001-099 100 = 100 years and over
4	4	11-14	[ARRTIME] ARRIVAL TIME (military time) (from PRF Q1.d) 0000-2359 9999=Blank
5	4	15-18	[WAITTIME] WAITING TIME TO SEE PHYSICIAN (minutes) Calculated from PRF Q1.d, arrival time and time seen by physician 0-1270 9999=Blank/Not seen by physician
6	4	19-22	[LOV] LENGTH OF VISIT (minutes) Calculated from PRF Q1.d, arrival time and discharge time 1-2872 9999=Blank

PAGE 34		2006 NHAMCS MICRO-DATA FILE DOCUMENTATION, Emergency Department Record Format			
ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES		
7	1	23	[RESIDNCE] PATIENT RESIDENCE (from PRF Q1.e) 1 = Private residence 2 = Nursing home 3 = Other institution 4 = Other residence 5 = Homeless 6 = Unknown 7 = Blank		
8	1	24	[ARRIVE] Mode of arrival (from PRF Q1.f) 0 = Blank 1 = Ambulance 2 = Public service 3 = Walk-in 4 = Unknown		
9	1	25	[SEX] SEX (from PRF Q1.g) 1 = Female 2 = Male		
10	1	26	[ETHNIC] ETHNICITY (from PRF Q1.h) 1 = Hispanic or Latino 2 = Not Hispanic or Latino		
11	1	27	[RACE] RACE (from PRF Q1.i) 1 = White 2 = Black/African American 3 = Asian 4 = Native Hawaiian/Other Pacific Islander 5 = American Indian/Alaska Native 6 = More than one race reported		
12	1	28	[PAYPRIV] EXPECTED SOURCE OF PAYMENT: PRIVATE INSURANCE (from PRF Q1.j) 0 = No 1 = Yes		
13	1	29	[PAYMCARE] EXPECTED SOURCE OF PAYMENT: MEDICARE (from PRF Q1.j) 0 = No 1 = Yes		
14	1	30	[PAYMCAID] EXPECTED SOURCE OF PAYMENT: MEDICAID (from PRF Q1.j) 0 = No 1 = Yes		
15	1	31	[PAYWKCMP] EXPECTED SOURCE OF PAYMENT: WORKER'S COMPENSATION (from PRF Q1.j) 0 = No 1 = Yes		

ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
16	1	32	[PAYSELF] EXPECTED SOURCE OF PAYMENT: SELF PAY (from PRF Q1.j) 0 = No 1 = Yes
17	1	33	[PAYNOCHG] EXPECTED SOURCE OF PAYMENT: NO CHARGE (from PRF Q1.j) 0 = No 1 = Yes
18	1	34	[PAYOTH] EXPECTED SOURCE OF PAYMENT: OTHER (from PRF Q1.j) 0 = No 1 = Yes
19	1	35	[PAYUNK] EXPECTED SOURCE OF PAYMENT: UNKNOWN (from PRF Q1.j) 0 = No 1 = Yes
20	1	36	[PAYTYPE] PRIMARY EXPECTED SOURCE OF PAYMENT FOR THIS VISIT (Recoded from PRF Q1.j using this hierarchy of payment categories: Medicaid, Medicare, Private Insurance, Worker's Compensation, Self-Pay, No Charge, Other, Unknown)
			0 = Blank 1 = Private insurance 2 = Medicare 3 = Medicaid/SCHIP 4 = Worker's Compensation 5 = Self-pay 6 = No charge/charity 7 = Other 8 = Unknown
			INITIAL VITAL SIGNS (from PRF Q2)
21	4	37-40	[TEMPF] TEMPERATURE (from PRF Q2.a.1).There is an implied decimal between the third and fourth digits. 0000 = Blank 0600-1112 = 60.0 - 111.2 Fahrenheit
22	3	41-43	[PULSE] PULSE (from PRF Q2.a.2) 000-200 998 = DOP, DOPPLER 999 = Blank
23.a	3	44-46	[BPSYS] SYSTOLIC BLOOD PRESSURE (from Q2.a.3) 0-290 = 0-290 999 = Blank

PAGE 36		2006 NHAMCS MICRO-DATA FILE DOCUMENTATION, Emergency Department Record Format		
ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES	
23.b	3	47-49	[BPDIAS] DIASTOLIC BLOOD PRESSURE (from Q2.a.3) 0-190 = 0-190 998 = P, Palp, DOP, or DOPPLER 999 = Blank	
24	1	50	[ORIENTED] ORIENTED x 3 (from Q2.a.4) 0 = Blank 1 = Yes 2 = No 3 = Unknown	
25	1	51	[IMMED] IMMEDIACY WITH WHICH PATIENT SHOULD BE SEEN (from PRF Q2.b)	
			NOTE: The PRF categories for this item changed in 2005 compared with 2004 and previous years. Please note the differences when combining data across years.	
			1 = Immediate 2 = 1-14 minutes 3 = 15-60 minutes 4 = >1 hour - 2 hours 5 = >2 hours - 24 hours 6 = No triage 7 = Unknown	
26	1	52	[PAIN] PRESENTING LEVEL OF PAIN (from PRF Q2.c)	
			NOTE: The PRF categories for this item changed in 2005. On the 2005 form, "Unknown" is the last category rather than the first as in 2004 and earlier years, so the numbering is different for the remaining categories; please keep in mind when combining data across years.	
			0 = Blank 1 = None 2 = Mild 3 = Moderate 4 = Severe 5 = Unknown	
27	1	53	[SEEN72] HAS PATIENT BEEN SEEN IN THIS ED WITHIN THE LAST 72 HOURS? (from PRF Q3.a) 0 = No box is marked 1 = Yes 2 = No 3 = Unknown	
28	1	54	[DISCH7DA] HAS PATIENT BEEN DISCHARGED FROM ANY HOSPITAL WITHIN THE LAST 7 DAYS? (from PRF Q3.b) 1= Yes 2= No 3= Unknown 4= Blank	

ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
29			PATIENT'S REASON(S) FOR VISIT (See page 17 in Section I and Code List in Appendix II.) (from PRF Q4.a)
29.1	5	55-59	[RFV1] REASON # 1 10050-89990 = 1005.0-8999.0 90000 = Blank
29.2	5	60-64	[RFV2] REASON # 2 10050-89990 = 1005.0-8999.0 90000 = Blank
29.3	5	65-69	[RFV3] REASON # 3 10050-89990 = 1005.0-8999.0 90000 = Blank
29.4	100	70-169	[VRFV] REASON FOR VISIT – VERBATIM TEXT The patient's complaint(s), symptom(s), or other reasons(s) for this visit, using the patient's own words if possible.

## IMPORTANT NOTES ON USING THE REASON FOR VISIT VERBATIM TEXT DATA

The reason for visit text entry is converted to a reason for visit code by NCHS contracted medical coders using NCHS's *A Reason for Visit Classification for Ambulatory Care* (RVC) (10). The actual verbatim text was included on the public use file for the first time with 2005 survey data. The inclusion of the verbatim text is meant to assist data users in two major ways. First, the verbatim text can be used by researchers to assign records to reason for visit classification schemes other than the RVC if so desired. Second, users can search for key text words to identify diverse reasons for visit.

It should be noted that, in an effort to preserve confidentiality, geographic names, personal names, commercial names, and exact dates have been stripped from the verbatim text. However, in other respects, the data are as keyed and may contain misspellings, typographical errors, etc. The public use file version of the verbatim text has been formatted to concatenate the 1<sup>st</sup>, 2<sup>nd</sup>, and 3<sup>rd</sup> entries (representing the most important reason, as well as up to two other reasons) of the item into a single verbatim string.

It is important to remember that, because of their very specific nature, exact verbatim text strings will not translate into national estimates and should not be used as such. In general, we consider any estimate based on fewer than 30 occurrences in the data to be unreliable. Therefore, a single record showing a specific reason for visit should not be weighted to produce a national estimate. If, however, a researcher is able to identify 30 or more records where the verbatim text involves a similar reason, it might then be possible to sum the patient visit weights for these records to generate a national estimate related to that reason. The reliability of such an estimate would still depend upon the associated relative standard error.

29.5	1	170	[VWORKREL] IS THIS VISIT WORK RELATED? (from PRF Q4.b) 0 = Blank 1 = Yes 2 = No 3 = Unknown
30.1	1	171	[INJURY] IS THIS VISIT RELATED TO AN INJURY, POISONING, OR ADVERSE EFFECT OF MEDICAL TREATMENT? (from PRF Q5.a) 0 = No 1 = Yes

PAGE 38		2006 NHAMCS MICRO-DATA FILE DOCUMENTATION, Emergency Department Record Form	
ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
30.2	1	172	<ul> <li>[INTENT] IS THIS INJURY/POISONING INTENTIONAL? (from PRF Q5.b) (Also see Item 66 [col. 815] which is a recoded item based on the stated cause of injury from Item 5c of the Patient Record form.)</li> <li>0 = Blank</li> <li>1 = Yes (Self-inflicted)</li> <li>2 = Yes (Assault)</li> <li>3 = No, Unintentional</li> <li>4 = Unknown</li> <li>8 = Not applicable (not an injury visit)</li> </ul>
30.3			CAUSE OF INJURY (See page 17 in Section I for explanation of codes.) (from PRF Q5.c)
30.3.a	4	173-176	[CAUSE1] CAUSE #1 (ICD-9-CM, E-Codes) There is an implied decimal between the third and fourth digits; for inapplicable fourth digits, a dash is inserted. A prefix 'E' is implied. Codes in the 7000 series were developed by the Ambulatory and Hospital Care Statistics Branch. 700- = Drug use/abuse
			710- = Alcohol use/abuse 7999 = Illegible entry 8000-999[-] = E800.0-E999 0000 = Not applicable/Blank
30.3b	4	177-180	[CAUSE2] CAUSE #2 (ICD-9-CM, E-Codes) There is an implied decimal between the third and fourth digits; for inapplicable fourth digits, a dash is inserted. A prefix 'E' is implied. See CAUSE #1 for details.
30.3c	4	181-184	[CAUSE3] CAUSE #3 (ICD-9-CM, E-Codes) There is an implied decimal between the third and fourth digits; for inapplicable fourth digits, a dash is inserted. A prefix 'E' is implied. See CAUSE #1 for details.
31	75	185-259	[VCAUSE] CAUSE OF INJURY - VERBATIM TEXT Description of events that preceded the injury. Some entries contain the acronym "MVA". MVA = motor vehicle accident.

### IMPORTANT NOTES ON USING THE CAUSE OF INJURY VERBATIM TEXT DATA

The cause of injury is converted to an external cause of injury code (E-code) by NCHS medical coders. Since 1997, the actual verbatim text has been included on the public use file in addition to the E-code. The inclusion of the verbatim text is meant to assist data users in two major ways. First, the verbatim text can be used by researchers to assign records to injury classification schemes other than the "Supplementary Classification of External Causes of Injury and Poisoning" found in the ICD-9-CM, if so desired. Second, users can search for key text words (for example, swimming pool) to identify diverse causes of injury. It should be noted that, in an effort to preserve confidentiality, all geographic names, personal names, commercial names, and exact dates of injury have been stripped from the verbatim text.

It is important to remember that, because of their very specific nature, exact verbatim text strings will not translate into national estimates and should not be used as such. In general, we consider any estimate based on fewer than 30 occurrences in the data to be unreliable. Therefore, a single record showing the specific cause of injury of "tripped over a student's backpack in her classroom and fell on left knee" should

# ITEM FIELD FILE NO. LENGTH LOCATION [ITEM NAME], DESCRIPTION, AND CODES

not be weighted to produce a national estimate. If, however, a researcher is able to identify 30 or more records where the verbatim text involves a "backpack" -related injury, it might then be possible to sum the patient visit weights for these records to generate a national estimate related to a broader category of visits for back-pack related injuries. The reliability of such an estimate would still depend upon the associated relative standard error.

32			PHYSICIAN'S DIAGNOSES (See page 17, Section 1 for explanation of coding.) (from PRF Q6)
32.1	5	260-264	[DIAG1] DIAGNOSIS #1 (ICD-9-CM) There is an implied decimal between the third and fourth digits; for inapplicable fourth or fifth digits, a dash is inserted.
			<ul> <li>0010[-] - V829[-] = 001.0[0]-V82.9[0]</li> <li>V990- = Non-codable, insufficient information for coding, illegible</li> <li>V991- = Left before being seen; patient walked out; not seen by doctor; left against medical advice</li> <li>V992- = Transferred to another facility; sent to see specialist</li> <li>V993- = HMO will not authorize treatment</li> <li>V997- = Entry of "none," "no diagnosis," "no disease," or "healthy"</li> <li>00000 = Blank</li> </ul>
32.2	5	265-269	[DIAG2] DIAGNOSIS # 2 (ICD-9-CM) There is an implied decimal between the third and fourth digits; for inapplicable fourth or fifth digits, a dash is inserted. See DIAGNOSIS #1 for details.
32.3	5	270-274	[DIAG3] DIAGNOSIS # 3 (ICD-9-CM) There is an implied decimal between the third and fourth digits; for inapplicable fourth or fifth digits, a dash is inserted. See DIAGNOSIS #1 for details.
33			PROBABLE, QUESTIONABLE, AND RULE OUT DIAGNOSES
33.1	1	275	[PRDIAG1] IS DIAGNOSIS #1 PROBABLE, QUESTIONABLE, OR RULE OUT? 0 = No 1 = Yes 8 = Not applicable
33.2	1	276	[PRDIAG2] IS DIAGNOSIS #2 PROBABLE, QUESTIONABLE, OR RULE OUT? 0 = No 1 = Yes 8 = Not applicable

PAGE 40		2006 NHAMCS MICRO-DATA FILE DOCUMENTATION, Emergency Department Record For	
ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
33.3	1	277	[PRDIAG3] IS DIAGNOSIS #3 PROBABLE, QUESTIONABLE, OR RULE OUT? 0 = No 1 = Yes 8 = Not applicable
34			DIAGNOSTIC/SCREENING SERVICES (from PRF Q7)
34.1	1	278	[DIAGSCRN] Were any diagnostic/screening services ordered or provided at this visit?
			0 = No 1 = Yes 2 = No answer (entire item blank, including "None" box)
			0 = No, 1 = Yes
34.2 34.3 34.4 34.5 34.6 34.7 34.8 34.9 34.10 34.11 34.12 34.13	1 1 1 1 1 1 1 1 1	279 280 281 282 283 284 285 286 287 288 289 290	[CBC] CBC (Complete blood count) [BUNCREAT] BUN/Creatinine [CARDENZ] Cardiac enzymes [ELECTROL] Electrolytes [GLUCOSE] Glucose [LFT] Liver function tests [ABG] Arterial blood gases [BAC] Blood alcohol [HIVSER] HIV serology [OTHERBLD] Other blood test [EKG] EKG/ECG [CARDMON] Cardiac monitor
34.14a 34.14b		291 292-294	[PULSOXIM] Pulse oximetry [POPCT] Pulse oximetry (percent) 0-100 999=Blank
34.15 34.16 34.17	1 1 1	295 296 297	[PREGTEST] Pregnancy test [URINE] Urinalysis [OTHRTEST] Other test/service
34.18 34.19 34.20 34.21 34.22 34.23	1 1 1 1 1	298 299 300 301 302 303	[ANYIMAGE] Any imaging [XRAY] X-ray [ULTRASND] Ultrasound [MRI] MRI [CATSCAN] CT scan [OTHIMAGE] Other imaging
34.24	2	304-305	[TOTDIAG] TOTAL NUMBER OF DIAGNOSTIC/SCREENING SERVICES ORDERED OR PROVIDED 0-21 99 = All check boxes blank, including "None" box

ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES	
35			PROCEDURES (from PRF Q8)	
35.1	1	306	[PROC] Were any procedures provided at this visit? 0 = No 1 = Yes 2 = No answer (Entire item blank, including "None" box.)	
			0 = No, 1 = Yes	
35.2 35.3 35.4 35.5 35.6 35.7 35.8 35.9 35.10 35.11 35.12	1 1 1 1 1 1 1 1 1	307 308 309 310 311 312 313 314 315 316 317	[BLADCATH] Bladder catheter [CPR] CPR [ENDOINT] Endotracheal intubation [IVFLUIDS] IV fluids [NEBUTHER] Nebulizer therapy [NGTUBE] NG tube/gastric lavage [OBGYN] OB/GYN care [ORTHO] Orthopedic care [THROMBO] Thrombolytic therapy [WOUND] Wound care [OTHPROC] Other procedure	
35.13	2	318-319	[TOTPROC] TOTAL NUMBER OF PROCEDURES PROVIDED 0-11 99 = Entire item blank, including "None" box	
36			MEDICATIONS/INJECTIONS (from PRF Q9) (See page 18 for more information. See page 210 for codes.)	
36.1	1	320	[MED] WERE MEDICATIONS ORDERED OR PROVIDED AT THIS VISIT? 0 = No 1 = Yes	
36.2	5	321-325	[MED1] MEDICATION #1 00001-99227 = 00001-99227 90000 = Blank 99980 = Unknown Entry; Other 99999 = Illegible Entry	
36.3	5	326-330	[MED2] MEDICATION #2 00001-99227 = 00001-99227 90000 = Blank 99980 = Unknown Entry; Other 99999 = Illegible Entry	
36.4	5	331-335	[MED3] MEDICATION #3 00001-99227 = 00001-99227 90000 = Blank 99980 = Unknown Entry; Other 99999 = Illegible Entry	

PAGE 42		2006 NHAMCS N	/ICRO-DATA FILE DOCUMENTATION, Emergency Department Record Format
ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
36.5	5	336-340	[MED4] MEDICATION #4 00001-99227 = 00001-99227 90000 = Blank 99980 = Unknown Entry; Other 99999 = Illegible Entry
36.6	5	341-345	[MED5] MEDICATION #5 00001-99227 = 00001-99227 90000 = Blank 99980 = Unknown Entry; Other 99999 = Illegible Entry
36.7	5	346-350	[MED6] MEDICATION #6 00001-99227 = 00001-99227 90000 = Blank 99980 = Unknown Entry; Other 99999 = Illegible Entry
36.8	5	351-355	[MED7] MEDICATION #7 00001-99227 = 00001-99227 90000 = Blank 99980 = Unknown Entry; Other 99999 = Illegible Entry
36.9	5	356-360	[MED8] MEDICATION #8 00001-99227 = 00001-99227 90000 = Blank 99980 = Unknown Entry; Other 99999 = Illegible Entry
36.10	1	361	[GPMED1] Was medication #1 given in ED or Rx at discharge? 1 = Given in ED 2 = Rx at discharge 3 = Both given in ED and Rx at discharge 8 = Not applicable 9= Blank
36.11	1	362	[GPMED2] Was medication #2 given in ED or Rx at discharge? See GPMED1.
36.12	1	363	[GPMED3] Was medication #3 given in ED or Rx at discharge? See GPMED1.
36.13	1	364	[GPMED4] Was medication #4 given in ED or Rx at discharge? See GPMED1.
36.14	1	365	[GPMED5] Was medication #5 given in ED or Rx at discharge? See GPMED1.
36.15	1	366	[GPMED6] Was medication #6 given in ED or Rx at discharge? See GPMED1.
36.16	1	367	[GPMED7] Was medication #7 given in ED or Rx at discharge? See GPMED1.

ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
36.17	1	368	[GPMED8] Was medication #8 given in ED or Rx at discharge? See GPMED1.
36.18	1	369	[NUMGIV] NUMBER OF MEDICATIONS GIVEN IN ED 0 - 8 NOTE: For this variable, the value '0' can reflect the following situations: a) no drug listed; b) drug listed but only Rx at discharge; and c) drug listed but unknown whether given in ED or Rx at discharge.
36.19	1	370	[NUMDIS] NUMBER OF MEDICATIONS Rx AT DISCHARGE 0 - 8 NOTE: For this variable, the value '0' can reflect the following situations: a) no drug listed; b) drug listed but only given in ED; and c) drug listed but unknown whether given in ED or prescribed at discharge.
36.20	1	371	[NUMMED] NUMBER OF MEDICATIONS CODED 0 – 8
37			PROVIDERS SEEN (from PRF Q10)
			0 = No, 1 = Yes
37.1 37.2 37.3 37.4 37.5 37.6 37.6 37.7 37.8 37.9	1 1 1 1 1 1 1 1	372 373 374 375 376 377 378 379 380	[NOPROVID] No answer to item [ATTPHYS] ED attending physician [RESINT] ED resident/Intern [ONCALL] On call attending physician/Fellow [RNLPN] RN/LPN [NURSEPR] Nurse practitioner [PHYSASST] Physician assistant [EMT] EMT [OTHPROV] Other provider
38			VISIT DISPOSITION (from PRF Q11)
			0 = No, 1 = Yes
38.1 38.2 38.3 38.4 38.5 38.6 38.7 38.8 38.9	1 1 1 1 1 1 1 1	381 382 383 384 385 386 387 388 389	[NODISP] No answer to item [NOFU] No follow-up planned [RETPRN] Return if needed, P.R.N./appt [RETREFFU] Return/Refer to physician/clinic for FU [REFSOCS] Refer to social services [LEFTAMA] Left AMA (against medical advice) [LEFT] Left without being seen [DOA] DOA/died in ED [TRANSFER] Transfer to different hospital

PAGE 44		006 NHAMCS N	IICRO-DATA FILE DOCUMENTATION, Emergency Department Record Format
ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
38.10	1	390	<ul> <li>[RFTRANS] Reason for transfer</li> <li>This variable is a recode of the verbatim reason for transfer text.</li> <li>1 = Continuity of care; request by patient, family, or physician</li> <li>2 = Higher level or specialized care needed</li> <li>3 = Psychiatric, mental health, or substance abuse care</li> <li>4 = Pediatric facility needed</li> <li>5 = Insurance requirement/request</li> <li>6 = Other/Insufficient information available</li> <li>8 = Not applicable (not transferred)</li> <li>9 = No reason for transfer specified</li> </ul>
38.11 38.12 38.13	1 1 1	391 392 393	[ADMITOBS] Admit to observation unit [ADMITHOS] Admit to hospital [OTHDISP] Other visit disposition The next 4 items were completed only if the patient was admitted to
			the hospital at the current visit.
38.14	1	394	[ADMIT] Admitted to: 1 = Critical care unit 2 = OR/Cath lab 3 = Other bed/unit 4 = Unknown 5 = Not applicable (not admitted to hospital) 9 = Blank
38.15	4	395-398	[LOS] Length of stay in hospital (days) Calculated from date of ED visit, hospital admission time, and hospital discharge date. 1-69 9999 = Not applicable/Missing data
38.16	5	399-403	<ul> <li>[HDDIAG] Principal hospital discharge diagnosis (ICD-9-CM)</li> <li>There is an implied decimal between the third and fourth digits; for inapplicable fourth or fifth digits, a dash is inserted.</li> <li>0010[-] - V829[-] = 001.0[0]-V82.9[0]</li> <li>V990- = Non-codable, insufficient information for coding, illegible</li> <li>V991- = Left before being seen; patient walked out; not seen by doctor; left against medical advice</li> <li>V992- = Transferred to another facility; sent to see specialist</li> <li>V993- = HMO will not authorize treatment</li> <li>V997- = Entry of "none," "no diagnosis," "no disease," or "healthy"</li> <li>00000 = Blank</li> </ul>
38.17	1	404	[HDSTAT] Hospital discharge status 1 = Alive 2 = Dead 3 = Unknown 4 = Not applicable (not admitted to hospital) 9 = Blank

ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES	
39	6	405-410	[PATWT] PATIENT VISIT WEIGHT (See page 22 in Section I.) A right-justified integer developed by NCHS staff for the purpose of producing national estimates from sample data.	
40	1	411	[REGION] GEOGRAPHIC REGION (Based on actual location of the hospital.) 1 = Northeast 2 = Midwest 3 = South 4 = West	
41	1	412	[MSA] METROPOLITAN/NON METROPOLITAN STATUS (Based on actual location in conjunction with the definition of the Bureau of the Census and the U.S. Office of Management and Budget.) 1 = MSA (Metropolitan Statistical Area) 2 = Non-MSA (includes micropolitan statistical areas)	
42	1	413	[OWNER] HOSPITAL OWNERSHIP 1 = Voluntary non-profit 2 = Government, non-Federal 3 = Proprietary	
43 44 45	1 1 1	414 415 416	Blank - reserved for possible future use Blank - reserved for possible future use Blank - reserved for possible future use	
46	3	417-419	[HOSPCODE] HOSPITAL CODE A unique code assigned to all the records from a particular hospital. For a few hospitals, additional masking was required to minimize risks of disclosure. For this reason, the number of hospital codes may be slightly different than the number of responding facilities. 1-364	
47	3	420-422	[PATCODE] PATIENT CODE - A number assigned to identify each individual record from a particular hospital. 1-270	
**** TH	E FOLLOWI	NG FIELDS SI	HOW WHETHER DATA WERE IMPUTED TO REPLACE BLANKS ****	
48			IMPUTED FIELDS 0 = Not imputed 1 = Imputed	
48.1 48.2 48.3 48.4 48.5	1 1 1 1	423 424 425 426 427	[BDATEFL] Patient birth year [SEXFL] Patient sex [ETHNICFL] Patient ethnicity [RACEFL] Patient race [IMMEDFL] Immediacy with which patient should be seen	
**************************************				

PAGE 46	2006 NHAMCS MICRO-DATA FILE DOCUMENTATION, Emergency Department Record Format		
ITEM FIELD	FILE LOCATION _ [ITEM NAME], DESCRIPTION, AND CODES		

# 49

DRUG-RELATED INFO FOR MEDICATION #1

NOTE: Starting with the 2006 data release, all drug codes based on entry name (using NCHS' standard classification system) were also assigned a unique generic drug code from Multum's Lexicon Drug Database, where possible. The structure of the Multum database is such that multiple ingredient drugs are assigned a single generic drug code encompassing all of a drug's ingredients rather than being assigned generic drug codes for each ingredient, as in past years of NAMCS drug data. All Multum codes start with the letter "d" but there were some drugs reported in NAMCS that could not be assigned a code in Multum. These received a prefix of either "a" (when ingredients could be determined) or "c" (when ingredients could not be determined). For more on the structure of the 2006 drug data (including information on therapeutic class and drug ingredients, please see page 18.)

49.1	6	428-433	[DRUGID1] DRUG ID (See p. 210 for more information.) a10001-a71037 = NCHS code (for drugs not found in Multum but for which ingredients could be determined) c00012-c00899 = NCHS code (for drugs not found in Multum and with undetermined ingredients) d00001-d06848 = Multum code	
49.2	1	434	[PRESCR1] PRESCRIPTION STATUS CODE 1 = Prescription Drug 2 = Nonprescription Drug 3 = Undetermined	
49.3	1	435	[CONTSUB1] CONTROLLED SUBST 1 = Schedule I (Researc 2 = Schedule II 3 = Schedule III 4 = Schedule IV	
49.4	1	436	[COMSTAT1] COMPOSITION STATUS CODE 1 = Single Entity Drug 2 = Combination Drug 3 = Undetermined	
49.5a	3	437-439	[RX1CAT1] MULTUM DRUG CATEGORY # 1 Reflects the most detailed therapeutic level to which the drug can be classified. For some drugs, Multum Level 1 (broadest level) is the most detailed, while others can be coded to Level 2, but the majority can be coded to Level 3 (most detailed level). For more on the Multum classification system, please see page 18. The complete Multum classification is shown in Appendix III.	
			<ul><li>" = Blank/Not applicable</li><li>001 - 899 = Drug category</li><li>999 = Undetermined category</li></ul>	
49.6a	3	440-442	[RX1CAT2] MULTUM DRUG CATEGORY # 2 See RX1CAT1.	
49.7a	3	443-445	[RX1CAT3] MULTUM DRUG CATEGORY # 3 See RX1CAT1.	
49.8a	3	446-448	[RX1CAT4] MULTUM DRUG CATEGORY # 4 See RX1CAT1.	

ITEM	FIELD	FILE	[ITEM NAME], DESCRIPTION, AND CODES
NO.	LENGTH	LOCATION	
			DRUG CATEGORY LEVELS
			See RX1CAT1 for general coding conventions that apply to all Multum drug categories. Complete Multum classification scheme is shown in Appendix III.
49.5a1	3	449-451	[RX1V1C1] Level 1 of MULTUM DRUG CATEGORY # 1
49.6a1	3	452-454	[RX1V1C2] Level 1 of MULTUM DRUG CATEGORY # 2
49.7a1	3	455-457	[RX1V1C3] Level 1 of MULTUM DRUG CATEGORY # 3
49.8a1	3	458-460	[RX1V1C4] Level 1 of MULTUM DRUG CATEGORY # 4
49.5a2	3	461-463	[RX1V2C1] Level 2 of MULTUM DRUG CATEGORY # 1
49.6a2	3	464-466	[RX1V2C2] Level 2 of MULTUM DRUG CATEGORY # 2
49.7a2	3	467-469	[RX1V2C3] Level 2 of MULTUM DRUG CATEGORY # 3
49.8a2	3	470-472	[RX1V2C4] Level 2 of MULTUM DRUG CATEGORY # 4
49.5a3	3	473-475	[RX1V3C1] Level 3 of MULTUM DRUG CATEGORY # 1
49.6a3	3	476-478	[RX1V3C2] Level 3 of MULTUM DRUG CATEGORY # 2
49.7a3	3	479-481	[RX1V3C3] Level 3 of MULTUM DRUG CATEGORY # 3
49.8a3	3	482-484	[RX1V3C4] Level 3 of MULTUM DRUG CATEGORY # 4

PAGE 48		2006 NHAMCS N	/ICRO-DATA FILE DOCUMENTATION, Emergency Department Record Format
ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
50			DRUG-RELATED INFO FOR MEDICATION #2
50.1	6	485-490	[DRUGID2] Drug ID (See p. 210 for more information.) a10001-a71037 = NCHS code (for drugs not found in Multum but for which ingredients could be determined) c00012-c00899 = NCHS code (for drugs not found in Multum and with undetermined ingredients) d00001-d06848 = Multum code
50.2	1	491	[PRESCR2] PRESCRIPTION STATUS CODE 1 = Prescription Drug 2 = Nonprescription Drug 3 = Undetermined
50.3	1	492	[CONTSUB2] CONTROLLED SUBSTANCE STATUS CODE1 = Schedule I (Research Only)2 = Schedule II5 = Schedule V3 = Schedule III6 = No Control4 = Schedule IV7 = Undetermined
50.4	1	493	[COMSTAT2] COMPOSITION STATUS CODE 1 = Single Entity Drug 2 = Combination Drug 3 = Undetermined
50.5a	3	494-496	[RX2CAT1] MULTUM DRUG CATEGORY # 1
			Reflects the most detailed therapeutic level to which the drug can be classified. For some drugs, Multum Level 1 (broadest level) is the most detailed, while others can be coded to Level 2, but the majority can be coded to Level 3 (most detailed level). For more on the Multum classification system, please see page 18. The complete Multum classification is shown in Appendix III.
			<ul> <li>" = Blank/Not applicable</li> <li>001 - 899 = Drug category</li> <li>999 = Undetermined category</li> </ul>
50.6a	3	497-499	[RX2CAT2] MULTUM DRUG CATEGORY # 2 See RX2CAT1.
50.7a	3	500-502	[RX2CAT3] MULTUM DRUG CATEGORY # 3 See RX2CAT1.
50.8a	3	503-505	[RX2CAT4] MULTUM DRUG CATEGORY # 4 See RX2CAT1.

ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
			DRUG CATEGORY LEVELS
			See RX2CAT1 for general coding conventions that apply to all Multum drug categories. Complete Multum classification scheme is shown in Appendix III.
50.5a1	3	506-508	[RX2V1C1] Level 1 of MULTUM DRUG CATEGORY # 1
50.6a1	3	509-511	RX2V1C2 Level 1 of MULTUM DRUG CATEGORY # 2
50.7a1	3	512-514	[RX2V1C3] Level 1 of MULTUM DRUG CATEGORY # 3
50.8a1	3	515-517	[RX2V1C4] Level 1 of MULTUM DRUG CATEGORY # 4
50.5a2	3	518-520	[RX2V2C1] Level 2 of MULTUM DRUG CATEGORY # 1
50.6a2	3	521-523	[RX2V2C2] Level 2 of MULTUM DRUG CATEGORY # 2
50.7a2	3	524-526	[RX2V2C3] Level 2 of MULTUM DRUG CATEGORY # 3
50.8a2	3	527-529	[RX2V2C4] Level 2 of MULTUM DRUG CATEGORY # 4
50.5a3 50.6a3 50.7a3 50.8a3	3 3 3 3	530-532 533-535 536-538 539-541	[RX2V3C1] Level 3 of MULTUM DRUG CATEGORY # 1 [RX2V3C2] Level 3 of MULTUM DRUG CATEGORY # 2 [RX2V3C3] Level 3 of MULTUM DRUG CATEGORY # 3 [RX2V3C4] Level 3 of MULTUM DRUG CATEGORY # 4
00.000	-		

PAGE 50		2006 NHAMCS N	IICRO-DATA FILE DOCUMENTATION, Emergency Department Record Format
ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
51			DRUG-RELATED INFO FOR MEDICATION #3
51.1	6	542-547	[DRUGID3] Drug ID (See p. 210 for more information.) a10001-a71037 = NCHS code (for drugs not found in Multum but for which ingredients could be determined) c00012-c00899 = NCHS code (for drugs not found in Multum and with undetermined ingredients) d00001-d06848 = Multum code
51.2	1	548	[PRESCR3] PRESCRIPTION STATUS CODE 1 = Prescription Drug 2 = Nonprescription Drug 3 = Undetermined
51.3	1	549	[CONTSUB3] CONTROLLED SUBSTANCE STATUS CODE1 = Schedule I (Research Only)2 = Schedule II5 = Schedule V3 = Schedule III6 = No Control4 = Schedule IV7 = Undetermined
51.4	1	550	[COMSTAT3] COMPOSITION STATUS CODE 1 = Single Entity Drug 2 = Combination Drug 3 = Undetermined
51.5a	3	551-553	[RX3CAT1] MULTUM DRUG CATEGORY # 1 Reflects the most detailed therapeutic level to which the drug can be classified. For some drugs, Multum Level 1 (broadest level) is the most detailed, while others can be coded to Level 2, but the majority can be coded to Level 3 (most detailed level). For more on the Multum classification system, please see page 18. The complete Multum classification is shown in Appendix III.
			<ul> <li>" = Blank/Not applicable</li> <li>001 - 899 = Drug category</li> <li>999 = Undetermined category</li> </ul>
51.6a	3	554-556	[RX3CAT2] MULTUM DRUG CATEGORY # 2 See RX3CAT1.
51.7a	3	557-559	[RX3CAT3] MULTUM DRUG CATEGORY # 3 See RX3CAT1.
51.8a	3	560-562	[RX3CAT4] MULTUM DRUG CATEGORY # 4 See RX3CAT1.

ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
			DRUG CATEGORY LEVELS
			See RX3CAT1 for general coding conventions that apply to all Multum drug categories. Complete Multum classification scheme is shown in Appendix III.
51.5a1 51.6a1	3 3	563-565 566-568	[RX3V1C1] Level 1 of MULTUM DRUG CATEGORY # 1 [RX3V1C2] Level 1 of MULTUM DRUG CATEGORY # 2
51.7a1	3	569-571	[RX3V1C3] Level 1 of MULTUM DRUG CATEGORY # 3
51.8a1	3	572-574	[RX3V1C4] Level 1 of MULTUM DRUG CATEGORY # 4
51.5a2	3	575-577	[RX3V2C1] Level 2 of MULTUM DRUG CATEGORY # 1
51.6a2	3	578-580	[RX3V2C2] Level 2 of MULTUM DRUG CATEGORY # 2
51.7a2	3 3	581-583	[RX3V2C3] Level 2 of MULTUM DRUG CATEGORY # 3
51.8a2	3	584-586	[RX3V2C4] Level 2 of MULTUM DRUG CATEGORY # 4
51.5a3	3	587-589	[RX3V3C1] Level 3 of MULTUM DRUG CATEGORY # 1
51.6a3	3	590-592	[RX3V3C2] Level 3 of MULTUM DRUG CATEGORY # 2
51.7a3	3	593-595	[RX3V3C3] Level 3 of MULTUM DRUG CATEGORY # 3
51.8a3	3	596-598	[RX3V3C4] Level 3 of MULTUM DRUG CATEGORY # 4

PAGE 52		2006 NHAMCS N	IICRO-DATA FILE DOCUMENTATION, Emergency Department Record Format
ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
52			DRUG-RELATED INFO FOR MEDICATION #4
52.1	6	599-604	[DRUGID4] Drug ID (See p. 210 for more information.) a10001-a71037 = NCHS code (for drugs not found in Multum but for which ingredients could be determined) c00012-c00899 = NCHS code (for drugs not found in Multum and with undetermined ingredients) d00001-d06848 = Multum code
52.2	1	605	[PRESCR4] PRESCRIPTION STATUS CODE 1 = Prescription Drug 2 = Nonprescription Drug 3 = Undetermined
52.3	1	606	[CONTSUB4] CONTROLLED SUBSTANCE STATUS CODE1 = Schedule I (Research Only)2 = Schedule II5 = Schedule V3 = Schedule III6 = No Control4 = Schedule IV7 = Undetermined
52.4	1	607	[COMSTAT4] COMPOSITION STATUS CODE 1 = Single Entity Drug 2 = Combination Drug 3 = Undetermined
52.5a	3	608-610	[RX4CAT1] MULTUM DRUG CATEGORY # 1
			Reflects the most detailed therapeutic level to which the drug can be classified. For some drugs, Multum Level 1 (broadest level) is the most detailed, while others can be coded to Level 2, but the majority can be coded to Level 3 (most detailed level). For more on the Multum classification system, please see page 18. The complete Multum classification is shown in Appendix III.
			<ul> <li>" = Blank/Not applicable</li> <li>001 - 899 = Drug category</li> <li>999 = Undetermined category</li> </ul>
52.6a	3	611-613	[RX4CAT2] MULTUM DRUG CATEGORY # 2 See RX4CAT1.
52.7a	3	614-616	[RX4CAT3] MULTUM DRUG CATEGORY # 3 See RX4CAT1.
52.8a	3	617-619	[RX4CAT4] MULTUM DRUG CATEGORY # 4 See RX4CAT1.

ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
			DRUG CATEGORY LEVELS
			See RX4CAT1 for general coding conventions that apply to all Multum drug categories. Complete Multum classification scheme is shown in Appendix III.
52.5a1	3	620-622	[RX4V1C1] Level 1 of MULTUM DRUG CATEGORY # 1
52.6a1	3	623-625	[RX4V1C2] Level 1 of MULTUM DRUG CATEGORY # 2
52.7a1	3	626-628	RX4V1C3 Level 1 of MULTUM DRUG CATEGORY # 3
52.8a1	3	629-631	[RX4V1C4] Level 1 of MULTUM DRUG CATEGORY # 4
52.5a2	3	632-634	[RX4V2C1] Level 2 of MULTUM DRUG CATEGORY # 1
52.6a2	3	635-637	[RX4V2C2] Level 2 of MULTUM DRUG CATEGORY # 2
52.7a2	3	638-640	[RX4V2C3] Level 2 of MULTUM DRUG CATEGORY # 3
52.8a2	3	641-643	[RX4V2C4] Level 2 of MULTUM DRUG CATEGORY # 4
52.5a3 52.6a3 52.7a3 52.8a3	3 3 3 3	644-646 647-649 650-652 653-655	[RX4V3C1] Level 3 of MULTUM DRUG CATEGORY # 1 [RX4V3C2] Level 3 of MULTUM DRUG CATEGORY # 2 [RX4V3C3] Level 3 of MULTUM DRUG CATEGORY # 3 [RX4V3C4] Level 3 of MULTUM DRUG CATEGORY # 4

PAGE 54		2006 NHAMCS N	IICRO-DATA FILE DOCUMENTATION, Emergency Department Record Format
ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
53			DRUG-RELATED INFO FOR MEDICATION #5
53.1	6	656-661	[DRUGID5] Drug ID (See p. 210 for more information.) a10001-a71037 = NCHS code (for drugs not found in Multum but for which ingredients could be determined) c00012-c00899 = NCHS code (for drugs not found in Multum and with undetermined ingredients) d00001-d06848 = Multum code
53.2	1	662	[PRESCR5] PRESCRIPTION STATUS CODE 1 = Prescription Drug 2 = Nonprescription Drug 3 = Undetermined
53.3	1	663	[CONTSUB5] CONTROLLED SUBSTANCE STATUS CODE1 = Schedule I (Research Only)2 = Schedule II5 = Schedule V3 = Schedule III6 = No Control4 = Schedule IV7 = Undetermined
53.4	1	664	[COMSTAT5] COMPOSITION STATUS CODE 1 = Single Entity Drug 2 = Combination Drug 3 = Undetermined
53.5a	3	665-667	[RX5CAT1] MULTUM DRUG CATEGORY # 1 Reflects the most detailed therapeutic level to which the drug can be classified. For some drugs, Multum Level 1 (broadest level) is the most detailed, while others can be coded to Level 2, but the majority can be coded to Level 3 (most detailed level). For more on the Multum classification system, please see page 18. The complete Multum classification is shown in Appendix III.
			<ul> <li>" = Blank/Not applicable</li> <li>001 - 899 = Drug category</li> <li>999 = Undetermined category</li> </ul>
53.6a	3	668-670	[RX5CAT2] MULTUM DRUG CATEGORY # 2 See RX3CAT1.
53.7a	3	671-673	[RX5CAT3] MULTUM DRUG CATEGORY # 3 See RX3CAT1.
53.8a	3	674-676	[RX5CAT4] MULTUM DRUG CATEGORY # 4 See RX3CAT1.

ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
			DRUG CATEGORY LEVELS
			See RX5CAT1 for general coding conventions that apply to all Multum drug categories. Complete Multum classification scheme is shown in Appendix III.
53.5a1	3	677-679	[RX5V1C1] Level 1 of MULTUM DRUG CATEGORY # 1
53.6a1	3	680-682	[RX5V1C2] Level 1 of MULTUM DRUG CATEGORY # 2
53.7a1	3	683-685	RX5V1C3 Level 1 of MULTUM DRUG CATEGORY # 3
53.8a1	3	686-688	[RX5V1C4] Level 1 of MULTUM DRUG CATEGORY # 4
53.5a2 53.6a2	3 3	689-691 692-694	[RX5V2C1] Level 2 of MULTUM DRUG CATEGORY # 1 [RX5V2C2] Level 2 of MULTUM DRUG CATEGORY # 2
53.7a2	3 3	695-697	[RX5V2C3] Level 2 of MULTUM DRUG CATEGORY # 3
53.8a2	3	698-700	[RX5V2C4] Level 2 of MULTUM DRUG CATEGORY # 4
53.5a3 53.6a3 53.7a3 53.8a3	3 3 3 3	701-703 704-706 707-709 710-712	[RX5V3C1] Level 3 of MULTUM DRUG CATEGORY # 1 [RX5V3C2] Level 3 of MULTUM DRUG CATEGORY # 2 [RX5V3C3] Level 3 of MULTUM DRUG CATEGORY # 3 [RX5V3C4] Level 3 of MULTUM DRUG CATEGORY # 4

PAGE 56		2006 NHAMCS N	IICRO-DATA FILE DOCUMENTATION, Emergency Department Record Format
ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
54			DRUG-RELATED INFO FOR MEDICATION #6
54.1	6	713-718	[DRUGID6] Drug ID (See p. 210 for more information.) a10001-a71037 = NCHS code (for drugs not found in Multum but for which ingredients could be determined) c00012-c00899 = NCHS code (for drugs not found in Multum and with undetermined ingredients) d00001-d06848 = Multum code
54.2	1	719	[PRESCR6] PRESCRIPTION STATUS CODE 1 = Prescription Drug 2 = Nonprescription Drug 3 = Undetermined
54.3	1	720	[CONTSUB6] CONTROLLED SUBSTANCE STATUS CODE1 = Schedule I (Research Only)2 = Schedule II5 = Schedule V3 = Schedule III6 = No Control4 = Schedule IV7 = Undetermined
54.4	1	721	[COMSTAT6] COMPOSITION STATUS CODE 1 = Single Entity Drug 2 = Combination Drug 3 = Undetermined
54.5a	3	722-724	[RX6CAT1] MULTUM DRUG CATEGORY # 1
			Reflects the most detailed therapeutic level to which the drug can be classified. For some drugs, Multum Level 1 (broadest level) is the most detailed, while others can be coded to Level 2, but the majority can be coded to Level 3 (most detailed level). For more on the Multum classification system, please see page 18. The complete Multum classification is shown in Appendix III.
			<ul> <li>" = Blank/Not applicable</li> <li>001 - 899 = Drug category</li> <li>999 = Undetermined category</li> </ul>
54.6a	3	725-727	[RX6CAT2] MULTUM DRUG CATEGORY # 2 See RX6CAT1.
54.7a	3	728-730	[RX6CAT3] MULTUM DRUG CATEGORY # 3 See RX6CAT1.
54.8a	3	731-733	[RX6CAT4] MULTUM DRUG CATEGORY # 4 See RX6CAT1.

ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
			DRUG CATEGORY LEVELS
			See RX6CAT1 for general coding conventions that apply to all Multum drug categories. Complete Multum classification scheme is shown in Appendix III.
54.5a1	3	734-736	[RX6V1C1] Level 1 of MULTUM DRUG CATEGORY # 1
54.6a1	3	737-739	[RX6V1C2] Level 1 of MULTUM DRUG CATEGORY # 2
54.7a1	3	740-742	[RX6V1C3] Level 1 of MULTUM DRUG CATEGORY # 3
54.8a1	3	743-745	[RX6V1C4] Level 1 of MULTUM DRUG CATEGORY # 4
54.5a2	3	746-748	[RX6V2C1] Level 2 of MULTUM DRUG CATEGORY # 1
54.6a2	3	749-751	[RX6V2C2] Level 2 of MULTUM DRUG CATEGORY # 2
54.7a2	3	752-754	[RX6V2C3] Level 2 of MULTUM DRUG CATEGORY # 3
54.8a2	3	755-757	[RX6V2C4] Level 2 of MULTUM DRUG CATEGORY # 4
54.5a3 54.6a3 54.7a3 54.8a3	3 3 3 3	758-760 761-763 764-766 767-769	[RX6V3C1] Level 3 of MULTUM DRUG CATEGORY # 1 [RX6V3C2] Level 3 of MULTUM DRUG CATEGORY # 2 [RX6V3C3] Level 3 of MULTUM DRUG CATEGORY # 3 [RX6V3C4] Level 3 of MULTUM DRUG CATEGORY # 4

PAGE 58		2006 NHAMCS N	IICRO-DATA FILE DOCUMENTATION, Emergency Department Record Format
ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
55			DRUG-RELATED INFO FOR MEDICATION #7
56.1	6	770-775	[DRUGID7] Drug ID (See p. 210 for more information.) a10001-a71037 = NCHS code (for drugs not found in Multum but for which ingredients could be determined) c00012-c00899 = NCHS code (for drugs not found in Multum and with undetermined ingredients) d00001-d06848 = Multum code
56.2	1	776	[PRESCR7] PRESCRIPTION STATUS CODE 1 = Prescription Drug 2 = Nonprescription Drug 3 = Undetermined
56.3	1	777	[CONTSUB7] CONTROLLED SUBSTANCE STATUS CODE1 = Schedule I (Research Only)2 = Schedule II5 = Schedule V3 = Schedule III6 = No Control4 = Schedule IV7 = Undetermined
56.4	1	778	[COMSTAT7] COMPOSITION STATUS CODE 1 = Single Entity Drug 2 = Combination Drug 3 = Undetermined
56.5a	3	779-781	[RX7CAT1] MULTUM DRUG CATEGORY # 1
			Reflects the most detailed therapeutic level to which the drug can be classified. For some drugs, Multum Level 1 (broadest level) is the most detailed, while others can be coded to Level 2, but the majority can be coded to Level 3 (most detailed level). For more on the Multum classification system, please see page 18. The complete Multum classification is shown in Appendix III.
			<ul> <li>" = Blank/Not applicable</li> <li>001 - 899 = Drug category</li> <li>999 = Undetermined category</li> </ul>
56.6a	3	782-784	[RX7CAT2] MULTUM DRUG CATEGORY # 2 See RX7CAT1.
56.7a	3	785-787	[RX7CAT3] MULTUM DRUG CATEGORY # 3 See RX7CAT1.
56.8a	3	788-790	[RX7CAT4] MULTUM DRUG CATEGORY # 4 See RX7CAT1.

ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
			DRUG CATEGORY LEVELS
			See RX7CAT1 for general coding conventions that apply to all Multum drug categories. Complete Multum classification scheme is shown in Appendix III.
56.5a1	3	791-793	[RX7V1C1] Level 1 of MULTUM DRUG CATEGORY # 1
56.6a1	3	794-796	RX7V1C2 Level 1 of MULTUM DRUG CATEGORY # 2
56.7a1	3	797-799	[RX7V1C3] Level 1 of MULTUM DRUG CATEGORY # 3
56.8a1	3	800-802	[RX7V1C4] Level 1 of MULTUM DRUG CATEGORY # 4
56.5a2	3	803-805	[RX7V2C1] Level 2 of MULTUM DRUG CATEGORY # 1
56.6a2	3	806-808	[RX7V2C2] Level 2 of MULTUM DRUG CATEGORY # 2
56.7a2	3	809-811	[RX7V2C3] Level 2 of MULTUM DRUG CATEGORY # 3
56.8a2	3	812-814	[RX7V2C4] Level 2 of MULTUM DRUG CATEGORY # 4
56.5a3	3	815-817	[RX7V3C1] Level 3 of MULTUM DRUG CATEGORY # 1
56.6a3	3	818-820	[RX7V3C2] Level 3 of MULTUM DRUG CATEGORY # 2
56.7a3	3	821-823	[RX7V3C3] Level 3 of MULTUM DRUG CATEGORY # 3
56.8a3	3	824-826	[RX7V3C4] Level 3 of MULTUM DRUG CATEGORY # 4

PAGE 60		2006 NHAMCS N	IICRO-DATA FILE DOCUMENTATION, Emergency Department Record Format
ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
56			DRUG-RELATED INFO FOR MEDICATION #8
56.1	6	827-832	[DRUGID8] Drug ID (See p. 210 for more information.) a10001-a71037 = NCHS code (for drugs not found in Multum but for which ingredients could be determined) c00012-c00899 = NCHS code (for drugs not found in Multum and with undetermined ingredients) d00001-d06848 = Multum code
56.2	1	833	[PRESCR8] PRESCRIPTION STATUS CODE 1 = Prescription Drug 2 = Nonprescription Drug 3 = Undetermined
56.3	1	834	[CONTSUB8] CONTROLLED SUBSTANCE STATUS CODE1 = Schedule I (Research Only)2 = Schedule II5 = Schedule V3 = Schedule III6 = No Control4 = Schedule IV7 = Undetermined
56.4	1	835	[COMSTAT8] COMPOSITION STATUS CODE 1 = Single Entity Drug 2 = Combination Drug 3 = Undetermined
56.5a	3	836-838	[RX8CAT1] MULTUM DRUG CATEGORY # 1 (therapeutic class)
			Reflects the most detailed therapeutic level to which the drug can be classified. For some drugs, Multum Level 1 (broadest level) is the most detailed, while others can be coded to Level 2, but the majority can be coded to Level 3 (most detailed level). For more on the Multum classification system, please see page 18. The complete Multum classification is shown in Appendix III.
			<ul> <li>" = Blank/Not applicable</li> <li>001 - 899 = Drug category</li> <li>999 = Undetermined category</li> </ul>
56.6a	3	839-841	[RX8CAT2] MULTUM DRUG CATEGORY # 2 See RX8CAT1.
56.7a	3	842-844	[RX8CAT3] MULTUM DRUG CATEGORY # 3 See RX8CAT1.
56.8a	3	845-847	[RX8CAT4] MULTUM DRUG CATEGORY # 4 See RX8CAT1.

ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
			DRUG CATEGORY LEVELS
			See RX8CAT1 for general coding conventions that apply to all Multum drug categories. Complete Multum classification scheme is shown in Appendix III.
56.5a1	3	848-850	[RX8V1C1] Level 1 of MULTUM DRUG CATEGORY # 1
56.6a1	3	851-853	RX8V1C2 Level 1 of MULTUM DRUG CATEGORY # 2
56.7a1	3	854-856	[RX8V1C3] Level 1 of MULTUM DRUG CATEGORY # 3
56.8a1	3	857-859	[RX8V1C4] Level 1 of MULTUM DRUG CATEGORY # 4
56.5a2	3	860-862	[RX8V2C1] Level 2 of MULTUM DRUG CATEGORY # 1
56.6a2	3	863-865	[RX8V2C2] Level 2 of MULTUM DRUG CATEGORY # 2
56.7a2	3	866-868	RX8V2C3 Level 2 of MULTUM DRUG CATEGORY # 3
56.8a2	3	869-871	[RX8V2C4] Level 2 of MULTUM DRUG CATEGORY # 4
	_		
56.5a3	3	872-874	[RX8V3C1] Level 3 of MULTUM DRUG CATEGORY # 1
56.6a3	3	875-877	[RX8V3C2] Level 3 of MULTUM DRUG CATEGORY # 2
56.7a3	3	878-880	[RX8V3C3] Level 3 of MULTUM DRUG CATEGORY # 3
56.8a3	3	881-883	[RX8V3C4] Level 3 of MULTUM DRUG CATEGORY # 4

PAGE 62		006 NHAMCS N	IICRO-DATA FILE DOCUMENTATION, Emergency Department Record Format
ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
57	1	884	[BIOTER] HAS YOUR HOSPITAL RECEIVED ANY FUNDING FOR BIOTERROR HOSPITAL PREPAREDNESS FROM YOUR STATE OR MUNICIPAL HEALTH DEPARTMENT WITHIN THE LAST 2 YEARS? 1 = Yes 2 = No 3 = Unknown 4 = Blank
58	1	885	[MDSP] DID YOUR HOSPITAL RECEIVE ANY MEDICAID DISPROPORTIONATE SHARE PROGRAM FUNDS IN 2005? 1 = Yes 2 = No 3 = Unknown 4 = Blank
59	1	886	[EMRED] DOES YOUR ED USE ELECTRONIC MEDICAL RECORDS (EMR) (NOT INCLUDING BILLING RECORDS)? 0 = Blank 1 = Yes, all electronic 2 = Yes, part paper and part electronic 3 = No 4 = Unknown The following 8 items were asked only if the ED had electronic medical records.
60	1	887	[EDEMOGE] DOES YOUR ED'S ELECTRONIC MEDICAL RECORD SYSTEM INCLUDE PATIENT DEMOGRAPHIC INFORMATION? 1= Yes 2= No 3= Unknown 4= Turned off 8= Not applicable 9= Blank
61	1	888	[ECPOEE] DOES YOUR ED'S ELECTRONIC MEDICAL RECORD SYSTEM INCLUDE COMPUTERIZED ORDERS FOR PRESCRIPTIONS? 1= Yes 2= No 3= Unknown 4= Turned off 8= Not applicable 9= Blank

ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
62	1	889	[EWARNE] IF YOUR ED'S ELECTRONIC MEDICAL RECORD SYSTEM SYSTEM INCLUDES COMPUTERIZED ORDERS FOR PRESCRIPTIONS, ARE THERE WARNINGS OF DRUG INTERACTIONS/CONTRAINDICATIONS PROVIDED? 1= Yes 2= No 3= Unknown 4= Turned off 8= Not applicable 9= Blank
63	1	890	[ESCRIPE] IF YOUR ED'S ELECTRONIC MEDICAL RECORD SYSTEM SYSTEM INCLUDES COMPUTERIZED ORDERS FOR PRESCRIPTIONS, ARE PRESCRIPTIONS SENT ELECTRONICALLY TO THE PHARMACY? 1= Yes 2= No 3= Unknown 4= Turned off 8= Not applicable 9= Blank
64	1	891	[ECTOEE] DOES YOUR ED'S ELECTRONIC MEDICAL RECORD SYTEM INCLUDE COMPUTERIZED ORDERS FOR TESTS? 1= Yes 2= No 3= Unknown 4= Turned off 8= Not applicable 9= Blank
65	1	892	[EORDERE] IF YOUR ED'S ELECTRONIC MEDICAL RECORD SYTEM INCLUDES COMPUTERIZED ORDERS FOR TESTS, ARE ORDERS SENT ELECTRONICALLY? 1= Yes 2= No 3= Unknown 4= Turned off 8= Not applicable 9= Blank
66	1	893	[ERESULTE] DOES YOUR ED'S ELECTRONIC MEDICAL RECORD SYSTEM INCLUDE LAB RESULTS? 1= Yes 2= No 3= Unknown 4= Turned off 8= Not applicable 9= Blank

PAGE 64 2		2006 NHAMCS N	IICRO-DATA FILE DOCUMENTATION, Emergency Department Record Format
ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
67	1	894	[ERANGEE] IF YOUR ED'S ELECTRONIC MEDICAL RECORD SYSTEM INCLUDES TEST RESULTS, ARE OUT OF RANGE LEVELS HIGHLIGHTED? 1= Yes 2= No 3= Unknown 4= Turned off 8= Not applicable 9= Blank
68	1	895	[EIMGRESE] DOES YOUR ED'S ELECTRONIC MEDICAL RECORD SYTEM INCLUDE IMAGING RESULTS? 1= Yes 2= No 3= Unknown 4= Turned off 8= Not applicable 9= Blank
69	1	896	[EIMAGEE] IF YOUR ED'S ELECTRONIC MEDICAL RECORD SYTEM INCLUDES IMAGING RESULTS, ARE ELECTRONIC IMAGES RETURNED? 1= Yes 2= No 3= Unknown 4= Turned off 8= Not applicable 9= Blank
70	1	897	[EPNOTESE] DOES YOUR ED'S ELECTRONIC MEDICAL RECORD SYTEM INCLUDE CLINICAL NOTES? 1= Yes 2= No 3= Unknown 4= Turned off 8= Not applicable 9= Blank
71	1	898	[EHXFUE] IF YOUR ED'S ELECTRONIC MEDICAL RECORD SYSTEM INCLUDES CLINICAL NOTES, DO THEY INCLUDE MEDICAL HISTORY AND FOLLOW-UP NOTES? 1= Yes 2= No 3= Unknown 4= Turned off 8= Not applicable 9= Blank

ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
72	1	899	[EREMINDE] IF YOUR ED'S ELECTRONIC MEDICAL RECORD SYSTEM INCLUDES CLINICAL NOTES, DO THEY INCLUDE REMINDERS FOR GUIDELINE-BASED INTERVENTIONS AND/OR SCREENING TESTS? 1= Yes 2= No 3= Unknown 4= Turned off 8= Not applicable 9= Blank
73	1	900	[EPUBHLTHE] DOES YOUR ED'S ELECTRONIC MEDICAL RECORD SYSTEM INCLUDE PUBLIC HEALTH REPORTING? 1= Yes 2= No 3= Unknown 4= Turned off 8= Not applicable 9= Blank
74	1	901	[ENOTDISE] IF YOUR ED'S ELECTRONIC MEDICAL RECORD SYSTEM INCLUDES PUBLIC HEALTH REPORTING, ARE NOTIFIABLE DISEASES SENT ELECTRONICALLY? 1= Yes 2= No 3= Unknown 4= Turned off 8= Not applicable 9= Blank
75	1	902	[EMRNEWE] ARE THERE PLANS FOR INSTALLING A NEW EMR SYSTEM OR REPLACING THE CURRENT SYSTEM WITHIN THE NEXT THREE YEARS? 1 = Yes 2 = No 3 = Maybe 4 = Unknown 9 = Blank
76	1	903	[INCSHX] IN THE LAST TWO YEARS, HAS YOUR ED INCREASED THE NUMBER OF STANDARD TREATMENT SPACES? 1 = Yes 2 = No 3 = Unknown 4 = Blank
76	1	904	[INCPHYS] IN THE LAST TWO YOURS, HAS YOUR ED'S PHYSICAL SPACE BEEN EXPANDED? 1 = Yes 2 = No 3 = Unknown 4 = Blank

PAGE 66		2006 NHAMCS MICRO-DATA FILE DOCUMENTATION, Emergency Department Record Format			
ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES		
76	1	905	[EXPSPACE] DO YOU HAVE PLANS TO EXPAND YOUR ED'S PHYSICAL SPACE WITHIN THE NEXT TWO YEARS? 1 = Yes 2 = No 3 = Unknown 4 = Blank		
77	1	906	[INITVIS] INITIAL VISIT FOR PROBLEM – IMPUTED ITEM 0 = No, not initial visit 1 = Yes, initial visit		
			NOTE: Beginning in 2001, a data item called "Episode of Care" [EPISODE] which included the values "Initial visit for problem", "Follow-up visit for problem" and "Unknown", was added to the ED component of NHAMCS. This item was not included in the 2005 and 2006 survey; however it will be re-introduced in the 2007 survey.		
			For researchers interested in the episode of care for visits in 2006 (and/or 2005) the imputed variable INITVIS was created using data from previous years. It should be noted, however, that because this is an imputed variable, it is NOT comparable to the EPISODE variable from previous years and should therefore be used with caution in any year-to-year trend analysis, and only with appropriate footnotes. More information about the methodology used to create the INITVIS item is available at the Ambulatory Health Care Data website.		
78	1	907	[RACER] RACE RECODE 1= White 2= Black 3= Other		
79	1	908	[RACEETH] RACE/ETHNICITY 1 = White Only, Non-Hispanic 2 = Black Only, Non-Hispanic 3 = Hispanic 4 = Asian Only 5 = Native Hawaiian, Other Pacific Islander Only 6 = American Indian/Alaska Native 7 = Multiple Races		
80	3	909-911	[AGEDAYS] AGE IN DAYS		
			001-365 = 001-365 days 999 = More than 365 days		
81	1	912	[AGER] AGE RECODE 1 = Under 15 years 2 = 15-24 years 3 = 25-44 years 4 = 45-64 years 5 = 65-74 years 6 = 75 years and over		

# ITEM FIELD FILE NO. LENGTH LOCATION [ITEM NAME], DESCRIPTION, AND CODES

### NUMERIC RECODES FOR CAUSE OF INJURY, DIAGNOSIS, AND PROCEDURES

The following items were included on the public use file to facilitate analysis of visits using ICD-9-CM codes. Prior to the 1995 public use file, all ICD-9-CM diagnosis codes on the NHAMCS micro-data files were converted from alphanumeric to numeric fields according to the following coding conventions: A prefix of "1" was added to ICD-9-CM codes in the range of 001.0[-] through 999.9[-]. A prefix of "20" was substituted for the letter "V" for codes in the range of V01.0[-] through V82.9[-]. Inapplicable fourth or fifth digits were zero-filled. This conversion was done to facilitate analysis of ICD-9-CM data using Ambulatory and Hospital Care Statistics software systems. Similar conversions were made for ICD-9-CM procedure codes and external cause of injury codes. Specific coding conventions are discussed in the public use documentation for each data year.

In 1995, however, the decision was made to use actual ICD-9-CM codes on the public use data file. Codes were not prefixed, and a dash was inserted for inapplicable fourth or fifth digits. For specific details pertaining to each type of code (diagnosis, procedure, cause of injury), refer to the documentation for the survey year of interest. This had the advantage of preserving actual codes and avoiding possible confusion over the creation of some artificial codes due to zero-filling.

It has come to our attention that some users of NHAMCS data find it preferable to use the numeric field recodes rather than the alphanumeric fields in certain data applications. Therefore, we have included numeric recodes for cause of injury, diagnosis, and procedure (ambulatory surgical procedure as well as "other" diagnostic/screening service and "other" therapeutic/preventive service) as listed below. These are in addition to the actual codes for these variables which appear earlier on the public use file. Users can make their own choice about which format best suits their needs. We would be interested in hearing from data users which format they prefer so that a decision can be made about whether to include both formats in future years. Please contact Susan Schappert, Ambulatory and Hospital Care Statistics Branch, at 301-458-4480.

82			CAUSE OF INJURY RECODE
82.1	4	913-916	[CAUSE1R] CAUSE OF INJURY #1 (Recode to Numeric Field) 7000 = Drug use/abuse 7100 = Alcohol use/abuse 7999 = Illegible entry 8000-9999 = E800.0 - E999.[9] 0000 = Blank
82.2	4	917-920	[CAUSE2R] CAUSE OF INJURY #2 (Recode to Numeric Field) 7000 = Drug use/abuse 7100 = Alcohol use/abuse 7999 = Illegible entry 8000-9999 = E800.0 - E999.[9] 0000 = Blank
82.3	4	921-924	[CAUSE3R] CAUSE OF INJURY #3 (Recode to Numeric Field) 7000 = Drug use/abuse 7100 = Alcohol use/abuse 7999 = Illegible entry 8000-9999 = E800.0 - E999.[9] 0000 = Blank

PAGE 68		2006 NHAMCS N	IICRO-DATA FILE DOCUMENTATION, Emergency Department Record Format
ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
83	1	925	[INTENTR] INTENTIONALITY OF INJURY (This is a recoded item based on the stated cause of injury in item 5c of the Patient Record form.) 0 = Not applicable (not an injury visit) 1 = Unintentional 2 = Self-inflicted 3 = Assault 4 = Legal intervention 5 = Unknown intent 6 = Adverse medical effects 7 = Blank cause
84			DIAGNOSIS RECODE
84.1	6	926-931	<ul> <li>[DIAG1R] DIAGNOSIS #1 (Recode to Numeric Field) 100100-208290 = 001.0[0]-V82.9[0]</li> <li>209900 = Noncodable, insufficient information for coding, illegible</li> <li>209910 = Left before being seen; patient walked out; not seen by doctor; left against medical advice</li> <li>209920 = Transferred to another facility; sent to see specialist</li> <li>209930 = HMO will not authorize treatment</li> <li>209970 = Entry of "none," "no diagnosis," "no disease," or "healthy"</li> <li>900000 = Blank</li> </ul>
84.2	6	932-937	[DIAG2R] DIAGNOSIS #2 (Recode to Numeric Field) 100100-208290 = 001.0[0]-V82.9[0] See DIAGNOSIS #1 for details.
84.3	6	938-943	[DIAG3R] DIAGNOSIS #3 (Recode to Numeric Field) See DIAGNOSIS #1 for details.
84.4	6	944-949	[HDDIAGR] PRINCIPAL HOSPITAL DISCHARGE DIAGNOSIS (Recode to Numeric Field) See DIAGNOSIS #1 for details. END OF NUMERIC RECODES
85	1	950	<ul> <li>[WHOCOMP] WHO COMPLETED THE PATIENT RECORD FORMS?</li> <li>1 = Hospital Staff</li> <li>2 = Census Field Representative - Abstraction during reporting period</li> <li>3 = Census Field Representative - Abstraction after reporting period</li> <li>4 = Other</li> <li>5 = Multiple categories checked</li> <li>6 = Unknown</li> </ul>

ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
86	1	951	[SETTYPE] SETTING TYPE This item is intended for use when combining data from the NAMCS or NHAMCS-OPD public use files with ED data. 1 = Physician Office (NAMCS) 2 = Outpatient Department (NHAMCS-OPD) 3 = Emergency Department (NHAMCS-ED)
87	4	952-955	[YEAR] SURVEY YEAR (2006)

#### NHAMCS DESIGN VARIABLES

Masked design variables were first released on the 2000 NHAMCS (and NAMCS) public use files, and were subsequently added to the 1993-1999 public use files. These variables reflected the multi-stage sampling design of the surveys, and were for use with statistical software like SUDAAN that takes such information into account. However, these variables could not be used in other statistical software packages, such as SAS and Stata, which employ an ultimate cluster model to estimate variance, without substantial modification. Therefore, two new variables were created and first added to the 2002 file, CSTRATM and CPSUM. They can be used to estimate variance with SUDAAN's with-replacement (WR) option, as well as with Stata, SPSS, SAS, and other statistical software packages utilizing an ultimate cluster model for variance estimation. These variables and their use are described more fully in the "Relative Standard Errors" section of the public use file documentation. The decision was made to include only these new variables, CSTRATM and CPSUM, and not the multi-stage design variables, beginning with the 2003 data release. For those who wish to combine data from 2003 forward with survey data from years prior to 2002 which do not contain CSTRATM and CPSUM, please see the technical paper, *Using Ultimate Cluster Models with NAMCS and NHAMCS Public Use Files*, at http://www.cdc.gov/nchs/nhamcs.htm.

88	8	956-963	[CSTRATM] CLUSTERED PSU STRATUM MARKER (masked) 20104201-40400000
89	6	964-969	[CPSUM] CLUSTERED PSU MARKER (masked) 5-100341
90	8	970-977	[EDWT] EMERGENCY DEPARTMENT WEIGHT EDWT enables data users to make emergency-department-level estimates. Please see pp. 23 and 98 for more information. 1-73
91	1	978	<ul> <li>[PCTPOVR] PERCENT POVERTY IN PATIENT'S ZIP CODE</li> <li>1 = Quartile 1 (Less than 5.00 percent)</li> <li>2 = Quartile 2 (5.00-9.99 percent)</li> <li>3 = Quartile 3 (10.00-19.99 percent)</li> <li>4 = Quartile 4 (20.00 percent or more)</li> <li>9 = Missing data</li> </ul>
92	1	979	[HINCOMER] MEDIAN HOUSEHOLD INCOME IN PATIENT'S ZIP CODE 1 = Quartile 1 (Below \$32,793) 2 = Quartile 2 (\$32,794-\$40,626) 3 = Quartile 3 (\$40,627-\$52,387) 4 = Quartile 4 (\$52,388 or more) 9 = Missing data

PAGE 70		2006 NHAMCS MICRO-DATA FILE DOCUMENTATION, Emergency Department Record Format			
ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES		
93	1	980	[PBAMORER] PERCENT OF ADULTS WITH BACHELOR'S DEGREE OR HIGHER IN PATIENT'S ZIP CODE 1 = Quartile 1 (Less than 12.84 percent) 2 = Quartile 2 (12.84-19.66 percent) 3 = Quartile 3 (19.67-31.68 percent) 4 = Quartile 4 (31.69 percent or more) 9 = Missing data		
94	1	981	[URBANRUR] URBAN-RURAL CLASSIFICATION OF PATIENT'S ZIP CODE 1 = Large central metro 2 = Large fringe metro 3 = Medium metro 4 = Small metro 5 = Non-metro (micropolitan and non-core) 9 = Missing data		

## II. B. RECORD FORMAT OF OUTPATIENT DEPARTMENT MICRO-DATA FILE

Number of records = 31,505

This section consists of a detailed breakdown of each data record. For each item on the record, the user is provided with a sequential item number, field length, file location, and brief description of the item, along with valid codes. Unless otherwise stated in the "item description" column, the data are derived from the Outpatient Department Patient Record form. The hospital induction interview and the Verispan, L.L.C. products, "Healthcare Market Index" and "Hospital Market Profiling Solution" (formerly known as the SMG Hospital Market Database) are other sources of information, and some data are derived by recoding selected items.

ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
			DATE OF VISIT (from PRF Q1.a)
1	2	1-2	[VMONTH] MONTH OF VISIT 01-12: January-December
2	4	3-6	[VYEAR] YEAR OF VISIT 2004, 2006 (Survey was conducted 12/27/2004-12/25/2006)
3	1	7	[VDAYR] DAY OF WEEK OF VISIT 1=Sunday 5=Thursday 2=Monday 6=Friday 3=Tuesday 7=Saturday 4=Wednesday
4	3	8-10	[AGE] PATIENT AGE (IN YEARS; DERIVED FROM DATE OF BIRTH) (from PRF Q1.c) 000 = Under 1 year 001-099 100 = 100 years and over
5	1	11	[SEX] SEX (from PRF Q1.d) 1 = Female 2 = Male
6	1	12	[PREGNANT] If female, is patient pregnant? (from PRF Q1.d)
			NOTE: It was discovered that this variable, along with GESTWK, was often completed incorrectly by survey respondents. This was because, in many cases where the patient's last menstrual period was known, that date was reported and the pregnancy box was checked, even though the patient was not pregnant. Much editing was done to correct these errors, but in some cases it was not possible to determine if the patient was really pregnant. The last menstrual period date was used to calculate GESTWK (or to corroborate a reported GESTWK) and is not included on the public use file. PREGNANT and GESTWK should be used with some caution. 1=Yes 2=No 3=Unknown 8=Not applicable (patient is not female) 9=Blank

PAGE 72		2006 NHAMCS MICRO-DATA FILE DOCUMENTATION, Outpatient Department Record Format		
ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES	
7	2	13-14	[GESTWEEK] Week of gestation (from PRF Q1.d) 01-44 88=Not applicable (patient is male, or patient is female with unknown or negative pregnancy status) 99=Blank	
8	1	15	[ETHNIC] ETHNICITY (from PRF Q1.e) 1 = Hispanic or Latino 2 = Not Hispanic or Latino	
9	1	16	<ul> <li>[RACE] RACE (from PRF Q1.f)</li> <li>Data users should be aware that some records have masked race values. This was required for disclosure avoidance.</li> <li>1 = White</li> <li>2 = Black/African American</li> <li>3 = Asian</li> <li>4 = Native Hawaiian/Other Pacific Islander</li> <li>5 = American Indian/Alaska Native</li> <li>6 = More than one race reported</li> </ul>	
10	1	17	[USETOBAC] DOES PATIENT USE TOBACCO? (from PRF Q1.g) 0 = Blank 1 = Not current 2 = Current 3 = Unknown	
11	1	18	[NOTOBAC] NON-CURRENT TOBACCO USE (from PRF Q1.g) 1 = Never 2 = Former 8 = Not Applicable 9 = Blank	
12	1	19	[PAYPRIV] EXPECTED SOURCE OF PAYMENT: PRIVATE INSURANCE (from PRF Q1.h) 0 = No 1 = Yes	
13	1	20	[PAYMCARE] EXPECTED SOURCE OF PAYMENT: MEDICARE (from PRF Q1.h) 0 = No 1 = Yes	
14	1	21	[PAYMCAID] EXPECTED SOURCE OF PAYMENT: MEDICAID (from PRF Q1.h) 0 = No 1 = Yes	
15	1	22	[PAYWKCMP] EXPECTED SOURCE OF PAYMENT: WORKER'S COMPENSATION (from PRF Q1.h) 0 = No 1 = Yes	

2006 NHAMCS MICRO-DATA FILE DOCUMENTATION,	Outpatient Department Record Format

ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
16	1	23	[PAYSELF] EXPECTED SOURCE OF PAYMENT: SELF PAY (from PRF Q1.h) 0 = No 1 = Yes
17	1	24	[PAYNOCHG] EXPECTED SOURCE OF PAYMENT: NO CHARGE (from PRF Q1.h) 0 = No 1 = Yes
18	1	25	[PAYOTH] EXPECTED SOURCE OF PAYMENT: OTHER (from PRF Q1.h) 0 = No 1 = Yes
19	1	26	[PAYUNK] EXPECTED SOURCE OF PAYMENT: UNKNOWN (from PRF Q1.h) 0 = No 1 = Yes
20	1	27	[PAYTYPE] PRIMARY EXPECTED SOURCE OF PAYMENT FOR THIS VISIT (Recoded from PRF Q1.h using this hierarchy of payment categories: Medicaid, Medicare, Private Insurance, Worker's Compensation, Self-Pay, No Charge, Other, Unknown.) 0 = Blank 1 = Private insurance 2 = Medicare 3 = Medicaid/SCHIP 4 = Worker's Compensation 5 = Self-pay 6 = No charge/charity 7 = Other 8 = Unknown
21	1	28	<ul> <li>[INJDET] INJURY/POISONING/ADVERSE EFFECT</li> <li>Is this visit related to any of the following</li> <li>(from PRF Q2)</li> <li>1 = Unintentional injury/poisoning</li> <li>2 = Intentional injury/poisoning</li> <li>3 = Adverse effect of medical/surgical care or adverse effect of medicinal drug</li> <li>4 = None of the above</li> <li>5 = Unknown</li> <li>9 = Blank</li> </ul>
22	1	29	[INJURY] Is this visit related to an injury, poisoning, or adverse effect of medical treatment? (recoded from PRF Q2, PRF Q3 and PRF Q5) 0 = No 1 = Yes

PAGE	74	2006 NHAMCS	MICRO-DATA FILE DOCUMENTATION, Outpatient Department Record Format
ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
23			PATIENT'S REASON(S) FOR VISIT (See page 18 in Section I and from PRF Q3)
23.1	5	30-34	[RFV1] REASON # 1 10050-89990 = 1005.0-8999.0 90000 = Blank
23.2	5	35-39	[RFV2] REASON # 2 10050-89990 = 1005.0-8999.0 90000 = Blank
23.3	5	40-44	[RFV3] REASON # 3 10050-89990 = 1005.0-8999.0 90000 = Blank
24	1	45	[PRIMCARE] ARE YOU THE PATIENT'S PRIMARY CARE PHYSICIAN/PROVIDER? (from PRF Q4.a) 0 = Blank 1 = Yes 2 = No 3 = Unknown
25	1	46	[REFER] WAS PATIENT REFERRED FOR THIS VISIT? (from PRF Q4.a) 0 = Blank 1 = Yes 2 = No 3 = Unknown 8 = Not applicable
26	1	47	[SENBEFOR] HAS PATIENT BEEN SEEN IN THIS CLINIC BEFORE? (from PRF Q4.b) 1 = Yes, established patient 2 = No, new patient
27	1	48	[PASTVIS] HOW MANY PAST VISITS IN THE LAST 12 MONTHS? (from PRF Q4.b) 1 = None 2 = 1-2 3 = 3-5 4 = 6 or more 8 = Not applicable
28	1	49	[MAJOR] MAJOR REASON FOR THIS VISIT (from PRF Q4.c) 0 = Blank 1 = New problem (<3 mos. onset) 2 = Chronic problem, routine 3 = Chronic problem, flare up 4 = Pre- or post surgery 5 = Preventive care (e.g. routine prenatal, well-baby, screening, insurance, general exams)

ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
29			PHYSICIAN'S DIAGNOSES (See page 19, Section 1 for explanation of coding.) (from PRF Q5)
29.1	5	50-54	[DIAG1] DIAGNOSIS #1 (ICD-9-CM) There is an implied decimal between the third and fourth digits; for inapplicable fourth or fifth digits, a dash is inserted.
			0010[-] - V829[-] = 001.0[0]-V82.9[0] V990- = Noncodable, insufficient information for coding, illegible V991- = Left before being seen; patient walked out; not seen by doctor; left against medical advice V992- = Transferred to another facility; sent to see specialist V993- = HMO will not authorize treatment V997- = Entry of "none," "no diagnosis," "no disease," or "healthy" 00000 = Blank
29.2	5	55-59	[DIAG2] DIAGNOSIS #2 (ICD-9-CM) There is an implied decimal between the third and fourth digits; for inapplicable fourth or fifth digits, a dash is inserted. See DIAGNOSIS #1 for details.
29.3	5	60-64	[DIAG3] DIAGNOSIS #3 (ICD-9-CM) There is an implied decimal between the third and fourth digits; for inapplicable fourth or fifth digits, a dash is inserted. See DIAGNOSIS #1 for details.
30			PROBABLE, QUESTIONABLE, AND RULE OUT DIAGNOSES
30.1	1	65	[PRDIAG1] IS DIAGNOSIS #1 PROBABLE, QUESTIONABLE, OR RULE OUT? 0 = No 1 = Yes 8 = Not applicable
30.2	1	66	[PRDIAG2] IS DIAGNOSIS #2 PROBABLE, QUESTIONABLE, OR RULE OUT? 0 = No 1 = Yes 8 = Not applicable
30.3	1	67	[PRDIAG3] IS DIAGNOSIS #3 PROBABLE, QUESTIONABLE, OR RULE OUT? 0 = No 1 = Yes 8 = Not applicable

PAGE	76	2006 NHAMCS M	ICRO-DATA FILE DOCUMENTATION, Outpatient Department Record Format
ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
31			REGARDLESS OF THE DIAGNOSES WRITTEN IN 5A, DOES THE PATIENT NOW HAVE: (from PRF Q5.b) 0 = No 1 = Yes
31.1 31.2 31.3 31.3a	1 1 1 1	68 69 70 71	[ARTHRTIS] Arthritis [ASTHMA] Asthma [CANCER] Cancer [CASTAGE] Stage of patient's cancer
			0=In situ 1=Local 2=Regional 3=Distant 4=Unknown 8=Not applicable
31.4 31.5 31.6 31.7 31.8 31.9 31.10 31.11 31.12 31.13 31.14	1 1 1 1 1 1 1 1	72 73 74 75 76 77 78 79 80 81 82	[CEBVD] Cerebrovascular disease [CHF] Congestive heart failure [CRF] Chronic renal failure [COPD] Chronic obstructive pulmonary disease [DEPRN] Depression [DIABETES] Diabetes [HYPLIPID] Hyperlipidemia [HTN] Hypertension [IHD] Ischemic heart disease [OBESITY] Obesity [OSTPRSIS] Osteoporosis
31.15	1	83	[NOCHRON] None of the above 0 = "None" not checked 1 = "None" checked 2 = Entire item blank
31.16	2	84-85	[TOTCHRON] TOTAL NUMBER OF CHRONIC CONDITIONS (derived from PRF Q5.b) 0-14 99 = Entire item blank
32	1	86	[DMP] STATUS OF PATIENT ENROLLMENT IN A DISEASE MANAGEMENT PROGRAM FOR CONDITION(S) MARKED IN 5B (from PRF Q5.c) 1 = Currently enrolled 2 = Ordered/advised to enroll at this visit 3 = Not enrolled 4 = Unknown 8 = Not applicable 9 = Blank

ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
33			VITAL SIGNS (from PRF Q6)
33.1	2	87-88	[HTIN] PATIENT'S HEIGHT (inches) 5-84 inches 99 = Blank
33.2	3	89-91	[WTLB] PATIENT'S WEIGHT (pounds) 3-492 999 = Blank
33.2a	6	92-97	[BMI] Body-Mass Index This was calculated from Patient's Height and Weight during data processing. It contains a decimal point and up to 2 decimal places. BMI was not calculated for pregnant females or patients under age 2. 10.33-85.33 999=Unknown/Not Applicable
33.3	4	98-101	[TEMPF] Temperature (Fahrenheit) There is an implied decimal between the third and fourth digits. 0000 = Blank 0600-1112 = 60.0 – 111.2 Fahrenheit
33.4a	3	102-104	[BPSYS] Blood pressure - systolic 0-290 999 = Blank
33.4b	3	105-107	[BPDIAS] Blood pressure – diastolic 0-190 = 0-190 998 = P, Palp, DOP, or DOPPLER 999 = Blank
34			DIAGNOSTIC/SCREENING SERVICES (from PRF Q7)
34.1	1	108	[DIAGSCRN] Were any diagnostic/screening services ordered or provided at this visit? 0 = No 1 = Yes 2 = No answer (Entire item blank, including "None" box.)
			0 = No, 1 = Yes (excludes write-ins)
34.2 34.3 34.4 34.5 34.6	1 1 1 1	109 110 111 112 113	EXAMINATIONS: [BREAST] Breast exam [PELVIC] Pelvic exam [RECTAL] Rectal exam [SKIN] Skin exam [DEPRESS] Depression screening exam
34.7	1	114	IMAGING: [ANYIMAGE] (derived from PRF Q7, boxes 7-12) This item was created during data processing and indicates whether any of the imaging boxes were checked.

PAGE 7	78	2006 NHAMCS M	ICRO-DATA FILE DOCUMENTATION, Outpatient Department Record Format
ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
34.8 34.9 34.10 34.11 34.12 34.13	1 1 1 1 1	115 116 117 118 119 120	[BONEDENS] Bone density exam [MAMMO] Mammography [MRI] MRI/CT/PET [ULTRASND] Ultrasound [XRAY] X-ray [OTHIMAGE] Other imaging BLOOD TESTS:
34.14 34.15 34.16 34.17 34.18 34.19 34.20	1 1 1 1 1 1	121 122 123 124 125 126 127	[CBC] Complete blood count [ELECTROL] Electrolytes [GLUCOSE] Glucose [HGBA] HgbA1C (glycohemoglobin) [CHOLEST] Cholesterol [PSA] PSA (Prostate specific antigen) [OTHERBLD] Other blood test
24 24	1	100	OTHER TESTS:
34.21 34.22	1	128 129	[SCOPPROC] Any scope procedure [SIGCOLON] (derived from PRF Q7, box 24) This item was created during data processing and indicates whether any type of sigmoidoscopy/colonoscopy was ordered or performed at the visit, based on write-in procedure entries. It is a summary variable only and should not be added to results from the write-in procedure fields.
34.23.a	a 4	130-133	[SCOPEWI1] Scope procedure write-in #1 (ICD-9-CM, Vol.3, Procedure Classification) A left-justified alphanumeric code with an implied decimal after the first two digits; inapplicable fourth digits have a dash inserted. 0101-999 = 01.01-99.99 0000 = Not applicable/blank
34.23.t	5 4	134-137	[SCOPEWI2] Scope procedure write-in #2 (ICD-9-CM, Vol.3, Procedure Classification) A left-justified alphanumeric code with an implied decimal after the first two digits; inapplicable fourth digits have a dash inserted. 0101-999 = 01.01-99.99 0000 = Not applicable/blank
34.24 34.25 34.26 34.27 34.28 34.29 34.30 34.31 34.32 34.33 34.34 34.35 34.36	1 1 1 1 1 1 1 1 1 1	138 139 140 141 142 143 144 145 146 147 148 149 150	[BIOPSY] Biopsy [CHLAMYD] Chlamydia test [PAPCONV] PAP test - conventional [PAPLIQ] PAP test - liquid-based [PAPUNSP] PAP test - unspecified [HPVDNA] HPV DNA test [EKG] EKG/ECG [SPIRO] Spirometry/Pulmonary function test [URINE] Urinalysis [HTTAKE] Height taken (derived from PRF Q6) [WTTAKE] Weight taken (derived from PRF Q6) [TEMPTAKE] Temperature taken (derived from PRF Q6) [BLODPRES] Blood pressure taken (derived from PRF Q6)

ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
34.37	1	151	[OTHDIAG] Other service
34.38.a	4	152-155	[DIAGSC1] Other diagnostic service write-in #1 (ICD-9-CM, Vol.3, Procedure Classification) A left-justified alphanumeric code with an implied decimal after the first two digits; inapplicable fourth digits have a dash inserted. 0101-999 = 01.01-99.99 0000 = Not applicable/blank
34.38.b	4	156-159	[DIAGSC2] Other diagnostic service write-in #2 (ICD-9-CM, Vol.3, Procedure Classification) A left-justified alphanumeric code with an implied decimal after the first two digits; inapplicable fourth digits have a dash inserted. 0101-999 = 01.01-99.99 0000 = Not applicable/blank
34.39	2	160-161	[TOTDIAG] Total number of diagnostic/screening services ordered or provided 0-31 99 = Entire Item blank
35			HEALTH EDUCATION (from PRF Q8)
35.1	1	162	[HLTHED] Was any health education ordered or provided at this visit? 0 = No 1 = Yes 2 = No answer (Entire item blank, including "None" box.)
			0 = No, 1 = Yes
35.2 35.3 35.4 35.5 35.6 35.7 35.8 35.9 35.10	1 1 1 1 1 1 1	163 164 165 166 167 168 169 170 171	[ASTHMAED] Asthma education DIETNUTR] Diet/Nutrition [EXERCISE] Exercise [GRWTHDEV] Growth/Development [INJPREV] Injury prevention [STRESMGT] Stress management [TOBACED] Tobacco use/exposure [WTREDUC] Weight reduction [OTHLTHED] Other health education
35.11	2	172-173	[TOTHLTED] Total health education ordered or provided 0-9 99 = Entire item blank
36			NON-MEDICATION TREATMENT (from PRF Q9)
36.1	1	174	[NONMED] Was any non-medication treatment ordered or provided? 0 = No 1 = Yes 2 = No answer (Entire item blank, including "None" box.)

PAGE 8	80	2006 NHAMCS M	ICRO-DATA FILE DOCUMENTATION, Outpatient Department Record Format
ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
			0 = No, 1 = Yes
36.2 36.3 36.4 36.5 36.6 36.7 36.8 36.9 36.10 36.11 36.12 36.13 36.14	1 1 1 1 1 1 1 1 1	175 176 177 178 179 180 181 182 183 184 185 186 187	[CAM] Complementary alternative medicine [DME] Durable medical equipment [HOMEHLTH] Home health care [HOSPICE] Hospice care [PT] Physical therapy [RADTHER] Radiation therapy [SPOCTHER] Speech/Occupational therapy [PSYCHOTH] Psychotherapy [OTHMNTL] Other mental health counseling [EXCISION] Excision [ORTHO] Orthopedic care [WOUND] Wound care [OTHPROC] Other surgical or non-surgical procedure This created checkbox combines data from item 9.14 and 9.15 on the Patient Record form. Procedures written in these items are listed below.
36.15.a	a 4	188-191	[OTHPROC1] Procedure #1 (ICD-9-CM, Vol.3, Procedure Classification) A left-justified alphanumeric code with an implied decimal after the first two digits; inapplicable fourth digits have a dash inserted. 0101-999 = 01.01-99.99 0000 = Not applicable/blank
36.13.t	o 4	192-195	[OTHPROC2] Procedure # 2 (ICD-9-CM, Vol.3, Procedure Classification) A left-justified alphanumeric code with an implied decimal after the first two digits; inapplicable fourth digits have a dash inserted. 0101-999 = 01.01-99.99 0000 = Not applicable/blank
36.13.0	2 4	196-199	[OTHPROC3] Procedure # 3 (ICD-9-CM, Vol.3, Procedure Classification) A left-justified alphanumeric code with an implied decimal after the first two digits; inapplicable fourth digits have a dash inserted. 0101-999 = 01.01-99.99 0000 = Not applicable/blank
36.13.c	14	200-203	[OTHPROC4] Procedure #4 (ICD-9-CM, Vol.3, Procedure Classification) A left-justified alphanumeric code with an implied decimal after the first two digits; inapplicable fourth digits have a dash inserted. 0101-999 = 01.01-99.99 0000 = Not applicable/blank
36.14	2	204-205	[TOTNONMED] Total number of non-medication treatments 0-16 99 = Entire item blank

ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
37			MEDICATIONS & IMMUNIZATIONS (See page 18 for more information. See Appendix III for Code List.) (from PRF Q10)
37.1	1	206	[MED] WERE MEDICATIONS ORDERED OR PROVIDED AT THIS VISIT? 0 = No 1 = Yes 2 = Entire item blank, including "None" box
37.2	5	207-211	[MED1] MEDICATION #1 00001-99227 = 00001-99227 90000 = Blank 99980 = Unknown Entry; Other 99999 = Illegible Entry
37.3	5	212-216	[MED2] MEDICATION #2 00001-99227 = 00001-99227 90000 = Blank 99980 = Unknown Entry; Other 99999 = Illegible Entry
37.4	5	217-221	[MED3] MEDICATION #3 00001-99227 = 00001-99227 90000 = Blank 99980 = Unknown Entry; Other 99999 = Illegible Entry
37.5	5	222-226	[MED4] MEDICATION #4 00001-99227 = 00001-99227 90000 = Blank 99980 = Unknown Entry; Other 99999 = Illegible Entry
37.6	5	227-231	[MED5] MEDICATION #5 00001-99227 = 00001-99227 90000 = Blank 99980 = Unknown Entry; Other 99999 = Illegible Entry
37.7	5	232-236	[MED6] MEDICATION #6 00001-99227 = 00001-99227 90000 = Blank 99980 = Unknown Entry; Other 99999 = Illegible Entry
37.8	5	237-241	[MED5] MEDICATION #7 00001-99227 = 00001-99227 90000 = Blank 99980 = Unknown Entry; Other 99999 = Illegible Entry

PAGE 8	82	2006 NHAMCS M	ICRO-DATA FILE DOCUMENTATION, Outpatient Department Record Format
ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
37.9	5	242-246	[MED5] MEDICATION #8 00001-99227 = 00001-99227 90000 = Blank 99980 = Unknown Entry; Other 99999 = Illegible Entry
37.10	1	247	[NCMED1] Was medication #1 new or continued? 1 = New 2 = Continued 3 = Both "New" and "Continued" were checked 8 = Not Applicable (no drug listed) 9 = Blank
37.11	1	248	[NCMED2] Was medication #2 new or continued? See NCMED1.
37.12	1	249	[NCMED3] Was medication #3 new or continued? See NCMED1.
37.13	1	250	[NCMED4] Was medication #4 new or continued?
37.14	1	251	See NCMED1. [NCMED5] Was medication #5 new or continued? See NCMED1.
37.15	1	252	[NCMED6] Was medication #6 new or continued? See NCMED1.
37.16	1	253	[NCMED7] Was medication #7 new or continued? See NCMED1.
37.17	1	254	[NCMED8] Was medication #8 new or continued? See NCMED1
37.18	1	255	[NUMNEW] NUMBER OF NEW MEDICATIONS CODED 0 – 8
37.19	1	256	[NUMCONT] NUMBER OF CONTINUED MEDICATIONS CODED 0 – 8
			NOTE: For NUMNEW and NUMCONT, the value '0' can reflect the following situations: for NUMNEW, a) no drug listed; b) drug listed as continued medication only; or c) drug listed but unknown whether new or continued; for NUMCONT, a) no drug listed; b) drug listed as new medication only, or c) drug listed but unknown whether new or continued
37.20	1	257	[NUMMED] NUMBER OF MEDICATIONS CODED 0 – 8
38			PROVIDERS SEEN (from PRF Q11)
			0 = No, 1 = Yes
38.1 38.2	1 1	258 259	[NOPROVID] No answer to item [PHYS] Physician

ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
38.3 38.4 38.5 38.6	1 1 1 1	260 261 262 263	[PHYSASST] Physician assistant [NPNMW] Nurse practitioner/Midwife [RNLPN] RN/LPN [OTHPROV] Other provider
39			VISIT DISPOSITION (from PRF Q12)
			0 = No, 1 = Yes
39.1 39.2 39.3 39.4 39.5 39.6 39.7 39.8 39.9	1 1 1 1 1 1 1 1	264 265 266 267 268 269 270 271 272	[NODISP] No answer to item [NOFU] No follow-up planned [RETPRN] Return if needed, P.R.N [REFOTHMD] Refer to other physician [RETAPPT] Return at specified time [TELEPHON] Telephone follow-up planned [REFERED] Refer to emergency department [ADMITHOS] Admit to hospital [OTHDISP] Other visit disposition
38	6	273-278	[PATWT] PATIENT VISIT WEIGHT (See page 22 in Section I) A right-justified integer developed by NCHS staff for the purpose of producing national estimates from sample data.
39	1	279	[REGION] GEOGRAPHIC REGION (Based on actual location of the hospital.) 1 = Northeast 2 = Midwest 3 = South 4 = West
40	1	280	[MSA] METROPOLITAN/NON METROPOLITAN STATUS (Based on actual location in conjunction with the definition of the Bureau of the Census and the U.S. Office of Management and Budget.) 1 = MSA (Metropolitan Statistical Area) 2 = Non-MSA (including micropolitan statistical areas)
41	1	281	[OWNER] HOSPITAL OWNERSHIP 1 = Voluntary non-profit 2 = Government, non-Federal 3 = Proprietary
42	1	282	Blank - reserved for possible future use
43	3	283-285	[HOSPCODE] HOSPITAL CODE A unique code assigned to all the records from a particular hospital. For a few hospitals, additional masking was required to minimize risks of disclosure. For this reason, the number of hospital codes may be slightly different than the number of responding facilities. 1-242

PAGE 84		2006 NHAMCS N	IICRO-DATA FILE DOCUMENTATION, Outpatient Department Record Format
ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
44	1	286	[CLINTYPE] TYPE OF CLINIC 1 = General medicine 2 = Surgery 3 = Pediatric 4 = Obstetrics and Gynecology 5 = Substance abuse 6 = Other
45	3	287-289	[PATCODE] PATIENT CODE - A number assigned to identify each individual record from a particular hospital. 1-698
**** TH	E FOLLOWI	ING FIELDS SH	OW WHETHER DATA WERE IMPUTED TO REPLACE BLANKS ****
46			IMPUTED FIELDS
			0 = Not imputed 1 = Imputed
46.1 46.2 46.3 46.4 46.5 46.6	1 1 1 1 1 1	290 291 292 293 294 295	[BDATEFL] Patient birth year [SEXFL] Patient sex [ETHNICFL] Patient ethnicity [RACEFL] Patient race [SENBEFL] Has the patient been seen in this clinic before? [PASTFL] If yes, how many past visits in last 12 months? ID OF IMPUTED DATA FIELDS ************

ITEM	FIELD	FILE	
NO.	LENGTH	LOCATION	[ITEM NAME], DESCRIPTION, AND CODES

<sup>49</sup> 

DRUG-RELATED INFO FOR MEDICATION #1

NOTE: Starting with the 2006 data release, all drug codes based on entry name (using NCHS' standard classification system) were also assigned a unique generic drug code from Multum's Lexicon Drug Database, where possible. The structure of the Multum database is such that multiple ingredient drugs are assigned a single generic drug code encompassing all of a drug's ingredients rather than being assigned generic drug codes for each ingredient, as in past years of NHAMCS drug data. All Multum codes start with the letter "d" but there were some drugs reported in NHAMCS that could not be assigned a code in Multum. These received a prefix of either "a" (when ingredients could be determined) or "c" (when ingredients could not be determined). For more on the structure of the 2006 drug data (including information on therapeutic class and drug ingredients, please see page 18.)

49.1	6	296-301	[DRUGID1] DRUG ID (See p. 210 for more information.) a10001-a71037 = NCHS code (for drugs not found in Multum but for which ingredients could be determined) c00012-c00899 = NCHS code (for drugs not found in Multum and with undetermined ingredients) d00001-d06848 = Multum code
49.2	1	302	[PRESCR1] PRESCRIPTION STATUS CODE 1 = Prescription Drug 2 = Nonprescription Drug 3 = Undetermined
49.3	1	303	[CONTSUB1] CONTROLLED SUBSTANCE STATUS CODE1 = Schedule I (Research Only)2 = Schedule II5 = Schedule V3 = Schedule III6 = No Control4 = Schedule IV7 = Undetermined
49.4	1	304	[COMSTAT1] COMPOSITION STATUS CODE 1 = Single Entity Drug 2 = Combination Drug 3 = Undetermined
49.5a	3	305-307	[RX1CAT1] MULTUM DRUG CATEGORY # 1 Reflects the most detailed therapeutic level to which the drug can be classified. For some drugs, Multum Level 1 (broadest level) is the most detailed, while others can be coded to Level 2, but the majority can be coded to Level 3 (most detailed level). For more on the Multum classification system, please see page 18. The complete Multum classification is shown in Appendix III.
			<ul> <li>" = Blank/Not applicable</li> <li>001 - 899 = Drug category</li> <li>999 = Undetermined category</li> </ul>
49.6a	3	308-310	[RX1CAT2] MULTUM DRUG CATEGORY # 2 See RX1CAT1.
49.7a	3	311-313	[RX1CAT3] MULTUM DRUG CATEGORY # 3 See RX1CAT1.
49.8a	3	314-316	[RX1CAT4] MULTUM DRUG CATEGORY # 4 See RX1CAT1.

PAGE 86		2006 NHAMCS M	ICRO-DATA FILE DOCUMENTATION, Outpatient Department Record Format
ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
			DRUG CATEGORY LEVELS
			See RX1CAT1 for general coding conventions that apply to all Multum drug categories. Complete Multum classification scheme is shown in Appendix III.
49.5a1	3	317-319	[RX1V1C1] Level 1 of MULTUM DRUG CATEGORY # 1
49.6a1		320-322	[RX1V1C2] Level 1 of MULTUM DRUG CATEGORY # 2
49.7a1	3	323-325	[RX1V1C3] Level 1 of MULTUM DRUG CATEGORY # 3
49.8a1	3	326-328	[RX1V1C4] Level 1 of MULTUM DRUG CATEGORY # 4
49.5a2		329-331	[RX1V2C1] Level 2 of MULTUM DRUG CATEGORY # 1
49.6a2		332-334	[RX1V2C2] Level 2 of MULTUM DRUG CATEGORY # 2
49.7a2	-	335-337	[RX1V2C3] Level 2 of MULTUM DRUG CATEGORY # 3
49.8a2	3	338-340	[RX1V2C4] Level 2 of MULTUM DRUG CATEGORY # 4
49.5a3	-	341-343	[RX1V3C1] Level 3 of MULTUM DRUG CATEGORY # 1
49.6a3		344-346	[RX1V3C2] Level 3 of MULTUM DRUG CATEGORY # 2
49.7a3		347-349	[RX1V3C3] Level 3 of MULTUM DRUG CATEGORY # 3
49.8a3	3	350-352	[RX1V3C4] Level 3 of MULTUM DRUG CATEGORY # 4

ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
50			DRUG-RELATED INFO FOR MEDICATION #2
50.1	6	353-358	[DRUGID2] Drug ID (See p. 210 for more information.) a10001-a71037 = NCHS code (for drugs not found in Multum but for which ingredients could be determined) c00012-c00899 = NCHS code (for drugs not found in Multum and with undetermined ingredients) d00001-d06848 = Multum code
50.2	1	359	[PRESCR2] PRESCRIPTION STATUS CODE 1 = Prescription Drug 2 = Nonprescription Drug 3 = Undetermined
50.3	1	360	[CONTSUB2] CONTROLLED SUBSTANCE STATUS CODE1 = Schedule I (Research Only)2 = Schedule II5 = Schedule V3 = Schedule III6 = No Control4 = Schedule IV7 = Undetermined
50.4	1	361	[COMSTAT2] COMPOSITION STATUS CODE 1 = Single Entity Drug 2 = Combination Drug 3 = Undetermined
50.5a	3	362-364	[RX2CAT1] MULTUM DRUG CATEGORY # 1 Reflects the most detailed therapeutic level to which the drug can be classified. For some drugs, Multum Level 1 (broadest level) is the most detailed, while others can be coded to Level 2, but the majority can be coded to Level 3 (most detailed level). For more on the Multum classification system, please see page 18. The complete Multum classification is shown in Appendix III. " " = Blank/Not applicable 001 - 899 = Drug category 999 = Undetermined category
50.6a	3	365-367	[RX2CAT2] MULTUM DRUG CATEGORY # 2 See RX2CAT1.
50.7a	3	368-370	[RX2CAT3] MULTUM DRUG CATEGORY # 3 See RX2CAT1.
50.8a	3	371-373	[RX2CAT4] MULTUM DRUG CATEGORY # 4 See RX2CAT1.

ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
			DRUG CATEGORY LEVELS
			See RX2CAT1 for general coding conventions that apply to all Multum drug categories. Complete Multum classification scheme is shown in Appendix III.
50.5a1	3	374-376	[RX2V1C1] Level 1 of MULTUM DRUG CATEGORY # 1
50.6a1	3	377-379	[RX2V1C2] Level 1 of MULTUM DRUG CATEGORY # 2
50.7a1	3	380-382	[RX2V1C3] Level 1 of MULTUM DRUG CATEGORY # 3
50.8a1	3	383-385	[RX2V1C4] Level 1 of MULTUM DRUG CATEGORY # 4
50.5a2		386-388	[RX2V2C1] Level 2 of MULTUM DRUG CATEGORY # 1
50.6a2		389-391	[RX2V2C2] Level 2 of MULTUM DRUG CATEGORY # 2
50.7a2	3	392-394	[RX2V2C3] Level 2 of MULTUM DRUG CATEGORY # 3
50.8a2	3	395-397	[RX2V2C4] Level 2 of MULTUM DRUG CATEGORY # 4
50.5a3 50.6a3 50.7a3	3	398-400 401-403 404-406	[RX2V3C1] Level 3 of MULTUM DRUG CATEGORY # 1 [RX2V3C2] Level 3 of MULTUM DRUG CATEGORY # 2 [RX2V3C3] Level 3 of MULTUM DRUG CATEGORY # 3
50.8a3		407-409	[RX2V3C4] Level 3 of MULTUM DRUG CATEGORY # 4

ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
51			DRUG-RELATED INFO FOR MEDICATION #3
51.1	6	410-415	[DRUGID3] Drug ID (See p. 210 for more information.) a10001-a71037 = NCHS code (for drugs not found in Multum but for which ingredients could be determined) c00012-c00899 = NCHS code (for drugs not found in Multum and with undetermined ingredients) d00001-d06848 = Multum code
51.2	1	416	[PRESCR3] PRESCRIPTION STATUS CODE 1 = Prescription Drug 2 = Nonprescription Drug 3 = Undetermined
51.3	1	417	[CONTSUB3] CONTROLLED SUBSTANCE STATUS CODE1 = Schedule I (Research Only)2 = Schedule II5 = Schedule V3 = Schedule III6 = No Control4 = Schedule IV7 = Undetermined
51.4	1	418	[COMSTAT3] COMPOSITION STATUS CODE 1 = Single Entity Drug 2 = Combination Drug 3 = Undetermined
51.5a	3	419-421	[RX3CAT1] MULTUM DRUG CATEGORY # 1 Reflects the most detailed therapeutic level to which the drug can be classified. For some drugs, Multum Level 1 (broadest level) is the most detailed, while others can be coded to Level 2, but the majority can be coded to Level 3 (most detailed level). For more on the Multum classification system, please see page 18. The complete Multum classification is shown in Appendix III.
			<ul> <li>" = Blank/Not applicable</li> <li>001 - 899 = Drug category</li> <li>999 = Undetermined category</li> </ul>
51.6a	3	422-424	[RX3CAT2] MULTUM DRUG CATEGORY # 2 See RX3CAT1.
51.7a	3	425-427	[RX3CAT3] MULTUM DRUG CATEGORY # 3 See RX3CAT1.
51.8a	3	428-430	[RX3CAT4] MULTUM DRUG CATEGORY # 4 See RX3CAT1.

PAGE 9	90
--------	----

2006 NHAMCS MICRO-DATA FILE DOCUMENTATION, Outpatient Department Record Format

ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
			DRUG CATEGORY LEVELS
			See RX3CAT1 for general coding conventions that apply to all Multum drug categories. Complete Multum classification scheme is shown in Appendix III.
51.5a1	3	431-433	[RX3V1C1] Level 1 of MULTUM DRUG CATEGORY # 1
51.6a1		434-436	[RX3V1C2] Level 1 of MULTUM DRUG CATEGORY # 2
51.7a1		437-439	[RX3V1C3] Level 1 of MULTUM DRUG CATEGORY # 3
51.8a1		440-442	[RX3V1C4] Level 1 of MULTUM DRUG CATEGORY # 4
51.5a2	3	443-445	[RX3V2C1] Level 2 of MULTUM DRUG CATEGORY # 1
51.6a2	3	446-448	[RX3V2C2] Level 2 of MULTUM DRUG CATEGORY # 2
51.7a2	3	449-451	[RX3V2C3] Level 2 of MULTUM DRUG CATEGORY # 3
51.8a2	3	452-454	[RX3V2C4] Level 2 of MULTUM DRUG CATEGORY # 4
51.5a3 51.6a3 51.7a3 51.8a3	3 3	455-457 458-460 461-463 464-466	[RX3V3C1] Level 3 of MULTUM DRUG CATEGORY # 1 [RX3V3C2] Level 3 of MULTUM DRUG CATEGORY # 2 [RX3V3C3] Level 3 of MULTUM DRUG CATEGORY # 3 [RX3V3C4] Level 3 of MULTUM DRUG CATEGORY # 4

ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
52			DRUG-RELATED INFO FOR MEDICATION #4
52.1	6	467-472	[DRUGID4] Drug ID (See p. 210 for more information.) a10001-a71037 = NCHS code (for drugs not found in Multum but for which ingredients could be determined) c00012-c00899 = NCHS code (for drugs not found in Multum and with undetermined ingredients) d00001-d06848 = Multum code
52.2	1	473	[PRESCR4] PRESCRIPTION STATUS CODE 1 = Prescription Drug 2 = Nonprescription Drug 3 = Undetermined
52.3	1	474	[CONTSUB4] CONTROLLED SUBSTANCE STATUS CODE1 = Schedule I (Research Only)2 = Schedule II5 = Schedule V3 = Schedule III6 = No Control4 = Schedule IV7 = Undetermined
52.4	1	475	[COMSTAT4] COMPOSITION STATUS CODE 1 = Single Entity Drug 2 = Combination Drug 3 = Undetermined
52.5a	3	476-478	[RX4CAT1] MULTUM DRUG CATEGORY # 1 Reflects the most detailed therapeutic level to which the drug can be classified. For some drugs, Multum Level 1 (broadest level) is the most detailed, while others can be coded to Level 2, but the majority can be coded to Level 3 (most detailed level). For more on the Multum classification system, please see page 18. The complete Multum classification is shown in Appendix III.
			<ul> <li>" = Blank/Not applicable</li> <li>001 - 899 = Drug category</li> <li>999 = Undetermined category</li> </ul>
52.6a	3	479-481	[RX4CAT2] MULTUM DRUG CATEGORY # 2 See RX4CAT1.
52.7a	3	482-484	[RX4CAT3] MULTUM DRUG CATEGORY # 3 See RX4CAT1.
52.8a	3	485-487	[RX4CAT4] MULTUM DRUG CATEGORY # 4 See RX4CAT1.

FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
		DRUG CATEGORY LEVELS
		See RX4CAT1 for general coding conventions that apply to all Multum drug categories. Complete Multum classification scheme is shown in Appendix III.
3	488-490	[RX4V1C1] Level 1 of MULTUM DRUG CATEGORY # 1
3	491-493	[RX4V1C2] Level 1 of MULTUM DRUG CATEGORY # 2
3	494-496	[RX4V1C3] Level 1 of MULTUM DRUG CATEGORY # 3
3	497-499	[RX4V1C4] Level 1 of MULTUM DRUG CATEGORY # 4
3	500-502	[RX4V2C1] Level 2 of MULTUM DRUG CATEGORY # 1
		[RX4V2C2] Level 2 of MULTUM DRUG CATEGORY # 2
3	506-508	[RX4V2C3] Level 2 of MULTUM DRUG CATEGORY # 3
3	509-511	[RX4V2C4] Level 2 of MULTUM DRUG CATEGORY # 4
3 3 3 3	512-514 515-517 518-520 521-523	[RX4V3C1] Level 3 of MULTUM DRUG CATEGORY # 1 [RX4V3C2] Level 3 of MULTUM DRUG CATEGORY # 2 [RX4V3C3] Level 3 of MULTUM DRUG CATEGORY # 3 [RX4V3C4] Level 3 of MULTUM DRUG CATEGORY # 4
	LENGTH 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3	LENGTH         LOCATION           3         488-490           3         491-493           3         494-496           3         497-499           3         500-502           3         503-505           3         509-511           3         512-514           3         515-517           3         518-520

ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
53			DRUG-RELATED INFO FOR MEDICATION #5
53.1	6	524-529	[DRUGID5] Drug ID (See p. 210 for more information.) a10001-a71037 = NCHS code (for drugs not found in Multum but for which ingredients could be determined) c00012-c00899 = NCHS code (for drugs not found in Multum and with undetermined ingredients) d00001-d06848 = Multum code
53.2	1	530	[PRESCR5] PRESCRIPTION STATUS CODE 1 = Prescription Drug 2 = Nonprescription Drug 3 = Undetermined
53.3	1	531	[CONTSUB5] CONTROLLED SUBSTANCE STATUS CODE1 = Schedule I (Research Only)2 = Schedule II5 = Schedule V3 = Schedule III6 = No Control4 = Schedule IV7 = Undetermined
53.4	1	532	[COMSTAT5] COMPOSITION STATUS CODE 1 = Single Entity Drug 2 = Combination Drug 3 = Undetermined
53.5a	3	533-535	[RX5CAT1] MULTUM DRUG CATEGORY # 1 Reflects the most detailed therapeutic level to which the drug can be classified. For some drugs, Multum Level 1 (broadest level) is the most detailed, while others can be coded to Level 2, but the majority can be coded to Level 3 (most detailed level). For more on the Multum classification system, please see page 18. The complete Multum classification is shown in Appendix III.
			<ul> <li>" = Blank/Not applicable</li> <li>001 - 899 = Drug category</li> <li>999 = Undetermined category</li> </ul>
53.6a	3	536-538	[RX5CAT2] MULTUM DRUG CATEGORY # 2 See RX3CAT1.
53.7a	3	539-541	[RX5CAT3] MULTUM DRUG CATEGORY # 3 See RX3CAT1.
53.8a	3	542-544	[RX5CAT4] MULTUM DRUG CATEGORY # 4 See RX3CAT1.

PAGE 94
---------

ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
			DRUG CATEGORY LEVELS
			See RX5CAT1 for general coding conventions that apply to all Multum drug categories. Complete Multum classification scheme is shown in Appendix III.
53.5a1	3	545-547	[RX5V1C1] Level 1 of MULTUM DRUG CATEGORY # 1
53.6a1	3	548-550	[RX5V1C2] Level 1 of MULTUM DRUG CATEGORY # 2
53.7a1	3	551-553	[RX5V1C3] Level 1 of MULTUM DRUG CATEGORY # 3
53.8a1	3	554-556	[RX5V1C4] Level 1 of MULTUM DRUG CATEGORY # 4
53.5a2	3	557-559	[RX5V2C1] Level 2 of MULTUM DRUG CATEGORY # 1
53.6a2	3	560-562	[RX5V2C2] Level 2 of MULTUM DRUG CATEGORY # 2
53.7a2		563-565	[RX5V2C3] Level 2 of MULTUM DRUG CATEGORY # 3
53.8a2		566-568	[RX5V2C4] Level 2 of MULTUM DRUG CATEGORY # 4
53.5a3	3	569-571	[RX5V3C1] Level 3 of MULTUM DRUG CATEGORY # 1
53.6a3		572-574	[RX5V3C2] Level 3 of MULTUM DRUG CATEGORY # 2
53.7a3		575-577	[RX5V3C3] Level 3 of MULTUM DRUG CATEGORY # 3
53.8a3		578-580	[RX5V3C4] Level 3 of MULTUM DRUG CATEGORY # 4

ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
54			DRUG-RELATED INFO FOR MEDICATION #6
54.1	6	581-586	[DRUGID6] Drug ID (See p. 210 for more information.) a10001-a71037 = NCHS code (for drugs not found in Multum but for which ingredients could be determined) c00012-c00899 = NCHS code (for drugs not found in Multum and with undetermined ingredients) d00001-d06848 = Multum code
54.2	1	587	[PRESCR6] PRESCRIPTION STATUS CODE 1 = Prescription Drug 2 = Nonprescription Drug 3 = Undetermined
54.3	1	588	[CONTSUB6] CONTROLLED SUBSTANCE STATUS CODE1 = Schedule I (Research Only)2 = Schedule II5 = Schedule V3 = Schedule III6 = No Control4 = Schedule IV7 = Undetermined
54.4	1	589	[COMSTAT6] COMPOSITION STATUS CODE 1 = Single Entity Drug 2 = Combination Drug 3 = Undetermined
54.5a	3	590-592	[RX6CAT1] MULTUM DRUG CATEGORY # 1 Reflects the most detailed therapeutic level to which the drug can be classified. For some drugs, Multum Level 1 (broadest level) is the most detailed, while others can be coded to Level 2, but the majority can be coded to Level 3 (most detailed level). For more on the Multum classification system, please see page 18. The complete Multum classification is shown in Appendix III.
			<ul> <li>" = Blank/Not applicable</li> <li>001 - 899 = Drug category</li> <li>999 = Undetermined category</li> </ul>
54.6a	3	593-595	[RX6CAT2] MULTUM DRUG CATEGORY # 2 See RX6CAT1.
54.7a	3	596-598	[RX6CAT3] MULTUM DRUG CATEGORY # 3 See RX6CAT1.
54.8a	3	599-601	[RX6CAT4] MULTUM DRUG CATEGORY # 4 See RX6CAT1.

2006 NHAMCS MICRO-DATA FILE DOCUMENTATION, Outpatient Department Record Format

ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
			DRUG CATEGORY LEVELS
			See RX6CAT1 for general coding conventions that apply to all Multum drug categories. Complete Multum classification scheme is shown in Appendix III.
54.5a1	3	602-604	[RX6V1C1] Level 1 of MULTUM DRUG CATEGORY # 1
54.6a1		605-607	[RX6V1C2] Level 1 of MULTUM DRUG CATEGORY # 2
54.7a1		608-610	[RX6V1C3] Level 1 of MULTUM DRUG CATEGORY # 3
54.8a1	3	611-613	[RX6V1C4] Level 1 of MULTUM DRUG CATEGORY # 4
54.5a2		614-616	[RX6V2C1] Level 2 of MULTUM DRUG CATEGORY # 1
54.6a2	3	617-619	[RX6V2C2] Level 2 of MULTUM DRUG CATEGORY # 2
54.7a2	3	620-622	[RX6V2C3] Level 2 of MULTUM DRUG CATEGORY # 3
54.8a2	3	623-625	[RX6V2C4] Level 2 of MULTUM DRUG CATEGORY # 4
54.5a3	-	626-628	[RX6V3C1] Level 3 of MULTUM DRUG CATEGORY # 1
54.6a3		629-631	[RX6V3C2] Level 3 of MULTUM DRUG CATEGORY # 2
54.7a3	-	632-634	[RX6V3C3] Level 3 of MULTUM DRUG CATEGORY # 3
54.8a3	3	635-637	[RX6V3C4] Level 3 of MULTUM DRUG CATEGORY # 4

ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
55			DRUG-RELATED INFO FOR MEDICATION #7
55.1	6	638-643	[DRUGID7] Drug ID (See p. 210 for more information.) a10001-a71037 = NCHS code (for drugs not found in Multum but for which ingredients could be determined) c00012-c00899 = NCHS code (for drugs not found in Multum and with undetermined ingredients) d00001-d06848 = Multum code
55.2	1	644	[PRESCR7] PRESCRIPTION STATUS CODE 1 = Prescription Drug 2 = Nonprescription Drug 3 = Undetermined
55.3	1	645	[CONTSUB7] CONTROLLED SUBSTANCE STATUS CODE1 = Schedule I (Research Only)2 = Schedule II5 = Schedule V3 = Schedule III6 = No Control4 = Schedule IV7 = Undetermined
55.4	1	646	[COMSTAT7] COMPOSITION STATUS CODE 1 = Single Entity Drug 2 = Combination Drug 3 = Undetermined
55.5a	3	647-649	[RX7CAT1] MULTUM DRUG CATEGORY # 1 Reflects the most detailed therapeutic level to which the drug can be classified. For some drugs, Multum Level 1 (broadest level) is the most detailed, while others can be coded to Level 2, but the majority can be coded to Level 3 (most detailed level). For more on the Multum classification system, please see page 18. The complete Multum classification is shown in Appendix III.
			" " = Blank/Not applicable 001 - 899 = Drug category 999 = Undetermined category
55.6a	3	650-652	[RX7CAT2] MULTUM DRUG CATEGORY # 2 See RX7CAT1.
55.7a	3	653-655	[RX7CAT3] MULTUM DRUG CATEGORY # 3 See RX7CAT1.
55.8a	3	656-658	[RX7CAT4] MULTUM DRUG CATEGORY # 4 See RX7CAT1.

ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
			DRUG CATEGORY LEVELS
			See RX7CAT1 for general coding conventions that apply to all Multum drug categories. Complete Multum classification scheme is shown in Appendix III.
55.5a1	3	659-661	[RX7V1C1] Level 1 of MULTUM DRUG CATEGORY # 1
55.6a1	3	662-664	[RX7V1C2] Level 1 of MULTUM DRUG CATEGORY # 2
55.7a1		665-667	[RX7V1C3] Level 1 of MULTUM DRUG CATEGORY # 3
55.8a1	3	668-670	[RX7V1C4] Level 1 of MULTUM DRUG CATEGORY # 4
55.5a2	3	671-673	[RX7V2C1] Level 2 of MULTUM DRUG CATEGORY # 1
55.6a2	3	674-676	[RX7V2C2] Level 2 of MULTUM DRUG CATEGORY # 2
55.7a2		677-679	[RX7V2C3] Level 2 of MULTUM DRUG CATEGORY # 3
55.8a2		680-682	[RX7V2C4] Level 2 of MULTUM DRUG CATEGORY # 4
55.5a3	-	683-685	[RX7V3C1] Level 3 of MULTUM DRUG CATEGORY # 1
55.6a3	-	686-688	[RX7V3C2] Level 3 of MULTUM DRUG CATEGORY # 2
55.7a3	-	689-691	[RX7V3C3] Level 3 of MULTUM DRUG CATEGORY # 3
55.8a3	3	692-694	[RX7V3C4] Level 3 of MULTUM DRUG CATEGORY # 4

ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
56			DRUG-RELATED INFO FOR MEDICATION #8
56.1	6	695-700	[DRUGID8] Drug ID (See p. 210 for more information.) a10001-a71037 = NCHS code (for drugs not found in Multum but for which ingredients could be determined) c00012-c00899 = NCHS code (for drugs not found in Multum and with undetermined ingredients) d00001-d06848 = Multum code
56.2	1	701	[PRESCR8] PRESCRIPTION STATUS CODE 1 = Prescription Drug 2 = Nonprescription Drug 3 = Undetermined
56.3	1	702	[CONTSUB8] CONTROLLED SUBSTANCE STATUS CODE1 = Schedule I (Research Only)2 = Schedule II5 = Schedule V3 = Schedule III6 = No Control4 = Schedule IV7 = Undetermined
56.4	1	703	[COMSTAT8] COMPOSITION STATUS CODE 1 = Single Entity Drug 2 = Combination Drug 3 = Undetermined
56.5a	3	704-706	[RX8CAT1] MULTUM DRUG CATEGORY # 1
			Reflects the most detailed therapeutic level to which the drug can be classified. For some drugs, Multum Level 1 (broadest level) is the most detailed, while others can be coded to Level 2, but the majority can be coded to Level 3 (most detailed level). For more on the Multum classification system, please see page 18. The complete Multum classification is shown in Appendix III.
			<ul> <li>" = Blank/Not applicable</li> <li>001 - 899 = Drug category</li> <li>999 = Undetermined category</li> </ul>
56.6a	3	707-709	[RX8CAT2] MULTUM DRUG CATEGORY # 2 See RX8CAT1.
56.7a	3	710-712	[RX8CAT3] MULTUM DRUG CATEGORY # 3 See RX8CAT1.
56.8a	3	713-715	[RX8CAT4] MULTUM DRUG CATEGORY # 4 See RX8CAT1.

PAGE 100		2006 NHAMCS MICRO-DATA FILE DOCUMENTATION, Outpatient Department Record Format	
ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
			DRUG CATEGORY LEVELS
			See RX8CAT1 for general coding conventions that apply to all Multum drug categories. Complete Multum classification scheme is shown in Appendix III.
56.5a1 56.6a1 56.7a1 56.8a1	3 3 3 3	716-718 719-721 722-724 725-727	[RX8V1C1] Level 1 of MULTUM DRUG CATEGORY # 1 [RX8V1C2] Level 1 of MULTUM DRUG CATEGORY # 2 [RX8V1C3] Level 1 of MULTUM DRUG CATEGORY # 3 [RX8V1C4] Level 1 of MULTUM DRUG CATEGORY # 4
56.5a2 56.6a2 56.7a2 56.8a2	3 3	728-730 731-733 734-736 737-739	[RX8V2C1] Level 2 of MULTUM DRUG CATEGORY # 1 [RX8V2C2] Level 2 of MULTUM DRUG CATEGORY # 2 [RX8V2C3] Level 2 of MULTUM DRUG CATEGORY # 3 [RX8V2C4] Level 2 of MULTUM DRUG CATEGORY # 4
56.5a3 56.6a3 56.7a3 56.8a3	3 3	740-742 743-745 746-748 749-751	[RX8V3C1] Level 3 of MULTUM DRUG CATEGORY # 1 [RX8V3C2] Level 3 of MULTUM DRUG CATEGORY # 2 [RX8V3C3] Level 3 of MULTUM DRUG CATEGORY # 3 [RX8V3C4] Level 3 of MULTUM DRUG CATEGORY # 4
57	1	752	[BIOTER] HAS YOUR HOSPITAL RECEIVED ANY FUNDING FOR BIOTERROR HOSPITAL PREPAREDNESS FROM YOUR STATE OR MUNICIPAL HEALTH DEPARTMENT WITHIN THE LAST 2 YEARS? 1 = Yes 2 = No 3 = Unknown 4 = Blank
58	1	753	[MDSP] DID YOUR HOSPITAL RECEIVE ANY MEDICAID DISPROPORTIONATE SHARE PROGRAM FUNDS IN 2005? 1 = Yes 2 = No 3 = Unknown 4 = Blank
59	1	754	[EMEDRECO] DOES YOUR OPD USE ELECTRONIC MEDICAL RECORDS (EMR) (NOT INCLUDING BILLING RECORDS)? 0 = Blank 1 = Yes, all electronic 2 = Yes, part paper and part electronic 3 = No 4 = Unknown The following 8 items were asked only if the OPD used electronic
			medical records.

ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
60	1	755	[EDEMOGO] DOES YOUR OPD'S ELECTRONIC MEDICAL RECORD SYSTEM INCLUDE PATIENT DEMOGRAPHIC INFORMATION? 1= Yes 2= No 3= Unknown 4= Turned off 8= Not applicable 9= Blank
61	1	756	[ECPOEO] DOES YOUR OPD'S ELECTRONIC MEDICAL RECORD SYSTEM INCLUDE COMPUTERIZED ORDERS FOR PRESCRIPTIONS? 1= Yes 2= No 3= Unknown 4= Turned off 8= Not applicable 9= Blank
62	1	757	[EWARNO] IF YOUR OPD'S ELECTRONIC MEDICAL RECORD SYSTEM SYSTEM INCLUDES COMPUTERIZED ORDERS FOR PRESCRIPTIONS, ARE THERE WARNINGS OF DRUG INTERACTIONS/CONTRAINDICATIONS PROVIDED? 1= Yes 2= No 3= Unknown 4= Turned off 8= Not applicable 9= Blank
63	1	758	[ESCRIPO] IF YOUR OPD'S ELECTRONIC MEDICAL RECORD SYSTEM SYSTEM INCLUDES COMPUTERIZED ORDERS FOR PRESCRIPTIONS, ARE PRESCRIPTIONS SENT ELECTRONICALLY TO THE PHARMACY? 1= Yes 2= No 3= Unknown 4= Turned off 8= Not applicable 9= Blank
64	1	759	[ECTOEO] DOES YOUR OPD'S ELECTRONIC MEDICAL RECORD SYTEM INCLUDE COMPUTERIZED ORDERS FOR TESTS? 1= Yes 2= No 3= Unknown 4= Turned off 8= Not applicable 9= Blank

PAGE 102		2006 NHAMCS MICRO-DATA FILE DOCUMENTATION, Outpatient Department Record Forma	
ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
65	1	760	[EORDERO] IF YOUR OPD'S ELECTRONIC MEDICAL RECORD SYTEM INCLUDES COMPUTERIZED ORDERS FOR TESTS, ARE ORDERS SENT ELECTRONICALLY? 1= Yes 2= No 3= Unknown 4= Turned off 8= Not applicable 9= Blank
66	1	761	[ERESULTO] DOES YOUR OPD'S ELECTRONIC MEDICAL RECORD SYSTEM INCLUDE LAB RESULTS? 1= Yes 2= No 3= Unknown 4= Turned off 8= Not applicable 9= Blank
67	1	762	[ERANGEO] IF YOUR OPD'S ELECTRONIC MEDICAL RECORD SYSTEM INCLUDES TEST RESULTS, ARE OUT OF RANGE LEVELS HIGHLIGHTED? 1= Yes 2= No 3= Unknown 4= Turned off 8= Not applicable 9= Blank
68	1	763	[EIMGRESO] DOES YOUR OPD'S ELECTRONIC MEDICAL RECORD SYTEM INCLUDE IMAGING RESULTS? 1= Yes 2= No 3= Unknown 4= Turned off 8= Not applicable 9= Blank
69	1	764	[EIMAGEO] IF YOUR OPD'S ELECTRONIC MEDICAL RECORD SYTEM INCLUDES IMAGING RESULTS, ARE ELECTRONIC IMAGES RETURNED? 1= Yes 2= No 3= Unknown 4= Turned off 8= Not applicable 9= Blank

ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES
70	1	765	[EPNOTESO] DOES YOUR OPD'S ELECTRONIC MEDICAL RECORD SYTEM INCLUDE CLINICAL NOTES? 1= Yes 2= No 3= Unknown 4= Turned off 8= Not applicable 9= Blank
71	1	766	[EHXFUEO] IF YOUR OPD'S ELECTRONIC MEDICAL RECORD SYSTEM INCLUDES CLINICAL NOTES, DO THEY INCLUDE MEDICAL HISTORY AND FOLLOW-UP NOTES? 1= Yes 2= No 3= Unknown 4= Turned off 8= Not applicable 9= Blank
72	1	767	[EREMINDO] IF YOUR OPD'S ELECTRONIC MEDICAL RECORD SYSTEM INCLUDES CLINICAL NOTES, DO THEY INCLUDE REMINDERS FOR GUIDELINE-BASED INTERVENTIONS AND/OR SCREENING TESTS? 1= Yes 2= No 3= Unknown 4= Turned off 8= Not applicable 9= Blank
73	1	768	[EPUBHLTHO] DOES YOUR OPD'S ELECTRONIC MEDICAL RECORD SYSTEM INCLUDE PUBLIC HEALTH REPORTING? 1= Yes 2= No 3= Unknown 4= Turned off 8= Not applicable 9= Blank
74	1	769	[ENOTDISO] IF YOUR OPD'S ELECTRONIC MEDICAL RECORD SYSTEM INCLUDES PUBLIC HEALTH REPORTING, ARE NOTIFIABLE DISEASES SENT ELECTRONICALLY? 1= Yes 2= No 3= Unknown 4= Turned off 8= Not applicable 9= Blank

PAGE 104		2006 NHAMCS MICRO-DATA FILE DOCUMENTATION, Outpatient Department Record Format		
ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES	
75	1	770	[EMRNEWO] ARE THERE PLANS FOR INSTALLING A NEW EMR SYSTEM OR REPLACING THE CURRENT SYSTEM WITHIN THE NEXT THREE YEARS? 1 = Yes 2 = No 3 = Maybe 4 = Unknown 9 = Blank	
76	1	771	[CCS] DOES THIS CLINIC OFFER ANY TYPE OF CERVICAL CANCER SCREENING? 1 = Yes 2 = No 3 = Unknown 8 = Not applicable (not a General Medicine or OB-GYN clinic) 9 = Blank	
		***The follow	ing 4 items are recoded from other survey items.***	
66	17	772	[RACER] RACE RECODE 1= White 2= Black 3= Other	
67	1	773	[RACEETH] RACE/ETHNICITY 1 = White Only, Non-Hispanic 2 = Black Only, Non-Hispanic 3 = Hispanic 4 = Asian Only 5 = Native Hawaiian, Other Pacific Islander Only 6 = American Indian/Alaska Native 7 = Multiple Races	
68	3	774-776	[AGEDAYS] AGE IN DAYS	
			001-365 = 001-365 days 999 = More than 365 days	
69	1	777	[AGER] AGE RECODE 1 = Under 15 years 2 = 15-24 years 3 = 25-44 years 4 = 45-64 years 5 = 65-74 years 6 = 75 years and over	

### NUMERIC RECODES FOR CAUSE OF INJURY, DIAGNOSIS, AND PROCEDURES

The following items were included on the public use file to facilitate analysis of visits using ICD-9-CM codes. Prior to the 1995 public use file, all ICD-9-CM diagnosis codes on the NHAMCS micro-data files were converted from alphanumeric to numeric fields according to the following coding conventions: A prefix of '1' was added to ICD-9-CM codes in the range of 001.0[-] through 999.9[-]. A prefix of '20' was substituted for the letter 'V' for codes in the range of V01.0[-] through V82.9[-]. Inapplicable fourth or fifth digits were zero-filled. This conversion was done to facilitate analysis of ICD-9-CM data using Ambulatory and Hospital Care Statistics software systems. Similar conversions were made for ICD-9-CM procedure

ITEM	FIELD	FILE	
NO.	LENGTH	LOCATION	[ITEM NAME], DESCRIPTION, AND CODES

codes and external cause of injury codes. Specific coding conventions are discussed in the public use documentation for each data year.

In 1995, however, the decision was made to use actual ICD-9-CM codes on the public use data file. Codes were not prefixed, and a dash was inserted for inapplicable fourth or fifth digits. For specific details pertaining to each type of code (diagnosis, procedure, cause of injury), refer to the documentation for the survey year of interest. This had the advantage of preserving actual codes and avoiding possible confusion over the creation of some artificial codes due to zero-filling.

It has come to our attention that some users of NHAMCS data find it preferable to use the numeric field recodes rather than the alphanumeric fields in certain data applications. Therefore, we have included numeric recodes for diagnoses and procedure reported under scope procedures, "other" diagnostic/screening services, and other surgical and non-surgical non-medication treatments, as listed below. These are in addition to the actual codes for these variables which appear earlier on the public use file. Users can make their own choice about which format best suits their needs. We would be interested in hearing from data users as to which format they prefer so that a decision can be made about whether to include both formats in future years. Please contact Susan Schappert, Ambulatory and Hospital Care Statistics Branch, at 301-458-4480.

70			DIAGNOSIS RECODE
70.1	6	778-783	<ul> <li>[DIAG1R] DIAGNOSIS #1 (Recode to Numeric Field) 100100-208290 = 001.0[0]-V82.9[0]</li> <li>209900 = Noncodable, insufficient information for coding, illegible</li> <li>209910 = Left before being seen; patient walked out; not seen by doctor; left against medical advice</li> <li>209920 = Transferred to another facility; sent to see specialist</li> <li>209930 = HMO will not authorize treatment</li> <li>209970 = Entry of "none," "no diagnosis," "no disease," or "healthy"</li> <li>900000 = Blank</li> </ul>
70.2	6	784-789	[DIAG2R] DIAGNOSIS #2 (Recode to Numeric Field) 100100-208290 = 001.0[0]-V82.9[0] See DIAGNOSIS #1 for details.
70.3	6	790-795	[DIAG3R] DIAGNOSIS #3 (Recode to Numeric Field) 100100-208290 = 001.0[0]-V82.9[0] See DIAGNOSIS #1 for details.
71.1	4	796-799	[SCOPWI1R] SCOPE PROCEDURE WRITE-IN #1 (Recode to Numeric Field) 0101-999 = 01.01 - 99.99 0 = Not applicable/Blank
71.2	4	800-803	[SCOPWI2R] SCOPE PROCEDURE WRITE-IN #2 (Recode to Numeric Field) 0101-999 = 01.01 - 99.99 0 = Not applicable/Blank
72.1	4	804-807	[DIAGSC1R] OTHER DIAGNOSTIC/SCREENING SERVICE WRITE-IN #1 (Recode to Numeric Field)

PAGE 106		2006 NHAMCS MICRO-DATA FILE DOCUMENTATION, Outpatient Department Record Format			
ITEM NO.	FIELD LENGTH	FILE LOCATION	[ITEM NAME], DESCRIPTION, AND CODES		
			0101-999 = 01.01 - 99.99 0 = Not applicable/Blank		
72.2	4	808-811	[DIAGSC2R] OTHER DIAGNOSTIC/SCREENING SERVICE WRITE-IN #2 (Recode to Numeric Field) 0101-999 = 01.01 - 99.99 0 = Not applicable/Blank		
73.1	4	812-815	[OTHPROC1R] OTHER PROCEDURE WRITE-IN #1 (Recode to Numeric Field) 0101-999 = 01.01 - 99.99 0 = Not applicable/Blank		
73.2	4	816-819	[OTHPROC2R] OTHER PROCEDURE WRITE-IN #2 (Recode to Numeric Field) 0101-999 = 01.01 - 99.99 0 = Not applicable/Blank		
73.3	4	820-823	[OTHPROC32R] OTHER PROCEDURE WRITE-IN #3 (Recode to Numeric Field) 0101-999 = 01.01 - 99.99 0 = Not applicable/Blank		
73.4	4	824-827	[OTHPROC4R] OTHER PROCEDURE WRITE-IN #4 (Recode to Numeric Field) 0101-999 = 01.01 - 99.99 0 = Not applicable/Blank		
			END OF NUMERIC RECODES		
74	1	828	[WHOCOMP] WHO COMPLETED THE PATIENT RECORD FORMS? 1 = Hospital Staff 2 = Census Field Representative - Abstraction during reporting period 3 = Census Field Representative - Abstraction after reporting period 4 = Other 5 = Multiple categories checked 6 = Unknown		
75	1	829	[SETTYPE] SETTING TYPE This item is intended for use when combining data from the NAMCS or NHAMCS-ED public use files with OPD data. 1 = Physician Office (NAMCS) 2 = Outpatient Department (NHAMCS-OPD) 3 = Emergency Department (NHAMCS-ED)		
76	4	830-833	[YEAR] SURVEY YEAR (2006)		

#### NHAMCS DESIGN VARIABLES

Masked design variables were first released on the 2000 NHAMCS (and NAMCS) public use files, and were subsequently added to the 1993-1999 public use files. These variables reflected the multi-stage sampling design of the surveys, and were for use with statistical software like SUDAAN that takes such information into account. However, these variables could not be used in other statistical software packages, such as SAS and Stata, which employ an ultimate cluster model to estimate variance, without

### ITEM FIELD FILE NO. LENGTH LOCATION [ITEM NAME], DESCRIPTION, AND CODES

substantial modification. Therefore, two new variables were created and first added to the 2002 file, CSTRATM and CPSUM. They can be used to estimate variance with SUDAAN's with-replacement (WR) option, as well as with Stata, SPSS, SAS, and other statistical software packages utilizing an ultimate cluster model for variance estimation. The decision was made to include only these new variables, CSTRATM and CPSUM, and not the multi-stage design variables, beginning with the 2003 data release. These variables and their use are described more fully in the "Relative Standard Errors" section of the public use file documentation. For those who wish to combine data from 2003 forward with survey data from years prior to 2002 which do not contain CSTRATM and CPSUM, please see the technical paper, *Using Ultimate Cluster Models with NAMCS and NHAMCS Public Use Files*, at http://www.cdc.gov/nchs/nhamcs.htm.

77	8	834-841	[CSTRATM] CLUSTERED PSU STRATUM MARKER (masked) 20105201-40400000
78	6	842-847	[CPSUM] CLUSTERED PSU MARKER (masked) 5-100189
79	8	848-855	[OPDWT] OPD WEIGHT OPDWT enables data users to make outpatient-department-level estimates. Please see pp. 23 and 98 for more information. 1-85
91	1	856	[PCTPOVR] PERCENT POVERTY IN PATIENT'S ZIP CODE 1 = Quartile 1 (Less than 5.00 percent) 2 = Quartile 2 (5.00-9.99 percent) 3 = Quartile 3 (10.00-19.99 percent) 4 = Quartile 4 (20.00 percent or more) 9 = Missing data
92	1	857	[HINCOMER] MEDIAN HOUSEHOLD INCOME IN PATIENT'S ZIP CODE 1 = Quartile 1 (Below \$32,793) 2 = Quartile 2 (\$32,794-\$40,626) 3 = Quartile 3 (\$40,627-\$52,387) 4 = Quartile 4 (\$52,388 or more) 9 = Missing data
93	1	858	[PBAMORER] PERCENT OF ADULTS WITH BACHELOR'S DEGREE OR HIGHER IN PATIENT'S ZIP CODE 1 = Quartile 1 (Less than 12.84 percent) 2 = Quartile 2 (12.84-19.66 percent) 3 = Quartile 3 (19.67-31.68 percent) 4 = Quartile 4 (31.69 percent or more) 9 = Missing data
94	1	859	[URBANRUR] URBAN-RURAL CLASSIFICATION OF PATIENT'S ZIP CODE 1 = Large central metro 2 = Large fringe metro 3 = Medium metro 4 = Small metro 5 = Non-metro (micropolitan and non-core) 9 = Missing data

## III. MARGINAL DATA

#### A. EMERGENCY DEPARTMENT PATIENT VISITS

PATIENT AGE

CATEGORY	RECORDS	WEIGHTED VISITS	PERCENT	
Total	35,849	119,191,528	100.000	
1 - Under 15 years	7,880	21,887,018	18.363	
2 - 15-24 years	5,659	19,525,959	16.382	
3 - 25-44 years	9,994	35,034,595	29.394	
4 - 45-64 years	7,257	25,460,968	21.361	
5 - 65-74 years	2,018	7,095,457	5.953	
6 - 75 years and over	3,041	10,187,531	8.547	
PATIENT SEX				
CATEGORY	RECORDS	WEIGHTED VISITS	PERCENT	
Total	35,849	119,191,528	100.000	
1 - Female	19,221	64,960,913	54.501	
2 - Male	16,628	54,230,615	45.499	
PATIENT RACE				
CATEGORY		RECORDS	WEIGHTED VISITS	PERCENT
Total		35,849	119,191,528	100.000
1 - White only	25,321	85,267,699	71.538	
2 - Black/African American	8,695	29,558,791	24.799	
3 - Asian only	1,097	2,368,683	1.987	
4 - Native Hawaiian/				
Other Pacific Islande	237	438,756	0.368	
5 - American Indian/Alaska	-	1,163,379		
6 - More than one race repo	orted	246	394,220	0.331

#### PATIENT ETHNICITY

CATEGORY	RECORDS	WEIGHTED VISITS	PERCENT
Total	35,849	119,191,528	100.000
1 - Hispanic or Latino	5,486	15,481,892	12.989
2 - Not Hispanic or Latino	30,363	103,709,636	87.011

CATEGORY	RECORDS	WEIGHTED VISITS	PERCENT
Total 0 - Blank 1 - Private insurance 2 - Medicare 3 - Medicaid 4 - Worker's compensation 5 - Self-pay 6 - No charge 7 - Other 8 - Unknown	35,849 420 12,113 4,705 9,941 574 5,336 423 831 1,506	119, 191, 528 1, 337, 615 40, 044, 194 16, 780, 850 30, 348, 952 2, 042, 096 19, 260, 669 1, 755, 541 3, 304, 493 4, 317, 118	100.000 1.122 33.597 14.079 25.462 1.713 16.159 1.473 2.772 3.622
e onknown	1,000	4,017,110	0.022

## PRIMARY EXPECTED SOURCE OF PAYMENT FOR THIS VISIT

IMMEDIACY WITH WHICH PATIENT SHOULD BE SEEN

Total35,849119,191,528100.0001 - Immediate1,6596,083,8975.1042 - 1 - 14 min4,17212,817,44810.7543 - 15 - 60 min12,57243,637,40436.6114 - > 1hr - 2hrs7,42526,163,51321.9515 - >2 hours - 24 hours4,25914,479,53312.1486 - No triage6761,860,6141.561	CATEGORY	RECORDS	WEIGHTED VISITS	PERCENT
7 - Unknown 5,086 14,149,119 11.871	1 - Immediate	1,659	6,083,897	5.104
	2 - 1 - 14 min	4,172	12,817,448	10.754
	3 - 15 - 60 min	12,572	43,637,404	36.611
	4 - > 1hr - 2hrs	7,425	26,163,513	21.951
	5 - >2 hours - 24 hours	4,259	14,479,533	12.148
	6 - No triage	676	1,860,614	1.561

## NUMBER OF MEDICATION CODES THIS VISIT

CATEGORY	RECORDS	WEIGHTED VISITS	PERCENT
Total	35,849	119,191,528	100.000
No drugs	8,630	27,873,440	23.385
1 drug	9,891	32,051,310	26.891
2 drugs	8,023	27,434,677	23.017
3 drugs	4,628	15,873,022	13.317
4 drugs	2,435	8,510,255	7.140
5 drugs	1,105	3,891,060	3.265
6 drugs	536	1,712,915	1.437
7 drugs	278	943,557	0.792
8 drugs	323	901,292	0.756

-

## **B. EMERGENCY DEPARTMENT DRUG MENTIONS**

.....

PATIENT AGE

CATEGORY	RECORDS	WEIGHTED MENTIONS	PERCENT	
Total	62,832	212,128,775	100.000	
1 - Under 15 years	10,735	29,521,519	13.917	
2 - 15-24 years	9,419	33,779,435	15.924	
3 - 25-44 years	19,012	67,809,400	31.966	
4 - 45-64 years	14,572	50,906,979	23.998	
5 - 65-74 years	3,835	13,315,670	6.277	
6 - 75 years and over	5,259	16,795,772	7.918	

PATIENT SEX

CATEGORY	RECORDS	WEIGHTED MENTION	6 PERCENT	
Total	62,832	212,128,775	100.000	
1 - Female	34,188	118,626,589	55.922	
2 - Male	28,644	93,502,186	44.078	

PATIENT RACE

CATEGORY	RECORDS	WEIGHTED MENTIONS	PERCENT
Total 1 - White only 2 - Black/African American only	62,832 45,048 14,580	212,128,775 152,471,286 51,925,441	100.000 71.877 24.478
3 - Asian only 4 - Native Hawaiian/	1,947	4,575,024	2.157
Other Pacific Islander only 5 - American Indian/Alaska Native only	436 418	798,394 1,752,155	0.376 0.826
6 - More than one race reported	403	606,475	0.286

CATEGORY	RECORDS	WEIGHTED MENTIONS	PERCENT
Total	70,940	239,518,197	100.000
'OO1'=Anti-infectives	9,857	34,030,600	14.208
'020'=Antineoplastics	37	127,618	0.053
'O28'=Biologicals	9	26,119	0.011
'040'=Cardiovascular agents	3,576	12,074,495	5.041
'057'=Central nervous system agents	31,814	109,393,763	45.672
'081'=Coagulation modifiers	1,525	5,104,923	2.131
'087'=Gastrointestinal agents	3,490	12,058,025	5.034
'097'=Hormones	1,969	6,836,068	2.854
'105'=Miscellaneous agents	2,076	6,869,621	2.868
<pre>'115'=Nutritional products</pre>	2,815	8,519,318	3.557
<pre>'122'=Respiratory agents</pre>	8,438	28,198,149	11.773
'133'=Topical agents	2,248	7,475,828	3.121
ʻ153'=Plasma expanders	12	32,193	0.013
'218'=Alternative medicines	26	36,903	0.015
'242'=Psychotherapeutic agents	1,212	2,714,190	1.133
'254'=Immunological agents	1,096	3,597,270	1.502
'331'=Radiologic agents	43	164,449	0.069
'358'=Metabolic agents	677	2,211,528	0.923
'899'=Pharmaceutical aids	20	47,137	0.020

Therapeutic categories are based on Lexicon Plus<sup>®</sup>, a proprietary database of Cerner Multum, Inc. The Lexicon Plus is a comprehensive database of all prescription and some nonprescription drug products available in the U.S. drug market. For additional information on the Multum Lexicon Drug Database, please refer to the following Web site: <u>http://www.multum.com/Lexicon.htm</u>. For more information on coding therapeutic categories in the NHAMCS, see page 18.

#### C. EMERGENCY DEPARTMENTS

\_\_\_\_\_

REGION

CATEGORY	RECORDS	WEIGHTED EMERGENCY DEPTS	PERCENT
Total	364	4,654	100.000
Northeast	80	648	13.924
Midwest	86	1,336	28.706
South	129	1,809	38.870
West	69	861	18.500

		WEIGHTED	
CATEGORY	RECORDS	EMERGENCY DEPTS	PERCENT
Total	364	4,654	100.000
MSA (Metropolitan Statistical Area)	315	3,092	66.437
Non-MSA	49	1,562	33.563
OWNER			
CATEGORY	RECORDS	WEIGHTED EMERGENCY DEPTS	PERCENT

Total	364	4,654	100.000
Voluntary non-profit	268	3,148	67.641
Government, non-Federal	66	1,024	22.003
Proprietary	30	482	10.357

# D. OUTPATIENT DEPARTMENT PATIENT VISITS

## -----

#### PATIENT AGE

CATEGORY	RECORDS	WEIGHTED VISITS	PERCENT
Total	35,105	102,208,171	100.000
1 - Under 15 years	8,154	19,864,183	19.435
2 - 15-24 years	4,398	12,011,882	11.752
3 - 25-44 years	8,765	25,103,839	24.561
4 - 45-64 years	8,969	28,706,467	28.086
5 - 65-74 years	2,623	8,930,696	8.738
6 - 75 years and over	2,196	7,591,104	7.427

PATIENT SEX

CATEGORY	RECORDS	WEIGHTED VISITS	PERCENT	
Total	35,105	102,208,171	100.000	
1 - Female	21,454	61,951,670	60.613	
2 - Male	13,651	40,256,501	39.387	

PAGE 113

## PATIENT RACE

CATEGORY		RECORDS	WEIGHTE	D VISITS	PERCENT	
Total 1 - White only 2 - Black/African American o 3 - Asian only 4 - Native Hawaiian/ Other Pacific Islander 5 - American Indian/Alaska N	nly only	174	73,87 23,47 2,65 41	8,994 1,484	22.972 2.594 0.404	
6 - More than one race repor		689				
PATIENT ETHNICITY CATEGORY Total 1 - Hispanic or Latino 2 - Not Hispanic or Latino		RECORDS 35,105 6,423 28,682	WEIGHTED 102,20 17,59	VISITS 8,171 4,542	PERCENT 100.000 17.214	
PRIMARY EXPECTED SOURCE OF P		THIS VIS	IT			
Total O - No box marked 1 - Private insurance 2 - Medicare 3 - Medicaid		•	8,249 8,280 0,228	35.866		

3	-	Medicald	12,740	31,787,909	31.101
4	-	Worker's compensation	229	722,144	0.707
5	-	Self-pay	2,264	6,629,522	6.486
6	-	No charge	1,115	3,919,916	3.835
7	-	Other	1,278	3,590,239	3.513
8	-	Unknown	1,155	3,011,684	2.947

HAS PATIENT BEEN SEEN IN THIS CLINIC BEFORE?

CATEGORY	RECORDS	WEIGHTED VISITS	PERCENT
Total	35,105	102,208,171	100.000
1 - Yes, established patient	28,344	86,449,909	84.582
2 - No, new patient	6,761	15,758,262	15.418

\_\_\_\_\_

#### CLINIC TYPE

CATEGORY	RECORDS	WEIGHTED VISITS	PERCENT	
Total 1 - General medicine	35,105 12,866	102,208,171 62,128,309	100.000 60.786	
2 - Surgery	6,836	11,750,543	11.497	
3 - Pediatrics	4,852	11,024,968	10.787	
4 - Obstetrics/Gynecology	4,846	9,407,128	9.204	
5 - Substance abuse	425	823,133	0.805	
6 - Other	5,280	7,074,090	6.921	

#### NUMBER OF MEDICATIONS

CATEGORY	RECORDS	WEIGHTED VISITS	PERCENT
Total	35,105	102,208,171	100.000
No drugs	11,426	25,522,514	24.971
1 drug	8,282	23,446,877	22.940
2 drugs	5,107	15,711,004	15.372
3 drugs	3,332	10,966,146	10.729
4 drugs	1,961	6,749,592	6.604
5 drugs	1,395	5,087,041	4.977
6 drugs	962	3,584,979	3.508
7 drugs	776	3,104,314	3.037
8 drugs	1,864	8,035,704	7.862

# -----

## D. OUTPATIENT DEPARTMENT DRUG MENTIONS

-----

## PATIENT AGE

CATEGORY	RECORDS	WEIGHTED MENTIONS	PERCENT	
Total	69,427	247,726,600	100.000	
1 - Under 15 years	10,558	28,316,539	11.431	
2 - 15-24 years	5,828	17,401,977	7.025	
3 - 25-44 years	15,311	50,845,164	20.525	
4 - 45-64 years	23,238	87,951,231	35.503	
5 - 65-74 years	7,906	33,342,177	13.459	
6 - 75 years and over	6,586	29,869,512	12.057	

PATIENT SEX					
CATEGORY	RECORDS	WEIGHTED MENTION	IS PERCENT		
Total 1 - Female 2 - Male	69,427 42,809 26,618	247,726,600 151,852,901 95,873,699	61.299		
PATIENT RACE					
CATEGORY			RECORDS	WEIGHTED MENTIONS	S PERCENT
Total			58,731	194,578,820	100.000
1 - White on	ly		41,634	140,776,596	72.349
2 - Black/Af	rican Ameri	ican only	13,390	47,440,588	24.381
3 - Asian on	ly		1,997	4,309,056	2.215
4 - Native H	awaiian/				
		Lander only	842	495,570	0.255
		aska Native only	283	906,628	0.557
6 - More tha	n one race	reported	570	782,242	0.402

DRUG THERAPEUTIC CATEGORIES (USING LEVEL 1 CODES)

CATEGORY	RECORDS	WEIGHTED MENTIONS	PERCENT
Total	74,612	264,963,802	100.000
'OO1'=Anti-infectives	5,754	22,921,389	8.651
'020'=Antineoplastics	1,058	3,458,034	1.305
'028'=Biologicals	183	566,898	0.214
'040'=Cardiovascular agents	8,796	36,430,460	13.749
'057'=Central nervous system agents	16,493	51,944,317	19.604
'081'=Coagulation modifiers	2,413	9,857,597	3.720
'087'=Gastrointestinal agents	3,819	15,098,255	5.698
'097'=Hormones	3,943	13,681,616	5.164
'105'=Miscellaneous agents	3,042	8,882,879	3.352
'115'=Nutritional products	5,026	16,745,583	6.320
'122'=Respiratory agents	6,424	22,960,944	8.666
'133'=Topical agents	4,319	14,285,971	5.392
ʻ153'=Plasma expanders	6	8,109	0.003
'218'=Alternative medicines	359	1,738,958	0.656
'242'=Psychotherapeutic agents	5,005	14,863,481	5.610
'254'=Immunological agents	2,526	8,738,117	3.298
'331'=Radiologic agents	80	133,732	0.050
'358'=Metabolic agents	5,338	22,531,770	8.504
'889'=Pharmaceutical aids	28	115,692	0.044

Therapeutic categories are based on Lexicon Plus<sup>®</sup>, a proprietary database of Cerner Multum, Inc. The Lexicon Plus is a comprehensive database of all prescription and some nonprescription drug products available in the U.S. drug market. For additional information on the Multum Lexicon Drug Database, please refer to the following Web site: <u>http://www.multum.com/Lexicon.htm</u>. For more information on coding therapeutic categories in the NHAMCS, see page 18.

## E. OUTPATIENT DEPARTMENTS

-----

REGION

		WEIGHTED	
CATEGORY	RECORDS	OUTPATIENT DEPTS	PERCENT
Total	235	2,663	100.000
Northeast	67	554	20.804
Midwest	59	745	27.976
South	71	959	36.012
West	38	405	15.208

MSA

CATEGORY	RECORDS	WEIGHTED OUTPATIENT DEPTS	PERCENT
Total MSA (Metropolitan Statistical Area) Non-MSA	235 204 31	2,663 1,701 962	100.000 63.875 36.125
OWNER CATEGORY	RECORDS	WEIGHTED OUTPATIENT DEPTS	PERCENT

Total	235	2,663	100.000
Voluntary non-profit	178	1,969	73.939
Government, non-Federal	48	505	18.964
Proprietary	9	189	7.097

#### APPENDIX I

## A. RELATIVE STANDARD ERRORS

The standard error is primarily a measure of the sampling variability that occurs by chance because only a sample is surveyed, rather than the entire universe. The relative standard error (RSE) of an estimate is obtained by dividing the standard error of the estimate by the estimate itself and is expressed as a percentage of the estimate. Standard errors and other measures of sampling variability are best determined by using a statistical software package that takes into account the sample designs of surveys to produce such measures.

While the initial release of masked design variables (starting with the 2000 data year, and continuing with re-released files for 1993-99) included the multi-stage variables necessary for running SUDAAN's full sample without-replacement design option, the 2002 release added two new variables (CSTRATM and CPSUM) needed for running programs that use an ultimate cluster model. Ultimate cluster variance estimates depend only on the first stage of the sample design, so that only first-stage cluster and first-stage stratum identification are required. The earlier version of the masked design variables could not be used with such software without substantial recoding. For 2003 forward, the decision was made to include only those two new variables on the files. The new variables, CSTRATM and CPSUM, differ from the earlier design variables STRATM and PSUM, in that providers are the first-stage sampling units in certainty areas (geographic areas selected with certainty), while geographic areas are the first-stage sampling units in non-certainty areas. Therefore, one should not use the new and old versions (CSTRATM and STRATM or CPSUM and PSUM) together (as for example, when combining years of data). Researchers who wish to combine data from 2003 forward with prior files which do not contain CSTRATM and CPSUM should refer to the technical paper, *Using Ultimate Cluster Models with NAMCS and NHAMCS Public Use Files*, at http://www.cdc.gov/nchs/nhamcs.htm.

Using computer software like SUDAAN to produce standard errors will, in general, yield results that are more accurate than those produced using the generalized variance curve described below. This is especially true for clustered variables like race, provider seen, or expected source of payment. The standard errors produced with such software using masked design variables, while improving substantially over the generalized variance curve results, will not always be as accurate as those produced using unmasked data. However, data files containing unmasked variables are confidential and are only available through the NCHS Research Data Center.

Examples using CSTRATM and CPSUM in Stata, SPSS, SUDAAN's 1-stage WR (with replacement) design option, and SAS's PROC SURVEYMEANS applications are presented below:

#### <u>Stata</u>

The pweight (PATWT), strata (CSTRATM), and PSU (CPSUM) are set with the svyset command as follows:

Stata 8: svyset [pweight=patwt], psu(cpsum) strata(cstratm)

Stata 9 and 10: svyset cpsum [pweight=patwt], strata(cstratm)

#### <u>SPSS</u>

This code pertains to SPSS Inc.'s Complex Samples 12.0 module. It would be used with the "Analysis Preparation Wizard" component of that module. The PLAN FILE statement would be invoked in statistical runs, as in the example for CSTABULATE shown below.

CSPLAN ANALYSIS /PLAN FILE='DIRECTORY\PLANNAME.CSAPLAN' /PLAN VARS ANALYSISWEIGHT=PATWT /PRINT PLAN /DESIGN STAGELABEL= 'ANY LABEL' STRATA=CSTRATM CLUSTER=CPSUM /ESTIMATOR TYPE=WR.

CSTABULATE /PLAN FILE='DIRECTORY\PLANNAME.CSAPLAN' /TABLES VARIABLES = var1 var2 /CELLS POPSIZE /STATISTICS SE /MISSING SCOPE = TABLE CLASSMISSING = EXCLUDE.

#### SUDAAN 1-stage WR Option

The program below provides a with replacement ultimate cluster (1-stage) estimate of standard errors for a cross-tabulation.

PROC CROSSTAB DATA=COMB1 DESIGN=WR FILETYPE=SAS; NEST CSTRATM CPSUM/MISSUNIT;

#### SAS - PROC SURVEYMEANS

PROC SURVEYMEANS DATA=COMB1; CLUSTER CPSUM; STRATA CSTRATM;

Since the ultimate cluster procedures discussed above compute Taylor series variance estimates, results should be identical. Results differ, however, when a single case stratum, or singleton, is present on the data file because each software package treats such cases differently. There are no singletons on the 2006 NHAMCS files, so this should not present a problem.

**IMPORTANT NOTE:** These examples can be used when producing visit or drug estimates. For department-level estimates, the statements are the same, but replace PATWT with either EDWT (for emergency department estimates) or OPDWT (for outpatient department estimates). The EDWT and OPDWT are only placed on the first record for each emergency department or outpatient department on the file. When running purely facility level analysis, it is recommended that only records with EDWT > 0 or OPDWT > 0 be selected; this will give the correct sample counts and will not affect estimation of variance. Weighted estimates will be correct either way.

In addition to producing estimates of department-level characteristics, it is possible to compute means of visit characteristics at the department level, for example, average waiting time to see a physician in the ED. This is a more complicated process, and is described with sample SAS code at the Ambulatory Health Care Data website (<a href="http://www.cdc.gov/nchs/nhamcs.htm">www.cdc.gov/nchs/nhamcs.htm</a>). For more information, contact the Ambulatory and Hospital Care Statistics Branch at 301-458-4600.

For data users who do not wish to use SUDAAN or similar programs to produce measures of sampling variability, we may be able to provide tables which contain relative standard errors based on generalized variance curves for a wide range of visit estimates and drug mention estimates by physician specialty. (Estimates with a relative standard error greater than 30 percent are considered unreliable by the standards of the National Center for Health Statistics. It should also be noted here that estimates based on fewer than 30 sample records are considered unreliable, regardless of the magnitude of the relative standard errors for visit estimates and be used to calculate approximate relative standard errors for visit estimates.

For aggregate estimates, relative standard errors may be calculated using the following general formula, where "x" is the aggregate of patient visits or drug mentions in thousands, and coefficients "A" and "B" are obtained from table III:

$$RSE(x) = \sqrt{A + \frac{B}{x}} \bullet 100$$

For estimates of percentages, relative standard errors may be calculated using the following general formula, where "p" is the percent of visits or drug mentions, "x" is the denominator of the percent in thousands, and coefficient "B" is obtained from table III:

$$RSE(x) = \sqrt{\frac{B \bullet (1 - p)}{p \bullet x}} \bullet 100$$

TABLE III. Coefficients appropriate for determining approximate relative standard errors of estimates by type of estimate and setting: National Hospital Ambulatory Medical Care Survey, 2006.

\_\_\_\_\_

	Coefficient for us	se with estimates i	<u>n thousands</u>	
	A	В	Lowest reliable estimate in thousands	
Patient visits				
Emergency departments Outpatient departments Drug mentions	0.002614 0.013352	6.228 9.262	71 121	
Emergency departments Outpatient departments	0.003864 0.019944	15.616 26.678	181 381	

For estimates of visit rates in which the numerator is the number of visits for a particular characteristic and the denominator is the total United States population, the relative standard error is equivalent to the relative standard error of the numerator, as shown in the previous paragraph on aggregate estimates.

**IMPORTANT NOTE:** For 2006, the OPD file masked design variables appear to understate the variance, on average, relative to what would be calculated with non-masked variables. Typically, masked design variables will overstate variance in some cases, and understate it in others, but with a general tendency to overstate slightly. The result is that variance estimates based on masked design variables are more conservative in general than estimates based on non-masked variables. Because of the trend towards understating variance noticed in with the 2006 OPD data, however, we recommend that data users set their p value at .01 rather than .05 in determining significance.

#### **B. INSTRUCTIONS FOR COMPLETING PATIENT RECORD FORMS (PRFs)**

#### I. EMERGENCY DEPARTMENT PATIENT RECORD FORM

#### 1. PATIENT INFORMATION

#### ITEM 1a. DATE OF VISIT

The month, day and year should be recorded in figures, for example, 05/17/2006 for May 17, 2006. Enter the last digit for the pre-filled 4-digit year.

#### ITEM 1b. ZIP CODE

Enter 5-digit zip code from patient's mailing address.

#### ITEM 1c. DATE OF BIRTH

The month, day, and year of the patient's birth should be recorded here, in the same fashion as Date of Visit above. In the rare event the date of birth is unknown, the year of birth should be estimated as closely as possible. Enter the 4-digit year.

#### ITEM 1d. TIME OF DAY

(1) Arrival - Record the hour and minutes that the patient arrived in figures. For example, enter 01:15 for 1:15 AM or 1:15 PM. Also, check the appropriate box (Military, AM or PM). Enter the first time listed in the medical record (i.e., arrival/registration/triage).

(2) Time seen by physician – Record the time (i.e., the hour and minute) when the physician began seeing the patient in figures. For example, enter 01:15 and then check the appropriate box (military, AM or PM). Check the box, if the patient was not seen by a physician.

(3) Discharge - Record the hour and minutes when the patient was discharged in figures. For example, enter 01:45 and then check the appropriate box (Military, AM or PM).

Check the box if the discharge time was more than 24 hours after the arrival time.

It is important that this item be recorded correctly. Please pay special attention to the Military, AM or PM boxes. Also, cross-check this item with Arrival Time (item 1d(1)). For example, time of discharge should be after the time patient entered the Emergency Department.

## **ITEM 1e. PATIENT RESIDENCE**

Res	sidence	Definition
1	Private residence	The patient's current place of residence is a private home (such as an apartment, single family home, townhouse, etc.)
2	Nursing home	The patient's current place of residence is a nursing home.
3	Other institution	The patient's current place of residence is an institution other than a nursing home (such as a prison, mental hospital, group home for the mentally retarded or physically disabled, etc.)
4	Other residence	The patient's current place of residence is a hotel, college dormitory, assisted living center, etc.
5	Homeless	The patient has no home (e.g., lives on the street) or patient's current place of residence is a homeless shelter.
6	Unknown	If you cannot determine the patient's current residence, mark "Unknown."

## ITEM 1f. MODE OF ARRIVAL

Mod	le	Definition
1	Ambulance	The patient arrives in an ambulance, either air or ground. This includes private and public ambulances that can provide either Advanced Life Support or Basic Life Support.
2	Public service	The patient arrives in a vehicle, such as a police car, a social service vehicle, beach patrol, etc., or is escorted or carried by a public service official.
3	Walk-in	The patient arrives by car, taxi, bus, or foot.
4	Unknown	The mode of arrival is unknown.

If two modes of arrival are shown, check the highest level box – Ambulance/Public service/Walk-in.

# ITEM 1g. SEX

Please check the appropriate category.

## ITEM 1h. ETHNICITY

Ethnicity refers to a person's national or cultural group. The ED Patient Record form has two categories for ethnicity, Hispanic or Latino and Not Hispanic or Latino.

Mark the appropriate category according to your hospital's usual practice or based on your knowledge of the patient or from information in the medical record. You are not expected to ask the patient for this information. If the patient's ethnicity is not known and is not obvious, mark the box which in your judgment is most appropriate. The definitions of the categories are listed below. Do not determine the patient's ethnicity from their last name.

Eth	inicity	Definition
1	Hispanic or Latino	A person of Cuban, Mexican, Puerto Rican, South or Central American or other Spanish culture or origin, regardless of race.
2	Not Hispanic or Latino	All other persons.

## ITEM 1i. RACE

Mark *all* appropriate categories based on observation or your knowledge of the patient or from information in the medical record. You are not expected to ask the patient for this information. If the patient's race is not known or not obvious, mark the box(es) which in your judgment is (are) most appropriate. Do not determine the patient's race from their last name.

	Race	Definition
1	White	A person having origins in any of the original peoples of Europe, Middle East, or North Africa.
2	Black/African American	A person having origins in any of the black racial groups of Africa.
3	Asian	A person having origins in any of the original peoples of the Far East, Southeast Asia, or the Indian subcontinent including, for example, Cambodia, China, India, Japan, Korea, Malaysia, Pakistan, the Philippine Islands, Thailand, and Vietnam.
4	Native Hawaiian/ Other Pacific Islander	A person having origins in any of the original peoples of Hawaii, Guam, Samoa, or other Pacific Islands.
5	American Indian/ Alaska Native	A person having origins in any of the original peoples of North America, and who maintains cultural identification through tribal affiliation or community recognition.

## ITEM 1j. EXPECTED SOURCE(S) OF PAYMENT FOR THIS VISIT

Mark the expected source or sources of payment that will pay for *this visit*. This information may be in the patient's file; however, in large hospitals, the billing information may be kept in the business office.

Mark all sources of payment that apply.

Primary Expected Source of Payment	Definition
1 Private insurance	Charges paid in-part or in-full by a private insurer (e.g., Blue Cross/Blue Shield) either directly to the hospital or reimbursed to the patient. Include
2 Medicare	charges covered under a private insurance sponsored prepaid plan. Charges paid in-part or in-full by a Medicare plan. Includes payments directly to the hospital as well as payments reimbursed to the patient. Include charges covered under a Medicare sponsored prepaid plan. Summacare is a health plan servicing the Akron, Ohio area and is
3 Medicaid/SCHIP	sometimes utilized in lieu of Medicare for that area. Charges paid in-part or in-full by a Medicaid plan. Includes payments made directly to the hospital as well as payments reimbursed to the patient. Include charges covered under a Medicaid sponsored prepaid plan or the State Children's Health Insurance Program (SCHIP).
4 Worker's compensation	Includes programs designed to enable employees injured on the job to receive financial compensation regardless of fault.
5 Self-pay	Charges, to be paid by the patient or patient's family, which will not be reimbursed by a third party. "Self-pay" is perhaps a poor choice of wording since we really have no interest in whether the patient actually pays the bill. This category is intended to include visits for which the patient is expected to be ultimately responsible for most of the bill. DO NOT check this box for a copayment or deductible.
6 No charge/Charity	Visits for which no fee is charged (e.g., charity, special research or teaching). Do not include visits paid for as part of a total package (e.g., prepaid plan visits, post-operative visits included in a surgical fee, and pregnancy visits included in a flat fee charged for the entire pregnancy). Mark the box or boxes that indicate how the services were originally paid.
7 Other	Any other sources of payment not covered by the above categories, such as CHAMPUS, state and local governments, private charitable organizations, and other liability insurance (e.g., automobile collision policy coverage).
8 Unknown	The primary source of payment is not known.

## 2. TRIAGE

## ITEM 2a. INITIAL VITAL SIGNS

Record the patient's initial body temperature and check the appropriate box (degrees C or F). Indicate the pulse and blood pressure of the patient at the time of arrival. Indicate if the patient is oriented to time, place, and person.

## ITEM 2b. IMMEDIACY WITH WHICH PATIENT SHOULD BE SEEN

Mark the box that best meets the clinical judgment made by the practitioner (e.g., triage nurse) about the patient's need for immediacy of evaluation, stabilization, and/or treatment. Level is assigned upon arrival at the ED.

Tr 1	iage Level Immediate	Definition (Emergent, Stat, Severe, Immediate, Expectant, Major trauma, Major medical problem) Severe condition where any delay would likely result in death.
2	1-14 minutes	(Emergent, Stat, Severe, Immediate, Expectant, Major trauma, Major medical problem) Severe illness or injury requiring immediate care to combat danger to life or limb and where any delay would likely result in deterioration.
3	15-60 minutes	(Urgent, ASAP) Illness or injury requiring treatment within 60 minutes.
4	>1 hour-2 hours	(Semi-urgent, Moderate, Delayed) Illness or injury requiring treatment within 60-120 minutes.
5	> 2 hours - 24 hours	(Non-urgent, Minimal, Minor trauma, Minor medical problem) Condition where delay of up to 24 hours would make no appreciable difference to the clinical condition, and where subsequent referral may be made to the appropriate alternative specialty.
6	No triage	Hospital does not perform triage or patient arrived DOA.
7	Unknown	Immediacy with which patient should be seen is not known.

## ITEM 2c. PRESENTING LEVEL OF PAIN

Mark the box that indicates the level of the patient's pain at triage as recorded in the medical record. Assessment of pain level should be based on the Clinical Practice Guidelines published by the Agency for Healthcare Research and Quality which provides a numerical pain intensity scale.

- 1 None Numerical rating of 0
- 2 Mild Numerical rating of 1-3
- 3 Moderate Numerical rating of 4-6
- 4 Severe Numerical rating of 7-10
- 5 Unknown Unable to determine level of pain

## 3. PREVIOUS CARE

#### ITEM 3a. HAS PATIENT BEEN SEEN IN THIS ED WITHIN THE LAST 72 HOURS?

Indicate whether the patient has been seen in this emergency department within the 72 hours prior to the current visit using the check boxes provided. If you are unable to determine whether the patient has been seen in this time period, please mark "Unknown."

#### ITEM 3b. HAS PATIENT BEEN DISCHARGED FROM ANY HOSPITAL WITHIN THE LAST 7 DAYS?

Indicate whether the patient has been discharged from any hospital within the last 7 days prior to the current visit by using the check boxes provided. If you are unable to determine whether the patient was discharged from any hospital within the last 7 days, please mark "unknown."

#### 4. REASON FOR VISIT

# ITEM 4a. PATIENT'S COMPLAINT(S), SYMPTOM(S) OR OTHER REASON(S) FOR THIS VISIT (*in patient's own words*)

Enter the Patient's complaint(s), symptom(s), or other reason(s) for this visit *in the Patient's own words*. Space has been allotted for the "most important" and two "other" complaints, symptoms, and reasons as indicated below.

- (1) Most important
- (2) Other
- (3) Other

The *Most Important* reasons should be entered in (1). Space is available for two other reasons in (2) and (3). By "most important" we mean the problem or symptom which in the physician's judgment, was most responsible for the patient making this visit. Since we are interested only in the patient's *most important complaints/ symptoms/ reasons,* it is not necessary to record more than three.

*This is one of the most important items on the Patient Record form.* No similar data on emergency department visits are available in any other survey and there is tremendous interest in the findings. Please take the time to be sure you understand what is wanted--especially the following two points:

We want the patient's principal complaint(s), symptom(s) or other reason(s) in the patient's own words. The physician may recognize right away, or may find out after the examination, that the real problem is something entirely different. In item 3a we are interested in how the patient defines the reason for the visit (e.g., "cramps after eating," "fell and twisted my ankle").

The item refers to the patient's complaint, symptom, or other reason for *this visit*. Conceivably, the patient may be undergoing a course of treatment for a serious illness, but if his/her principal reason for this visit is a cut finger or a twisted ankle, that is the information we want.

#### 2006 NHAMCS MICRO-DATA FILE DOCUMENTATION

There will be visits by patients for reasons other than some complaint or symptom. Examples might be follow-up for suture removal or recheck of a heart condition. In such cases, simply record the reason for the visit.

Reminder: If the reason for a patient's visit is to pay a bill, ask the physician to complete an insurance form, or drop off a specimen, then the patient is not eligible for the sample. A Patient Record form should not be completed for this patient.

## ITEM 4b. IS THIS VISIT WORK RELATED?

Mark "Yes" if the patient's condition is a result of an illness, injury or poisoning stemming from work-related activities. For example, mark "Yes" if the patient was injured while at work, or has a stress-related illness from working. Often payment by Worker's Compensation indicates a work-related illness or injury, but not always. Mark "No" if there is an indication that the condition is NOT work related. Mark "Unknown" if there is no mention of whether or not the patient's condition is work related.

"Yes" should be marked if the illness or injury occurred on employer premises while the patient was:

- Engaged in work activity, apprenticeship, or vocational training
- On break, in hallway, rest room, cafeteria, or storage area
- In employer parking lot while working, arriving, or leaving

"Yes" should also be checked if the illness or injury occurred off the employer's premises while the patient was:

- Working for pay or compensation, including at home
- Working as a volunteer EMS, firefighter, or law enforcement officer
- Working in the family business, including family farm
- Traveling on business, including to and from customer/business contacts
- Engaged in work activity where vehicle is considered the work environment (e.g., taxi driver, truck driver, etc.)

"No" should also be checked if the illness or injury occurred:

- 1) On employer premises but--the patient was:
- Engaged in recreational activities on employer controlled facilities (games, etc.) for personal enjoyment
- A visitor for non-work purposes, not on official business, or
  - 2) Off employer premises--but the patient was:
- A homemaker working at homemaking activities
- Working for self non profit (i.e., mowing lawn, repairing own roof, hobby, or recreation activities)
- A student engaged in school activities
- Operating vehicle (personal or commercial) for non-work purposes
- Commuting to or from work site

#### 5. INJURY/POISONING/ADVERSE EFFECT

# ITEM 5a. IS THIS VISIT RELATED TO AN INJURY, OR POISONING, OR ADVERSE EFFECT OF MEDICAL TREATMENT?

Mark the "Yes" or "No" box to indicate whether the patient's visit was due to any type of injury, poisoning, or adverse effect of medical treatment. The injury/poisoning/adverse effect does not need to be recent. It can include those visits for follow up of previously treated injuries and visits for flare-ups of problems due to old injuries. This not only includes injuries or poisonings, but also adverse effects of medical treatment or surgical procedures (e.g., unintentional cut during a surgical procedure, foreign object left in body during procedure, and adverse drug events). Include any prescription, over-the-counter medication or illegal drugs involved in an adverse drug event (e.g., allergies, overdose, medication error, drug interactions).

## ITEM 5b. IS THIS INJURY/POISONING INTENTIONAL?

Indicate whether the injury was intentional (i.e., self-inflicted or an assault), unintentional, or unknown.

#### ITEM 5c. CAUSE OF INJURY, POISONING OR ADVERSE EFFECT

Provide a brief description of the *who, what, when, where, and why* associated with the injury, poisoning or the adverse effects of medical treatment or surgical procedures including adverse drug events (e.g., allergy to penicillin). Indicate the place of the injury (e.g., residence, recreation or sports area, street or highway, school, hospital, public building, or industrial place). Include any post-surgical complications and if it involved an implant, specify what kind. If safety precautions were taken, describe them (e.g., seat belt use). Be sure to include the mechanism that caused the injury (e.g., farm equipment, fire, arsenic, knife, pellet gun). If it was a work-related injury or poisoning, specify the industry of the patient's employment (e.g., food service, agricultural, mining, health services, etc.).

Describe in detail the circumstances that caused the injury (e.g., fell off monkey bars, motor vehicle involving collision with another car, spouse beaten with fists by spouse). Include information on the role of the patient associated with the injury (e.g., bicyclist, pedestrian, unrestrained driver or passenger in a motor vehicle, horseback rider), the specific place of occurrence (e.g., lake, school football field), and the activity in which the patient was engaged at the time of the injury (e.g., swimming, boating, playing football).

Also include what happened to the patient and identify the proximate cause of the injury or injuries for which the patient sought treatment. The proximate cause of injury is the mechanism of injury that is temporarily or immediately responsible for the injury. An example is a laceration caused by a broken piece of glass. Include, in addition, the underlying or precipitating cause of injury (i.e., the event, mechanism, or external cause of injury that initiated and led to the proximate cause of injury). An example is a house fire that caused a person to jump out of the window. Both the precipitating or underlying cause (house fire) and the proximate cause (fall from roof) would be important to record. It's especially important to record as much detail about falls and motor vehicle crashes as possible. For each, indicate what the fall was from (e.g., steps) and where the patient landed (e.g., pavement). The National Center for Health Statistics will use the information collected to classify the cause of the injury using the International Classification of Diseases, Supplementary Classification of External Causes of Injury and Poisoning codes (ICD-9-CM E-Codes).

#### 6. PHYSICIAN'S DIAGNOSIS FOR THIS VISIT

(1) Primary diagnosis

(2) Other

(3) Other

This is one of the most important items on the Patient Record Form. Item 6(1) refers to the physician's primary diagnosis for this visit. While the diagnosis may be tentative, provisional, or definitive it should represent the physician's best judgment at this time, expressed in acceptable medical terminology including "problem" terms. If the patient was not seen by a physician, then the diagnosis by the main medical provider should be recorded.

If a patient appears for *postoperative* care (follow up visit after surgery), record the postoperative diagnosis as well as any other. The postoperative diagnosis should be indicated with the letters "P.O."

Space has been allotted for two "other" diagnoses. In Items 6(2) and 6(3) list the diagnosis of other conditions related to this visit. Include chronic conditions (e.g., hypertension, depression, etc.) if related to this visit.

#### 7. DIAGNOSTIC/SCREENING SERVICES

Mark all services that were ordered or provided during *this visit* for the purpose of screening (i.e., early detection of health problems in asymptomatic individuals) or diagnosis (i.e., identification of health problems causing individuals to be symptomatic). EACH SERVICE ORDERED OR PROVIDED SHOULD BE MARKED.

Mark the "NONE" box if no blood tests, imaging services, or other tests were ordered or provided.

For "Electrolytes," include any of the following tests: electrolytes, sodium (Na), chloride (Cl), potassium (K), biocarbonate (HCO<sub>3</sub>), calcium (Ca), magnesium (Mg).

For "Cardiac enzymes," include any of the following tests: CPK (creatine phosphokinase), CK (creatine kinase), LD or LDH (lactic dehydrogenase), SGOT (serum glutamic-oxaloacetic transaminase) or AST (aspartate aminotransferase), myoglobin, and troponin (include forms T, I, and L).

For "Liver function tests," include any of the following tests: ALP (akaline phosphatase), SGPT (serum glutamate pyruvate transaminase) or ALT (alanine transaminase), SGOT (serum glutamic-oxaloacetic transaminase) or AST (aspartate aminostransferase), GGT (gamma-glutamyl transpeptidase), and serum bilirubin.

For "Pulse oximetry," enter the percent of arterial oxyhemoglobin saturation.

For "Arterial blood gases," include the measurement of the levels of pH, oxygen ( $PO_2$  or  $PaO_2$ ) carbon dioxide ( $PCO_2$  or  $PaCO_2$ ), bicarbonate ( $HCO_3$ ), and oxygen saturation ( $SaO_2$ ).

If services were ordered or provided but not listed, mark the "Other blood test," "Other test/service," or "Other imaging." boxes.

#### 8. PROCEDURES

Mark all procedures provided at this visit. Mark the "NONE" box if no procedures were provided.

2 3 4	Bladder catheter CPR Endotracheal	Any type of catheter used to obtain urine from the bladder (e.g., Foley). Cardiopulmonary resuscitation. Insertion of a laryngoscope into the mouth followed by a tube into the
5	intubation IV fluids	trachea. Administration of intravenous fluids.
6	Nebulizer therapy	Therapy where bronchodilator (airway-opening) medications (e.g., albuterol), are delivered through a nebulizer which changes liquid medicine into fine droplets (in aerosol or mist form) that are inhaled
7	NG tube/	through a mouthpiece or mask. Insertion of a nasogastric (NG) tube through the nose, down the esophagus and into the stomach.
	Gastric suction	A procedure used to empty the contents of the stomach, usually for analysis or removal of irritating elements, such as poisons.
8 9	OB/GYN care Orthopedic care	Treatment of obstetric or gynecologic conditions, including routine care. Treatment of orthopedic injuries or conditions; includes reduction, casting, wrapping, splinting, and aspiration of fluid from joints.
10	Thrombolytic therapy	The use of one or more medications to break up or destroy blood clots, which are the main cause of both heart attack and stroke.
11	Wound care	Includes cleaning, debridement, and dressing of burns; repair of lacerations with skin tape or sutures; removal of foreign bodies;
12	Other	excisions; and incision and drainage of wounds. Mark if other procedures were provided but not listed.

#### 9. MEDICATIONS & IMMUNIZATIONS

## ITEM 9. LIST UP TO EIGHT MEDICATION/IMMUNIZATION NAMES BELOW.

Please list up to eight drugs given at this visit or prescribed at ED discharge, using either the brand or generic names. Include prescription and over-the-counter drugs, immunizations, dietary supplements, and anesthetics.

Record the exact drug name (brand or generic) written on any prescription or medical record.

Do not enter broad drug classes, such as "laxative," "cough preparation," "analgesic," "antacids," "birth control pill," or "antibiotics." The one exception is "allergy shot."

#### 2006 NHAMCS MICRO-DATA FILE DOCUMENTATION

For each drug listed, mark the appropriate box indicating if the medication was given in the ED or prescribed at discharge. If the same drug was both given in the ED and prescribed at discharge, then mark (X) both boxes.

## 10. PROVIDERS SEEN

Mark all providers seen during this visit. If care was provided, at least in part, by a person not represented in the seven categories, mark the "Other" box.

## **11. VISIT DISPOSITION**

Mark all that apply.

Visit	Disposition	Definition
1	No follow-up	No return visit or telephone contact is scheduled or planned for
2	planned Return if needed, PRN/appointment	the patient's problem. The patient is instructed to return to the ED as needed; or the patient was told to schedule an appointment or was given an appointment to return to the ED at a particular time.
3	Return/Refer to physician/clinic for FU	The patient was referred to the ED by his or her personal physician or some other physician and is now instructed to consult with the physician who made the referral. The patient was screened, evaluated, stabilized and then referred to another physician or clinic for follow-up.
4	Refer to social services	The patient was referred to social services, including both those provided in the hospital and the community (e.g., social work, alcohol or drug treatment program, home health care, counseling services).
5	Left AMA	The patient left against medical advice, that is, the patient was evaluated by the hospital staff and advised to stay and receive or complete treatment.
6	Left without being seen	The patient left the hospital after being triaged, but before receiving any medical care.
7	DOA/died in ED	If the patient was dead on arrival (DOA) or died in the ED, this patient is still included in the sample if listed on the arrival log.
8	Transfer to different hospital	The patient was transferred to a different hospital. Indicate the reason why the patient was transferred in the space provided.
9	Admit to	The patient was sent to a designated observation unit in the ED
10	observation unit Admit to hospital	for evaluation and management or to wait for an inpatient bed. The patient was instructed that further care or treatment was needed and was admitted to a hospital. If "Admit to hospital" was marked, then please continue with item 12 – HOSPITAL ADMISSION on the reverse side.
11	Other	Any other disposition not included in the above list.

## **12. HOSPITAL ADMISSION**

If box "10 – Admit to Hospital" in ITEM 11. VISIT DISPOSITION was marked, continue on the reverse side of the NHAMCS-100(ED) and complete ITEM 12 HOSPITAL ADMISSION. If the information for items 12c-12e are not available at the time of the abstraction, please complete the NHAMCS-105, Hospital Admission Log.

#### ITEM 12a. ADMITTED TO:

Тур	e of Unit	Definition
1	Critical care unit –	A critical care unit of the hospital, (e.g., Intensive Care Unit (ICU), Coronary Care Unit (CCU), Pediatric Intensive Care Unit (PICU)).
2	OR/Cath lab –	The patient was sent directly to the operating room or cardiac catheterization lab from the ED.
3	Other bed/unit –	The patient was admitted to a bed/unit in the hospital not listed above (e.g., med/surg unit).
4	Unknown –	Information is not available to determine where the patient was admitted.

#### **ITEM 12b. HOSPITAL ADMISSION TIME**

Record the hours and minutes that the patient was admitted to the hospital in figures. For example, enter 05:45 and then check the appropriate box (Military, AM, or PM).

## ITEM12c. HOSPITAL DISCHARGE DATE

The month, day and year, should be recorded in figures, for example 05/17/2005 for May 17, 2005. Enter last digit for the pre-filled 4-digit year.

## ITEM 12d. PRINCIPAL HOSPITAL DISCHARGE DIAGNOSIS

Enter the principal hospital discharge diagnosis.

### ITEM 12e. HOSPITAL DISCHARGE STATUS

Mark the appropriate check box.

## **II. OUTPATIENT DEPARTMENT PATIENT RECORD FORM**

#### 1. PATIENT INFORMATION

**ITEM 1a. DATE OF VISIT** – same as ED.

ITEM 1b. ZIP CODE – same as ED.

**ITEM 1c. DATE OF BIRTH** – same as ED.

#### ITEM 1d. SEX

Please check the appropriate category. If "female" is marked, please answer the sub-question: "Is patient pregnant?" If "Yes" is marked, specify gestation week. If gestation week is unknown, then record LMP (last menstrual period) date in same fashion as Date of Visit.

ITEM 1e. ETHNICITY - same as ED Item 1h.

ITEM 1f. RACE – same as ED Item 1j.

#### ITEM 1g. TOBACCO USE

Tobacco use is defined as smoking cigarettes/cigars, using snuff, or chewing tobacco. Mark "Not current" if the patient does not currently use tobacco. If "Not current" is marked, then mark "Never" if the patient has never used tobacco or "Former" if the patient formerly used tobacco. Mark "Current" if the patient uses tobacco. Mark "Unknown" if it cannot be determined whether the patient currently uses or does not use tobacco.

1 Not current	2 Current
1 Never	3 Unknown
2 Former	

## ITEM 1h. EXPECTED SOURCE OF PAYMENT FOR THIS VISIT

Mark (X) ALL appropriate expected source(s) of payment.

Expected Source of Payment 1 Private insurance	Definition Charges paid in-part or in-full by a private insurer (e.g., Blue Cross/Blue Shield) either directly to the hospital or reimbursed to the patient. Include charges covered under a private insurance sponsored prepaid plan.
2 Medicare	Charges paid in-part or in-full by a Medicare plan. Includes payments directly to the hospital as well as payments reimbursed to the patient. Include charges covered under a Medicare sponsored prepaid plan.
3 Medicaid/SCHIP	Charges paid in-part or in-full by a Medicaid plan. Includes payments made directly to the hospital as well as payments reimbursed to the patient. Include charges covered under a Medicaid sponsored prepaid plan or the State Children's Health Insurance Program (SCHIP).
4 Worker's	Includes programs designed to enable employees injured on the job to
compensation 5 Self-pay	receive financial compensation regardless of fault. Charges, to be paid by the patient or patient's family, which will not be reimbursed by a third party. "Self-pay" is perhaps a poor choice of wording since we really have no interest in whether the patient actually pays the bill. This category is intended to include visits for which the patient is expected to be ultimately responsible for most of the bill. DO NOT check this box for a copayment or deductible.
6 No charge/Charity	Visits for which no fee is charged (e.g., charity, special research or teaching). Do not include visits paid for as part of a total package (e.g., prepaid plan visits, post-operative visits included in a surgical fee, and pregnancy visits included in a flat fee charged for the entire pregnancy). Mark the box or boxes that indicate how the services were originally paid.
7 Other	Any other sources of payment not covered by the above categories, such as CHAMPUS, state and local governments, private charitable organizations, and other liability insurance (e.g., automobile collision policy coverage).
8 Unknown	The primary source of payment is not known.

## 2. INJURY/POISONING/ADVERSE EFFECT

## ITEM 2. IS THIS VISIT RELATED TO ANY OF THE FOLLOWING?

If ANY PART of this visit was related to an injury or poisoning or adverse effect of medical or surgical care or an adverse effect of a medicinal drug, then mark (X) the appropriate box. Indicate whether the injury or poisoning was intentional (i.e., self-inflicted or an assault) or unintentional. The injury/poisoning/adverse effect does not need to be recent. It can include those visits for follow up of previously treated injuries and visits for flare-ups of problems due to old injuries. This item not only includes injuries or poisonings, but also adverse effects of medical treatment or surgical procedures (e.g., unintentional cut during a surgical procedure, foreign object left in body during procedure, and adverse drug events). Include any prescription or over-the-counter medication involved in an adverse drug event (e.g., allergies, overdose, medication error, drug interactions).

If the visit was not related to an injury, or poisoning or adverse effect of medical or surgical care or an adverse effect of a medicinal drug, then mark (X) "None of the above" and if it could not be determined mark (X) "Unknown."

#### 3. REASON FOR VISIT – same as ED Item 4.

#### 4. CONTINUITY OF CARE

#### ITEM 4a. ARE YOU THE PATIENT'S PRIMARY CARE PHYSICIAN/PROVIDER?

The primary care physician/provider plans and provides the comprehensive primary health care of the patient. Mark "Yes" if the health care provided to the patient during this visit was from his/her primary care physician/provider and skip to Item 4b. If the physician/provider seen at this visit was substituting for the primary care physician/provider, also check "Yes." Mark "No" if care was not from the primary care physician/provider and "Unknown" if it is not known.

If "No" or "Unknown" is checked, also indicate whether the patient was referred for this visit by another physician or health care provider. This item provides an idea of the "flow" of ambulatory patients from one physician/provider to another. Mark the "Yes," "No," or "Unknown" category, as appropriate.

Notice that this item concerns referrals to the sample clinic by a different physician/provider or clinic. The interest is in referrals for this visit and not in referrals for any prior visit.

Referrals are any visits that are made because of the advice or direction of a clinic or physician/provider other than the clinic or physician/provider being visited.

#### ITEM 4b. HAS THE PATIENT BEEN SEEN IN THIS CLINIC BEFORE?

"Seen" means "provided care for" at any time in the past. Mark "Yes, established patient" if the patient was seen before by any physician or staff member in the clinic. Exclude this visit.

Mark "No, new patient" if the patient has not been seen in the clinic before.

If "Yes" is checked, also indicate approximately how many past visits the patient has made to this clinic within the last 12 months using the check boxes provided. Do not include the current visit in your total. If you cannot determine how many past visits were made, then please mark "Unknown." Include all visits to other physicians or health care providers in this clinic.

#### ITEM 4c. MAJOR REASON FOR THIS VISIT

Mark the major reason for the patient's current visit. Be sure to check only one of the following "Major Reasons:"

1	Problem New Problem	Definition A visit for a condition, illness, or injury having a relatively
-		sudden or recent onset (within three months of this visit).
2	Chronic Problem, Routine	A visit primarily to receive care or examination for a pre-existing chronic condition, illness, or injury (onset of condition was three months or more before this visit).
3	Chronic Problem, Flare up	A visit primarily due to sudden exacerbation of a pre-existing chronic condition.
4	Pre- or Post- Surgery	A visit scheduled primarily for care required prior to or following surgery (e.g., pre-surgery tests, removing sutures).
5	Preventive Care	General medical examinations and routine periodic examinations. Includes prenatal and postnatal care, annual physicals, well-child exams, screening, and insurance examinations.

## 5. PHYSICIAN'S DIAGNOSIS FOR THIS VISIT

# ITEM 5a. AS SPECIFICALLY AS POSSIBLE, LIST DIAGNOSES RELATED TO THIS VISIT INCLUDING CHRONIC CONDITIONS. – Same as ED item 6.

## ITEM 5b. REGARDLESS OF THE DIAGNOSES WRITTEN IN 5a, DOES PATIENT NOW HAVE:

The intent of this item is to supplement the diagnosis reported in item 5a(1), 5a(2), and 5a(3). Mark all of the selected condition(s) regardless if it is already reported in item 5a. Even if the condition is judged to be not clinically significant for this visit, it should still be checked. General descriptions for each condition are listed below.

Condition	Description
1 Arthritis	Includes those types of rheumatic diseases in which there is an inflammation involving joints, (e.g., osteoarthritis, rheumatoid arthritis, acute arthritis, juvenile chronic arthritis, hypertrophic arthritis, Lyme arthritis, and psoriatic arthritis).
2 Asthma	Includes extrinsic, intrinsic, and chronic obstructive asthma.
3 Cancer (ca)	Includes any type of cancer (ca), such as, carcinoma, sarcoma, leukemia, and lymphoma.

#### 2006 NHAMCS MICRO-DATA FILE DOCUMENTATION

Several cancer staging systems exist. A cancer patient's prognosis and treatment is determined using the American Joint Committee on Cancer (AJCC) *Cancer Staging Handbook*. For comparability of stage and treatment results over time, the Surveillance, Epidemiology and End Results (SEER) Summary State is still collected and used. Below is a scheme of how the staging systems compare.

# Comparability between AJCC staging system and SEER Summary Stage with the exception of prostate cancer

AJCC Stage	SEER Summary Stage	In item 5b(3), mark box:
0 (In-situ)	In-situ	0 – In situ
I	Localized	1 - Local
11	Regional (by direct extension or	2 - Regional
111	positive lymph nodes)	
IV	Distant (cancer found in other	3 - Distant
	organs)	
Unknown	Unknown	4 - Unknown

## Comparability between AJCC staging system and SEER Summary Stage for prostate cancer

Prostate cancer represents a special situation as most patients do not undergo surgery. The table below provides a summary of the equivalent correlations between the staging systems.

Prostate Cancer (AJCC)	Prostate Cancer SEER Summary Stage	In item 5b(3), mark box:
0 (In-situ)	In-situ	0 – In situ
I (T1) no extension (Stage A) II (T2) no extension, no lymph nodes involved (Stage B)	Localized (confined to prostate gland)	1 - Local
III (T3) negative lymph nodes involved (Stage C)	Regional (extends to other organs, no lymph nodes involved)	2 - Regional
IV (T4) positive lymph nodes (Stage D) Distant metastasises	Regional (extends to other organs, positive lymph nodes involved) Distant metastasises	3 - Distant
Unknown	Unknown	4 - Unknown

- 4 Cerebrovascular disease
- 5 CHF (congestive heart failure)
- 6 Chronic renal
- 7 COPD (chronic obstructive pulmonary disease)
- 8 Depression

Includes stroke and transient ischemic attacks (TIAs).

Includes end-stage renal disease (ESRD) and chronic kidney failure due to failure diabetes or hypertension.

Includes chronic bronchitis and emphysema. Excludes asthma.

Includes affective disorders and major depressive disorders, such as episodes of depressive reaction, psychogenic depression, and reactive depression.

9 Diabetes	Includes both diabetes mellitus and diabetes insipidus.
10 Hyperlipidemia	Includes hyperlipidemia and hypercholesterolemia.
11 Hypertension	Includes essential (primary or idiopathic) and secondary hypertension.
12 Ischemic heart	Includes angina pectoris, coronary atherosclerosis, acute myocardial disease infarction, and other forms of ischemic heart disease.
13 Obesity	Includes body weight 20% over the standard optimum weight.
14 Osteoporosis	
15 None of the above	Mark (X) if none of the conditions above exist.

# ITEM 5c. STATUS OF PATIENT ENROLLMENT IN A DISEASE MANAGEMENT PROGRAM FOR ANY OF THE CONDITIONS MARKED IN 5b

A disease management program is defined as a set of interventions designed to improve the health of individuals by working more directly with them and their physicians and support-service providers on their treatment plans regarding diet, adherence to medicine schedules, and other self-management techniques. Other components of the program include outcomes measurement and a routine reporting/feedback loop which may involve communication with the patient, physician, health plan, and ancillary providers.

## 6. VITAL SIGNS

(1) Height	Record the patient's height if measured at this visit. If it was not measured at this visit and the patient is 21 years of age or over, then review the chart for the last time that height was recorded and enter that value. Mark the appropriate box (ft/in or cm).
(2) Weight	Record the patient's weight if measured at this visit. If it was not measured at this visit and the patient is 21 years of age or over, then review the chart for the last time that weight was recorded and enter that value. Mark the appropriate box (lbs or kg).
(3) Temperature	Record the patient's temperature if measured at this visit. Mark the appropriate box (degrees C or F).
(4) Blood pressure	Record the patient's blood pressure if measured at this visit.

#### 7. DIAGNOSTIC/SCREENING SERVICES

Mark all services that were ordered or provided during this visit for the purpose of screening (i.e., early detection of health problems in asymptomatic individuals) or diagnosis (i.e., identification of health problems causing individuals to be symptomatic). EACH SERVICE ORDERED OR PROVIDED SHOULD BE MARKED. At visits for a complete physical exam, several tests may be ordered prior to the visit, so that the results can be reviewed during the visit. Since these services are related to the visit, the appropriate box(es) should be marked.

Mark the "NONE" box if no Diagnostic/Screening Services were ordered or provided.

For "Electrolytes," include any of the following tests: electrolytes, sodium (Na), chloride (Cl), potassium (K), calcium (Ca), magnesium (Mg).

For "Lipids/Cholesterol," include any of the following tests: cholesterol, LDL, HDL, cholesterol/HDL ratio, triglycerides, coronary risk profile, lipid profile.

For "Biopsy," include any form of open or closed biopsy of lesions or tissues.

For "Chlamydia test," only include the following tests if chlamydia is specifically mentioned: enzyme-linked immunosorbent assay (ELISA, EIA), direct fluorescent antibody test (DFA), nucleic acid amplification test (NAAT), nucleic acid hybridization test (DNA probe testing), or chlamydia culture.

"Pap test – conventional" refers to a smear spread on a glass slide and fixed.

"Pap test – liquid-based cytology" refers to a specimen suspended in a liquid solution.

"HPV DNA test" detects the presence in women of human papillomavirus and is performed by collecting cells from the cervix.

If a scope procedure was ordered or provided, mark the "Scope Procedure – Specify" box and write-in the type in the space provided.

If services were ordered or provided, but are not listed, mark the "Other test/service - Specify" box and write-in the service(s) in the space provided.

## 8. HEALTH EDUCATION

Mark all appropriate boxes for any of the following types of health education ordered or provided to the patient during the visit. Exclude medications.

Mark the "NONE" box if no counseling, educational, or therapeutic services were provided.

Health Education		Definition
2	Asthma Education	Information regarding the elimination of allergens that may exacerbate asthma, or other activities that could lead to an asthma attack or instruction on the use of medication, such as an inhaler.
3	Diet/Nutrition	Any topic related to the foods and/or beverages consumed by the patient. Examples include general dietary guidelines for health promotion and disease prevention, dietary restrictions to treat or control a specific medical problem or condition, and dietary instructions related to medications. Includes referrals to other health professionals, for example, dietitians and nutritionists.
4	Exercise	Any topics related to the patient's physical conditioning or fitness. Examples include information aimed at general health promotion and disease prevention and information given to treat or control a specific medical condition. Includes referrals to other health and fitness professionals. Does not include referrals for physical therapy. Physical therapy ordered or provided at the visit is listed as a separate check box in item 9.
5	Growth/ Development	Any topics related to human growth and development.
6	Injury Prevention	Any topic aimed at minimizing the chances of injury in one's daily life. May include issues as diverse as drinking and driving, seat belt use, child safety, avoidance of injury during various physical activities, and use of smoke detectors.
7	Stress Management	Information intended to help patients reduce stress through exercise, biofeedback, yoga, etc. Includes referrals to other health professionals for the purpose of coping with stress.
8	Tobacco use/exposure	Information given to the patient on issues related to tobacco use in any form, including cigarettes, cigars, snuff, and chewing tobacco, and on the exposure to tobacco in the form of "secondhand smoke." Includes information on smoking cessation as well as prevention of tobacco use. Includes referrals to other health professionals for smoking cessation programs.
9	Weight reduction	Information given to the patient to assist in the goal of weight reduction. Includes referrals to other health professionals for the purpose of weight reduction.
10	Other	Check if there were other types of health education ordered or provided that were not listed above.

## 9. NON-MEDICATION TREATMENT

Mark (X) all non-medication treatments ordered or provided at this visit.

Non-Medication treatment		Definition
treat 1	NONE	No non-medication treatments were ordered, scheduled, or performed at this visit.
2	Complementary or alternative medicine (CAM)	Includes medical interventions neither widely taught in medical schools nor generally available in physician offices or hospitals (e.g., acupuncture, chiropractic, homeopathy, massage, or herbal therapies).
3	Durable medical equipment	Equipment which can withstand repeated use, (i.e., could normally be rented and used by successive patients; is primarily used to serve a medical purpose; generally is not useful to a person in the absence of illness or injury); and is appropriate for use in the patient's home, (e.g., cane, crutch, walker, wheelchair)
4	Home health care	Includes services provided to individuals and families in their places of residence for the purpose of promoting, maintaining, or restoring health or for maximizing the level of independence while minimizing the effects of disability and illness, including terminal illness. Services may include skilled nursing care; help with bathing, using the toilet, or dressing provided by home health aides; and physical therapy, speech language pathology services, and occupational therapy.
5	Hospice care	A program of palliative care (i.e., care which serves to relieve or alleviate without curing) and supportive care services providing physical, psychological, social, and spiritual care for dying persons, their families, and other loved ones. Hospice services are available in both the home and inpatient settings. Home hospice care is provided on a part-time, intermittent, regularly scheduled, and around-the-clock basis. Bereavement services and other types of counseling are available to the family and other loved ones.
6	Physical therapy	Physical therapy includes treatments using heat, light, sound, or physical pressure or movement, (e.g., ultrasonic, ultraviolet, infrared, whirlpool, diathermy, cold, or manipulative therapy).
7	Radiation therapy	The use of high-energe penetrating rays or subatomic particles to treat disease.
8	Speech/ Occupational therapy	Speech therapy includes the treatment of defects and disorders of the voice and of spoken and written communication. Occupational therapy includes the therapeutic use of work, self-care, and play activities to increase independent function, enhance development, and prevent disability.
9	Psychotherapy	All treatments involving the intentional use of verbal techniques to explore or alter the patient's emotional life in order to effect symptom reduction or behavior change.
10	Other mental health counseling	General advice and counseling about mental health issues and education about mental disorders. Includes referrals to other mental health professionals for mental health counseling.
11	Excision of tissue	Includes any excision of tissue such as polyps, cysts, or moles. Excludes would care and biopsy.

Non-Medication treatment		Definition
12	Orthopedic care	Includes reduction, casting, wrapping, splinting, and aspiration of fluid from joints.
13	Wound care	Includes cleaning, debridement, and dressing of burns; repair of lacerations with skin tape or sutures; removal of foreign bodies; and incision and draining of wounds.
14	Other non- surgical procedures	Write-in any non-surgical procedure ordered or performed at this visit that was not previously recorded.
15	Other surgical procedures	Write-in any surgical procedure ordered or performed at this visit that was not previously recorded. Surgical procedures may be simple (e.g., insertion of intrauterine contraceptive device) or complex (e.g., cataract extraction, hernia repair, hip replacement, etc.)

## **10. MEDICATIONS & IMMUNIZATIONS**

If medications or immunizations were ordered, supplied, administered, or continued at this visit, please list them (up to 8) in the space provided using either the brand or generic names. Record the exact drug name (brand or generic) written on any prescription or on the medical record. Do not enter broad drug classes, such as "laxative," "cough preparation," "analgesic," "antacid," "birth control pill," or "antibiotic." The one exception is "allergy shot." If no medication was prescribed, provided, or continued, then mark (X) the "NONE" box and continue.

Medication, broadly defined, includes the specific name of any:

prescription and over-the-counter medications, anesthetics, hormones, vitamins, immunizations, allergy shots, and dietary supplements.

medications and immunizations which the physician/provider ordered or provided prior to this visit and instructs or expects the patient to continue taking regardless of whether a "refill" is provided at the time of visit.

For each medication, record if it was new or continued.

#### 11. PROVIDERS

Mark all providers seen during this visit. If care was provided, at least in part, by a person not represented in the four categories, mark the "Other" box.

#### **12. VISIT DISPOSITION**

Mark all that apply.

Visit Disposition		Definition
1	No follow-up planned	No return visit or telephone contact was scheduled or planned for the patient's problem.
2	Return if needed, PRN	The patient was instructed to return to the clinic as needed.
3	Refer to other physician	The patient was instructed to consult or seek care from another physician. The patient may or may not return to this clinic at a later date.
4	Return at specified time	The patient was told to schedule an appointment or was given an appointment to return to the clinic at a particular time.
5	Telephone follow-up planned	The patient was instructed to telephone the physician or other clinic staff on a particular day to report on his or her progress, or a member of the clinic staff plans to call the patient to check on his or her condition.
6	Refer to emergency department	The patient was instructed to go to the emergency department for further evaluation and care immediately.
7	Admit to hospital	The patient was instructed that further care or treatment will be provided as an inpatient in the hospital.
8	Other	Any other disposition not included in the above list.

#### C. DEFINITIONS OF CERTAIN TERMS USED IN THE SURVEY

<u>Patient</u> - An individual seeking personal health services not currently admitted to any health care institution on the premises. Patients arriving by ambulance are included. Patients are defined as in scope or out of scope as follows:

In scope - A patient seen by hospital staff in an in scope emergency service area or clinic except as excluded below.

<u>Out of scope</u> - Patients seen by a physician in their private office, nursing home, or other extended care institution or in the patient's home. Patients who contact and receive advice from hospital staff via telephone. Patients who come to the hospital only to leave a specimen, to pick up insurance forms, to pick up medication, or to pay a bill.

<u>Visit</u> - A direct, personal exchange between an ambulatory patient seeking care and a physician or other hospital staff member working under the physician's supervision for the purpose of rendering personal health services.

<u>Drug mention</u> - The health care provider's entry on the Patient Record form of a pharmaceutical agent ordered, supplied, administered or continued during the visit-- by any route of administration--for prevention, diagnosis, or treatment. Generic as well as brand name drugs are included, as are nonprescription as well as prescription drugs. Along with all new drugs, the hospital staff also records continued medications if the patient was specifically instructed during the visit to continue the medication.

<u>Hospital</u> - All hospitals with an average length of stay for all patients of less than 30 days (short-stay) or hospital whose specialty is general (medical or surgical) or children's general are eligible for the National

Hospital Ambulatory Medical Care Survey except Federal hospitals and hospital units of institutions, and hospitals with less than six beds staffed for patient use.

<u>Ownership</u> - Hospitals are designated according to the primary owner of the hospital based on the Verispan Hospital Data Base.

<u>Voluntary nonprofit</u> - Hospitals that are church-related, are a nonprofit corporation, or have other nonprofit ownership.

<u>Government</u>, non-Federal - Hospitals that are operated by State, county, city, city-county, or hospital district or authority.

<u>Proprietary</u> - Hospitals that are individually or privately owned or are partnerships or corporations for profit.

<u>MSA</u> - Metropolitan Statistical Area as defined by the U.S. Office of Management and Budget. The definition of an individual MSA involves two considerations: first, a city or cities of specified population that constitute the central city and identify the county in which it is located as the central county; second, economic and social relationships with "contiguous" counties that are metropolitan in character so that the periphery of the specific metropolitan area may be determined. MSAs may cross state lines. In New England, MSAs consist of cities and towns rather than counties.

Non-MSA - Non-Metropolitan Statistical Area (area other than metropolitan).

<u>Emergency department</u> - Hospital facility for the provision of unscheduled outpatient services to patients whose conditions require immediate care and which is staffed 24 hours a day. Emergency departments that are open less than 24 hours a day are included as part of the hospital's outpatient department.

<u>Emergency service area</u> - Area within the emergency department where emergency services are provided. This includes services provided under the "hospital as landlord" arrangement in which the hospital rents space to a physician group.

<u>Outpatient department</u> - Hospital facility where non-urgent ambulatory medical care is provided under the supervision of a physician.

<u>Clinic</u> - Administrative unit within an organized outpatient department that provides ambulatory medical care under the supervision of a physician. This excludes the "hospital as landlord" arrangement in which the hospital only rents space to a physician group and is not otherwise involved in the delivery of services.

Clinics are grouped into the following six specialty groups for purposes of systematic sampling and non-response adjustment: general medicine, surgery, pediatrics, obstetrics/gynecology, substance abuse, and other. Clinics are defined as in scope or out of scope as follows:

#### In scope - General Medicine

23/24 Hour Observation Adult - Screening Adult HIV AIDS Allergy (Adult) Ambulatory Care Andrology Anticoagulation Apnea (Adult) Arthritis/Rheumatology (Adult) Asthma

Brain Tumor Breast Medical Oncology Cancer Center Cancer Screening Cardiology (Adult) Cardiovascular CD4 Cerebral Palsy (Adult) Chest Chest TB

#### In scope - General Medicine (cont.)

Chorea/Huntington's Disease Coagulant **Connective Tissue** Cystic Fibrosis (Adult) Cytomegalovirus (CMV) Dermatology Diabetes **Digestive Disease** Down's Syndrome (Adult) Endocrinology (Adult) Epilepsy Family Practice Gastroenterology (Adult) **General Medicine** General Medicine (Outreach Program) **General Practice** Genetics (Adult) Geriatric Medicine Head (Non-Surgical) Head & Neck (Non-Surgical) Hematology (Adult) Hemophilia (Adult) Hepatology HIV (Adult) Holistic Medicine Homeless Huntington's Disease/Chorea Hyperlipidemia (Adult) Hypertension Immunology Immunosuppression Infectious Diseases (Adult) Internal Medicine (Adult) Lead Poisoning (Adult) Leukemia Lipid Liver Lupus (Systemic Lupus Erythematosus/SLE) Medical Oncology Medical Screening Melanoma Metabolic Movement and Memory Disorders Multiple Sclerosis (MS) Muscular Dystrophy (MD) Nephrology (Adult) Neurocutaneous Non-Surgical Head Non-Surgical Head & Neck **Obesity (Adult) Occupational Medicine** Oncology Outreach Program (General Medicine)

Pacemaker Pentamidine Peripheral Vascular Disease Pheresis **Pigmented Lesion** Plasmapheresis Primary Care Pulmonary (Adult) Renal Rheumatology/Arthritis (Adult) Sarcoidosis Screening (Adult) Screening - Cancer Screening and/or Walk-In Seizure Senior Care Sexually Transmitted Diseases (STD) Sickle Cell (Adult) SLE/Systemic Lupus Erythematosus (Lupus) Spina Bifida (Adult) STD/Sexually Transmitted Diseases Systemic Lupus Erythematosus/SLE (Lupus) Thyroid Transplant Medicine **Travel Medicine** Tuberculosis Tumor Urgent Care Walk-in and/or Screening Weight Management Wellness In scope - Surgery Abdominal Surgery Amputee (Surgery and Rehabilitation) Ano-Rectal Back Care **Bone Marrow Aspiration** Breast Breast Care Burn Cardiothoracic Surgery Cardiovascular Surgery Cast/Brace Chief Resident (Follow-up Surgery) Chronic Wound Cleft Palate Club Foot Cochlear Colon & Rectal Surgery Cryosurgery Elective Surgery ENT (Ear, Nose, and Throat) (Adult) ENT (Ear, Nose, and Throat) (Pediatric) Eye Fine Needle Aspiration

#### In scope – Surgery (cont.)

Fracture General Surgery Genitourinary **Genitourinary Surgery** Hand Surgery Head and Neck Surgery Heart Transplant Injury Knee Myelomeningocele Neurosurgery **Oncologic Surgery Ophthalmologic Surgery** Ophthalmology (Adult) **Ophthalmology** (Pediatric) Orthopedic Surgerv Orthopedics (Adult) Orthopedics (Pediatric) Ostomy **Otolaryngologic Surgery** Otolaryngology (Adult) Otolaryngologic (Pediatric) Otology Otorhinolaryngology Plastic Surgery (Adult) Plastic Surgery (Pediatric) Post-Operative **Pre-Operative** Proctology Pulmonary/Thoracic Surgery Rectal & Colon Surgery Renal Surgery Renal Transplant Scoliosis (Adult) Scoliosis (Pediatric) Spinal Cord Injury Spine (Adult) Spine (Pediatric) Sports Medicine Surg Surgery (Adult) Surgery (Pediatric) Surgery Cancer Detection Surgical Oncology Suture Thoracic Surgery/Pulmonary Transplant Surgery Traumatic Surgery Urodynamics **Urologic Surgery** Urology (Adult) Urology (Pediatric) Vascular Surgery Visual Fields Wound Care

#### In scope – Pediatrics

Abuse (Child)/Sexual Assault Adolescent Medicine Adolescent/Young Adult Airway (Pediatric) Allergy (Pediatric) Apnea (Infant) Arthritis/Rheumatology (Pediatric) Attention Deficit Disorder Behavior and Development (Child) Birth Defect Cardiac (P Cardiology (Pediatric) Cerebral Palsy (Child) Clotting (Pediatric) **Congenital Heart** Craniofacial Craniomalformation Critical Care (Pediatric) Cystic Fibrosis (Child) Dermatology (Pediatric) **Developmental Disability Developmental Evaluation** Diabetes (Pediatric) Diagnostic (Pediatric) Down's Syndrome (Child) Endocrinology (Pediatric) Feeding Disorder (Pediatric) Gastroenterology (Pediatric) **General Pediatrics** Genetics (Pediatric) GI (Pediatric) Growth Hormone Hematology (Pediatric) Hemoglobinopathy (Pediatric) Hemophilia (Child) **High Risk Pediatrics HIV Pediatrics** Hyperlipidemia (Pediatric) Immunization Immunology (Pediatric) Infectious Diseases (Pediatric) Internal Medicine (Pediatric) Lead Poisoning (Pediatric) Learning Disorder Neonatal Neonatology Nephrology (Pediatric) Newborn Obesity (Pediatric) Oncology (Pediatric) Pediatrics Perinatal Phenylketonuria Prader-Willi Syndrome Pulmonary (Pediatric)

#### In scope – Pediatrics (cont.)

Renal and Diabetes (Pediatric) Rheumatic Heart Disease Rheumatology/Arthritis (Pediatric) Sexual Assault/Abuse (Child) Short stay (Pediatric) Sickle Cell (Child) Spina Bifida (Child) Teen Health Teen-Tot Teenage Well Child Care

#### In scope - Obstetrics/Gynecology

Adolescent Gynecology Antepartum Birth Control Counseling - Pregnancy Dysplasia (Gynecologic) Endocrinology (Gynecologic) Endocrinology (Reproductive) Family Planning Gynecology Gynecology (Adolescent) Gynecology (Dysplasia) Gynecology (Endocrinologic) Gynecology (Oncologic) Gynecology (Pediatric) Gynecology (Preteen) **High Risk Obstetrics HIV Obstetrics** In Vitro Fertilization Infertility Maternal Health Maternity **Obstetrics** Oncology (Gynecologic) Perinatal (Obstetrics) Postpartum (Obstetrics) Pregnancy Verification Prenatal Prenatal (Obstetrics) Preteen Gynecology Reproductive Reproductive Endocrinology Well Woman Women's Care

#### In scope - Substance Abuse

Alcohol Abuse Alcohol Detoxification Alcohol Walk-in Chemical Dependency (excluding Methadone Maintenance) Drug Abuse (excluding Methadone Maintenance)
Drug Detoxification (excluding Methadone Maintenance)
Substance Abuse (excluding Methadone Maintenance)
Walk-in – Alcohol
Women's Alcohol Program

#### In scope - Other

Anxietv **Behavioral Medicine** Biofeedback Eating Disorder **General Preventive Medicine** Geriatric Psychiatry Headache (Neurology) Mental Health Mental Hygiene Myasthenia Gravis Neurofibromatosis Neurology (Adult) Neurology (Pediatric) Neuromuscular Neurophysiology Pain Pain Medicine Pain Management Palliative Medicine **Preventive Medicine** Psychiatry (Adolescent) Psychiatry (Adult) Psychiatry (Child) Psychiatry (Geriatric) Psychiatry (Pediatric) Psychopharmacology Sleep Disorder Sleep Medicine Social Evaluation Toxicology

#### Out of scope

Abortion/Pregnancy Termination Acupuncture Adult Day Care Ambulatory Surgery Centers Amniocentesis Anesthesia Anesthesiology Arthroscopy Audiology Blood Bank Bone Density Screening

#### Out of scope (cont.)

Bronchoscopy Cardiac Catheterization CAT Scan & Imaging Chemotherapy Chiropractic Colonoscopy Colposcopy Cystoscopy Day Hospital Dental **Dental Surgery** Diabetic Foot Clinic Diagnostic X-ray (Imaging)/Radiology Dialysis Dietary Drug Immunotherapy Echocardiology Electrocardiogram (ECG) Electroconvulsive Therapy (ECT) Electromyography **Employee Health Service** Endoscopy Fetal Diagnostic Testing Hearing & Speech Hemodialysis Home Intravenous Therapy Imaging & CAT Scan Infusion Infusion Therapy Kidney (Renal) Dialysis Laser Surgery Lasik Surgery Lithotripsy Mammography Methadone Maintenance Nuclear Medicine Nurse Clinic/Nurse Only Nutrition Occupational Health Occupational Safety and Health **Occupational Therapy** Optometry **Oral Surgery** Partial Hospitalization Partial Hospitalization Program (Psyc) Path Lab Pathology Pharmacy Physiatry **Physical Medicine** Physical Therapy Physiotherapy Podiatry Preadmission Testing Pregnancy Termination/Abortion

Psychology Pulmonary Function Lab Radiation Diagnosis Radiation Oncology Radiation Therapy Radiology/Diagnostic X-ray (Imaging) Reading & Language Reference Lab Reference X-Ray Rehabilitation Renal (Kidney) Dialysis Same Day Surgery School Programs Sigmoidoscopy Social Work Speech & Hearing Tele-Health Transfusion Ultrasound Vertical Balance

<u>Region</u> - Hospitals are classified by location in one of the four geographic regions of the United States that correspond to those used by the U.S. Bureau of the Census.

Mexico, Oregon, Utah, Washington, and Wyoming

RegionStates includedNortheast.....Connecticut, Maine, Massachusetts, New Hampshire, New Jersey, New York,<br/>Pennsylvania, Rhode Island, and VermontMidwest.....Illinois, Indiana, Iowa, Kansas, Michigan, Minnesota, Missouri, Nebraska,<br/>North Dakota, Ohio, South Dakota, and WisconsinSouth.....Alabama, Arkansas, Delaware, District of Columbia, Florida, Georgia, Kentucky,<br/>Louisiana, Maryland, Mississippi, North Carolina, Oklahoma, South Carolina,<br/>Tennessee, Texas, Virginia, and West VirginiaWest......Alaska, Arizona, California, Colorado, Hawaii, Idaho, Montana, Nevada, New

# APPENDIX II REASON FOR VISIT CLASSIFICATION

# A. SUMMARY OF CODES

#### MODULE

# SYMPTOM MODULE

CODE NUMBER

# **DISEASE MODULE**

Infective and Parasitic Diseases	2001-2099
Neoplasms	2100-2199
Endocrine, Nutritional, Metabolic, and Immunity Diseases	2200-2249
Diseases of the Blood and Blood-forming Organs	2250-2299
Mental Disorders	2300-2349
Diseases of the Nervous System	2350-2399
Diseases of the Eye	2400-2449
Diseases of the Ear	2450-2499
Diseases of the Circulatory System	2500-2599
Diseases of the Respiratory System	2600-2649
Diseases of the Digestive System	2650-2699
Diseases of the Genitourinary System	2700-2799
Diseases of the Skin and Subcutaneous Tissue	2800-2899
Diseases of the Musculoskeletal System and Connective Tissue	2900-2949
Congenital Anomalies	2950-2979
Perinatal Morbidity and Mortality Conditions	2980-2999

# DIAGNOSTIC, SCREENING AND PREVENTIVE MODULE

General Examinations	3100-3199
Special Examinations	3200-3299
Diagnostic Tests	3300-3399
Other Screening and Preventive Procedures	3400-3499
Family Planning	3500-3599

# TREATMENT MODULE

Medications	4100-4199
Preoperative and Postoperative Care	4200-4299
Specific Types of Therapy	4400-4499
Specific Therapeutic Procedures	4500-4599
Medical Counseling	4600-4699
Social Problem Counseling	4700-4799
Progress Visit, NEC	4800-4899

# MODULE

#### **CODE NUMBER**

# INJURIES AND ADVERSE EFFECTS MODULE

Injury by Type and/or Location Injury, NOS Poisoning and Adverse Effects	5001-5799 5800-5899 5900-5999
TEST RESULTS MODULE	6100-6700
ADMINISTRATIVE MODULE	7100-7140
UNCODABLE ENTRIES	8990-8999
BLANK	9000

NOTE: NOS = Not otherwise specified; NEC = not elsewhere classified

# **B. REASON FOR VISIT CLASSIFICATION TABULAR LISTING**

	OM MODULE L SYMPTOMS (1001-1099)	1035.0	Symptoms of fluid abnormalities Includes: Fluid retention
1005.0	Chills		Holding water
1010.0	Fever Includes: High temperature		1035.1 Edema Includes: Ankles swelling (both) Bloated
1012.0	Other symptoms of body temperature Excludes: Chills (1005.0) Fever (1010.0)		Dropsy Legs (both) Peripheral Swollen with water
	1012.1 Feeling cold 1012.2 Feeling hot 1012.3 Feeling hot and cold		Excludes: Swelling of one ankle (1930.5) Swelling of one leg (1920.5)
1015.0	Tiredness, exhaustion Includes:		1035.2 Excessive sweating, perspiration Includes: Diaphoresis
	Exercise intolerance Fatigue Lack of energy No energy	1040.0	1035.3 Excessive thirst Weight gain
1020.0	Run down Worn out		Includes: Fat pads (localized)
1020.0 1025.0	General weakness General ill feeling		Fatty deposits Obesity Overweight
	Includes: Diffuse Cx Illness, NOS Malaise Not feeling well Multiple complaints	1045.0	Too fat Excludes: Counseling for weight problem (4600.0) Weight loss
	Multiple complaints Sick, NOS		1045.1 Recent weight loss
1030.0	Fainting (syncope) Includes:	1046.0	Symptoms of face, NEC
	Blacking out Fainting spells Passing out		Excludes: Facial pain 1055.4 Facial paralysis 1230.0
	Excludes: Unconsciousness (5840.0)	1050.0	Chest pain and related symptoms (not referable to a specific body system)
			1050.1 Chest pain
			Excludes: Heart pain (1265.0)

1050.2 Chest discomfort, pressure, tightness, heaviness

Includes: C - pressure

1050.3 Burning sensation in the chest

1055.0	955.0 Pain, specified site not referable to a specific body system		1075.0	1075.0 Symptoms of growth and developmental disorders	
	Includes: Buttock pain Gluteal pain Perineal pain			Includes: Develo	pmental regression
				1075.1	Lack of growth
	Chest j Phanto	ninal pain (see 1545.1-1545.3) pain (1050.1) pm leg/limb (2307.0)			Includes: Failure to thrive Immaturity, physical Poor weight gain Slowness, physical Too short
	1055.1	Rib pain		1075.2	Excessive growth
	1055.2	Side pain, flank pain			Includes:
	1055.3	Groin pain			Development, early (physical) Too big for age
		Includes: Pubic pain			Too tall
	1055.4	Facial pain	1080.0	General symptoms o NEC	f infants (under 1 year of age),
		Includes: Jaw pain		1080.1	Cranky, crying too much, fussy, fidgety, irritable
		Pain over eye		1080.2	Regurgitation, spitting up
1060.0	Pain and related sym	-			Excludes: Vomiting (1530.0)
	1060.1	Pain, unspecified		1080.3	Feeding problem, eating difficulty
		Includes: Ache all over (generalized) Incisions	1085.0	General or unspecifie	ed nonviral infection
	1060.2	Cramps, spasms, site unspecified		Includes Infection	:: on, NOS
		Excludes: Menstrual cramps (1745.2)	1090.0	Allergy, NOS Includes	
	1060.3	Stiffness, site unspecified			c reaction, NOS
1065.0	Tumor or mass, site	unspecified			llergy, NOS llergy, NOS
	1065.1	Internal mass, NOS		Exclude	
1066.0	Lesion, Internal NO	S (excludes brain and skin)		Allerg	c skin reaction (2825.0) y to medications (5905.0) allergy (2635.0)
1070.0	Bleeding, multiple o	r unspecified sites	1095.0	Disorders of motor f Include Ataxia Clumsi	unctions es: mess ilty in walking iesia OS ig ring

Stumbling Uncoordinated Unsteady gait

1096.0 Dyslexia, NOS

# PAGE 153

	OMS REFERABLE TO PSYCHOLOGICAL L DISORDERS (1100-1199)	AND	1125.0	Restlessness	
1100.0	Anxiety and nervousness Includes: Apprehension			Include: Can't i Hyper Overad	rest activity
	Bad nerves		1130.0	Behavioral disturbar	nces
	Jittery Panicky feeling Stress Tension Upset Worried			Includes: Behavior problem Gambling problem Lack of self control Staring spells	
1105.0	Fears and phobias			1130.1	Antisocial behavior
1110.0	Includes: General fearfulness Agoraphobia Depression				Includes: Avoiding people Excessive shyness Lying Social isolation Withdrawal
	Includes: Crying excessively Dejected Distress (NOS) Feeling down Feeling low Grief Hopelessness Sadness Tension Tension headache (also code 1210.0) Unhappy			1130.2	Hostile behavior Includes: Aggressiveness Child abuser Child neglecter Combative Criminality Cruelty Destructiveness Elder abuser Homicidal Negativism
1115.0	Anger Includes: Bitterness				Parent abuser Quarrelsome Spouse abuser Spouse batterer
	Hostile feelings			1130.3	Hysterical behavior
	Excludes: Temper problems (1130.4)			1130.4	Temper problems
1120.0	Problems with identity and self-esteem Includes: Co-dependency Dependency Don't like myself Guilt Helpless Identity crisis				Includes: Blowing up Fussy Irritability Losing temper Temper tantrums Excludes: Fussy infants (1080.1)
	Insecurity, emotional Lack of motivation Loss of identity No confidence No goals Poor boundaries			1130.5	Obsessions and compulsions

Too much is expected of me

1135.0	Disturbances of sleep	p	1155.0	Delusions or hallucin	nations	
Includes: Night terrors 1135.1 Insomnia Includes: Can't sleep		errors Insomnia Includes: Can't sleep		Includes: Flashback Grandiosity Hearing voices Ideas of reference Medicine is poisoned Seeing things		
		Sleeplessness Trouble falling asleep	1160.0	Psychosexual disorders		
	1135.2	Sleepiness (hypersomnia)		1160.1	Frigidity, loss of sex drive, lack of response, lack of libido	
		Includes:			•	
		Can't stay awake		1160.2	Homosexuality, concerns with	
		Drowsiness		11.00.0		
		Groggy		1160.3	Impotence, Erectile dysfunction	
	1135.3 1135.4	Nightmares Sleepwalking		1160.4	Premature ejaculation	
	1135.5	Apnea		1160.5	Masturbation excessive, concerns about	
		Includes: Sleep apnea (use additional code 1420.0 if breathing		1160.6	Orgasm, problem with	
		problem)		1160.7	Preoccupation with sex	
1140.0	Smoking problems		1165.0	• • •	problems relating to psychological al disorders, NEC	
	Includes:			· · · · · · · · · · · · · · · · · · ·		
	Can't quit smoking			Includes:		
	Smoki	ng too much		d affect		
				ope		
	Exclude		Chemical imbalance Constricted affect			
		al symptoms of smoking (see cular symptom)		Danger to self Deja vu feelings		
		r's cough (1440.0)				
	Shloke	15 cough (1110.0)		Disorie		
1145.0	Alcohol-related prob	lems		Difficu Frustra	lty concentrating	
	Includes	:		Going		
		bl abuse		Hate everybody		
	Drinki	ng problem		Inhibit	ed	
					ng disability	
	Exclude	s: e effects of alcohol (5915.0)		Losing my mind Mood fluctuation		
		blism (2320.0)		Mood		
	1100110	(202010)			ommunicative	
1150.0	Abnormal drug usage	e		Peculia	ur thinking	
	Includes: Drug abuse Frequent or excessive use of stimulants, hallucinogens, depressants, etc.				logical problems, NOS	
					wn syndrome	
				Trouble concentrating Wandering around		
				() unde		
				Exclude		
	Exclude				ter disorder (2315.0)	
		ddiction (2321.0)		Person	ality disorder (2315.0)	
	U	ependence (2321.0) ation with drugs (5910.0)		1165.1	Nailbiting	
		ose, intentional (5820.1)		1105.1	manululig	
		ose, unintentional, NOS (5910.0)		1165.2	Thumbsucking	

SYMPTOMS REFERABLE TO THE NERVOUS SYSTEM (EXCLUDING SENSE ORGANS) (1200 - 1259)		1220.0	Disturbances of sensation		
1200.0			1220.1	Loss of feeling (anesthesia)	
1200.0	Abnormal involuntary movements			Includes:	
	Includes:			Lack of sensation	
	Jerking			No response to pain	
	Shaking			Numbness	
	Tics			Stunned	
	Tremors				
	Twitch			Excludes: Post-op complications of	
	Excludes:			anesthesia	
	Eye movements (see 1325.0-1325.4)				
	Eyelid twitch (1340.4)		Note: Us pa	e additional code to identify body rt.	
1205.0	Convulsions		1220.2	Increased sensation (hyperesthesia)	
	Includes:		1220.2	increased sensation (hyperestnesia)	
	Febrile convulsions		1220.3	Abnormal sensation (paresthesia)	
	Fits			v ,	
	Seizures			Includes:	
	Spells			Burning legs	
	I			Burning, tingling sensation	
	Excludes:			Needles and pins	
	Fainting (1030.0)			Prickly feeling	
1207.0	Symptoms of head, NEC		1220.4	Other disturbances of sense, including smell and taste	
	Excludes:			6	
	Headache, pain in head (1210.0)	1225.0	Vertigo - dizziness		
1210.0	Headache, pain in head		Include		
	Includes:			g sensation	
	Post-traumatic (also code 5575.0)			uess (dizziness)	
	Excludes:			eadedness	
	Migraine (2365.0)			f sense of equilibrium or balance	
	Sinus headache (1410.1)			spinning	
	Symptoms of head, NEC (1207.0)			-F8	
		1230.0	Weakness (neurolog	ic)	
1215.0	Memory, disturbances of				
			Include	5:	
	Includes:		Droop	ing, facial or NOS	
	Amnesia		1	or left-sided weakness	
	Forgetfulness		U		
	Lack or loss of memory		Exclude	es:	
	Temporary loss of memory		Genera	al weakness (1020.0)	
		1235.0	Disorders of speech,	speech disturbance	
			Include	5:	
				ng for words	
				h/verbal apraxia	
				e to speak	
			1235.1	Stuttering, stammering	

1235.2 Slurring

1240.0	Other symptoms referable to the nervous system

Includes: Brain lesion Confusion Cognitive decline Damaged nerves Neuralgia Pinched nerve

Excludes: Nerve block 4560.0

1240.1 Apraxia

Excludes:

Speech/verbal apraxia 1235.0

#### SYMPTOMS REFERABLE TO THE CARDIOVASCULAR AND LYMPHATIC SYSTEMS (1260-1299)

1260.0 Abnormal pulsations and palpitations

1260.1 Increased heartbeat

Includes: Pulse too fast Rapid heartbeat

1260.2 Decreased heartbeat

Includes: Pulse too slow Slow heart

1260.3 Irregular heartbeat

Includes: Fluttering Jumping Racing Skipped beat

1265.0 Heart pain

Includes: Anginal pain Heart distress Pain over heart

Excludes: Angina pectoris (2515.0) Chest pain (1050.1)

1270.0 Other symptoms of the heart

Includes: Bad heart Heart condition Poor heart Weak heart

- 1275.0 Symptoms of lymph glands (or nodes)
  - - 1275.1 Swollen or enlarged glands
      - 1275.2 Sore glands
- 1280.0 Other symptoms referable to the cardiovascular/lymphatic system, NEC
  - Includes: Telangiectasia 1280.1 Poor circulation 1280.2 Pallor, paleness

Flushed, blushing

# SYMPTOMS REFERABLE TO THE EYES AND EARS (1300-1399)

1280.3

1305.0 Vision dysfunctions Excludes: Refractive errors (2405.0) 1305.1 Blindness and half vision Includes: Visual field deficit 1305.2 Diminished vision Includes: Blurred vision Can't see distances Difficulty reading Focus, Eyes won't (other than Infant 1335.0) Obstruction, Vision Poor vision Scotoma Trouble seeing Weak eyes 1305.3 Extraneous vision Includes: Cloudy vision Hazy vision Spots in front of eyes (floaters) 1305.4 Double vision (diplopia) 1310.0 Discharge from eye

1310.1 Bleeding1310.2 Tearing, watering (lacrimation)1310.3 Pus, matter, white discharge

1315.0	Eye infection and in	flammation	1340.0	Symptoms of eyelids	
	1315.1	Pinkeye			Includes: Can't close eye
1320.0	Abnormal sensations	s of the eye			Lesion Rash
	Includes			1340.1	Infection, inflammation, swelling
		n body sensation		1340.2	Itching
	1320.1	Pain		1340.3	Mass or growth
		Includes: Irritation		1340.4	Abnormal movement
	1320.2	Itching			Includes:
	1320.3	Burning, stinging			Blinking Drooping Squinting
	1320.4	Strain			Twitching
1325.0	Abnormal eye move	ments	1345.0	Hearing dysfunctions	
	1325.1	Abnormal retraction		1345.1	Diminished hearing
	1325.2	Cross-eyed			Includes: Deafness
	1325.3	Pupils unequal			Hearing loss Trouble hearing
	1325.4	Deviation		1345.2	Heightened or acute hearing
1330.0	Abnormal appearance	e of eyes		1345.3	Extraneous hearing
	1330.1	Abnormal color			Includes: Ringing (tinnitus)
		Includes: Bloodshot			Excludes: Hearing things (1155.0)
		Red	1350.0	Discharge from ear	
		Excludes: Yellow (1610.2)		Includes:	
	1330.2	Protrusion (exophthalmos)		Fluid in 1350.1	
	1330.3	Cloudy, dull, hazy appearance		1350.1	Bleeding Pus (purulent drainage)
1335.0	Other and unspecifie	ed symptoms referable to eye, NEC		1350.2	Swimmer's ear
	Includes Defect		1355.0	Earache, or ear infect	
	1335.1	Contact lens problems		1355.1	Earache, pain
	1335.2	Allergy		1355.2	Ear infection
	1335.3	Swelling	1360.0	Plugged feeling in ear	r
		Excludes: Foreign body (5600.0) Injury (5510.0) Abrasion (5410.0)		Crackin Ear feel	l tion in ear g s full ed cleaning

1365.0	Other and unspecifie NEC	d symptoms referable to the ears,	1410.0	Sinus problems	
	Includes red, redness			Include Sinus	
	1365.1	Itching		Sinus	drainage
	1365.2	Growths or mass		1410.1	Pain and pressure
	1365.3	Pulling at ears, picking at ears			Includes: Sinus headache
	1365.4	Abnormal size or shape, "ears stick out"		1410.2	Sinus inflammation, infection
		Excludes: Foreign body in ear (5620.0)		1410.3	Sinus congestion
SYMPTO	)MS REFERABLE T	O THE RESPIRATORY SYSTEM	1415.0	Shortness of breath	
( <b>1400-14</b> ) 1400.0					s: ilessness `breath
	-			Sensar	tion of suffocation
	Includes Drippy Excess		1420.0	Labored or difficult	breathing (dyspnea)
	Nasal o	obstruction		Include	
	Post-na Runny	nsal drip		Anoxi Can't b	
	Sniffle			Нуроз	
	Stuffy			Smoth	
1405.0	Other symptoms of r	ose			atory distress le breathing
	• •		1425.0		
	Exclude Nasal a	s. Illergy (2635.0)	1425.0	Wheezing	
	1405.1	Nosebleed (epistaxis)		Include Sighir	s: g respiration
	1405.2	Sore in nose	1430.0	Breathing problems	, NEC
	1405.3	Inflammation and swelling		Include Hurts	s: to breathe
		Includes: Infection		1430.1	Disorders of respiratory sound,
		Red nose Sore nose			NEC
	1405.4	Problem with appearance of nose			Includes: Abnormal breathing sounds Snoring
		Includes:			Rales
		Bump(s)			Rattles
		Too large Undesirable appearance			Stridor
		endesnuble appearance		1430.2	Rapid breathing (hyperventilation)
			1435.0	Sneezing	
			1440.0	Cough	

1445.0

1450.0

1455.0

1460.0

# 2006 NHAMCS MICRO-DATA FILE DOCUMENTATION

Head cold, upper res	spiratory infection (coryza)	1470.0	Abnormalities of sputum or phlegm
Include Cold, 1			1470.1 Coughing up blood
Excludes: Chest cold (1475.0) General viral infection			Includes: Hemoptysis
			1470.2 Pus in sputum
1450.1	Flu		1470.3 Excessive sputum
1450.1	Includes: Grip		Includes: Productive
	Influenza	1475.0	Congestion in chest
	Excludes: Croup (2600.0)		Includes: Lung congestion Chest cold
Symptoms referable	to throat	1480.0	Disorders of voice
1455.1	Soreness		1480.1 Hoarseness, loss of voice
	Includes: Throat hurts		Includes: Croaky
1455.2	Pain		1480.2 Hypernasality
1455.3	Infection	1495.0	
Includes: Throat virus		1485.0	Other symptoms referable to the respiratory system, NEC
	Excludes: Strep throat (2010.0)		Includes: Drainage in throat
1455.4	Irritation, scratch, tickle, itch		1485.1 Lung pain
			1485.2 Lung infection
1455.5	Swelling		
1455.6	Lump or mass	SYMPT (1500-16	OMS REFERABLE TO THE DIGESTIVE SYSTEM (539)
	Includes: Sensation of something in throat	1500.0	Symptoms of teeth and gums
	Excludes: Foreign body in throat (5615.0)		Includes: Loose tooth (no injury) Tooth infection
Symptoms referable	to tonsils		1500.1 Toothache
Include Hyper			1500.2 Gum pain
Infecti	fection flammation		1500.3 Bleeding gums
		1501.0	Symptoms of the jaw, NOS
			Includes: Jaw problem, unspecified

1501.1 Swelling

1501.2 Lump or mass

1505.0	Symptoms referable	to lips	1535.0	Heartburn and indig	estion (dyspepsia)
	1505.1	Cracked, bleeding, dry		Include	
	1505.2	Abnormal color	1540.0		e belching
	1505.3	Cold sore	1540.0	Gastrointestinal infe	
1510.0	Symptoms referable	to mouth		Include: Intestin Stoma	nal virus
	Include	s.			ch virus
		ng at the mouth			gastroenteritis
		too thick			
	White		1545.0	Stomach and abdom	inal pain, cramps and spasms
	() 11100	spots	10 1010	Stoniaen and action	inai pani, crampo ana spasno
	1510.1	Pain, burning, soreness		Include	s.
	1510.2	Bleeding		Gastric	
	1510.2	Dryness		Gustin	2 pain
	1510.5	Ulcer, sore		Exclude	×C*
	1510.4	Olcer, sole			pain (1055.3)
1515.0	Symptoms referable	to tongua		GIOIII	pain (1055.5)
1515.0	Symptoms referable	to tongue		1545.1	Abdominal pain, cramps, spasms, NOS
	Include	s:			
	Ulcer	on tongue			Includes:
	Sore o	n tongue			Abdominal discomfort, NO
		-			Gas pains
	1515.1	Pain			Intestinal colic
	1515.2	Bleeding		1545.2	Lower abdominal pain, cramps,
		-		1545.2	spasms,
	1515.3	Inflammation, infection, swelling			
	1515.4	Abnormal color, ridges, coated			Includes: Right lower quadrant (RLQ) pain
1520.0	Difficulty in swallow	wing (dysphagia)			Left lower quadrant (LLQ) pain Inguinal pain
	Include	a.		1545.3	Upper abdominal pain aromna
				1545.5	Upper abdominal pain, cramps,
	Choki	ity to swallow			spasms
	maom	ity to swallow			Includes:
1525.0	Nausea				
1323.0	Inausea				Epigastric pain
	Include				Left upper quadrant (LUQ) pain
	Include East li				Pain in umbilical region
		ke throwing up			Right upper quadrant (RUQ) pain
		us stomach	1565.0	Change in abdomina	1 airea
		o stomach	1565.0	Change in abdomina	li size
	Upset	stomach		1575 1	
1530.0	Vomiting			1565.1	Distention, fullness, NOS
					Includes:
	Include	s:			Abdominal bloating
	Can't l	keep food down			Stomach fullness
	Dry he	•			
	Retchi			1565.2	Mass or tumor
		ving up			
					Includes:
	Exclude	es:			Mass in groin
		gitation, infants (1080.2)			Mass, inguinal
		ing blood (1580.2)			,
		<u> </u>		1565.3	Abdominal swelling, NOS
					0,

# PAGE 161

# PAGE 162

1570.0	Appetite, abnormal 1570.1	Excessive appetite	1605.0	Symptoms refera	able to anus-rectum
		Eats too much Always hungry		1605.	.1 Pain
	1570.2	Decreased appetite Not hungry			Includes: Burning Irritation
		Loss of appetite Decreased fluid intake		1605.1	.2 Bleeding
1575.0	Difficulty eating			1605.	.3 Swelling or mass
1580.0	Gastrointestinal blee Includes:	ding		1605.	.4 Itching
	Bowel		1610.0	Symptoms of live	er, gallbladder, and biliary tract
	1580.1	Blood in stool (melena)		1610.	.1 Pain
	1580.2	Vomiting blood (hematemesis)		1610.	.2 Jaundice
1585.0	Flatulence	u.			Includes: Yellow eyes Yellow skin
	Bloated Distent Excess Gas	tion due to gas	1615.0 system	Other and unspec	ecified symptoms referable to digestive
	Exclude	s: ins (1545.1)		Abo Bad	udes: odominal pressure breath vigastric distress
1590.0	Constipation			Gas	astrointestinal distress alitosis
1595.0	Diarrhea			Hic	ccoughs gurgitation (adult)
	Includes: Loose : The rui	stools		Sto	omach problem omach trouble
1600.0	Other symptoms or c	hanges in bowel function		OMS REFERAB 1 (1640-1829)	BLE TO THE GENITOURINARY
	1600.1	Discharge in stools	1640.0	Abnormalities of	f urine
		Includes: Guaiac positive Hemocult positive			ludes: onormal findings of urine tests (6200.0)
		Mucus Pus		1640.	.1 Blood in urine (hematuria)
	1600.2	Worms		1640.2	.2 Pus in urine
	1600.3	Changes in size, color, shape, or		1640.	.3 Unusual color or odor
		odor	1645.0	Frequency and un	rgency of urination
		Includes: Bulky stools		1645.	.1 Excessive urination, night (nocturia)
		Too narrow Unusual odor or color	1650.0	Painful urination	1
	1600.4	Incontinence of stool			udes: ırning, discomfort
		Includes: Dirty pants (encopresis) Leaking stools			

1655.0	) Incontinence of urine (enuresis)		1700.0	Symptoms of penis	
	1655.1	Involuntary urination, can't hold urine, dribbling, wetting pants		1700.1	Pain, aching, soreness, tenderness, painful erection
	1655.2	Bedwetting		1700.2	Infection, inflammation, swelling
1660.0	Other urinary dysfu	nctions		1700.3	Lumps, bumps, growths, warts
	Include		1705.0	Penile discharge	
		le going Stream	1710.0	Symptoms of prostat	te
	1660.1	Retention of urine		Includes Prostat	s: te trouble
		Includes: Can't urinate		1710.1	Swelling
	1660.2	Hesitancy		1710.2	Infection
		Includes:	1715.0	Symptoms of the scrotum and testes	
	1660.3	Difficulty in starting stream Large volume		1715.1	Pain, aching, tenderness
	1000.5	-		1715.2	Swelling, inflammation
		Includes: Polyuria		1715.3	Growths, warts, lumps, bumps
	1660.4	Small volume		1715.4	Itching, jock itch
1665.0	Symptoms of bladd	er	1720.0	Other symptoms of r Includes	nale reproductive system s:
	Include Bladd	er trouble		Painfu	ll ejaculation
	1665.1	Pain		Exclude Psycho	es: osexual problems (1160.0-1160.6)
	1665.2	Infection	1730.0	Absence of menstrua	ation (amenorrhea)
	1665.3	Mass		Exclude	
1670.0	Symptoms of the ki	dneys		Suspected pregnancy (3200.0) Missed a period (3200.0) Period late (3200.0)	
	Include Kidne	es: ey trouble	1735.0	Irregularity of menst	rual interval
	1670.1	Pain		1735.1	Frequent
	1670.2 1670.3	Infection Mass		1735.2	Infrequent
1675.0	Urinary tract infecti	on, NOS		1735.3	Unpredictable
	Include	s:	1740.0	Irregularity of menst	rual flow
		ourinary infection infection		1740.1	Excessively heavy (menorrhagia)
1680.0	Other symptoms ref	erable to urinary tract		1740.2	Scanty flow (oligomenorrhea)
	Ureth Urinar Exclude	d stones ral bleeding ry irritation		1740.3	Abnormal material, including clots

# PAGE 164

1745.0	Menstrual symptom	s, other and unspecified	1770.0	Vulvar disorders	
	Include Long	s: periods		1770.1 1770.2 1770.3	Itching and irritation, swelling Mass, lump Growth, wart, cyst, ulcer, sore
	1745.1	Premenstrual symptoms, PMS	1775.0	Pelvic symptoms	Growin, wart, cyst, incer, sore
		Includes: Bloating before periods		1775.1	Pain
		Premenstrual tension or irritability		1775.2	Pressure or dropping sensation
	1745.2 Painful r	nenstruation (dysmenorrhea)			Includes: Feeling of uterus falling out
		Includes: Menstrual cramps Pain in legs and back	1200.0	1775.3	Infection, inflammation
1750.0	Menopausal sympto	during menstruation	1790.0	Problems of pregnat Includes: Fetal movemen	
170010					
	1750.1 1750.2	Early or late onset of menopause		Exclude Routin	es: ne prenatal visits (3205.0)
	1750.2	Vasomotor symptoms-hot flashes Emotional symptoms, change of		1790.1	Pain during pregnancy
	1750.5	life problems	pregnanc	v 1790.2	Spotting, bleeding during
1755.0	Uterine and vaginal	bleeding	r8	1790.3	Symptoms of onset of labor
	Exclude				
	Bleedi	ing during pregnancy (1790.2)			Includes: Water broke
	1755.1	Intermenstrual bleeding (metrorrhagia)			Ruptured membranes Labor pain, contractions Labor, NOS
		Includes: Bleeding between periods Breakthrough bleeding	1791.0	Postpartum problem	IS
	1755.2	Postmenopausal bleeding		Include Bleedi Pain	
	1755.3	Postcoital bleeding, female			
1760.0	Vaginal discharge			Exclude Postpa	es: artum examination, routine (3215.0)
	Include Blood exces	y, brown, white (leukorrhea),	1795.0	Other symptoms ref system	erable to the female reproductive
1765.0	Other vaginal symp	toms	1800.0	Pain or soreness of Include Tende	s:
	1765.1	Pain			
	1765.2	Infection	1805.0	Lump or mass of br	
	1765.3	Itching, burning		Include Bump Knot	
	1765.4	Vaginal dryness		Nodul Cyst	e

1810.0	Other symptoms ret	ferable to breast	1835.0	Discoloration or abr	normal pigmentation
	1810.1	Bleeding or discharge from nipple or breast		Include Birthn Blotch	nark
	1810.2	Postpartum problems		Blotch Circle Freckl	s under eyes
		Includes:		Redne	
		Engorgement Postpartum infection		Spots	
		Nursing difficulties		Exclude	
	1810.3	Problems with shape or size		Bruise	ing (1280.3) e (see 5405.0-5430.0) ng (1280.3)
		Includes:			ice (1610.2)
		Too large Too small	1840.0	Infections of skin, N	IOS
		Sagging	1640.0	infections of skin, N	103
		Uneven development		Include	
1815.0	1815.0 Symptoms of infertility			Infecto	ing wound ed blister ed wound
	Include				
		get pregnant ity to conceive		Exclude	es: e's foot (2025.0)
	Steril				d drainage (as treatment)
1820.0	Hormone deficiency	y or problem		1840.1	Infection of skin of head or neck area
1825.0	Symptoms of sexua	l dysfunction		1840.2	Infection of skin of arm, hand, or
	Include	25:		1040.2	finger
		areunia			
	Painf	ul intercourse		1840.3	Infection of skin of leg, foot, or toe
	Exclud Psych	es: ological disorders (see 1160.0-	1845.0	Symptoms of skin n	noles
	1160	.6)		Include	s.
					nole, NOS
(1830-18		FO THE SKIN, NAILS, AND HAIR		1845.1	Change in size or color
1830.0	Acne or pimples			1845.2	Bleeding mole
	Include Bad c	es: omplexion	1850.0	Warts, NOS	
		heads		Include	
	Blemi Break	isnes ing out		Condy Condy	/loma acuminatum
		plexion, NOS			
	White	cheads		Exclude	
					r's warts (2015.0)
			1855.0	Other growths of sk	in
				Include	
				Callus Corns	
				Cysts,	
				Cyst,	scalp
				Skin g Skin ta	rowth, NOS
				SKIII U	o

# PAGE 165

# PAGE 166

1860.0	Skin rash Includes Rash		1890.0	Symptoms referable Includes: Scalp lesion	to hair and scalp
	Skin er	ruption			
				1890.1	Too little hair
	Exclude	s: ivy (2825.0)			Includes:
		oak (2825.0)			Alopecia
	FOISOII	Oak (2823.0)			Baldness
	1860.1	Diaper rash			Falling out
	1000.1	Diuper rush			Losing hair
1865.0	Skin lesion, NOS				6
				1890.2	Unwanted hair
	Includes				
	Blister				Includes:
	Face				Abnormal hairiness
	Papule				Hirsutism
	Pustule Raw ar				Superfluous hair
	Sore	ea		1890.3	Dryness, flaky scalp, dry scalp
	Ulcer			1070.5	Dryness, maky searp, dry searp
	cicci			1890.4	Itching
1870.0	Skin irritations, NEC				
			1895.0	Navel problems	
	1870.1	Pain			
				Include	s:
	1870.2	Itching			
1975 0	Constition of station				icus not healing
1875.0	Swelling of skin			Protru	ISIOII
	Includes		SYMPTO	OMS REFERABLE '	TO THE MUSCULOSKELETAL
		, lumps		I (1900-1999)	
	Nodule			· · · ·	
	Welts,	except hives (2825.0)	These co	des exclude all injurie	s (See Injuries and Adverse Effects
	Tumor	, skin	Module.)		
1000.0	Oth		The felle		d ha and a side and a side
1880.0	Other symptoms refe	erable to skin			d be used with categories when there is adequate information
	Exclude	e.	given:	o in place of the zero	when there is adequate information
		problems (1895.0)	given.		
	i tu toi j		.1	pain, ache, soreness	, discomfort
	1880.1	Oiliness	.2	cramps, contracture	
			.3	limitation of moven	*
	1880.2	Dryness, peeling, scaliness,	.4	weakness	
		roughness	.5	swelling	
	1000.0		.6	lump, mass, tumor	
	1880.3	Wrinkles	1000.0	NT 1 (	
1885.0	Symptoms referable	to pails	1900.0	Neck symptoms	
1885.0	Symptoms reretable	to hans	1905.0	Back symptoms	
	1885.1	Infected	1905.0	Dack symptoms	
	1005.1	Infected	1910.0	Low back symptoms	3
	1885.2	Ingrown			
		C	1915.0	Hip symptoms	
	1885.3	Brittle, breaking, splitting, cracked,			
		ridged	1920.0	Leg symptoms	
			1025.0	77	
			1925.0	Knee symptoms	
			1930.0	Ankle symptoms	
			1950.0	- inte symptoms	
			1935.0	Foot and toe sympto	oms
				-	

- 1940.0 Shoulder symptoms
- 1945.0 Arm symptoms

2000 1					17(8E 10)
1950.0	Elbow symptoms		2015.0	Viral diseases	
1055.0	• •				
1955.0	Wrist symptoms			Include	
10.00.0					enpox
1960.0	Hand and finger sym	ptoms			al warts
	Includes:				an measles (rubella)
	Ring stu	ick on finger		-	itis (infectious and NOS)
	~ ~				es simplex
1965.0	Symptoms of unspec	fified muscles			ious mononucleosis
1050 0	<b>a</b>			Measl	
1970.0	Symptoms of unspec	affied joints		Menir	0
				Mump	
1975.0	Musculoskeletal defe	ormities			ur's warts
					nyelitis
	Exclude			Rabie	
		ot (2960.0)			ratory syncytival virus (RSV)
	Curvat	ure of spine (2910.0)		U	les (Herpes zoster)
					pox, NOS
	1975.1	Bowlegged, knock-kneed			real warts
				Verru	ca
	1975.2	Posture problems			
				2015.1	Human immunodeficiency virus
	1975.3	Pigeon-toed, feet turn in		(HIV) v	vith or without associated conditions
1980.0	Other musculoskelet	al symptoms			Includes:
		• •			Acquired immunodeficiency
	Includes				syndrome
	Bone p	pain			AIDS
	Stump	pain			AIDS-like syndrome
					AIDS-related complex
					ARC
	DISEAS	E MODULE			HIV positive
					Excludes:
INFECT	TIVE AND PARASIT	IC DISEASES (2001-2099)			Results, follow-up of test for
					HIV (6106.0)
2005.0	Intestinal infectious	diseases			
				2015.2	Hemorrhagic fevers
	Includes				-
	Choler	a			Includes:
	Dysent	ery			Botulism
	Enterit				Ebola
	Gastro	enteritis			Fever, Hemorrhagic
	Giardia				Marburg
	Salmor	nella			C
			2020.0	Sexually transmitte	d diseases
2010.0	Streptococcal infecti	on		····	
	.1			Include	es:
	Includes	3:		Chlan	
		ococcal tonsillitis		Gonor	•
	Gul	C		0 1	1'

Streptococcal tonsillitis Scarlet fever

#### 2025.0 Fungus infections (mycoses)

Includes: Athlete's foot Candidiasis monilia Dermatophytoses Moniliasis Ringworm Thrush Tinea Yeast infection

Syphilis

2030.0	Parasitic diseases	2125.0	Cancer, male genital tract
2050.0	Includes:	2125.0	Surfeer, male gemaa taet
			To also do as
	Ascaris		Includes:
	Leeches		Epididymitis
	Lice		Penis
	Maggots		Prepuce (foreskin)
	Pinworms		Prostate
	Scabies		Scrotum
	Seables		
			Spermatic Cord
2031.0	Sepsis, septicemia		Testes
2035.0	Other and unspecified infectious and parasitic diseases	2126.0	Cancer of urinary tract
			,
	Includes:		Includes:
	Cattleman's disease		
			Bladder
	Lyme disease		Kidney
	PCP (pneumocystis carinii)		Renal pelvis
	Plague		Ureter
	Staphylococcal infections		Urethra
	Trichomonas vaginitis		
	Tuberculosis		
		<b>2</b> 120.0	
	Tularemia	2130.0	Other malignant neoplasms
NEOPLA	ASMS (2100-2199)		Includes:
			Bone cancer
Malignar	nt neoplasms:		Metastatic carcinoma
Manghan	it neoprasitis.		
			Brain tumor
2100.0	Cancer, gastrointestinal tract		Carcinoma-in-situ, NOS
	Includes:	2135.0	Hodgkin's disease, lymphomas, leukemias
	Colon		
			To also do as
	Esophagus		Includes:
	Liver		Cancer of blood
	Small intestine		Lymphosarcoma
	Stomach		Multiple myeloma
			Polycythemia vera
2105.0	Company many implementations		Folycymenna vera
2105.0	Cancer, respiratory tract		
		Benign a	nd uncertain nature neoplasms:
	Includes:		
	Bronchus	2140.0	Fibroids and other uterine neoplasms
	Larynx		Includes:
	Lung		Cervical polyp
	Throat		Leiomyomata
	Trachea		Myoma
			Nabothian cyst
2110.0	Cancer, skin and subcutaneous tissues		······································
211010	Cultor, shin and subbataloous histores	2145.0	Other hanian naonlasms
	In the design	2143.0	0 1
	Includes:		Includes:
	Basal cell carcinoma		Bartholin's cyst
	Melanoma		Dermoid cyst (ovary)
	Squamous cell carcinoma		Hemangioma
	oquanious con carentonia		
0115.0	Courses have at		Lipoma
2115.0	Cancer, breast		Nasal polyp
			Nevus
2120.0	Cancer, female genital tract		Ovarian cyst
	-		Rectal polyp
	Includes:		Vaginal inclusion
	Cervix		
			Vocal cord
	Endometrium		
	Fallopian tube(s)		Excludes:
	Ovary(ies)		Cyst, NOS (1855.0)
	Uterus		Epidermoid cyst (2825.0)
	Vagina		Pilonidal cyst (2825.0)
	Vulva		Sebaceous cyst (2825.0)

#### 2150.0 Neoplasm of uncertain nature

Excludes:

#### Brain tumor (2130.0)

#### ENDOCRINE, NUTRITIONAL, METABOLIC AND **IMMUNITY DISEASES (2200-2249)**

2200.0 Diseases of the thyroid gland

> Includes: Goiter Hyperthyroidism Hypothyroidism Myxedema Thyroid nodule Thyrotoxicosis

2205.0 Diabetes mellitus

- 2210.0 Gout, hyperuricemia
- 2215.0 Other endocrine, nutritional, metabolic and immunity diseases
  - Includes: Amyloidosis Barter's Syndrome Calcium deficiency Cystinosis Disorders of intestinal absorption Electrolyte imbalance Female hormone deficiency Hematochromatosis HL, elevated Hormone imbalance Hypercholesterolemia Hyperlipidemia Hypoglycemia Impaired immune system Iron deficiency Low blood sugar Malnutrition Ovarian dysfunction Poor nutrition

DISEASES OF THE BLOOD AND BLOOD-FORMING **ORGANS (2250-2299)** 

2250.0	Anemia		
	Includes: Anemia, NOS Iron deficiency anemia Pernicious anemia Sickle cell anemia	2325.0	Mental
2255.0	Other diseases of blood and blood-forming organs Includes: Hemophilia Thrombocytopenia yon Willebrand's disease		

#### MENTAL DISORDERS (2300-2349)

- 2300.0 Organic psychoses Includes: Alcoholic psychoses Drug withdrawal Organic brain syndromes Senile dementia
- 2305.0 Functional psychoses
  - Includes: Autism Bipolar disease Depression, Major Manic-depressive psychoses Paranoid states Psychosis, NOS Schizophrenia, all types

#### 2310.0 Neuroses

Includes: Anxiety reaction Depressive neurosis Depressive reaction Neurosis, NOS Obsessive compulsive neurosis

Excludes: Anxiety (1100.0) Depression (1110.0)

- 2315.0 Personality and character disorders
- 2320.0 Alcoholism

Includes: Alcohol dependence

Excludes: Adverse effect of alcohol (5915.0) Alcohol abuse (1145.0) Alcohol-related problems (1145.0)

Drug dependence 2321.0

> Includes: Drug addiction

Excludes: Abnormal drug usage (1150.0) Adverse effect of drug abuse (5910.0) Overdose, intentional (5820.1)

retardation

#### **PAGE 170**

# 2006 NHAMCS MICRO-DATA FILE DOCUMENTATION

2330.0	Other and unspecified mental disorders	2405.0	Refractive error (continued) Excludes:
	Includes:		Test for refractive errors (3230.0)
	Adolescent adjustment reaction		
	Attention deficit disorder (ADD)	2410.0	Cataract
	Attention deficit hyperactivity disorder		
	(ADHD)	2415.0	Glaucoma
	Note: Use additional code (1125.0) for		Includes:
	hyperactivity.		Hypertensive ocular disease
	Bruxism		Increased ocular pressure
	Dyslexia, Mental		
	Grief reaction	2420.0	Other diseases of the eye
	Sexual deviations		
	Transient situational disturbances		Includes:
			Amblyopia
DISEAS	ES OF THE NERVOUS SYSTEM (2350-2399)		Aphakia
			Color blindness

- 2350.0 Multiple sclerosis2355.0 Parkinson's disease (paralysis agitans)2360.0 Epilepsy
- 2365.0 Migraine headache
- 2370.0 Other and unspecified diseases of the nervous system

Includes: Alzheimer's disease Bell's palsy Carpal tunnel syndrome Cerebral palsy Demyelinating disease Meningitis Morton's neuroma Muscular dystrophy Myasthenia gravis Neuropathy Paralysis, NEC Phantom leg/limb pain Thoracic outlet syndrome Tourette's syndrome

#### Amblyopia Aphakia Color blindness Esotropia Exotropia Krukenberg's spindle Macular degeneration

Pterygium Retinal detachment Strabismus

#### DISEASES OF THE EAR (2450-2499)

- 2450.0 Otitis media
- 2455.0 Other diseases of the ear

Includes: Abscess Labyrinthitis Ruptured tympanic membrane

Excludes: Deafness (1345.1) Infection, NOS (1355.2)

#### DISEASES OF THE CIRCULATORY SYSTEM (2500-2599)

2500.0 Rheumatic fever and chronic rheumatic heart disease

Includes: Chorea

2505.0 Hypertension with involvement of target organs

Includes: HCD HCVD Hypertensive cardiovascular disease Hypertensive heart disease Pulmonary hypertension Renal hypertension

2510.0 Hypertension, hypertensive

Includes: High blood pressure

# DISEASES OF THE EYE (2400-2449)

2400.0 Inflammatory diseases of the eye

Includes: Blepharitis Conjunctivitis Ophthalmia Iritis Keratitis (includes sicca) Sty Ulcer

Excludes: Infection, NOS (1315.0)

2405.0 Refractive error

Includes: Anisometropia Astigmatism Hyperopia, farsightedness Myopia, nearsightedness Presbyopia

2515.0	Ischemic heart disease	2550.0	Other disease of circulatory system Includes:
	Includes:		Aneurysm
	Angina pectoris		Blood clots
	• •		
	Arteriosclerotic cardiovascular disease		Pulmonary embolism
	(ACVD)		Heart disease, NOS
	Arteriosclerotic heart disease (ASHD)		Infarct(s), NOS
	Coronary		Lymphadenitis
	Coronary artery disease		Lymphadenopathy
	Heart attack		Stasis dermatitis
	Myocardial infarction		Temporal arteritis
	•		Vasculitis
			Venous insufficiency
2520.0	Other heart disease		
	Includes:	DISEAS	ES OF THE RESPIRATORY SYSTEM (2600-2649)
	Aortic valve stenosis	DIGLIG	
	Arrhythmia, NOS	2600.0	Upper respiratory infections except tonsillitis
		2000.0	Opper respiratory infections except tonshiftis
	Atrial fibrillation		T 1 1
	Cardiac arrhythmia		Includes:
	Cardiac dysrhythmias		Croup
	Cardiomyopathy		Laryngitis
	Cardiomyopathy (congestive)		Pharyngitis
	Congestive heart failure		Rhinitis
	Cor pulmonale		Sinusitis
	Heart failure		
	Heart murmur		Excludes:
	Mitral valve prolapse		Allergic rhinitis (2635.0)
	Mitral valve regurgitation		Cold (1445.0)
	Paroxysmal tachycardia		Nose infection, NOS (1405.3)
	Premature ventricular contractions		Sinus infection, NOS (1410.2)
	(PVCs)		Throat infection, NOS (1415.3)
			Throat Infection, NOS (1455.5)
	Ventricular tachycardia	2605.0	T
2525.0		2605.0	Tonsillitis
2525.0	Cerebrovascular disease	2610.0	D 11/1
		2610.0	Bronchitis
	Includes:		
	Carotid stenosis		Includes:
	Cerebral arteriosclerosis		Acute bronchitis
	Cerebral hemorrhage		Bronchitis, NOS
	Cerebral stenosis		Chronic bronchitis
	Cerebrovascular accident (CVA)		
	Stroke	2620.0	Emphysema
	TIA	2625.0	Asthma
		2630.0	Pneumonia
2530.0	Atherosclerosis		
200010			Includes:
	Includes:		Bacterial pneumonia
	Arteriosclerosis		Bronchopneumonia
	Hardening of the arteries		Pneumonitis
			Viral pneumonia
	Excludes:		
	Cerebral arteriosclerosis (2525.0)	2635.0	Hay fever
2535.0	Phlebitis, thrombophlebitis		Includes:
			Allergic rhinitis
	Includes:		Allergy to:
	Phlebothrombosis		Dust
			Pollen
2540.0	Varicose veins		Animals
			Ragweed
2545.0	Hemorrhoids		Nasal allergy
			Pollenosis
	Includes:		
	Perineal tags		
	romour ugs		

# PAGE 171

#### **PAGE 172**

2640.0 Other respiratory diseases

Includes: Bronchospasm Chronic obstructive pulmonary disease Deviated nasal septum Hemothorax Pleurisy Pneumothorax Pulmonary edema Respiratory failure SARS

#### **DISEASES OF THE DIGESTIVE SYSTEM (2650-2699)**

2650.0 Diseases of the esophagus, stomach, and duodenum

Includes: Barrett's esophagus Duodenal ulcer Esophageal ulcer Esophagitis Gastritis GERD Peptic ulcer Stomach ulcer

Excludes: Gastroenteritis (2005.0) Stomach flu (1540.0)

- 2655.0 Appendicitis, all types
- 2660.0 Hernia of abdominal cavity
  - Includes: Abdominal Femoral Hiatus Inguinal Umbilical Ventral

2665.0 Diseases of the intestine and peritoneum

Includes: Abscess, rectal Adhesions Crohn's disease Diverticulitis Diverticulosis Fissure - rectal, anal Fistula - rectal, anal Ileitis Irritable bowel syndrome Proctitis Small bowel obstruction Spastic colitis Ulcerative colitis

Excludes: Intestinal virus (1540.0)

#### 2006 NHAMCS MICRO-DATA FILE DOCUMENTATION

2670.0 Diseases of the liver, gallbladder, and pancreas

Includes: Biliary colic Cholecystitis Cholelithiasis (gallstones) Cirrhosis Liver diseases Pancreatitis

2675.0 Other diseases of digestive system, NEC Includes: Mandibular cyst

2675.1 Dental abscess 2675.2 Dental cavities 2675.3 Canker sore 2675.4 Stomatitis 2675.5 Temperomandibular joint (TMJ) pain, Temperomandibular joint (TMJ) syndrome

#### **DISEASES OF THE GENITOURINARY SYSTEM (2700-2799)**

2700.0 Cystitis

Excludes: Bladder infection (1665.2)

- 2705.0 Urinary tract disease except cystitis
  - Includes: Bladder stones Glomerulonephritis Glomerulonephrosis Kidney stones Neurogenic bladder Pyelonephritis Renal failure Ureteral calculus Urethritis

Excludes: Bladder infection (1665.2) Kidney infection, NOS (1670.2) Passed stones (1680.0) Urinary tract infection (1675.0)

2710.0 Diseases of the male genital organs

Includes: Benign prostatic hypertrophy (BPH) Epididymitis Hydrocele Peyronie's disease Phimosis Prostatitis

Excludes: Prostate infection (1710.2)

2715.0	Fibrocvstic a	and other	diseases	of breast

Includes: Abscess Mastitis

Excludes: Infection (1810.0) Cancer (2115.0)

2720.0 Pelvic inflammatory disease (PID)

Includes: Oophoritis Pelvic peritonitis Salpingitis

Excludes: Pelvic infection, NOS (1775.3)

2725.0 Cervicitis, vaginitis

Includes: Cervical erosion Vulvovaginitis

2730.0 Other diseases of female reproductive system

Includes: Cervical dysplasia Cystocele Dysfunctional uterine bleeding Endometriosis Polycystic ovaries Procidentia uteri Prolapse of uterus Rectal-vaginal fistula Rectocele Vulvitis

2735.0 Diagnosed complications of pregnancy and puerperium

Includes: Advanced maternal age Diabetes during pregnancy Ectopic pregnancy Edema of pregnancy Fetal death in utero High blood pressure during pregnancy High risk pregnancy Hyperemesis Intrauterine growth retardation (IUGR) Miscarriage (if patient is pregnant) Multiple pregnancy Placenta previa Post dates RH sensitization Spontaneous abortion Threatened abortion Toxemia

Excludes: Abortion induced (3520.0) **PAGE 173** 

270010 Other diseases of the genitodifinary system, (120				
DISEASES OF THE SKIN AND SUBCUTANEOUS TISSUE (2800-2899)				
2800.0	Carbuncle, furuncle, boil, cellulitis, abscess, NEC			
2805.0	Impetigo			
2810.0	Seborrheic dermatitis Includes: Dandruff			
2815.0 2820.0 2825.0	Eczema and dermatitis, NOS Psoriasis Other diseases of the skin			

Other diseases of the genitourinary system, NEC

Includes: Allergic skin reactions Epidermal inclusion cyst Folliculitis Hidradenitis Hives Keloid Keratosis Lupus erythematosus, NOS Paronychia Pilonidal cyst Poison ivy Poison oak Rosacea Sebaceous cyst Urticaria

Excludes: Acne (1830.0) Cyst, NOS (1855.0)

# DISEASES OF THE MUSCULOSKELETAL SYSTEM AND CONNECTIVE TISSUE (2900-2949)

2900.0 Arthritis

2736.0

Includes: Osteoarthritis Rheumatism, NOS Rheumatoid arthritis Septic

2905.0 Nonarticular rheumatism

Includes: Bursitis Ganglion cyst Lumbago Myositis Radiculitis/Radiculopathy Synovitis Tendinitis Tenosynovitis

Excludes: Rheumatism, NOS (2900.0)

2910.0	Other musculoskeletal or connective tissue disease	3100.0	General medical examination
	Includes:		Includes:
	Baker's cyst		Annual exam
	Bone cysts		Checkup, NOS
	Bone spur		Checkup, routine
	Bunions		Evaluation, NOS
	Cervical myelopathy		General exam
	Curvatures of spine		Healthy adult
	Degenerative disc diseases		Healthy child
	Dupuytren's contracture		History and physical (H&P)
	Exostosis		Multiphasic screening exam
	Kyphoscoliosis		Physical exam
	Kyphosis		Preventive
	Osteomyelitis		Regular exam
	Osteoporosis		Routine exam
	Paget's		
	Plantar fistula		Excludes:
	Scleroderma		Administrative exam (7100.0-7140.0)
	Scoliosis		Followup visit (4800.0)
	Sjogen's		Gynecological exam (3225.0)
	Slipped disc		Pre-op exam (4200.0)
	Spondylosis		Prenatal exam (3205.0)
	Spur, NOS		Progress visit (4800.0)
	Systemic lupus erythematosus		
		3105.0	Well baby examination (any child under 1 year of
			age)
CONGE	NITAL ANOMALIES (2950-2979)		
		3130.0	General psychiatric or psychological examination
2950.0	Congenital anomalies of heart and circulatory system		
			Includes:
2955.0	Undescended testicles		Psychological testing
	Includes:		Excludes:
	Hypospadias		Court- or school-ordered examination
2960.0	Other and unergatified concentral energy lies		(7140.0)
2900.0	Other and unspecified congenital anomalies	SPECIA	L EXAMINATIONS (3200-3299)
	Includes:	SILCIA	LE EXAMINATIONS (5200-5233)
	Absence of organs	3200.0	Pregnancy, unconfirmed
	Blocked tear duct	5200.0	Tregnancy, uncommitted
	Cleft palate		Includes:
	Cleft lip		HCG
	Clubfoot		Late menses
	Congenital dislocation of hip		Late menstruation
	Deformed earlobe		Might be pregnant
	Down syndrome		Missed period
	Duplication of organs		Period late
	Dysmorphic		Possible pregnancy
	Harelip		Pregnancy test
	Turner's Syndrome		
		3205.0	Prenatal examination, routine
	TAL MORBIDITY AND MORTALITY CONDITIONS		
(2980-29	99)		Includes:
			Normal antepartum visit
2980.0	Prematurity		Pregnancy, NOS
			Routine obstetrical care
	Includes:		
	Late effects of prematurity	3215.0	Postpartum examination, routine
	Premature infant	3220.0	Breast examination
2990.0	All other perinatal conditions		Excludes
	All other perinatal conditions		Excludes: Breast thermography (3340.0)
DIA	AGNOSTIC, SCREENING, AND PREVENTIVE MODULE		Breast thermography (3340.0) Mammography (3340.0)
	MODULE		Xerography (3340.0)
GENER	AL EXAMINATIONS (3100-3199)		Actography (5540.0)

3225.0	Gynecological examination Includes:	3305.0	Skin immunity test Includes: PPD test
	Pelvic exam		Tuberculin test
	Excludes:		Excludes:
	Examination for birth control medication (3505.0)		To check results of skin tests (6600.0)
	Examination for birth control, NOS (3500.0)	3310.0	Glucose level determination
	Examination involving IUD (3510.0) Repeat or abnormal Pap smear (6300.0)		Includes: Blood sugar test Check sugar
3230.0	Eye examination		Glucose tolerance test Test for diabetes
	Includes:	3314.0	Human immunodeficiency virus (HIV) test
	Check contacts		To also do co
	Check glasses For contacts		Includes: AIDS test
	For glasses		AIDS test
	Glasses, NOS		Excludes:
	Need new glasses		To check results of human
	Routine ophthalmologic exam		immunodeficiency
	Test for nearsightedness, farsightedness		virus test (6106.0)
	To test my eyes		
	Vision test	3315.0	Other blood test
	Visual field test		Includes:
	Excludes:		Blood alcohol Blood count
	Fitting glasses or contacts (4515.0)		Blood culture
			Blood test, NOS
3235.0	Heart examination		Blood thinning test Check cholesterol
	Includes:		Prothrombin time
	Cardiac checkup		Sickle cell anemia test
	Heart checkup		Excludes:
3240.0	Other special examination		Premarital blood test (7135.1)
	Includes:		3315.1 Blood test for sexually
	AICD check Check tubes		transmitted disease
	Examination of functioning internal	3320.0	Blood pressure test
	prosthetic devices: implants,		Includes:
	stents, shunts, etc.		Blood pressure check
	Hearing aid		Check blood pressure
	ICD check		
	Neurological exam Thyroid	3325.0	Urine test
			Includes:
DIAGNO	OSTIC TESTS (3300-3399)		Estriol for fetal evaluation Test urine for sugar
3300.0	Sensitization test		Urinalysis
	Includes:		Urine culture
	Allergy test	3330.0	Diagnostic endoscopies
	Excludes:		
	To check results of skin tests (6600.0)		Includes:
			Arthroscopy Cystoscopy
			Laparoscopy
			Proctoscopy
			Sigmoidoscopy
			- 17

# PAGE 176

IUD (3510.0)

3335.0 3340.0	Biopsies Mammography, xerography, breast thermography		OTHER SCREENING AND PREVENTIVE PROCEDURES (3400-3499)		
	Exclude Breast	es: examination (3220.0)	3400.0	Prophylactic inoculations	
3345.0	Diagnostic radiolog			Includes: Flu shot Immunization Influenza shot	
	Angio Bone s Hyster	gram/angiography		Rhogam Tetanus shot Vaccination	
	IVP MRI Myelo	gram	3405.0	Exposure to sexually transmitted disease (STD)	
	•	sotope scanning		Includes: Check for STD May have STD	
3350.0	EKG, ECG, electroc	ardiogram, treadmill, stress testing	3408.0	Possible HIV	
3355.0	EEG, electroenceph	alogram	3409.0	Exposure to human immunodeficiency virus (HIV)	
3360.0	Hearing test			Includes: Exposed to AIDS	
	Include Hearin	s: ig exam	3410.0	Exposure to other infectious diseases	
3365.0	Pap smear Nasal swab			Includes: Chickenpox	
3366.0 3370.0	Other and unspecific Include			Infectious hepatitis Measles Mumps Pathogens	
	Amniocentesis Centesis Drug screening Electronic fetal monitoring Lab test, NOS Pulmonary function test Spinal tap		2415.0	Tuberculosis	
			3415.0	Exposure to bodily fluids of another person, NOS Includes:	
				Blood exposure Exposure to another's secretions	
	3370.1	Glaucoma test Includes:	FAMILY	Y PLANNING (3500-3599)	
		ATN check Check intraocular pressure	3500.0	Family Planning, NOS	
	3370.2	Throat culture		Includes: Birth control, NOS	
	3370.3	Heart catheterization		Counseling, examinations, and general advice regarding:	
	3370.4	Other cultures Includes:		Genetics Sterilization	
		Skin		Fertility, NOS Unwanted pregnancy, contraceptive, NOS Excludes: Procedures performed [See Counseling and examinations for pregnancy interruption (3515.0) through Artificial insemination (3530.0)] Specified types of birth control: Birth control medication (3505.0)	

3505.0	Contraceptive medication		TREATMENT MODULE
	Includes:	MEDIC	ATIONS (4100-4199)
	Depo Provera Examinations, instructions, and advice regarding:	4100.0	Allergy medication
	Birth control pills		Includes:
	Contraceptive implants		Allergy shots
	Foams, jellies Oral contraceptives		Allergy treatments
	Renewing pill prescription		Excludes:
	Norplant checkup		Allergy testing (3300.0)
	Norplant insertion/removal (also code		
	4520.0)	4110.0	Injections
3510.0	Contraceptive device		Includes:
			Antibiotics
	Includes:		Fat
	Diaphragm insertion, removal, checkup		Hormones
	IUD insertion, removal, checkup		Injections, NOS Iron
3515.0	Counseling and examinations for pregnancy		Lupron Depot
5515.0	interruption		Shots, NOS
	interruption		Steroid
	Includes:		Vitamins
	Evaluation for an arrangement for		
	abortion		Excludes:
	Wants abortion		Allergy shots (4100.0)
3520.0	Abortion to be performed (at this visit)		Immunizations (3400.0)
			Inoculations (3400.0)
3525.0	Sterilization and sterilization reversal to be performed		Vaccinations (3400.0)
(at this vi	SIL)	4111.0	Noncompliance with medication thereasy
	Includes:	4111.0	Noncompliance with medication therapy
	Male - vasectomy	4115.0	Medication, other and unspecified kinds
	Female - tubal ligation	1115.0	Medication, other and anspectified kinds
			Includes:
			Antibiotics, NOS
3530.0	Artificial insemination (at this visit)		Check medication
	Includes:		Drug studies
	Assisted reproductive technologies		For medication
	Fetal reduction		Medication for pain
	Intrauterine insemination		Oral
	In vitro fertilization		Prescribe medication
3535.0	Proconception counceling and education		Renew prescription
5555.0	Preconception counseling and education Includes:		Renew scripts Request prescription
	Counseling, examinations, and general		Scripts
	advice regarding:		benpa
	Artificial insemination		Excludes:
	Desires pregnancy		Antibiotic medication injections
	Egg donor		(4110.0)
	Infertility		Birth control medication (3505.0)
	Semen analysis		Eyeglass prescription (see Eye
	Sperm donor		examination (3230.0) and
	Sperm washing		Fitting glasses and contact lenses
			(4515.0))

#### PREOPERATIVE AND POSTOPERATIVE CARE (4200-4299)

- 4200.0 Preoperative visit for specified and unspecified types of surgery
  - Includes: Discussion of cosmetic surgery Pre-op examination Surgical consultation

4205.0 Postoperative visit

- Includes: Check graft Check implant Check shunt Check stoma Check surgical wound Clotted graft/shunt Endoscopy follow-up Postop care Postop pain Postop suture removal Suture removal follow-up
- Excludes: Complications of surgical or medical procedures and treatments (5930.0)

#### SPECIFIC TYPES OF THERAPY (4400-4499)

4400.0 Physical medicine and rehabilitation

> Includes: Back adjustment Cardiac rehabilitation Heat therapy Hydrotherapy Occupational therapy Physical therapy Pulmonary rehabilitation Recreational therapy Speech therapy Therapeutic exercises Vocational rehabilitation

4401.0 Cardiopulmonary resuscitation (CPR) 4405.0 Respiratory therapy

> Includes: Asthma treatment Inhalation therapy Inhaler/breathing treatment

4410.0 Psychotherapy

> Includes: Group counseling Includes: 12 Step programs (e.g. AA, Overeaters Anonymous, etc.) Group therapy Psychoanalysis

4415.0 Radiation therapy Includes treatment of s/p

#### 2006 NHAMCS MICRO-DATA FILE DOCUMENTATION

- 4420.0
- 4425.0 Chemotherapy

#### **SPECIFIC THERAPEUTIC PROCEDURES (4500-4599)**

4500.0 Tube insertion

> Includes: Chest tube Flushed catheter PEG, Replacement Port-a-cath placement

Excludes: Flushed urinary catheter 4510.0

- 4505.0 Cauterization, all sites
- IV therapy, infusion

Includes: Flushed urinary catheter Urethral dilation Urinary catheterization

Excludes: Cystoscopy [see Diagnostic endoscopies (3330.0)]

4515.0 Fitting glasses and contact lenses

> Includes: Broken or lost glasses or contacts Clean glasses or contacts Pick up glasses or contacts Prescription renewal

Excludes: Eye examination (3230.0)

#### 4518.0 Detoxification

4518.1 Alcohol

4518.2 Drug

#### Acupuncture

1505.0

- 4507.0
  - 4510.0 Urinary tract instrumentation and catheterization

4520.0

4521.0

4525.0 4529.0

4530.0

4535.0

Minor surgery	4555.0	Suture - insertion, removal
Includes:	4556.0	Cosmetic injection, NOS
Ear tube removal	4550.0	Cosmetie injection, 1005
		4556 1 Doton injustion
Ears pierced		4556.1 Botox injection
Joint manipulation		4556.2 Collagen injection
Norplant insertion/removal (also code		
3505.0)	4560.0	Other specific therapeutic procedures, NEC
Tattoo removal		Includes:
Tube removal		Adjust device
		Cryotherapy
4520.1 Wart removed		Debridement
1520.1 Wattrenioved		Enema
Maior autoom		
Major surgery		Epidural
		Eye exercises
Includes:		Nerve block
		Pessary, Change/Clean
Aspiration bone marrow		Phototherapy
Balloon angiogram		Skin rejuvenation
Cholecystectomy		TENS unit. NOS
Laser surgery, eye		Ultraviolet treatment
Lens extraction		Wound care, NOS
Liver biopsy		would care, NOS
		F 1 1
Percutaneous transluminal angiogram		Excludes:
Polypectomy		Pinched nerve (1240.0)
PTCA (balloon)		
	4565.0	Transplants, NOS
Kidney dialysis		
		Includes:
Internal prosthetic devices (fit, adjust, remove)		Stem cell
Includes:		
Breast implants		4565.1 Failure
Cardiac pacemaker		4505.11 andre
1		
Joint prostheses		Includes:
		Bone marrow
Excludes:		
Complications of surgical or medical		4565.2 Rejection
procedures and treatments		
(5930.0)	MEDIC	AL COUNSELING (4600-4699)
	4600.0	Diet and nutritional counseling
External prosthetic devices, artificial body parts (fit,		č
adjust, remove)		Includes:
aujus, 1011010)		Check weight
Excludes:		
		Counseling for weight reduction
Prosthetic complications (5930.0)		

4604.0 Human immunodeficiency virus (HIV) counseling

Includes: AIDS counseling AIDS information, education ARC counseling Worried, concerned about getting, transmitting AIDS

4540.0	Cast, splint - application, removal
--------	-------------------------------------

Corrective appliances

Includes:

Fitting and adjusting:

Back brace

Hearing aid

Leg brace

Neck brace Orthopedic shoes Walking cane

4545.0 Dressing, bandage - application, change

4550.0 Irrigation, lavage

4605.0	Medical Counseling, NOS	4715.0	Other problems of fa	mily relationship
	Includes: Alcohol		Includes	s: parents or in-laws
	Disease counseling			red parents
	Drug			fights and disruptions
	Drug rehabilitation			ms with relatives
	Medical consultation			
	New patient	4720.0	Educational problem	15
	Patient education			
	Personal problem		Includes	
	Referral			teeism, truancy
	Second opinion To learn about a condition		Hates :	
	To meet doctor			ms with teachers
	Trouble toilet training		School	behavior problems
	Wants to talk to doctor	4725.0	Occupational proble	ms
			o coupational provid	
	4605.1 Family history of cardiovascular		Includes	3:
	disease		Job dis	ssatisfaction
			Out of	work
	4605.2 Family history of cancer			m with boss or coworkers
				e to work
	4605.3 Family history of diabetes		Unemp	ployment
	4605.4 Family history of other disease or condition	4730.0	0 Social adjustment problems	
			Includes	3:
SOCIAL	PROBLEM COUNSELING (4700-4799)			nination problems nave any friends
4700.0	Economic problem		Loneliness Neighborhood and	
	Includes:		prob	
	Can't pay bills		Social	isolation
	Too little income	1725.0	T 1 11	
4702.0	Problem with access to medical care	4735.0	Legal problems	
4702.0	Froblem with access to medical care		Includes	
	Includes:			onment, prosecution
	Blocked access to medical care			its, litigation
	Limited access to medical care			
			4735.1	Police involvement in
4705.0	Marital problems			outpatient visit circumstances
	Includes:			Includes:
				Brought in by police
	Alcoholic spouse			Police called
	Custody battle Divorce, desertion, separation	4740.0	Other social problem	
	Marriage counseling, NOS	4740.0	Other social problem	15
	Premarital counseling		Includes	
	Problem with husband, wife		Disabl	
			Disaste	
4710.0	Parent-child problems		Housir	ng and clothing problems
	1 I			ncy out-of-wedlock
	Includes:		Proble	m with boyfriend or girlfriend
	Adopted or foster child		Proble	ms of aging
	Concern about childhood behavior			
	Discipline			
	Maturation problems			
	Working mother			

PROGRESS VISIT, NEC (4800-4899)		5020.0	Leg
4800.0	Progress visit, NOS (Use only when the only information given is progress or followup)		Includes: Femur Fibula Hip
	Includes:		Knee
	Chronic, NOS Followup, NOS	5025.0	Tibia Ankle
	Getting better	5025.0	Alikie
	I'm better	5030.0	Foot and toes
	I'm the same		
	I'm worse	5035.0	Arm
	Monthly visit		
	Ongoing treatment, NOS		Includes:
	Recheck		Elbow
	Routine followup		Humerus Radius
	Same problems, NOS Touching base		Shoulder
	Touching base		Ulna
	Excludes:		enia
	Followup, disease (Code to disease)	5040.0	Wrist
	Followup, injury (Code to injury) Followup, symptom (Code to symptom) Followup, test results (Code to 6100.0-	5045.0	Hand and fingers
	6700.0)	5050.0	Fracture, other and unspecified
	General checkup (3100.0) Postoperative followup (4205.0) Preventive medicine (3100.0)	<u>Sprains a</u>	nd strains:
revenuve medicine (3100.0)		5105.0	Cervical spine, neck
INJURIES AND ADVERSE EFFECTS MODULE			Includes: Whiplash
INJURY BY TYPE AND/OR LOCATION (5001-5799)		5110.0	Back
Fractures	and dislocations:	5115.0	Knee
5005.0	Head and face Includes:	5120.0	Ankle
	Facial bones	5125.0	Wrist
	Jaw Nose Skull	5130.0	Sprain or strain, other and unspecified
		Laceratio	ns and cuts:
5010.0	Spinal column	5205.0	Head and neck area Excludes:
	Includes:		Face (5210.0)
	Back		
	Neck	5210.0	Facial area
	Vertebrae		Includes:
5015.0	Trunk area, except spinal column		Eye Ear
5015.0	Trunk area, except spinar column		Forehead
	Includes:		Lip
	Clavicle		Nose
	Collarbone		
	Pelvic scapula	5215.0	Trunk area
	Rib		Includes:
			Perineum

5220.0	Lower extremity	Injury, of	ther and unspecified type:
	Includes:	5505.0	Head, neck, and face
	Ankle Foot		Includes:
5225.0	Upper extremity		Post concussive syndrome Tooth fracture Tooth knocked out
	Includes: Arm		Traumatic brain injury (TBI)
	Fingers Hand Wrist		Excludes: Loose tooth (no injury) 1500.0
		5510.0	Еуе
5230.0	Laceration and cuts, site unspecified	5515.0	Back
Puncture	wounds:		To she door
5305.0	Head, neck and facial area		Includes: Tail bone
5310.0	Trunk area	5520.0	Chest and abdomen
5315.0	Lower extremity		Includes: Internal injuries
5320.0	Upper extremity	5525.0	Hip
5325.0	Puncture wound, site unspecified	5530.0	Leg
	Includes: Needlestick, NOS	5535.0	Knee
Contusio	ns, abrasions, and bruises:	5540.0	Ankle
5405.0	Head, neck, and face	5545.0	Foot and toe(s)
	Excludes:	5550.0	Shoulder
	Eye (5410.0)	5555.0	Arm
5410.0	Eye		
	Includes:	5560.0	Elbow
	Black eye Contusion	5565.0	Wrist
	Corneal abrasion	5570.0	Hand and finger(s)
5415.0	Trunk area	5575.0	Injury, multiple or unspecified Includes post-traumatic (NOS) headache
	Includes: Injury to scrotum	Foreign l	(and 1210.0) body:
		5600.0	Eye
5420.0	Lower extremity	5605.0	Nose
5425.0	Upper extremity	5610.0	Skin
5430.0	Contusion, abrasion, bruise, site unspecified	5615.0	Digestive tract
			Includes: Mouth Rectum

Throat

5616.0

Respiratory tract Other and unspecified sites 5620.0

<u>Burns, all</u>	l degrees:	5815.0	Violence, NOS
5705.0	Head, neck, and face Includes eyes		Includes: Abuse
5710.0	Trunk area		Beat up In a fight Stabbing
5715.0	Extremities		Excludes:
	Includes: Lower Upper		Violence against oneself (5818.0, 5820.0)
5720.0 5750.0	Burn, site unspecified Sunburn, windburn Excludes:		5815.1 Child abuse or neglect Excludes: Child sexual abuse (5830.1)
	Sun poisoning 5920.0		5815.2 Battered spouse
Bites:			5815.3 Elder abuse
5755.0	Insect		5815.4 Gunshot wound
5760.0	Includes: Sting Tick	5818.0	Intentional self-mutilation Includes: Self-abuse Tried to hurt self
	Animal ,snake, human		
5800.0	NOS (5800-5899) Late effects of an old injury	5820.0	Excludes: Suicide attempt (5820.0) Suicide attempt
5805.0	Includes: Deformities Scars Motor vehicle accident, type of injury unspecified		Includes: Found in car with motor running Hanging oneself Slashed wrists Code also: Laceration of wrists (5225.0)
	Includes: Auto accident Car accident Motorcycle accident		Stabbed oneself 5820.1 Overdose, intentional Excludes: Unintentional overdose
5810.0	Accident, NOS	5830.0	(5910.0) Rape
	Includes: Fall, type or location of injury unspecified		Includes: Sexual assault
			5830.1 Sexual abuse
			Includes: Molestation
		5835.0	Dead on arrival (DOA)

Includes: Death

Excludes: Cardiac arrest (5837.0) Cardiopulmonary arrest (5839.0) Respiratory arrest (5836.0) 5836.0

5836.0	Respiratory arrest	POISONING AND ADVERSE EFFECTS (5900-5999)		
	Excludes:	5900.0	Unintentional poiso	ning
	Cardiac arrest (5837.0) Cardiopulmonary arrest (5839.0) Dead on arrival (5835.0)		5900.1	Food poisoning
	Drowning (5838.0)		5900.2	Ingestion, inhalation, or
	Near drowning (5838.0)		5700.2	exposure to potentially
				poisonous products
5837.0	Cardiac arrest			
	Includes:			Includes:
	Code blue			Household products
	Exclusion.			Chemicals
	Excludes:			Drugs
	Cardiopulmonary arrest (5839.0)			Gas
	CPR (4401.0)			Smoke Lead
	Dead on arrival (5835.0)			
	Respiratory arrest (5836.0)			Mace in eyes
5838.0	Drowning	5905.0	Adverse effect of me	edication
	Includes:		Include	s:
	Near drowning		Allerg	y to medication
			1	ylactic shock
5839.0	Cardiopulmonary arrest			action to prescribed medication
	Excludes:		Penici	llin allergy
	Cardiac arrest (5837.0)			
	Respiratory arrest (5836.0)	5910.0	Adverse effect of dr	6
	••• · · · ·		Include	
5840.0	Unconscious on arrival		Bad tr	1
	<b>T</b> 1 1			ination of drugs and alcohol
	Includes:			suicidal)
	Coma			induced hallucinations
	Found unconscious			ed out on drugs
	Knocked out			ion of drugs for nonmedicinal
	Shock		purp	entional overdose
	Stupor Unresponsive		Uninte	entional overdose
	Unresponsive		Exclude	e.
5841.0	State of consciousness not specified			onal overdose (5820.1)
	Includes:	5915.0	Adverse effect of al	cohol
	Brought in by ambulance			
	Found on floor		Include	
	Verbally unresponsive			intoxication
5942.0			Drunk	
5842.0	Altered level of consciousness, NOS		Intoxi	cation
	Excludes:	5920.0	Adverse effects of e	nvironment
	Adverse effect of alcohol 5915.0			
	Adverse effect of drug abuse 5910.0		Include	s:
			Air po	llution
			Frostb	ite

Hypothermia Noise pollution Sun damage Sun poisning Water pollution

5922.0	Adverse effects of terrorism and bioterrorism Includes:	6106.0	For results of test for human immunodeficiency virus (HIV)
	Anthrax, skin		
	Anthrax, respiratory (inhalation)		Includes:
	Bombing		Results of AIDS test
	Food/water contamination		
	Smallpox		Excludes:
	I I		History of positive HIV test findings
Note: Us	se an additional code to identify the complaint, symptom,		(2015.1)
or disease			(=====)
or anocase	<i>z</i> , ii uii <i>y</i> .	6110.0	For other findings of blood tests
		0110.0	Tor other findings of blood tests
5925.0	Adverse effects, other and unspecified		Includes:
5725.0	Includes:		Elevated sed rate
	Seasickness		Low potassium
	Seasickness		1
			Positive blood culture
5930.0	Complications of surgical or medical procedures and		Positive serology, VDRL
	treatments		
		6200.0	For results of urine tests
	Includes:		
	Artificial openings (ostomies, stoma)		Includes:
	Catheter		Abnormal urinalysis
	Foreign body (accidentally left during		Positive urine culture
	surgery e.g. sponge, instrument)		Sugar in urine
	Medical complication, NOS		bugui in unite
	-	(200.0	E fin din
	Non-healing surgical wound	6300.0	For cytology findings
	Post-op fever		
	Post-op hemorrhage (bleeding)		Includes:
	Post-op infection or inflammation		Atypical Pap smear
	Post-op sepsis (septicemia)		For results of Pap smear of cervix or
	Shunt		other area
	Tubes		Positive Pap smear
	Wound dehiscence		Repeat Pap smear
	Use additional code to identify condition	6400.0	For radiological findings
	Such as: UTI (1675.0)		
	Fever (1010.0)		Includes:
	1 ever (1010.0)		
			Abnormal X-ray
	Excludes:		X-ray results
	Postpartum conditions (1791.0 and		Xeromammography results
	1810.2)		
	Complication of transplant organs	6500.0	For results of EKG, Holter monitor review
	(4565.1-4565.2)		
		6600.0	For results of skin tests
TEST RI	ESULTS MODULE	6700.0	For other and unspecified test results
Includ	les all abnormal test results and following for test results)		Includes:
(metuc	les all abnormal test results and followups for test results)		Abnormal EEG
(100.0	E-manufa -file-d-lange (		
6100.0	For results of blood glucose tests		Abnormal lab test results, NOS
			Abnormal scans
	Includes:		Abnormal pulmonary function test
	Abnormal glucose tolerance test		Results of fetal evaluation tests
	Elevente d'hier el en en en		To dia secondary to stand an available second and the second second

Elevated blood sugar Glucose control High blood sugar Hyperglycemia Sugar in blood

6105.0 For results of cholesterol and triglyceride tests

> Includes: High cholesterol

To discuss test results with physician Ultrasonography results

employment

7100.1

7100.2

7100.3

7100.4

Driver's license examination

7100.0

ADMINISTRATIVE MODULE

Physical examination required for school or

Physical examination required

Preemployment examination Required company physical Return to work checkup Teacher's certificate physical

Executive physical examination

Physical examination required

Physical examination for extracurricular activities

Boy Scouts or Girl Scouts

for employment

Includes:

for school Includes: College Day care center Grade school High school Nursery school

Includes: Athletics

> Camp Little League

#### 2006 NHAMCS MICRO-DATA FILE DOCUMENTATION

7140.0	Other reason for visit required by party other than
	the patient or the health care provider

Includes: Physical examination for adoption Psychiatric examination required by court

#### UNCODABLE ENTRIES

8990.0	Problems, complaints, NEC
8991.0	Patient unable to speak English
8993.0	Patient (or patient's spokesperson) refused care
	Includes: Left AMA Walked out
8997.0	Entry of "none" or "no complaint"
	Includes: Asymptomatic, NOS Doing well
8998.0	Insufficient information
8999.0	Illegible entry
	SPECIAL CODE
90000	Blank

7125.0 Insurance examination

7130.0 Disability examination

7120.0

Includes: Evaluation of disability Social Security examination

- 7131.0 Worker's comp exam
- 7135.0 Premarital examination

7135.1 Premarital blood test

7137.0 Direct admission to hospital

Includes: Admit to hospital Direct admit For admission Here for admission Involuntary commitment Pre admission exam Voluntary commitment

#### APPENDIX III

#### A. GENERIC CODES AND NAMES IN NUMERIC ORDER

This list reflects the new classification being used to code drugs reported in the NAMCS. Starting with 2006 data, the Multum Lexicon Plus system was used to classify drugs in the NAMCS. Drugs starting with a "d" prefix are those for which a match was found in the Multum Lexicon Plus<sup>®</sup>, a proprietary database of Cerner Multum, Inc., and the code reflects the Multum code for the drug. Drugs starting with an "a" prefix are those for which a match could not be found in Multum but for which ingredients could be identified. Drugs starting with a "c" prefix are those for which ingredients could not be determined. Drugs starting with "a" or "c" were assigned codes by NCHS. Ingredients are separated by semi-colons.

a10000 ACACIA GUM; ALOE VERA TOPICAL; GUM GHATTI a10001 ACACIA GUM; HYDROCORTISONE; LEVONORGESTREL; NEOMYCIN; POLYMYXIN B SULFATE a10003 ACETONE; CASTOR OIL; COLLODION; PODOPHYLLUM RESIN TOPICAL; SALICYLIC ACID TOPICAL a10004 ACETONE; ETHANOL; FUCHSIN; PHENOL TOPICAL; RESORCINOL TOPICAL a10005 ACETONE; CALENDULA; CAPSAICIN TOPICAL; ECHINACEA; MENTHOL TOPICAL a10032 ANETHOLE; BENZOCAINE TOPICAL; DEXTROMETHORPHAN; MENTHOL; PEPPERMINT a10042 BENACTYZINE; MEPROBAMATE a10049 BENZYL ALCOHOL; DIMETHICONE; PETROLATUM TOPICAL a10051 BENZYL ALCOHOL; SOYBEAN OIL; STARCH TOPICAL a10054 BENZYL ALCOHOL; LIDOCAINE a10068 ASCORBIC ACID; BIOTIN; VITAMIN B COMPLEX a10085 BISMUTH ANTI-DIARRHEA; KAOLIN; OPIUM; PECTIN a10096 ASPIRIN; BUFFERS a10105 CALCIUM REPLACEMENT: MAGNESIUM ANTACIDS: POTASSIUM ACIDIFYING: SODIUM CHLORIDE a10111 CALCIUM REPLACEMENT: SODIUM FLUORIDE a10114 CALCIUM REPLACEMENT: ERGOCALCIFEROL: PHOSPHORUS a10125 CALCIUM REPLACEMENT; ERGOCALCIFEROL a10127 CALCIUM REPLACEMENT; CHOLECALCIFEROL a10133 CALCIUM ION; CHLORIDE ION; MAGNESIUM ANTACIDS; POTASSIUM ION; SODIUM ION a10135 CALCIUM ION; CHLORIDE ION; POTASSIUM ION; SODIUM ACETATE; SODIUM ION a10136 CALCIUM ION; CHOLECALCIFEROL; IRON PREPARATIONS; VITAMIN A; VITAMIN B COMPLEX a10138 CALCIUM ION; IRON PREPARATIONS; MULTIVITAMIN a10140 CALCIUM ION; MAGNESIUM CHLORIDE; POTASSIUM ION; SODIUM CHLORIDE a10143 CALCIUM PANTOTHENATE; NIACIN; PYRIDOXINE; RIBOFLAVIN; THIMEROSAL a10150 CANTHARIDIN; PODOPHYLLUM RESIN TOPICAL; SALICYLIC ACID TOPICAL a10154 BENZOCAINE TOPICAL; CARMELLOSE; GELATIN; MINERAL OIL; PECTIN a10156 ALGINIC ACID; BORIC ACID TOPICAL; CARMELLOSE; GLYCERIN TOPICAL; PROPYLENE GLYCOL a10159 CASEIN; COCONUT OIL; CORN OIL; MULTIVITAMIN; SUCROSE a10160 CASEIN; COCONUT OIL; MAGNESIUM AMINO ACIDS CHELATE; SUCROSE; TAPIOCA a10161 CASEIN; CORN OIL; MULTIVITAMIN; PHENYLALANINE; PROTEIN a10162 CASEIN; CORN OIL; LECITHIN; MULTIVITAMIN; SODIUM ION a10163 CASEIN; MULTIVITAMIN; SAFFLOWER OIL; SOYBEAN OIL; SUCROSE a10166 CERESIN WAX; MINERAL OIL; PETROLATUM TOPICAL; WOOLWAX ALCOHOL a10172 CETEARETH; PETROLATUM TOPICAL; PROPYLENE GLYCOL; SORBITOL a10179 CETYL ALCOHOL; PROPYLENE GLYCOL; SODIUM LAURYL SULFATE; STEARYL ALCOHOL a10181 CETYL ALCOHOL; LANOLIN TOPICAL; MULTIVITAMIN; PROPYLENE GLYCOL; PURIFIED WATER a10193 BENZOCAINE TOPICAL; BENZOIC ACID; CHLOROBUTANOL; CHLOROTHYMOL; SALICYLIC ACID TOPICAL a10224 COLLODION; ETHANOL; ETHER; SALICYLIC ACID TOPICAL; ZINC TOPICAL AGENTS, EXTERNAL USE a10230 CYSTINE; METHIONINE; UREA TOPICAL a10240 CALCIUM ACETATE: DEXTROSE; ELECTROLYTES; MAGNESIUM AMINO ACIDS CHELATE a10241 DEXTROSE; ELECTROLYTES; MAGNESIUM AMINO ACIDS CHELATE

**PAGE 188** 2006 NHAMCS MICRO-DATA FILE DOCUMENTATION, APPENDIX III – GENERIC LIST a10242 DEXTROSE; FRUCTOSE; PHOSPHORIC ACID a10244 DEXTROSE; MAGNESIUM ACETATE; POTASSIUM REPLACEMENT SOLUTIONS; SODIUM CHLORIDE a10249 DEXTROSE; RINGERS LACTATED a10252 DEXTROSE; NORMAL SALINE a10253 DEXTROSE; LACTATED RINGERS a10254 DEXTROSE; LACTATED RINGERS; POTASSIUM CHLORIDE a10263 DEXTROSE; NITROGLYCERIN a10264 DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE a10267 DEXTROSE; SODIUM CHLORIDE a10279 DEXTROSE; STERILE WATER a10281 BETAINE; DIASTASE; OX BILE EXTRACT; PANCREATIN; PAPAIN TOPICAL a10282 DICHLOROPHENE; HEXACHLOROPHENE TOPICAL; TETRACAINE TOPICAL; UNDECYLENIC ACID TOPICAL; ZINC TOPICAL AGENTS, EXTERNAL USE a10285 DIMETHICONE; GLYCERIN; METHYLPARABEN; PETROLATUM TOPICAL a10289 ALOE VERA TOPICAL; DIMETHICONE; ETHANOL; GLYCERIN TOPICAL; MICONAZOLE TOPICAL a10290 ALOE VERA TOPICAL; DIMETHICONE; ETHANOL; GLYCERIN TOPICAL; PETROLATUM TOPICAL a10296 CAMPHOR TOPICAL; CAPSICUM; DIPROPYLENE GLYCOL SALICYLATE; METHYL NICOTINATE; METHYL SALICYLATE TOPICAL a10300 ASCORBIC ACID; ELECTROLYTES; MINERALS; VITAMIN B COMPLEX a10303 ELECTROLYTES; MAGNESIUM AMINO ACIDS CHELATE a10304 ELECTROLYTES; POLYETHYLENE GLYCOL 3350 a10312 ETHANOL; EUCALYPTUS OIL; MENTHOL TOPICAL; METHYL SALICYLATE TOPICAL; THYMOL a10313 BENZOIN TOPICAL; CAMPHOR TOPICAL; EUCALYPTUS OIL; MENTHOL TOPICAL; THYMOL a10321 CAMPHOR TOPICAL; EUCALYPTUS OIL; MENTHOL TOPICAL; METHYL SALICYLATE TOPICAL a10327 FIBRINOLYSIN; FIBRINOLYSIN AND DESOXYRIBONUCLEASE TOPICAL a10336 CALCIUM CARBONATE; CITRIC ACID; GLUCONIC ACID; MAGNESIUM CARBONATE; MAGNESIUM CITRATE a10338 GLYCINE; IMMUNE GLOBULIN INTRAMUSCULAR a10340 FENNEL; GLYCYRRHIZA; SENNA; SUCROSE; SULFUR TOPICAL a10348 ASCORBIC ACID; HESPERIDIN a10362 HYDROCORTISONE TOPICAL; IODOCHLORHYDROXYQUIN; PRAMOXINE TOPICAL a10363 HYDROCORTISONE TOPICAL; IODOCHLORHYDROXYQUIN a10366 IRON PREPARATIONS; MINERALS; MULTIVITAMIN a10379 IRON PREPARATIONS; VITAMIN B COMPLEX a10383 IRON PREPARATIONS; VITAMINS a10385 ETHINYL ESTRADIOL; IRON PREPARATIONS; NORETHINDRONE a10387 CALCIUM CARBONATE; FOLIC ACID; IRON PREPARATIONS; MULTIVITAMIN; NIACIN a10388 ASCORBIC ACID; FOLIC ACID; IRON PREPARATIONS; PYRIDOXINE; VITAMIN A a10391 CYANOCOBALAMIN; FOLIC ACID; IRON PREPARATIONS a10392 ASCORBIC ACID; CYANOCOBALAMIN; FOLIC ACID; IRON PREPARATIONS a10399 FOLIC ACID; IRON PREPARATIONS; MULTIVITAMIN a10405 IRON PREPARATIONS; NIACIN; PYRIDOXINE; RIBOFLAVIN; THIAMINE a10414 ASCORBIC ACID; CHOLECALCIFEROL; IRON PREPARATIONS; VITAMIN A; VITAMIN E a10418 ASCORBIC ACID; CHOLECALCIFEROL; FLUORIDE; IRON PREPARATIONS; VITAMIN A a10419 ASCORBIC ACID; ERGOCALCIFEROL; IRON PREPARATIONS; VITAMIN A a10421 CYANOCOBALAMIN; IRON PREPARATIONS; PYRIDOXINE; RIBOFLAVIN; THIAMINE a10426 ASCORBIC ACID; IRON PREPARATIONS; MULTIVITAMIN; RIBOFLAVIN; THIAMINE a10428 CYANOCOBALAMIN; IRON PREPARATIONS; PYRIDOXINE a10435 ASCORBIC ACID; IRON PREPARATIONS a10438 FLUORIDE; IRON PREPARATIONS; MULTIVITAMIN a10439 DOCUSATE; IRON PREPARATIONS a10442 IRON PREPARATIONS; MULTIVITAMIN a10443 BREWER'S YEAST; IRON PREPARATIONS a10445 CHLORPHENIRAMINE; ISOPROPAMIDE; PHENYLPROPANOLAMINE a10452 LACTOSE; NORETHINDRONE a10453 LACTOSE; MOMETASONE NASAL a10454 EPLERENONE; LACTOSE a10455 LACTOSE; TROSPIUM a10463 ALUMINUM HYDROXIDE; DIPHENHYDRAMINE TOPICAL; LIDOCAINE; MAGNESIUM ANTACIDS a10464 ASPIRIN; CALCIUM CARBONATE; MAGNESIUM ANTACIDS

	ALUMINUM HYDROXIDE; ASPIRIN; MAGNESIUM ANTACIDS
	ALUMINUM HYDROXIDE; MAGNESIUM ANTACIDS; PHENOBARBITAL
	ALUMINUM HYDROXIDE; CALCIUM CARBONATE; MAGNESIUM ANTACIDS
	ALUMINUM HYDROXIDE; MAGNESIUM ANTACIDS
	ALUMINUM HYDROXIDE; MAGNESIUM ANTACIDS; SIMETHICONE
a10500	ALLANTOIN TOPICAL; ALLIUM CEPA; METHYLPARABEN; POLYETHYLENE GLYCOL 3350; SORBIC
	ACID
a10504	LANOLIN TOPICAL; METHYLPARABEN; MULTIVITAMIN; PETROLATUM TOPICAL; ZINC OXIDE
	TOPICAL
a10511	MINERALS; VITAMINS
a10514	CALCIUM CASEINATE; MINERALS; MULTIVITAMIN; WATER
a10529	MINERALS; MULTIVITAMIN; PYRIDOXINE; RIBOFLAVIN
	MINERALS; MULTIVITAMIN
a10533	CAMPHOR TOPICAL; ISOPROPYL ALCOHOL TOPICAL; MENTHOL TOPICAL; METHYL SALICYLATE
	TOPICAL; MUSTARD OIL
a10537	BENZOCAINE TOPICAL; NUTMEG OIL; PETROLATUM TOPICAL; ZINC TOPICAL AGENTS, EXTERNAL
	USE
	ALOE VERA TOPICAL; CALENDULA; OLIVE OIL; OREGON GRAPE
	GLYCERIN TOPICAL; LACTIC ACID TOPICAL; OLEIC ACID; PROPYLENE GLYCOL
	HYDROQUINONE TOPICAL; OCTYL METHOXYCINNAMATE; OXYBENZONE; PADIMATE O
a10557	MISCELLANEOUS TOPICAL AGENTS; OXYBENZONE
	ANTIPYRINE OTIC; BENZOCAINE TOPICAL; GLYCERIN; OXYQUINOLONE
	CYANOCOBALAMIN; NIACIN; PANTHENOL; RIBOFLAVIN
	GREEN TEA; PANTOTHENIC ACID; VITAMINS
	NIACIN; PANTOTHENIC ACID; PYRIDOXINE; RIBOFLAVIN; THIAMINE
	MINERAL OIL; PEANUT OIL
	BENZOCAINE TOPICAL; NIACIN; PENTYLENETETRAZOL; PHENIRAMINE
	PETROLEUM DISTILLATE; PIPERONYL BUTOXIDE TOPICAL; PYRETHRINS TOPICAL
	ASPIRIN; BUTALBITAL; CAFFEINE; PHENACETIN
	PHOSPHORUS; POTASSIUM REPLACEMENT SOLUTIONS; SODIUM CHLORIDE
	POTASSIUM REPLACEMENT SOLUTIONS; SODIUM CHLORIDE
	IODINE; POTASSIUM REPLACEMENT SOLUTIONS
	POTASSIUM ION; SODIUM CHLORIDE
	POTASSIUM ACIDIFYING; SODIUM ACID PHOSPHATE MINERAL SPIRITS; OCTYLPHENOXY; POLYETHOXYETHANO; POLYETHYLENE GLYCOL 3350;
a10059	PROPYLENE GLYCOL; SOAP
210662	GLYCOLIC ACID; POLYQUATERNIUM; 10; PROPYLENE GLYCOL
	HP GUAR; POLYETHYLENE GLYCOL 3350; PROPYLENE GLYCOL; SODIUM BORATE TOPICAL
	AVOCADO OIL; LIQUID PARAFFIN; PROPYLENE GLYCOL; PURIFIED WATER; TROLAMINE
a10005	SALICYLATE TOPICAL
a10678	CARBOHYDRATES; MULTIVITAMIN; PROTEIN SUPPLEMENT
	ASCORBIC ACID; CALCIUM ACETATE; PYCNOGENOL; QUERCETIN; RUTIN
	ETHANOL; GLYCERIN; MAGNESIUM CARBONATE; SACCHARIN; TOLU BALSAM
	GINSENG; MEADOWFOAM OIL; PETROLATUM TOPICAL; SAFFLOWER OIL; SESAME OIL
	MINERAL OIL; PETROLATUM TOPICAL; PHENYLEPHRINE TOPICAL; SHARK LIVER OIL
	BALSAM PERU TOPICAL; MINERAL OIL; SILICONE; ZINC TOPICAL AGENTS, EXTERNAL USE
	MISCELLANEOUS TOPICAL AGENTS; SILICONE
	SOAP: WATER
	CAMPHOR TOPICAL; SOAP
	MULTIVITAMIN; SODIUM FLUORIDE
	ERTAPENEM; SODIUM BICARBONATE; SODIUM HYDROXIDE
	CITRIC ACID; SODIUM CITRATE; SODIUM ION
	MENTHOL TOPICAL; METHYL SALICYLATE TOPICAL; SODIUM BICARBONATE; SODIUM CHLORIDE;
	SODIUM PERBORATE

SODIUM PERBORATE

PAGE 19	2006 NHAMCS MICRO-DATA FILE DOCUMENTATION, APPENDIX III – GENERIC LIST
a10726	POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE
a10732	CORN STARCH TOPICAL; LANOLIN TOPICAL; PETROLEUM; STEARYL ALCOHOL; ZINC OXIDE TOPICAL
a10738	AMPICILLIN; SULBACTIN SODIUM
	SULFABENZAMIDE; SULFACETAMIDE SODIUM TOPICAL; SULFATHIAZOLE
	LANOLIN TOPICAL; MULTIVITAMIN; PETROLATUM TOPICAL; TALC; ZINC TOPICAL AGENTS, EXTERNAL USE
	TALC; ZINC OXIDE TOPICAL
	ASCORBIC ACID; MAGNESIUM; TARTRAZINE; VITAMIN B COMPLEX; ZINC SULFATE
	ASCORBIC ACID; ERGOCALCIFEROL; RIBOFLAVIN; THIMEROSAL; VITAMIN A
	CALCIUM CARBONATE; CHOLECALCIFEROL; VITAMIN K
	PETROLATUM TOPICAL; WAX; ZINC TOPICAL AGENTS, EXTERNAL USE
	CAMPHOR TOPICAL; MINERAL OIL; PETROLATUM TOPICAL; WAX
	ASCORBIC ACID; ZINC TOPICAL AGENTS, EXTERNAL USE
	DIPERODON TOPICAL; PHENYLEPHRINE; PYRILAMINE; ZINC TOPICAL AGENTS, EXTERNAL USE
	ETHANOL; FORMALDEHYDE TOPICAL; ZINC TOPICAL AGENTS, EXTERNAL USE BALSAM PERU TOPICAL; BENZYL BENZOATE TOPICAL; BISMUTH RESORCIN TOPICAL; BISMUTH
a10010	SUBGALLATE; ZINC TOPICAL AGENTS, EXTERNAL USE
210826	CALAMINE TOPICAL; RESORCINOL TOPICAL; ZINC TOPICAL AGENTS, EXTERNAL USE
	BALSAM PERU TOPICAL; BENZYL BENZOATE TOPICAL; ZINC TOPICAL AGENTS, EXTERNAL USE
	CYANOCOBALAMIN; FOLIC ACID; VITAMIN B
	VITAMIN B; VITAMIN E
	ASCORBIC ACID; VITAMIN B; VITAMIN E
	ASCORBIC ACID; FOLIC ACID; IRON; VITAMIN B COMPLEX
a10848	ASCORBIC ACID; CALCIUM ACETATE; FOLIC ACID; VITAMIN A; VITAMIN B COMPLEX
a10849	ASCORBIC ACID; FOLIC ACID; VITAMIN B COMPLEX
	CALCIUM ACETATE; FOLIC ACID; VITAMIN B COMPLEX
	ASCORBIC ACID; CHOLECALCIFEROL; VITAMIN A; VITAMIN B COMPLEX; VITAMIN E
	ASCORBIC ACID; CALCIUM ACETATE; CHOLECALCIFEROL; VITAMIN B COMPLEX; VITAMIN E
	ASCORBIC ACID; VITAMIN B COMPLEX
	ASCORBIC ACID; LIVER DERIVATIVE COMPLEX; VITAMIN B COMPLEX CARBOHYDRATES; FAT EMULSION, ORAL; MAGNESIUM AMINO ACIDS CHELATE; MULTIVITAMIN; PROTEIN
a10866	CARBOHYDRATES; FAT EMULSION, ORAL; PROTEIN
	FAT EMULSION, ORAL; IRON; LINOLEIC ACID; POTASSIUM ACETATE; PROTEIN
	MULTIVITAMIN; PROTEIN
	ARGININE; ASCORBIC ACID; CARBOHYDRATES; POTASSIUM CITRATE; VITAMIN E
a10871	IRON; VITAMINS
a10872	CHORIONIC GONADOTROPIN (HCG); FOLLICLE STIMULATING HORMONE; LEUTENIZING HORMONE
	FOLLICLE STIMULATING HORMONE; LEUTENIZING HORMONE
	GLUCOSAMINE; METHYLSULFONYL; METHANE
	BALSAM PERU TOPICAL; PETROLEUM; ZINC OXIDE TOPICAL
	PENICILLIN; PENICILLIN G BENZATHINE
	DOCOSAHEXAENOIC ACID; EICOSAPENTAENOIC ACID; VITAMIN E CLINDAMYCIN TOPICAL; METHYL PARABEN
	HOMATROPINE METHYL BROMIDE; HYDROCODONE
	ESTRADIOL; ESTRIOL; ESTRONE
	ESTRADIOL; ESTRIOL
	ASCORBIC ACID; COPPER GLUCONATE; LUTEIN; VITAMIN E; ZINC
	BETA; CAROTENE; BILBERRY; LUTEIN; LYCOPENE; VITAMIN E
a10908	ACONITUM NAPELLUS; ARNICA TOPICAL; BELLADONNA; CHAMOMILE; COMFREY
	ADRENALINE; TETRACAINE TOPICAL; XYLOCAINE
	TRIAMCINOLONE; XYLOCAINE
	CALCIUM ACETATE; CHOLECALCIFEROL; COPPER GLUCONATE; MAGNESIUM; ZINC
	CALCIUM ACETATE; COPPER GLUCONATE; IRON; MULTIVITAMIN; ZINC
	BLACK COHOSH; BORIC ACID TOPICAL; ISOFLAVONES; KAVA; MULTIVITAMIN
	EDETATE DISODIUM (EDTA); METRONIDAZOLE TOPICAL; PARABENS BENZONATATE; PARABENS
010920	

a10929 DOCUSATE: PARABENS: SORBITOL a10934 GYMNEMA SYLVESTRE; LIPOIC ACID; MAGNESIUM CITRATE; PYRIDOXINE; VANADIUM a10935 CHROMIUM PICOLINATE; MAGNESIUM AMINO ACIDS CHELATE; PYRIDOXINE; VANADIUM a10937 ADRENALINE; LIDOCAINE; TETRACAINE TOPICAL a10938 ADRENALINE; COCAINE TOPICAL; TETRACAINE TOPICAL a10941 CITRIC ACID; COLLAGEN PROTEIN; POTASSIUM SORBATE; TRYPTOPHAN; WATER a10944 CADEXOMER IODINE; POLYETHYLENE GLYCOL 3350 a10950 CHORIOGONADOTROPIN ALFA; MANNITOL; ORTHOPHOSPHORIC ACID a10956 CHLORPHENIRAMINE; HYDROCODONE POLISTIREX a10959 ANGELICA ROOT; ARECA PEEL; PERILLA LEAF; WRINKLED GIANT HYSSOP a10961 BUROW'S SOLUTION; CAMPHOR TOPICAL; MENTHOL TOPICAL; PHENOL TOPICAL a10962 BENZOCAINE TOPICAL; BUTYL AMINOBENZOATE; TETRACAINE TOPICAL a10966 ASPIRIN; CAFFEINE; DOVER'S POWDER a10968 MINERAL OIL; MINERAL WAX; PETROLATUM TOPICAL; WOOLWAX ALCOHOL a10971 ACETIC ACID TOPICAL; PROPYLENE GLYCOL DIACETATE; SODIUM ACETATE a10972 ACETIC ACID TOPICAL; HYDROCORTISONE OTIC; PROPYLENE GLYCOL DIACETATE; SODIUM ACFTATE a10973 ALUMINUM HYDROXIDE: DONNATAL: LIDOCAINE: MAGNESIUM HYDROXIDE: SIMETHICONE a10975 DIBASIC SODIUM PHOSPHATE: SODIUM PHOSPHATE a10976 BETA; SISTEROL; LYCOPENE; MULTIVITAMIN; PYGEUM AFRICANUM; SAW PALMETTO a10978 DIPHTHERIA TOXOID; FILAMENTOUS HEMAGGLUTININ; PERTACTIN; PERTUSSIS, ACELLULAR; **TETANUS TOXOID** a10983 ERGOTAMINE; L; ALKALOIDS OF BELLADONNA; PHENOBARBITAL a10986 MULTIVITAMIN; WHEY a10988 L; METHYLFOLATE; METHYLCOBALAMIN; PYRIDOXINE a10989 CALCIUM ACETATE; GLUCOSAMINE; MAGNESIUM OXIDE; METHYLCOBALAMIN; MULTIVITAMIN a10990 ASCORBIC ACID; CALCIUM CHLORIDE; CALCIUM PHOSPHATE, TRIBASIC; MG GLYCEROPHOSPHATE; PYRIDOXINE a10991 CHICORY ROOT EXTRACT; LACTOBACILLUS GG a10994 ALUMINUM ACETATE TOPICAL; MAGNESIUM; SIMETHICONE a10995 CALCIUM ACETATE; MAGNESIUM a11003 ALLANTOIN TOPICAL; CALCIUM LACTATE; CHOLINE BITARTRATE; PORCINE STOMACH a11006 FLAVOCOXID; MALTODEXTRIN a11007 ASCORBIC ACID; MALTODEXTRIN a11009 FOLIC ACID; IRON; NIACINAMIDE; PANTOTHENATE; PYRIDOXINE a11010 ASCORBIC ACID; CYANOCOBALAMIN; FOLIC ACID; IRON a11011 CALCIUM ACETATE; FOLIC ACID; IRON; MULTIVITAMIN a11013 IRON; MULTIVITAMIN a11020 ASCORBIC ACID; CALCIUM SULFATE; CHOLECALCIFEROL; VITAMIN A; VITAMIN E a11022 AMYLASE; CELLULASE; GLUCOAMYLASE; LIPASE; PROTEASE a11025 FIBRINOGEN; THROMBIN TOPICAL a11027 ACETAMINOPHEN; MISCELLANEOUS ANALGESICS a11029 LAXATIVES; SENNA a11030 CONTRACEPTIVES; NORETHINDRONE a11031 MISCELLANEOUS UNCATEGORIZED AGENTS; PHENTOLAMINE a11033 ANTISEPTIC AND GERMICIDES; ETHANOL a11034 MISCELLANEOUS TOPICAL AGENTS; PETROLATUM TOPICAL a11036 COAL TAR TOPICAL; MISCELLANEOUS TOPICAL AGENTS a11037 GLYCERIN TOPICAL; MISCELLANEOUS TOPICAL AGENTS; POLYETHYLENE GLYCOL 3350 a11040 ARGININE; CEFTAZIDIME a11041 CIPROFLOXACIN; DEXAMETHASONE a11042 CIPROFLOXACIN; HYDROCORTISONE a11047 ACETAMINOPHEN; CAFFEINE; CODEINE; SALICYLAMIDE a11055 CHLORPHENIRAMINE; CODEINE; PHENYLEPHRINE a11072 CITRIC ACID; CODEINE; PHENIRAMINE; PYRILAMINE a11082 ABACAVIR; AMPRENAVIR; LAMIVUDINE; ZIDOVUDINE a11084 CYCLOPHOSPHAMIDE; FLUOROURACIL; METHOTREXATE a11087 CYCLOPHOSPHAMIDE; DOXORUBICIN; MITOMYCIN

**PAGE 192** 2006 NHAMCS MICRO-DATA FILE DOCUMENTATION, APPENDIX III – GENERIC LIST a11088 CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; VINCRISTINE a11089 CYCLOPHOSPHAMIDE; PREDNISONE; VINCRISTINE a11092 ERYTHROMYCIN; NEOMYCIN a11103 ACETAMINOPHEN; CHLORPHENIRAMINE; PHENYLPROPANOLAMINE; PHENYLTOLOXAMINE a11114 ACETAMINOPHEN; PHENYLPROPANOLAMINE a11117 ACETAMINOPHEN; PHENYLPROPANOLAMINE; PHENYLTOLOXAMINE a11125 ATROPINE; HYOSCYAMINE; LIDOCAINE; PHENOBARBITAL; SCOPOLAMINE a11126 BUPIVACAINE; LIDOCAINE a11127 BUPIVACAINE; LIDOCAINE; TRIAMCINOLONE a11129 DIPHENHYDRAMINE; LIDOCAINE a11130 HYDROCORTISONE; LIDOCAINE a11131 BACITRACIN; LIDOCAINE; NEOMYCIN; POLYMYXIN B SULFATE a11132 LIDOCAINE; SODIUM BICARBONATE a11134 LIDOCAINE; TRIAMCINOLONE a11135 LIDOCAINE; METHYLPREDNISOLONE TOPICAL a11137 ALUMINUM HYDROXIDE; LIDOCAINE; MAGNESIUM HYDROXIDE; SIMETHICONE a11138 EPINEPHRINE TOPICAL; LIDOCAINE; TETRACAINE TOPICAL a11143 HYDROXYZINE; PREDNISOLONE a11146 GENTAMICIN OPHTHALMIC; PREDNISOLONE a11151 ATROPINE; HYOSCYAMINE; METHENAMINE; METHYLENE BLUE; PHENYL SALICYLATE a11154 ATROPINE; BENZOIC ACID; METHENAMINE; METHYLENE BLUE; PHENYL SALICYLATE a11156 HYOSCYAMINE; METHENAMINE; METHYLENE BLUE; PHENYL SALICYLATE; SODIUM PHOSPHATE a11159 HYOSCYAMINE; METHENAMINE; METHYLENE BLUE; PHENYL SALICYLATE; SODIUM BIPHOSPHATE a11161 BELLADONNA; METHENAMINE; SALICYLAMIDE a11163 POLYMYXIN B SULFATE; TRIMETHOPRIM a11166 DORZOLAMIDE OPHTHALMIC; TIMOLOL a11169 EPHEDRINE; GUAIFENESIN; PHENOBARBITAL; THEOPHYLLINE a11190 ASPIRIN; CAFFEINE; CINNAMEDRINE a11192 ASPIRIN; CALCIUM ACETATE a11198 ATROPINE; CHLORPHENIRAMINE; HYOSCYAMINE; PHENYLEPHRINE; PHENYLPROPANOLAMINE a11202 ATROPINE; MORPHINE a11204 ATROPINE; HYOSCYAMINE; PHENAZOPYRIDINE; SCOPOLAMINE a11206 ALUMINUM HYDROXIDE; ATROPINE; HYOSCYAMINE; PHENOBARBITAL; SCOPOLAMINE a11208 ATROPINE; PHYSOSTIGMINE a11216 BUPIVACAINE; TRIAMCINOLONE a11217 CARBOPLATIN; CISPLATIN; FLUOROURACIL a11235 AMMONIUM CHLORIDE; CHLORPHENIRAMINE; GUAIFENESIN; PHENYLEPHRINE; SODIUM CITRATE a11239 CHLORPHENIRAMINE; HYDROCODONE; PHENYLEPHRINE; PSEUDOEPHEDRINE; PYRILAMINE a11244 CHLORPHENIRAMINE; PHENYLEPHRINE; SALICYLAMIDE; SCOPOLAMINE a11253 CARAMIPHEN; CHLORPHENIRAMINE; PHENYLPROPANOLAMINE a11257 CYTARABINE; DAUNORUBICIN a11258 DEXAMETHASONE; TRIAMCINOLONE a11259 AMMONIUM CHLORIDE; DEXTROMETHORPHAN a11269 DEXTROMETHORPHAN; PSEUDOEPHEDRINE; SORBITOL a11273 DEXTROMETHORPHAN; IODINATED GLYCEROL a11274 DEXTROMETHORPHAN; DOXYLAMINE; ETHANOL; SODIUM CITRATE a11278 ALUMINUM HYDROXIDE; DIPHENHYDRAMINE; MAGNESIUM HYDROXIDE; SIMETHICONE a11279 ALOE VERA TOPICAL; DIPHENHYDRAMINE; ETHANOL; ZINC ACETATE TOPICAL a11284 ETHINYL ESTRADIOL; FERROUS FUMARATE; NORETHINDRONE a11285 FLUOROURACIL; IRINOTECAN; LEUCOVORIN a11286 FLUOROURACIL; LEUCOVORIN; OXALIPLATIN a11287 FLUOROURACIL; MITOXANTRONE; VINCRISTINE a11291 CYANOCOBALAMIN; FOLIC ACID; PYRIDOXINE a11294 CYANOCOBALAMIN; FOLIC ACID a11296 ASCORBIC ACID; CARBONYL IRON; CYANOCOBALAMIN; FOLIC ACID a11298 FOLIC ACID; MULTIVITAMIN; SODIUM CHLORIDE; THIAMINE a11299 FOLIC ACID; MAGNESIUM SULFATE; MULTIVITAMIN; THIAMINE a11300 FOLIC ACID; MULTIVITAMIN a11302 FOLIC ACID; NICOTINAMIDE TOPICAL; ZINC OXIDE TOPICAL a11306 COLISTIN SULFATE OTIC; HYDROCORTISONE; NEOMYCIN; THONZONIUM BROMIDE OTIC

- a11328 BACITRACIN TOPICAL; NEOMYCIN; POLYMYXIN B SULFATE
- a11329 BACITRACIN OPHTHALMIC; NEOMYCIN; POLYMYXIN B SULFATE
- a11330 BACITRACIN OPHTHALMIC; HYDROCORTISONE OPHTHALMIC; NEOMYCIN; POLYMYXIN B SULFATE
- a11331 DEXAMETHASONE OPHTHALMIC; NEOMYCIN; POLYMYXIN B SULFATE
- a11332 HYDROCORTISONE OTIC; NEOMYCIN; POLYMYXIN B SULFATE
- a11344 HYDROCORTISONE OTIC; NEOMYCIN; POLYMYXIN B OPHTHALMIC
- a11345 NEOMYCIN; POLYMYXIN B OPHTHALMIC

a11315 INSULIN; INSULIN ISOPHANE a11319 MANNITOL; PEMETREXED a11320 AZACITIDINE; MANNITOL

a11325 NEOMYCIN; POLYMYXIN B SULFATE

- a11349 ERGOCALCIFEROL; NIACIN; RIBOFLAVIN; VITAMIN A
- a11350 ERGOCALCIFEROL; NIACIN; RIBOFLAVIN; THIAMINE; VITAMIN A
- a11353 ASCORBIC ACID; DOCUSATE; ERGOCALCIFEROL; NIACIN; VITAMIN A
- a11354 ASCORBIC ACID; NIACIN; RIBOFLAVIN; THIAMINE; VITAMIN E
- a11355 CYANOCOBALAMIN; NIACIN; PYRIDOXINE; RIBOFLAVIN
- a11357 CYANOCOBALAMIN; NIACIN; PYRIDOXINE; RIBOFLAVIN; THIAMINE
- a11360 DEXPANTHENOL; NIACIN; PYRIDOXINE; RIBOFLAVIN; THIAMINE
- a11361 NIACIN; PYRIDOXINE; RIBOFLAVIN; THIAMINE
- a11374 PHENOBARBITAL; PROPANTHELINE
- a11378 EPHEDRINE; PHENOBARBITAL
- a11382 HYOSCYAMINE; PHENOBARBITAL; THIAMINE; VALERIAN
- a11391 HOMATROPINE; PHENOBARBITAL
- a11394 BACITRACIN TOPICAL; POLYMYXIN B SULFATE
- a11396 DEXAMETHASONE OPHTHALMIC; NEOMYCIN OPHTHALMIC; POLYMYXIN B SULFATE
- a11413 VITAMIN A; VITAMIN E
- a11415 ERGOCALCIFEROL; RIBOFLAVIN; THIAMINE; VITAMIN A; VITAMIN E
- a11416 ASCORBIC ACID; VITAMIN A; VITAMIN E
- a11418 ASCORBIC ACID; ERGOCALCIFEROL; VITAMIN A; VITAMIN E
- a11420 CYANOCOBALAMIN; PYRIDOXINE; RIBOFLAVIN; VITAMIN A
- a11421 CYANOCOBALAMIN; PYRIDOXINE; RIBOFLAVIN; THIAMINE; VITAMIN A
- a11423 ERGOCALCIFEROL; PYRIDOXINE; RIBOFLAVIN; VITAMIN A
- a11424 ERGOCALCIFEROL; PYRIDOXINE; RIBOFLAVIN; THIAMINE; VITAMIN A
- a11429 ASCORBIC ACID; ERGOCALCIFEROL; RIBOFLAVIN; THIAMINE; VITAMIN A
- a11431 ASCORBIC ACID; CHOLECALCIFEROL; FLUORIDE; VITAMIN A
- a11432 ASCORBIC ACID; ERGOCALCIFEROL; VITAMIN A
- a11433 ERGOCALCIFEROL; VITAMIN A
- a11436 CHOLECALCIFEROL; VITAMIN A
- a11437 ALLANTOIN TOPICAL; ALOE VERA TOPICAL; CALAMINE TOPICAL; CHOLECALCIFEROL; VITAMIN A
- a11440 ASCORBIC ACID; VITAMIN E
- a11446 ASCORBIC ACID; CYANOCOBALAMIN; PYRIDOXINE; RIBOFLAVIN; THIAMINE
- a11447 CYANOCOBALAMIN; L; METHYLFOLATE; PYRIDOXINE; RIBOFLAVIN
- a11448 CHOLINE; CYANOCOBALAMIN; INOSITOL; RIBOFLAVIN; THIAMINE
- a11456 CYANOCOBALAMIN; PYRIDOXINE
- a11458 PANCREATIN; PYRIDOXINE
- a11460 DOXYLAMINE; PYRIDOXINE
- a11466 CYANOCOBALAMIN; MULTIVITAMIN
- a11471 CALCIUM CARBONATE; CALCIUM CITRATE; MAGNESIUM CITRATE; MAGNESIUM OXIDE
- a11472 CALCIUM CARBONATE; CHOLECALCIFEROL
- a11473 CALCIUM CARBONATE; MAGNESIUM GLUCONATE; MAGNESIUM OXIDE
- a11476 ASCORBIC ACID; CARBONYL IRON
- a11477 FLUORIDE; MULTIVITAMIN
- a11479 CHONDROITIN; GLUCOSAMINE; MANGANESE SULFATE
- a11482 SODIUM ACETATE; SODIUM CHLORIDE
- a11483 SODIUM CHLORIDE; SODIUM PHOSPHATE
- a11488 BORIC ACID TOPICAL; SODIUM CHLORIDE
- a11493 SODIUM CHLORIDE; STERILE WATER

PAGE 1	2006 NHAMCS MICRO-DATA FILE DOCUMENTATION, APPENDIX III – GENERIC LIST
a11501	SODIUM BICARBONATE; SODIUM CHLORIDE NASAL
a11509	AMMONIUM CHLORIDE; SODIUM CITRATE
	ALOE VERA TOPICAL; CYSTEINE; GRAPE SEED OIL; MULTIVITAMIN; SELENIUM
	MULTIVITAMIN; OMEGA; 3 POLYUNSATURATED FATTY ACIDS
a11518	CONJUGATED ESTROGENS; PROGESTERONE
	PROGESTERONE; TESTOSTERONE
	NYSTATIN; TRIAMCINOLONE
	CAMPHOR TOPICAL; TRIAMCINOLONE
a11523	NYSTATIN TOPICAL; TRIAMCINOLONE
	EDETATE DISODIUM (EDTA); UREA TOPICAL
a11525	BENZOYL PEROXIDE TOPICAL; EDETATE DISODIUM (EDTA); GLYCERIN TOPICAL; UREA TOPICAL
	CHLOROPHYLLIN COPPER COMPLEX TOPICAL; PAPAIN TOPICAL; UREA TOPICAL
	CAFFEINE; EPHEDRINE; PHENYLPROPANOLAMINE
	EDETATE DISODIUM (EDTA); RIFAXIMIN
	SODIUM POLYSTYRENE SULFONATE; SORBITOL
	GUAIFENESIN; PHENIRAMINE; PHENYLPROPANOLAMINE; PYRILAMINE
	DIHYDROCODEINE; PHENYLPROPANOLAMINE
	PROMETHAZINE; PSEUDOEPHEDRINE
	NAPHAZOLINE OPHTHALMIC; PHENIRAMINE
	OXYMETAZOLINE NASAL; TETRACAINE TOPICAL
	GUAIFENESIN; POTASSIUM IODIDE
	CAFFEINE; MAGNESIUM SALICYLATE; PHENYLTOLOXAMINE
	ANTIPYRINE OTIC; BENZOCAINE TOPICAL
	BENZOCAINE TOPICAL; RESORCINOL TOPICAL
a11602	CAPSICUM; CASCARA SAGRADA; PHENOLPHTHALEIN
a11608	BALSAM PERU TOPICAL; BORIC ACID TOPICAL; CASTOR OIL; PETROLATUM TOPICAL; ZINC OXIDE
- 1 1 0 1 0	
	BARIUM SULFATE; BISACODYL
	DOCUSATE; MINERAL OIL
	GLYCERIN TOPICAL; HYDROCORTISONE TOPICAL; MINERAL OIL; PETROLATUM TOPICAL
	MINERAL OIL; PETROLATUM TOPICAL LANOLIN TOPICAL; MINERAL OIL; PETROLATUM TOPICAL
	AMMONIUM LACTATE TOPICAL; MINERAL OIL
	CAPSICUM; MINERAL OIL; PEPPERMINT
	CHARCOAL; IPECAC
	HAEMOPHILUS B CONJUGATE VACCINE (OBSOLETE); HEPATITIS B VACCINE
	DIPHTHERIA TOXOID; HAEMOPHILUS B CONJUGATE VACCINE (OBSOLETE); PERTUSSIS,
a11001	ACELLULAR; TETANUS TOXOID
a11632	HEPATITIS A VACCINE (OBSOLETE); HEPATITIS B VACCINE
	COAL TAR; SALICYLIC ACID TOPICAL; SODIUM HYALURONATE OPHTHALMIC
	BORIC ACID TOPICAL; ISOPROPYL ALCOHOL TOPICAL
	DEXTRAN, LOW MOLECULAR WEIGHT; HYDROXYPROPYL METHYLCELLULOSE OPHTHALMIC
	CHLORHEXIDINE TOPICAL; ISOPROPYL ALCOHOL TOPICAL
	ALOE VERA TOPICAL; BENZOYL PEROXIDE TOPICAL
	FLUOCINOLONE TOPICAL; HYDROQUINONE TOPICAL; TRETINOIN
	PETROLATUM TOPICAL; SALICYLIC ACID TOPICAL
	ALUMINUM SULFATE TOPICAL; CAMPHOR TOPICAL; LACTOBACILLUS ACIDOPHILUS; MENTHOL
	TOPICAL; SALICYLIC ACID TOPICAL
a11669	LANOLIN TOPICAL; SALICYLIC ACID TOPICAL; SULFUR TOPICAL
	COLLOIDAL OATMEAL TOPICAL; SALICYLIC ACID TOPICAL; SULFUR TOPICAL
	LACTIC ACID TOPICAL; SALICYLIC ACID TOPICAL
	TANNIC ACID TOPICAL; THIMEROSAL TOPICAL
	BENZALKONIUM CHLORIDE TOPICAL; BROMFENAC
	ALBUMIN HUMAN; PACLITAXEL
	IODINE; IOPAMIDOL
	DEXTRAN 1; METHYLCELLULOSE
	AMYLASE; LIPASE; PROTEASE
	AMYLASE; PAPAIN TOPICAL
	CHOLECALCIFEROL; MULTIVITAMIN
a11703	CALCIUM ACETATE; CHOLECALCIFEROL

a11705 CALCIUM ACETATE: MULTIVITAMIN a11706 CETYLPYRIDINIUM TOPICAL; ETHANOL a11714 MICONAZOLE TOPICAL; PETROLATUM TOPICAL; ZINC OXIDE TOPICAL a11715 MENTHOL TOPICAL; ZINC OXIDE TOPICAL a11717 BETAMETHASONE TOPICAL; CLOTRIMAZOLE TOPICAL a11721 HYDROCORTISONE TOPICAL; NYSTATIN TOPICAL a11724 BACITRACIN TOPICAL; NEOMYCIN TOPICAL; POLYMYXIN B OPHTHALMIC a11725 LACTIC ACID TOPICAL; VITAMIN E TOPICAL a11726 ACETIC ACID TOPICAL; ALUMINUM ACETATE TOPICAL a11732 LANOLIN TOPICAL; PETROLATUM TOPICAL a11738 CAMPHOR TOPICAL; MENTHOL TOPICAL; PHENOL TOPICAL a11748 BACITRACIN TOPICAL; POLYMYXIN B OPHTHALMIC a11750 CHLOROXYLENOL TOPICAL; HYDROCORTISONE OTIC; PRAMOXINE OTIC a11751 RITONAVIR; TENOFOVIR a11752 ATAZANAVIR; RITONAVIR a11758 MAGNESIUM AMINO ACIDS CHELATE; MINERALS a11759 CETEARETH; DIMETHICONE; GLYCERIN TOPICAL; HYALURONIC ACID a11761 MANNITOL: PHENYLALANINE: SELEGILINE a11762 HYDROQUINONE TOPICAL: OCTYL METHOXYCINNAMATE: OXYBENZONE a11763 CARBOMER 940; ISOPROPYL ALCOHOL TOPICAL a11764 DIPHTHERIA TOXOID; PERTACTIN; TETANUS TOXOID a11765 HYDROCORTISONE TOPICAL; LIDOCAINE a11766 BENZALKONIUM CHLORIDE TOPICAL; OCULAR LUBRICANT; SODIUM CHLORIDE a11768 ACETAMINOPHEN; ETHANOL; GLYCERIN; HYDROCODONE; PARABENS a11769 ASCORBIC ACID; BIOTIN; FOLIC ACID; VITAMIN B COMPLEX; ZINC a11770 ASCORBIC ACID; CHOLECALCIFEROL; GLYCERIN TOPICAL; VITAMIN B COMPLEX a50520 BENZETHONIUM a52845 IODOCHLORa54575 POLIO VACCINE CHLORIDE HYDROXYQUIN a54645 POTASSIUM a50620 BIOTIN a52885 IRON BROMIDE PREPARATIONS a50770 CALCIUM REPLACEMENT a52968 KELP a54655 POTASSIUM a50912 CARBOXYMETHYLa52990 LACTOSE REPLACEMENT CELLULOSE a53040 LEVALLORPHAN SOLUTIONS a51080 CHLOROFORM a53155 LYPRESSIN a54705 POTASSIUM a51185 CHOLESTEROL a53175 MAGNESIUM HYDROXIDE a51209 CHROMIUN ANTACIDS a54735 POTASSIUM a51225 CINNAMON OIL a53298 MEGLUMINE ACIDIFYING a51325 COCOA BUTTER a54900 PROPYHEXEDRINE a53315 MENINGOCOCCAL a54922 PROTEIN a51390 CONTACT LENS VACCINE SOLUTION a53375 MERBROMIN SUPPLEMENT a51495 CYCLOTHIAZIDE a53718 MILK SOLIDS a55075 RESCINNAMINE a51675 DEXTROSE NONFAT a55115 RINGERS LACTATED a55145 SAFFLOWER OIL a51740 DIETARY a53723 MINERALS SUPPLEMENT a53778 MOXALACTAM a55170 SCARLET RED a51770 DIGITALIS a53835 MYRRH a55300 SODIUM BROMIDE a52023 ELECTROLYTES a53940 NITROGEN a55310 SODIUM CARBONATE a55330 SODIUM FLUORIDE a52105 ETHER a54015 OINTMENT a52125 ETHOPROPAZINE HYDROPHILIC a55360 SODIUM LAURYL a52358 FOOD SUPPLEMENT a54030 OLIVE OIL SULFATE a52390 GALLAMINE a54115 OXYGEN a55400 SODIUM SUCCINATE a52395 GELATIN a54275 PENTAERYTHRITOL a55440 SOYBEAN OIL a55510 SUCCINLYCHOLINE a52475 GOLD SODIUM a54325 PERTUSSIS IMMUNE a55520 SUCROSE THIOSULFATE GLOBULIN a52535 HAMAMELIS WATER a54350 PHENACETIN a55580 SULFATHIAZOLE a55623 SURFACTANT a52640 HYDROCHLORIC a54555 PNEUMOCOCCAL a55645 TALC ACID VACCINE a52775 INFANT FORMULA a54565 POISON IVY a55970 TRIGLYCERIDES a52794 INTERFERON ALFA EXTRACT a56145 VALPROTIC ACID

a56161 VEGETABLE OIL a56198 VITAMIN K a56265 ZINC TOPICAL AGENTS, EXTERNAL USE a56275 ZOMEPIRAC a56340 VITAMIN B a56345 VITAMIN B COMPLEX a56580 POLOXAMER 188 a56615 RETINOIC ACID a56740 INTERFERON BETA a56800 SODIUM TETRABORATE DECAHYDRATE a57001 BLOOD SUGAR DIAGNOSTIC a57014 ERYTHROPOIETIN a57024 MAGNESIUM ION a57034 PHOSPHORUS a57040 MECLOCYCLINE a57050 HYDROACTIVE DRESSING a57084 COLLAGEN a57092 RECOMBINANT HUMAN DEOXYRIBO-NUCLEASE a57154 CD4 a57158 TECHNETIUM a57188 LOVERSOL a57194 HYPERTONIC SALINE a57204 HEPATITIS C VACCINE a59603 HEPATITIS VACCINE a59611 THYROID STIMULATING HORMONE a59632 DEHYDROEPI-ANDROSTERENE a59717 ANDROGENS a59812 DOMPERIDONE a59813 FOLLITROPIN BETA a59814 FOLLITROPIN ALPHA a59841 GRAPESEED a70009 HYALURONIC ACID a70010 SEROTONIN a70046 PENICILLIN G BENZATHINE a70048 OIL OF EVENING PRIMROSE a70062 FENRETINIDE a70064 TETRABENAZINE a70105 HAWTHORN a70113 PERINDOPRIL ERBUMINE a70116 SOY a70123 BISMUTH a70159 SILVER a70181 GLUTAMINE

a70194	
	COPOLYMER
a70203	RACEMIC
	EPINEPHRINE
a70204	ACEMANNAN
a70385	SILYBUM
a70465	SUPER OXIDE
	DISMUTASE
a70476	VIGABATRIN
a70479	BORAGE OIL
a70480	ALPHA LIPOIC ACID
a70484	CARBOXYMETHYL-
	CELLULOSE SODIUM
a70491	HYOSCYNAMINE
	SULFATE
a70550	SOLUMET
a70607	OXYQUINOLONE
	SULFATE
a70674	TOTAL
	UNDECYLENATE
a70699	LYCOPENE
a70725	ASPARTAME
a70732	EPIDURAL
a70747	PROLINE
a70759	ALFALFA
a70799	MAGNESIUM
a70832	OAT BRAN
a70836	GAMMA;
	AMINOBUTRYIC
	ACID
a70841	POLOXAMER 331
a70886	IRON
a70891	HYDROGEL
a70996	PREGNENOLONE
a70998	ACETYLSALICYLIC
	ACID
a71002	FLOXACILLIN
a71008	TECHNETIUM TC 99M
	MERTIATIDE
	INJECTION
-71001	
a/1021	
a71021 a71034	HISTERLIN
a71034	HISTERLIN DECLABEN
a71034 a71036	HISTERLIN DECLABEN GLIFLUMIDE
a71034 a71036 a71037	HISTERLIN DECLABEN GLIFLUMIDE POLY; LACTIC ACID
a71034 a71036 a71037 a71042	HISTERLIN DECLABEN GLIFLUMIDE POLY; LACTIC ACID NISOXETINE
a71034 a71036 a71037 a71042 a71045	HISTERLIN DECLABEN GLIFLUMIDE POLY; LACTIC ACID
a71034 a71036 a71037 a71042 a71045 a71048	HISTERLIN DECLABEN GLIFLUMIDE POLY; LACTIC ACID NISOXETINE REBOXETINE FLUZINAMIDE
a71034 a71036 a71037 a71042 a71045 a71048 a71057	HISTERLIN DECLABEN GLIFLUMIDE POLY; LACTIC ACID NISOXETINE REBOXETINE FLUZINAMIDE CITRULLINE
a71034 a71036 a71037 a71042 a71045 a71048 a71057 a71058	HISTERLIN DECLABEN GLIFLUMIDE POLY; LACTIC ACID NISOXETINE REBOXETINE FLUZINAMIDE CITRULLINE D; RIBOSE
a71034 a71036 a71037 a71042 a71045 a71048 a71057 a71058 a71063	HISTERLIN DECLABEN GLIFLUMIDE POLY; LACTIC ACID NISOXETINE REBOXETINE FLUZINAMIDE CITRULLINE D; RIBOSE CODOXIME
a71034 a71036 a71037 a71042 a71045 a71048 a71057 a71058 a71063 a71065	HISTERLIN DECLABEN GLIFLUMIDE POLY; LACTIC ACID NISOXETINE REBOXETINE FLUZINAMIDE CITRULLINE D; RIBOSE CODOXIME CLOBAZAM
a71034 a71036 a71037 a71042 a71045 a71048 a71057 a71058 a71063 a71065	HISTERLIN DECLABEN GLIFLUMIDE POLY; LACTIC ACID NISOXETINE REBOXETINE FLUZINAMIDE CITRULLINE D; RIBOSE CODOXIME CLOBAZAM DEFLAZACORT
a71034 a71036 a71037 a71042 a71045 a71048 a71057 a71058 a71063 a71066 c00007	HISTERLIN DECLABEN GLIFLUMIDE POLY; LACTIC ACID NISOXETINE REBOXETINE FLUZINAMIDE CITRULLINE D; RIBOSE CODOXIME CLOBAZAM DEFLAZACORT ANTIVIRAL AGENTS
a71034 a71036 a71037 a71042 a71045 a71048 a71057 a71058 a71063 a71066 c00007 c00009	HISTERLIN DECLABEN GLIFLUMIDE POLY; LACTIC ACID NISOXETINE REBOXETINE FLUZINAMIDE CITRULLINE D; RIBOSE CODOXIME CLOBAZAM DEFLAZACORT ANTIVIRAL AGENTS CEPHALOSPORINS
a71034 a71036 a71037 a71042 a71045 a71048 a71057 a71058 a71063 a71066 c00007	HISTERLIN DECLABEN GLIFLUMIDE POLY; LACTIC ACID NISOXETINE REBOXETINE FLUZINAMIDE CITRULLINE D; RIBOSE CODOXIME CLOBAZAM DEFLAZACORT ANTIVIRAL AGENTS CEPHALOSPORINS MISCELLANEOUS
a71034 a71036 a71037 a71042 a71045 a71048 a71057 a71058 a71063 a71065 a71066 c00007 c00009 c00012	HISTERLIN DECLABEN GLIFLUMIDE POLY; LACTIC ACID NISOXETINE REBOXETINE FLUZINAMIDE CITRULLINE D; RIBOSE CODOXIME CLOBAZAM DEFLAZACORT ANTIVIRAL AGENTS CEPHALOSPORINS MISCELLANEOUS ANTIBIOTICS
a71034 a71036 a71037 a71042 a71045 a71048 a71057 a71058 a71063 a71065 a71066 c00007 c00009 c00012	HISTERLIN DECLABEN GLIFLUMIDE POLY; LACTIC ACID NISOXETINE REBOXETINE FLUZINAMIDE CITRULLINE D; RIBOSE CODOXIME CLOBAZAM DEFLAZACORT ANTIVIRAL AGENTS CEPHALOSPORINS MISCELLANEOUS ANTIBIOTICS QUINOLONES
a71034 a71036 a71037 a71042 a71045 a71048 a71057 a71058 a71063 a71065 a71066 c00007 c00009 c00012	HISTERLIN DECLABEN GLIFLUMIDE POLY; LACTIC ACID NISOXETINE REBOXETINE FLUZINAMIDE CITRULLINE D; RIBOSE CODOXIME CLOBAZAM DEFLAZACORT ANTIVIRAL AGENTS CEPHALOSPORINS MISCELLANEOUS ANTIBIOTICS QUINOLONES SULFONAMIDES
a71034 a71036 a71037 a71042 a71045 a71048 a71057 a71058 a71063 a71065 a71066 c00007 c00009 c00012 c00014 c00015	HISTERLIN DECLABEN GLIFLUMIDE POLY; LACTIC ACID NISOXETINE REBOXETINE FLUZINAMIDE CITRULLINE D; RIBOSE CODOXIME CLOBAZAM DEFLAZACORT ANTIVIRAL AGENTS CEPHALOSPORINS MISCELLANEOUS ANTIBIOTICS QUINOLONES

c00027	RADIO- PHARMACEUTICALS
c00039	MISCELLANEOUS BIOLOGICALS
c00040	CARDIOVASCULAR
c00042	AGENTS ANGIOTENSIN CONVERTING ENZYME
c00045	INHIBITORS ANTIANGINAL AGENTS
c00046	ANTIARRHYTHMIC
c00047	BETA; ADRENERGIC BLOCKING AGENTS
c00048	CALCIUM CHANNEL BLOCKING AGENTS
c00049	DIURETICS
c00052	PERIPHERAL
000052	VASODILATORS
000055	ANTIHYPERTENSIVE
c00055	COMBINATIONS
000E7	CENTRAL NERVOUS
c00057	SYSTEM AGENTS
-00050	MISCELLANEOUS
c00059	
-00001	ANALGESICS
c00061	NONSTEROIDAL ANTI-
c00065	INFLAMMATORY AGENTS ANTIEMETIC; ANTIVERTIGO
	AGENTS
c00067	ANXIOLYTICS,
	SEDATIVES, AND
	HYPNOTICS
c00068	BARBITURATES
c00070	MISCELLANEOUS
000070	ANXIOLYTICS,
	SEDATIVES AND
	HYPNOTICS
c00072	GENERAL
00072	ANESTHETICS
c00076	MISCELLANEOUS
000070	ANTIDEPRESSANTS
c00077	MISCELLANEOUS
000077	ANTIPSYCHOTIC
	AGENTS
c00080	MISCELLANEOUS
00000	CENTRAL NERVOUS
	SYSTEM AGENTS
00000	ANTICOAGULANTS
c00082 c00085	
000000	MISCELLANEOUS
	COAGULATION MODIFIERS
-00007	
c00087	GASTROINTESTINAL
-00000	AGENTS
c00088	
c00090	ANTIDIARRHEALS

c00095	LAXATIVES	c00187	MISCELLANEOUS
c00096	MISCELLANEOUS GI		SEX HORMONES
	AGENTS	c00193	ANTIMIGRAINE
c00098	ADRENAL CORTICAL		AGENTS
	STEROIDS	c00198	MISCELLANEOUS
c00099	ANTIDIABETIC		ANTIEMETICS
	AGENTS	c00204	
c00100	MISCELLANEOUS		ANTICONVULSANTS
000100	HORMONES	c00219	
c00102		000210	PRODUCTS
	MISCELLANEOUS	c00220	HERBAL PRODUCTS
00105	AGENTS	c00220	
c00100	LOCAL INJECTABLE	00234	AGENTS
00109	ANESTHETICS	c00269	
-00110		00209	
00110	MISCELLANEOUS	-00000	VAGINAL AGENTS
	UNCATEGORIZED	c00286	
-00445	AGENTS	c00296	
c00115			CORTICOSTEROIDS
00447	PRODUCTS	c00304	
c00117	MINERALS AND	c00899	
	ELECTROLYTES		AID
	VITAMINS		ACYCLOVIR
	ANTIHISTAMINES		AMIODARONE
	ANTITUSSIVES		AMPICILLIN
	DECONGESTANTS	d00004	
c00129	MISCELLANEOUS		CAPTOPRIL
	RESPIRATORY	d00007	CEFAZOLIN
	AGENTS	d00008	CEFOTAXIME
c00131	ANTIASTHMATIC	d00009	CEFTAZIDIME
	COMBINATIONS	d00010	CEFTIZOXIME
c00132	UPPER	d00011	CIPROFLOXACIN
	RESPIRATORY	d00012	CODEINE
	COMBINATIONS	d00013	ENALAPRIL
c00135	ANTISEPTIC AND	d00014	GENTAMICIN
	GERMICIDES	d00015	IBUPROFEN
c00137	TOPICAL ANTI-	d00016	LABETALOL
	INFECTIVES	d00017	
c00138	TOPICAL STEROIDS		NADOLOL
c00140	MISCELLANEOUS	d00019	NAPROXEN
000110	TOPICAL AGENTS	d00020	-
c00143	TOPICAL ACNE		RANITIDINE
000110	AGENTS		WARFARIN
c00164	OPHTHALMIC		ALLOPURINOL
000104	GLAUCOMA AGENTS		AZATHIOPRINE
c00168	OPHTHALMIC	d00024	
00100	LUBRICANTS AND	d00020	
	IRRIGATIONS	d00027 d00028	
-00160		d00028 d00029	
c00169	MISCELLANEOUS		
	OPHTHALMIC	d00030	
-00470	AGENTS	d00031	
c00172	MISCELLANEOUS	d00032	
00171	OTIC AGENTS	d00033	
c00174	MISCELLANEOUS	d00034	
	ANTIHYPERLIPI-	d00035	
•••	DEMIC AGENTS	d00036	CYCLOPHOS-
c00178	SKELETAL MUSCLE		PHAMIDE
	RELAXANTS	d00037	
		d00039	INDOMETHACIN

d00040 d00041 d00042 d00043 d00045 d00046 d00047 d00048 d00050 d00051 d00052 d00053 d00054 d00055 d00056 d00057 d00058 d00057 d00068 d00067 d00068 d00067 d00068 d00067 d00068 d00071 d00072 d00073 d00075 d00077 d00078 d00077 d00078 d00077 d00078 d00077 d00078 d00077 d00078 d00077 d00078 d00077 d00078 d00077 d00078 d00077 d00078 d00077 d00078 d00077 d00078 d00077 d00078 d00077 d00078 d00077 d00078 d00077 d00078 d00077 d00078 d00077 d00078 d00077 d00080 d00077 d00080 d00077 d00080 d00077 d00080 d00077 d00080 d00077 d00080 d00077 d00078 d00077 d00078 d00077 d00078 d00077 d00078 d00077 d00078 d00077 d00078 d00077 d00078 d00077 d00078 d00077 d00078 d00077 d00078 d00077 d00078 d00077 d00078 d00077 d00078 d00077 d00078 d00077 d00078 d00077 d00078 d00077 d00079 d000070 d00077 d00079 d0000000000	OXAZEPAM TETRACYCLINE CHLORPROPAMIDE CLINDAMYCIN CLONIDINE DILTIAZEM ERYTHROMYCIN RIFAMPIN VERAPAMIL ACETAMINOPHEN METHADONE NIFEDIPINE CEFTRIAXONE CEPHRADINE TOLMETIN CEFOTETAN CEFOTETAN CEFUROXIME PIPERACILLIN CARBAMAZEPINE LIDOCAINE METHOTREXATE LITHIUM CHLORPROMAZINE GANCICLOVIR AZTREONAM ETHAMBUTOL TOBRAMYCIN FUROSEMIDE FLUCONAZOLE CEFIXIME CEFPROZIL PROCAINAMIDE AMPHOTERICIN B DIDANOSINE CYCLOSPORINE CYCLOSPORINE CEFADROXIL CEFACLOR IMIPENEM; CILASTATIN PREDNISOLONE RIBAVIRIN AMANTADINE AMIKACIN AMOXICILLIN; CLAVULANATE AZITHROMYCIN CEFOXITIN
000100	

<page-header>PACE 1922006 NACCONCOUNT OF A CONCOUNT OF A CO

d00248	GLYBURIDE
d00240	HEPARIN
d00253	HYDROCHLORO-
400254	THIAZIDE
d00254 d00255	HYDROCORTISONE HYDROMORPHONE
d00257	IFOSFAMIDE
d00259	IMIPRAMINE
d00260	INDAPAMIDE
d00262 d00265	INSULIN IPRATROPIUM
d00203	ISOFLURANE
d00268	ISOSORBIDE
100000	DINITRATE
d00269	ISOSORBIDE MONONITRATE
d00270	ISRADIPINE
d00272	KETAMINE
d00273	KETOROLAC
d00275 d00276	LEUCOVORIN LEVAMISOLE
d00278 d00277	LEVODOPA
d00278	LEVOTHYROXINE
d00279	LINCOMYCIN
d00280 d00282	LOVASTATIN MANNITOL
d00282 d00283	MECLOFENAMATE
d00284	MEDROXY-
	PROGESTERONE
d00285	MEFENAMIC ACID MEFLOQUINE
d00286 d00287	MELPHALAN
d00288	MEPROBAMATE
d00289	MERCAPTOPURINE
d00290	METHIMAZOLE METHYL-
d00293	PREDNISOLONE
d00297	METIPRANOLOL
	OPHTHALMIC
d00298	METOCLOPRAMIDE
d00299 d00300	METOLAZONE MEXILETINE
d00301	MIDAZOLAM
d00303	MISOPROSTOL
d00305	
d00306 d00308	MITOXANTRONE MORPHINE
d00310	NABUMETONE
d00311	NALOXONE
d00312	NEOMYCIN
d00313 d00314	NEOSTIGMINE NIACIN
d00315	NICARDIPINE
d00316	NICOTINE
d00318	
d00321 d00322	NITROGLYCERIN NIZATIDINE
d00323	NOREPINEPHRINE
d00325	OMEPRAZOLE
d00328	OXYBUTYNIN

.....

**PAGE 199** 

d00329 OXYCODONE d00330 PANCURONIUM d00333 PENICILLAMINE d00334 PENTAZOCINE d00335 PENTOBARBITAL d00336 PENTOXIFYLLINE d00337 PHENAZOPYRIDINE d00340 PHENOBARBITAL d00343 PIROXICAM d00344 POLYMYXIN B SULFATE d00345 POTASSIUM CHLORIDE d00346 POVIDONE IODINE TOPICAL d00348 PRAVASTATIN d00350 PREDNISONE d00351 PRIMAQUINE d00352 PRIMIDONE d00354 PROCARBAZINE d00355 PROCHLOR-PERAZINE d00358 PROPAFENONE d00359 PROPANTHELINE d00360 PROPOXYPHENE d00361 PROPYLTHIOURACIL d00362 PROTAMINE d00363 PYRIDOSTIGMINE d00364 PYRIMETHAMINE d00365 QUINAPRIL d00366 QUININE d00367 RESERPINE d00370 OCTREOTIDE d00371 SOTALOL d00373 SPIRONOLACTONE d00377 SUCRALFATE d00378 SUFENTANIL d00379 SULFASALAZINE d00381 TAMOXIFEN d00384 TEMAZEPAM d00386 TERAZOSIN d00387 TERFENADINE d00388 THIOPENTAL d00389 THIORIDAZINE d00390 THIOTEPA d00391 THIOTHIXENE d00393 TOLAZAMIDE d00394 TOLBUTAMIDE d00395 TRAZODONE d00396 TRIAMTERENE d00397 TRIAZOLAM d00399 VECURONIUM d00400 VINBLASTINE d00401 VINCRISTINE d00402 VITAMIN A d00405 VITAMIN E d00409 RIBOFLAVIN d00412 PYRIDOXINE

d00413 d00425	CYANOCOBALAMIN CALCIUM CARBONATE
d00426	ASCORBIC ACID
d00428	FLUORIDE
d00428	SODIUM CHLORIDE
d00440	SODIUM
d00468	BICARBONATE
	SULFATE
d00471	SODIUM ACETATE
d00475	SODIUM PHOSPHATE
d00485	IODINE TOPICAL
d00488	LYSINE
d00489	METHIONINE
d00491	LEVOCARNITINE
d00492	CHOLINE SALICYLATE
d00497	OMEGA-3
000407	POLYUNSAT-
	URATED FATTY
-100540	ACIDS
d00512	FILGRASTIM
d00513	SARGRAMOSTIM
d00514	TICLOPIDINE
d00521	ALTEPLASE
d00525	ANTIHEMOPHILIC
	FACTOR
	(OBSOLETE)
d00527	FACTOR IX COMPLEX
	(OBSOLETE)
d00528	AMINOCAPROIC ACID
d00534	ESTRONE
d00537	ESTRADIOL
d00541	CONJUGATED
	ESTROGENS
d00543	ESTROPIPATE
d00545	QUINESTROL
d00550	PROGESTERONE
d00555	NODETUNDBONE
d00557	NORETHINDRONE
000557	NORETHINDRONE
	LEVONORGESTREL
d00558	LEVONORGESTREL TESTOSTERONE
d00558 d00563	LEVONORGESTREL TESTOSTERONE FINASTERIDE
d00558 d00563 d00566	LEVONORGESTREL TESTOSTERONE FINASTERIDE OXANDROLONE
d00558 d00563 d00566 d00568	LEVONORGESTREL TESTOSTERONE FINASTERIDE OXANDROLONE NANDROLONE
d00558 d00563 d00566 d00568 d00569	LEVONORGESTREL TESTOSTERONE FINASTERIDE OXANDROLONE NANDROLONE CLOMIPHENE
d00558 d00563 d00566 d00568 d00569 d00570	LEVONORGESTREL TESTOSTERONE FINASTERIDE OXANDROLONE NANDROLONE CLOMIPHENE UROFOLLITROPIN
d00558 d00563 d00566 d00568 d00569 d00570 d00571	LEVONORGESTREL TESTOSTERONE FINASTERIDE OXANDROLONE NANDROLONE CLOMIPHENE UROFOLLITROPIN MENOTROPINS
d00558 d00563 d00566 d00568 d00569 d00570	LEVONORGESTREL TESTOSTERONE FINASTERIDE OXANDROLONE NANDROLONE CLOMIPHENE UROFOLLITROPIN MENOTROPINS CHORIONIC
d00558 d00563 d00566 d00568 d00569 d00570 d00571	LEVONORGESTREL TESTOSTERONE FINASTERIDE OXANDROLONE NANDROLONE CLOMIPHENE UROFOLLITROPIN MENOTROPINS CHORIONIC GONADOTROPIN
d00558 d00563 d00566 d00568 d00569 d00570 d00571 d00572	LEVONORGESTREL TESTOSTERONE FINASTERIDE OXANDROLONE NANDROLONE CLOMIPHENE UROFOLLITROPIN MENOTROPINS CHORIONIC GONADOTROPIN (HCG)
d00558 d00563 d00566 d00568 d00569 d00570 d00571 d00572 d00576	LEVONORGESTREL TESTOSTERONE FINASTERIDE OXANDROLONE NANDROLONE CLOMIPHENE UROFOLLITROPIN MENOTROPINS CHORIONIC GONADOTROPIN (HCG) SOMATREM
d00558 d00563 d00566 d00569 d00570 d00571 d00572 d00576 d00577	LEVONORGESTREL TESTOSTERONE FINASTERIDE OXANDROLONE NANDROLONE CLOMIPHENE UROFOLLITROPIN MENOTROPINS CHORIONIC GONADOTROPIN (HCG) SOMATREM SOMATROPIN
d00558 d00563 d00566 d00569 d00570 d00571 d00572 d00576 d00577 d00578	LEVONORGESTREL TESTOSTERONE FINASTERIDE OXANDROLONE NANDROLONE CLOMIPHENE UROFOLLITROPIN MENOTROPINS CHORIONIC GONADOTROPIN (HCG) SOMATREM SOMATROPIN ARGININE
d00558 d00563 d00566 d00569 d00570 d00571 d00572 d00576 d00577 d00578 d00583	LEVONORGESTREL TESTOSTERONE FINASTERIDE OXANDROLONE NANDROLONE CLOMIPHENE UROFOLLITROPIN MENOTROPINS CHORIONIC GONADOTROPIN (HCG) SOMATREM SOMATROPIN ARGININE DESMOPRESSIN
d00558 d00563 d00566 d00569 d00570 d00571 d00572 d00576 d00577 d00578 d00583 d00583	LEVONORGESTREL TESTOSTERONE FINASTERIDE OXANDROLONE NANDROLONE CLOMIPHENE UROFOLLITROPIN MENOTROPINS CHORIONIC GONADOTROPIN (HCG) SOMATREM SOMATROPIN ARGININE DESMOPRESSIN OXYTOCIN
d00558 d00563 d00566 d00569 d00570 d00571 d00572 d00576 d00577 d00578 d00583	LEVONORGESTREL TESTOSTERONE FINASTERIDE OXANDROLONE NANDROLONE CLOMIPHENE UROFOLLITROPIN MENOTROPINS CHORIONIC GONADOTROPIN (HCG) SOMATREM SOMATROPIN ARGININE DESMOPRESSIN OXYTOCIN METHYLER-
d00558 d00563 d00566 d00569 d00570 d00571 d00572 d00576 d00577 d00578 d00583 d00583	LEVONORGESTREL TESTOSTERONE FINASTERIDE OXANDROLONE NANDROLONE CLOMIPHENE UROFOLLITROPIN MENOTROPINS CHORIONIC GONADOTROPIN (HCG) SOMATREM SOMATROPIN ARGININE DESMOPRESSIN OXYTOCIN

d00589	DINOPROSTONE
	TOPICAL
d00592	METYRAPONE
d00593	GLUCAGON
d00598	CALCITONIN
d00599	ETIDRONATE
d00601	PAMIDRONATE
d00604	CORTICOTROPIN
d00608	FLUDROCORTISONE
d00609	CORTISONE
d00620	TRIAMCINOLONE
d00626	DEXAMETHASONE
400020	TOPICAL
d00640	METHAZOLAMIDE
d00649	ETHACRYNIC ACID
d00049	UREA TOPICAL
d00652	GLYCERIN
d00653	ISOSORBIDE THYROID
d00655	
-100050	DESICCATED
d00658	LIOTHYRONINE
d00683	LIDOCAINE TOPICAL
d00688	BEPRIDIL
d00689	AMLODIPINE
d00693	ISOXSUPRINE
d00695	PAPAVERINE
d00697	ISOPROTERENOL
d00699	EPINEPHRINE
d00700	EPHEDRINE
d00702	METARAMINOL
d00704	PHENYLEPHRINE
d00708	CARTEOLOL
d00709	BISOPROLOL
d00717	GUANFACINE
d00726	DOXAZOSIN
d00728	RAMIPRIL
d00730	BENAZEPRIL
d00732	LISINOPRIL
d00735	METYROSINE
d00738	TRIMETHAPHAN
	CAMSYLATE
d00743	SODIUM
	POLYSTYRENE
	SULFONATE
d00744	COLESTIPOL
d00746	SIMVASTATIN
d00749	ALBUTEROL
d00750	METAPROTERENOL
d00752	TERBUTALINE
d00755	PIRBUTEROL
d00758	AMINOPHYLLINE
d00759	DYPHYLLINE
d00760	BECLOMETHASONE
d00762	ACETYLCYSTEINE
d00769	PSEUDOEPHEDRINE
d00771	NAPHAZOLINE
	OPHTHALMIC

d00772	OXYMETAZOLINE
	NASAL
d00773	TETRAHY-
	DROZOLINE
	OPHTHALMIC
d00780	CLEMASTINE
d00785	BROMPHENIRAMINE
d00785 d00786	TRIPROLIDINE
	PROMETHAZINE
d00787	
d00790	CYPROHEPTADINE
d00794	ASTEMIZOLE
d00796	BENZONATATE
d00797	GUAIFENESIN
d00800	POTASSIUM IODIDE
d00801	CAFFEINE
d00803	AMPHETAMINE
d00804	DEXTROAMPHET-
	AMINE
d00806	PHENTERMINE
d00809	PHENDIMETRAZINE
d00810	DIETHYLPROPION
d00812	FENFLURAMINE
d00813	BENZOCAINE
	TOPICAL
d00817	HYDROXY-
	CHLOROQUINE
d00818	AURANOFIN
d00824	OPIUM
d00838	BUTORPHANOL
d00839	NALBUPHINE
d00840	BUPRENORPHINE
d00840 d00842	SALSALATE
d00842 d00843	SODIUM SALICYLATE
d00843	
000044	
400046	THIOSALICYLATE MAGNESIUM
d00846	SALICYLATE
-100040	
d00848	DICLOFENAC
d00851	ETODOLAC
d00853	OXAPROZIN
d00855	PERPHENAZINE
d00857	THIETHYLPERAZINE
d00859	MECLIZINE
d00861	DIMENHYDRINATE
d00862	TRIMETHO-
	BENZAMIDE
d00866	
	DRONABINOL
d00867	
	DRONABINOL
d00867	DRONABINOL ONDANSETRON
d00867 d00873	DRONABINOL ONDANSETRON TRIMIPRAMINE
d00867 d00873 d00874	DRONABINOL ONDANSETRON TRIMIPRAMINE AMOXAPINE CLOMIPRAMINE
d00867 d00873 d00874 d00876	DRONABINOL ONDANSETRON TRIMIPRAMINE AMOXAPINE CLOMIPRAMINE MAPROTILINE
d00867 d00873 d00874 d00876 d00877 d00880	DRONABINOL ONDANSETRON TRIMIPRAMINE AMOXAPINE CLOMIPRAMINE MAPROTILINE SERTRALINE
d00867 d00873 d00874 d00876 d00877 d00880 d00882	DRONABINOL ONDANSETRON TRIMIPRAMINE AMOXAPINE CLOMIPRAMINE MAPROTILINE SERTRALINE ISOCARBOXAZID
d00867 d00873 d00874 d00876 d00877 d00880 d00882 d00883	DRONABINOL ONDANSETRON TRIMIPRAMINE AMOXAPINE CLOMIPRAMINE MAPROTILINE SERTRALINE ISOCARBOXAZID PHENELZINE
d00867 d00873 d00874 d00876 d00877 d00880 d00882 d00883 d00884	DRONABINOL ONDANSETRON TRIMIPRAMINE AMOXAPINE CLOMIPRAMINE MAPROTILINE SERTRALINE ISOCARBOXAZID PHENELZINE TRANYLCYPROMINE
d00867 d00873 d00874 d00876 d00877 d00880 d00882 d00883 d00884 d00890	DRONABINOL ONDANSETRON TRIMIPRAMINE AMOXAPINE CLOMIPRAMINE MAPROTILINE SERTRALINE ISOCARBOXAZID PHENELZINE TRANYLCYPROMINE TRIFLUOPERAZINE
d00867 d00873 d00874 d00876 d00877 d00880 d00882 d00883 d00884 d00890 d00896	DRONABINOL ONDANSETRON TRIMIPRAMINE AMOXAPINE CLOMIPRAMINE MAPROTILINE SERTRALINE ISOCARBOXAZID PHENELZINE TRANYLCYPROMINE TRIFLUOPERAZINE MOLINDONE
d00867 d00873 d00874 d00876 d00877 d00880 d00882 d00883 d00884 d00890	DRONABINOL ONDANSETRON TRIMIPRAMINE AMOXAPINE CLOMIPRAMINE MAPROTILINE SERTRALINE ISOCARBOXAZID PHENELZINE TRANYLCYPROMINE TRIFLUOPERAZINE

d00900	METHYLPHENIDATE
d00901	PEMOLINE
d00901	ERGOLOID
d00902	MESYLATES
d00904	HALAZEPAM
d00907	HYDROXYZINE
d00910	ZOLPIDEM
d00915	ESTAZOLAM
d00919 d00929	MEPHOBARBITAL
d00933	PROPOFOL
d00934	NITROUS OXIDE
d00951 d00957	MIVACURIUM
d00960	CARISOPRODOL
d00962	CHLORZOXAZONE
d00963	CYCLOBENZAPRINE
d00964	METAXALONE
d00965	METHOCARBAMOL
d00966	ORPHENADRINE
d00967	BACLOFEN
d00968	DANTROLENE
d00969	PROCYCLIDINE
d00970	TRIHEXYPHENIDYL
d00972	BIPERIDEN
d00976	SELEGILINE
d00977	PERGOLIDE
d00978	ALUMINUM
d00982	HYDROXIDE MAGNESIUM
d00984	HYDROXIDE MAGALDRATE
d00985	HYOSCYAMINE
d00986	SCOPOLAMINE
d00988	BELLADONNA
d00989	METHSCOPOLAMINE
d00991	CLIDINIUM
d00992	GLYCOPYRROLATE
d00999	DICYCLOMINE
d01002	PANCRELIPASE
d01003	PANCREATIN
d01005	URSODIOL
d01008	MAGNESIUM
d01012	CITRATE PHENOLPHTHALEIN
d01013	SENNA
d01014	CASTOR OIL
d01015	BISACODYL
d01017	POLYCARBOPHIL
d01018	PSYLLIUM
d01019	MINERAL OIL
d01021	DOCUSATE
d01024	LACTULOSE
d01024 d01025	LOPERAMIDE
d01026	BISMUTH SUBSALICYLATE
d01027	SIMETHICONE
d01028	CHARCOAL
d01028 d01030	DEHYDROCHOLIC
	ACID

404004	
d01031	MESALAMINE
d01068	DEMECLOCYCLINE
d01070	OXYTETRACYCLINE
d01097	RIFABUTIN
	-
d01104	PAROMOMYCIN
d01113	COLISTIMETHATE
d01115	BACITRACIN
	ATOVAQUONE
d01120	
d01133	IMMUNE GLOBULIN
	INTRAVENOUS
d01134	CYTOMEGALOVIRUS
dorror	IMMUNE GLOBULIN
d01135	IMMUNE GLOBULIN
	INTRAMUSCULAR
d01137	TETANUS IMMUNE
	GLOBULIN
104400	
d01138	VARICELLA ZOSTER
	IMMUNE GLOBULIN
d01139	RHO (D) IMMUNE
401100	GLOBULIN
-10444	
d01147	RABIES VACCINE
	(OBSOLETE)
d01148	RABIES IMMUNE
	GLOBULIN, HUMAN
-104450	
d01150	BCG
d01154	CHOLERA VACCINE
d01156	TYPHOID VACCINE,
	INACTIVATED
d01158	HAEMOPHILUS B
001156	
	CONJUGATE
	VACCINE
	(OBSOLETE)
104450	
d01159	MEASLES VIRUS
	VACCINE
d01160	RUBELLA VIRUS
	VACCINE
401101	MUMPS VIRUS
d01161	
	VACCINE
d01164	INFLUENZA VIRUS
	VACCINE,
	INACTIVATED
104405	
d01165	YELLOW FEVER
	VACCINE
d01166	HEPATITIS B
	VACCINE
401100	
d01168	TETANUS TOXOID
d01171	TUBERCULIN
	PURIFIED PROTEIN
	DERIVATIVE
d01184	DIPIVEFRIN
001104	
	OPHTHALMIC
d01185	OPHTHALMIC APRACLONIDINE
d01185	OPHTHALMIC
	OPHTHALMIC APRACLONIDINE OPHTHALMIC
d01185 d01187	OPHTHALMIC APRACLONIDINE OPHTHALMIC LEVOBUNOLOL
d01187	OPHTHALMIC APRACLONIDINE OPHTHALMIC LEVOBUNOLOL OPHTHALMIC
	OPHTHALMIC APRACLONIDINE OPHTHALMIC LEVOBUNOLOL OPHTHALMIC CARBACHOL
d01187	OPHTHALMIC APRACLONIDINE OPHTHALMIC LEVOBUNOLOL OPHTHALMIC
d01187	OPHTHALMIC APRACLONIDINE OPHTHALMIC LEVOBUNOLOL OPHTHALMIC CARBACHOL
d01187 d01189	OPHTHALMIC APRACLONIDINE OPHTHALMIC LEVOBUNOLOL OPHTHALMIC CARBACHOL OPHTHALMIC PILOCARPINE
d01187 d01189	OPHTHALMIC APRACLONIDINE OPHTHALMIC LEVOBUNOLOL OPHTHALMIC CARBACHOL OPHTHALMIC

d01195	ECHOTHIOPHATE IODIDE	d01
d01199	OPHTHALMIC HOMATROPINE OPHTHALMIC	d01
d01200	TROPICAMIDE OPHTHALMIC	d01
d01201	CYCLOPENTOLATE OPHTHALMIC	d01 d01
d01204	SUPROFEN OPHTHALMIC	d01
d01208	SULFACETAMIDE	d01
d01213	OPHTHALMIC NATAMYCIN	d01
d01215	OPHTHALMIC TRIFLURIDINE OPHTHALMIC	d01 d01
d01217 d01218	TETRACAINE	d01
d01210	OPHTHALMIC FLUORESCEIN	d01
	OPHTHALMIC	d01
d01222	SODIUM HYALURONATE OPHTHALMIC	d01
d01225 d01226	BORIC ACID TOPICAL HYDROXYPROPYL	d01
u01220	METHYLCELLULOSE OPHTHALMIC	d01 d01
d01227	BOTULINUM TOXIN TYPE A	d01
d01231	CHLORHEXIDINE	d01
d01232	CARBAMIDE PEROXIDE TOPICAL	d01
d01234	BUTOCONAZOLE	
d01236	TOPICAL CLOTRIMAZOLE	d01
d01238	TERCONAZOLE TOPICAL	d01
d01239	GENTIAN VIOLET TOPICAL	d01 d01
d01240	SULFANILAMIDE TOPICAL	d01
d01241	CLINDAMYCIN TOPICAL	d01 d01
d01242	NONOXYNOL 9 TOPICAL	d01
d01244	TRETINOIN TOPICAL	
d01245 d01246	ISOTRETINOIN BENZOYL PEROXIDE TOPICAL	d01 d01
d01254 d01257	ANTHRALIN TOPICAL	d01
d01257	TOPICAL	d01
001200		

doi233SilverSulfADIAZINETOPICALd01263PYRITHIONE ZINCTOPICALd01265SULFACETAMIDESODIUM TOPICALd01267MUPIROCIN TOPICALd01271ECONAZOLETOPICALd01272CICLOPIROXTOPICALd01274TOLNAFTATETOPICALd01277NAFTIFINE TOPICALd01278LINDANE TOPICALd01279PERMETHRINTOPICALd01280CROTAMITONTOPICALd01282ALCLOMETASONETOPICALd01283CNORTOLONETOPICALd01284CLOBETASOLTOPICALd01285CLOBETASOLTOPICALd01280DESONIDE TOPICALd01290DESONIDE TOPICALd01291DESOXIMETASONETOPICALd01292DIFLORASONETOPICALd01293FLUOCINOLONETOPICALd01294FLUOCINOLONETOPICALd01295FLURANDRENOLIDETOPICALd01295FLURANDRENOLIDETOPICALd01303PRAMOXINETOPICALd01304PODOFHLOX TOPICALd01305DYCLONINE TOPICALd01306COCAINE TOPICALd01307SALICYLIC ACIDTOPICALd01308d01309PODOFILOX TOPICALd01301DIBUCAINE TOPICALd01303PRAMOXINETOPICALd01303d01304 <td< th=""><th>d01259</th><th>SILVER</th></td<>	d01259	SILVER
d01263PYRITHIONE ZINC TOPICALd01265SULFACETAMIDE SODIUM TOPICALd01267MUPIROCIN TOPICALd01271ECONAZOLE TOPICALd01272CICLOPIROX TOPICALd01274TOLNAFTATE TOPICALd01277NAFTIFINE TOPICALd01278LINDANE TOPICALd01280CROTAMITON TOPICALd01281ALCLOMETASONE TOPICALd01283AMCINONIDE TOPICALd01284CLOBETASOL TOPICALd01285CLOCORTOLONE TOPICALd01280CEOCORTOLONE TOPICALd01281DESONIDE TOPICALd01282DESONIDE TOPICALd01283FLUOCINOLONE TOPICALd01284CLOCORTOLONE TOPICALd01295DESONIDE TOPICALd01296DESONIDE TOPICALd01297PILORASONE TOPICALd01298FLUOCINOLONE TOPICALd01293FLUOCINOLONE TOPICALd01294FLUOCINONIDE TOPICALd01305PCLONINE TOPICALd01306COCAINE TOPICALd01307SALICYLIC ACID TOPICALd01308PODOPHYLLUM RESIN TOPICALd01309PODOFILOX TOPICALd01312DICHLOROACETIC ACID TOPICALd01313TRICHLOROACETIC ACID TOPICALd01313TRICHLOROACETIC ACID TOPICALd01313COLLAGENASE	001259	SULFADIAZINE
d01265SULFACETAMIDE SODIUM TOPICALd01267MUPIROCIN TOPICALd01271ECONAZOLE TOPICALd01272CICLOPIROX TOPICALd01274TOLNAFTATE TOPICALd01277NAFTIFINE TOPICALd01278LINDANE TOPICALd01279PERMETHRIN TOPICALd01280CROTAMITON TOPICALd01282ALCLOMETASONE TOPICALd01283AMCINONIDE TOPICALd01284CLOCORTOLONE TOPICALd01289CLOCORTOLONE TOPICALd01290DESONIDE TOPICALd01291DESONIDE TOPICALd01292DIFLORASONE TOPICALd01293FLUOCINOLONE TOPICALd01294FLUOCINOLONE TOPICALd01295FLURANDRENOLIDE TOPICALd01296FURANDRENOLIDE TOPICALd01301DIBUCAINE TOPICALd01303PRAMOXINE TOPICALd01304PODOFILAd01305DYCLONINE TOPICALd01306COCAINE TOPICALd01307SALICYLIC ACID TOPICALd01308PODOPHYLLUM RESIN TOPICALd01309PODOFILOX TOPICALd01311TRICHLOROACETIC ACID TOPICALd01313TRICHLOROACETIC ACID TOPICALd01313TRICHLOROACETIC ACID TOPICALd01313COLLAGENASE	d01263	PYRITHIONE ZINC
d01267MUPIROCIN TOPICALd01271ECONAZOLE TOPICALd01272CICLOPIROX TOPICALd01274TOLNAFTATE TOPICALd01277NAFTIFINE TOPICALd01278LINDANE TOPICALd01279PERMETHRIN TOPICALd01280CROTAMITON TOPICALd01282ALCLOMETASONE TOPICALd01283AMCINONIDE TOPICALd01284CLOBETASOL TOPICALd01285CLOCORTOLONE TOPICALd01280CEOCORTOLONE TOPICALd01283AMCINONIDE TOPICALd01284CLOCORTOLONE TOPICALd01295DESONIDE TOPICALd01291DESONIDE TOPICALd01292DIFLORASONE TOPICALd01293FLUOCINOLONE TOPICALd01294FLUOCINONIDE TOPICALd01295FLURANDRENOLIDE TOPICALd01301DIBUCAINE TOPICALd01303PRAMOXINE TOPICALd01304PODOPHYLLUM RESIN TOPICALd01305PODOPHYLLUM RESIN TOPICALd01304PODOFILOX TOPICALd01305ODOPHYLLUM RESIN TOPICALd01304PODOFILOX TOPICALd01305ODOFILOX TOPICALd01304PODOFILOX TOPICALd01305COLLAGENASE	d01265	SULFACETAMIDE
d01271ECONAZOLE TOPICALd01272CICLOPIROX TOPICALd01274TOLNAFTATE TOPICALd01277NAFTIFINE TOPICALd01278LINDANE TOPICALd01279PERMETHRIN TOPICALd01280CROTAMITON TOPICALd01282ALCLOMETASONE TOPICALd01283AMCINONIDE TOPICALd01284CLOBETASOL TOPICALd01285CLOCORTOLONE TOPICALd01289CLOCORTOLONE TOPICALd01290DESONIDE TOPICALd01291DESOXIMETASONE TOPICALd01292DIFLORASONE TOPICALd01293FLUOCINOLONE TOPICALd01294FLUOCINOLONE TOPICALd01295FLURANDRENOLIDE TOPICALd01301DIBUCAINE TOPICALd01303PRAMOXINE TOPICALd01304PODOPHYLLUM RESIN TOPICALd01305PODOPHYLLUM RESIN TOPICALd01304PODOFILOX TOPICALd01305ODOPHYLLUM RESIN TOPICALd01303RAMOXINE TOPICALd01303RAMOXINE TOPICALd01304PODOFILOX TOPICALd01305DYCLONINE TOPICALd01306COCAINE TOPICALd01307SALICYLIC ACID TOPICALd01308PODOFILOX TOPICALd01313TRICHLOROACETIC ACID TOPICALd01313TRICHLOROACETIC ACID TOPICALd01313TRICHLOROACETIC ACID TOPICALd01313TRICHLOROACETIC ACID TOPICALd01315COLLAGENASE	401267	
d01272CICLOPIROX TOPICALd01274TOLNAFTATE TOPICALd01277NAFTIFINE TOPICALd01278LINDANE TOPICALd01279PERMETHRIN TOPICALd01280CROTAMITON TOPICALd01282ALCLOMETASONE TOPICALd01283AMCINONIDE TOPICALd01284CLOBETASOL TOPICALd01285CLOCORTOLONE TOPICALd01289CLOCORTOLONE TOPICALd01290DESONIDE TOPICALd01291DESONIDE TOPICALd01292DIFLORASONE TOPICALd01293FLUOCINOLONE TOPICALd01294FLUOCINOLONE TOPICALd01295FLURANDRENOLIDE TOPICALd01301DIBUCAINE TOPICALd01303PRAMOXINE TOPICALd01304DYCLONINE TOPICALd01305DYCLONINE TOPICALd01306COCAINE TOPICALd01307SALICYLIC ACID TOPICALd01308PODOPHYLLUM RESIN TOPICALd01309PODOFILOX TOPICALd013113TRICHLOROACETIC ACID TOPICALd01313TRICHLOROACETIC ACID TOPICALd01313TRICHLOROACETIC ACID TOPICALd01313TRICHLOROACETIC ACID TOPICALd01313TRICHLOROACETIC ACID TOPICALd01315COLLAGENASE		
TOPICALd01274TOLNAFTATE TOPICALd01277NAFTIFINE TOPICALd01278LINDANE TOPICALd01279PERMETHRIN TOPICALd01280CROTAMITON TOPICALd01282ALCLOMETASONE TOPICALd01283AMCINONIDE TOPICALd01283CLOBETASOL TOPICALd01289CLOCORTOLONE TOPICALd01289CLOCORTOLONE TOPICALd01290DESONIDE TOPICALd01291DESONIDE TOPICALd01292DIFLORASONE TOPICALd01293FLUOCINOLONE TOPICALd01294FLUOCINONIDE TOPICALd01295FLURANDRENOLIDE TOPICALd01296FLURANDRENOLIDE TOPICALd01301DIBUCAINE TOPICALd01303PRAMOXINE TOPICALd01304PODOPHYLLUM RESIN TOPICALd01305PODOPHYLLUM RESIN TOPICALd01307SALICYLIC ACID TOPICALd01308PODOPHYLLUM RESIN TOPICALd013103TRICHLOROACETIC ACID TOPICALd01313TRICHLOROACETIC ACID TOPICALd01313COLLAGENASE		
d01274TOLNAFTATE TOPICALd01277NAFTIFINE TOPICALd01278LINDANE TOPICALd01279PERMETHRIN TOPICALd01280CROTAMITON TOPICALd01282ALCLOMETASONE TOPICALd01283AMCINONIDE TOPICALd01283AMCINONIDE TOPICALd01284CLOBETASOL TOPICALd01285CLOCORTOLONE TOPICALd01289CLOCORTOLONE TOPICALd01290DESONIDE TOPICALd01291DESONIDE TOPICALd01292DIFLORASONE TOPICALd01293FLUOCINOLONE TOPICALd01294FLUOCINONIDE TOPICALd01295FLURANDRENOLIDE TOPICALd01296FLURANDRENOLIDE TOPICALd01301DIBUCAINE TOPICALd01303PRAMOXINE TOPICALd01304PODOPHYLLUM RESIN TOPICALd01305PODOPHYLLUM RESIN TOPICALd01307SALICYLIC ACID TOPICALd01303PODOFILOX TOPICALd01304PODOFILOX TOPICALd01305ODOFILOX TOPICALd01307SALICYLIC ACID TOPICALd01308PODOFILOX TOPICALd01309PODOFILOX TOPICALd01313TRICHLOROACETIC ACID TOPICALd01313TRICHLOROACETIC ACID TOPICALd01315COLLAGENASE	d01272	
d01277NAFTIFINE TOPICALd01278LINDANE TOPICALd01279PERMETHRIN TOPICALd01280CROTAMITON TOPICALd01282ALCLOMETASONE TOPICALd01283AMCINONIDE TOPICALd01283CLOBETASOL TOPICALd01289CLOCORTOLONE TOPICALd01290DESONIDE TOPICALd01291DESONIDE TOPICALd01292DIFLORASONE TOPICALd01293FLUOCINOLONE TOPICALd01294FLUOCINOLONE TOPICALd01295FLURANDRENOLIDE TOPICALd01301DIBUCAINE TOPICALd01303PRAMOXINE TOPICALd01305DYCLONINE TOPICALd01306COCAINE TOPICALd01307SALICYLIC ACID TOPICALd01308PODOPHYLLUM RESIN TOPICALd01309PODOFILOX TOPICALd013103TRICHLOROACETIC ACID TOPICALd013133TRICHLOROACETIC ACID TOPICALd01313COLLAGENASE	d01274	TOLNAFTATE
d01278LINDANE TOPICALd01279PERMETHRIN TOPICALd01280CROTAMITON TOPICALd01282ALCLOMETASONE TOPICALd01283AMCINONIDE TOPICALd01283CLOBETASOL TOPICALd01289CLOCORTOLONE TOPICALd01290DESONIDE TOPICALd01291DESONIDE TOPICALd01292DIFLORASONE TOPICALd01293FLUOCINOLONE TOPICALd01294FLUOCINOLONE TOPICALd01295FLURANDRENOLIDE TOPICALd01298HALOBETASOL TOPICALd01301DIBUCAINE TOPICALd01303PRAMOXINE TOPICALd01304DYCLONINE TOPICALd01305DYCLONINE TOPICALd01306COCAINE TOPICALd01307SALICYLIC ACID TOPICALd01308PODOPHYLLUM RESIN TOPICALd01309PODOFILOX TOPICALd013103TRICHLOROACETIC ACID TOPICALd01313TRICHLOROACETIC ACID TOPICALd01313TRICHLOROACETIC ACID TOPICALd01313COLLAGENASE	d01277	
d01279PERMETHRIN TOPICALd01280CROTAMITON TOPICALd01282ALCLOMETASONE TOPICALd01283AMCINONIDE TOPICALd01283CLOBETASOL TOPICALd01289CLOCORTOLONE TOPICALd01290DESONIDE TOPICALd01291DESONIDE TOPICALd01292DIFLORASONE TOPICALd01293FLUOCINOLONE TOPICALd01294FLUOCINOLONE TOPICALd01295FLURANDRENOLIDE TOPICALd01296FLURANDRENOLIDE TOPICALd01297FLURANDRENOLIDE TOPICALd01298HALOBETASOL TOPICALd01301DIBUCAINE TOPICALd01303PRAMOXINE TOPICALd01304POLOPININE TOPICALd01305DYCLONINE TOPICALd01306COCAINE TOPICALd01307SALICYLIC ACID TOPICALd01308PODOPHYLLUM RESIN TOPICALd01309PODOFILOX TOPICALd01312DICHLOROACETIC ACID TOPICALd01313TRICHLOROACETIC ACID TOPICALd01313COLLAGENASE		
d01280CROTAMITON TOPICALd01282ALCLOMETASONE TOPICALd01283AMCINONIDE TOPICALd01283CLOBETASOL TOPICALd01288CLOCORTOLONE TOPICALd01289CLOCORTOLONE TOPICALd01290DESONIDE TOPICALd01291DESOXIMETASONE TOPICALd01292DIFLORASONE TOPICALd01293FLUOCINOLONE TOPICALd01294FLUOCINONIDE TOPICALd01295FLURANDRENOLIDE TOPICALd01298HALOBETASOL TOPICALd01301DIBUCAINE TOPICALd01303PRAMOXINE TOPICALd01304DYCLONINE TOPICALd01305DYCLONINE TOPICALd01306COCAINE TOPICALd01307SALICYLIC ACID TOPICALd01308PODOPHYLLUM RESIN TOPICALd01309PODOFILOX TOPICALd01312DICHLOROACETIC ACID TOPICALd01313TRICHLOROACETIC ACID TOPICALd01315COLLAGENASE		PERMETHRIN
TOPICAL d01282 ALCLOMETASONE TOPICAL d01283 AMCINONIDE TOPICAL d01288 CLOBETASOL TOPICAL d01289 CLOCORTOLONE TOPICAL d01290 DESONIDE TOPICAL d01290 DESONIDE TOPICAL d01291 DESOXIMETASONE TOPICAL d01292 DIFLORASONE TOPICAL d01293 FLUOCINOLONE TOPICAL d01294 FLUOCINONIDE TOPICAL d01295 FLURANDRENOLIDE TOPICAL d01298 HALOBETASOL TOPICAL d01301 DIBUCAINE TOPICAL d01303 PRAMOXINE TOPICAL d01305 DYCLONINE TOPICAL d01305 DYCLONINE TOPICAL d01306 COCAINE TOPICAL d01307 SALICYLIC ACID TOPICAL d01308 PODOPHYLLUM RESIN TOPICAL d01309 PODOFILOX TOPICAL d01310 TRICHLOROACETIC ACID TOPICAL d01313 TRICHLOROACETIC ACID TOPICAL d01313 TRICHLOROACETIC ACID TOPICAL d01315 COLLAGENASE	-104000	
d01282ALCLOMETASONE TOPICALd01283AMCINONIDE TOPICALd01288CLOBETASOL TOPICALd01289CLOCORTOLONE TOPICALd01290DESONIDE TOPICALd01291DESONIDE TOPICALd01292DIFLORASONE TOPICALd01293FLUOCINOLONE TOPICALd01294FLUOCINONIDE TOPICALd01295FLURANDRENOLIDE TOPICALd01298HALOBETASOL TOPICALd01301DIBUCAINE TOPICALd01303PRAMOXINE TOPICALd01305DYCLONINE TOPICALd01306COCAINE TOPICALd01307SALICYLIC ACID TOPICALd01308PODOPHYLLUM RESIN TOPICALd01309PODOFILOX TOPICALd01312DICHLOROACETIC ACID TOPICALd01313TRICHLOROACETIC ACID TOPICALd01313TRICHLOROACETIC ACID TOPICALd01313COLLAGENASE	001280	
d01283AMCINONIDE TOPICALd01288CLOBETASOL TOPICALd01289CLOCORTOLONE TOPICALd01290DESONIDE TOPICALd01291DESOXIMETASONE TOPICALd01292DIFLORASONE TOPICALd01293FLUOCINOLONE TOPICALd01294FLUOCINONIDE TOPICALd01295FLURANDRENOLIDE TOPICALd01298HALOBETASOL TOPICALd01301DIBUCAINE TOPICALd01303PRAMOXINE TOPICALd01305DYCLONINE TOPICALd01306COCAINE TOPICALd01307SALICYLIC ACID TOPICALd01308PODOPHYLLUM RESIN TOPICALd01309PODOFILOX TOPICALd01312DICHLOROACETIC ACID TOPICALd01313TRICHLOROACETIC ACID TOPICALd01313TRICHLOROACETIC ACID TOPICALd01313COLLAGENASE	d01282	
TOPICALd01288CLOBETASOL TOPICALd01289CLOCORTOLONE TOPICALd01290DESONIDE TOPICALd01291DESOXIMETASONE TOPICALd01292DIFLORASONE TOPICALd01293FLUOCINOLONE TOPICALd01294FLUOCINONIDE TOPICALd01295FLURANDRENOLIDE TOPICALd01298HALOBETASOL TOPICALd01301DIBUCAINE TOPICALd01303PRAMOXINE TOPICALd01305DYCLONINE TOPICALd01306COCAINE TOPICALd01307SALICYLIC ACID TOPICALd01308PODOPHYLLUM RESIN TOPICALd01309PODOFILOX TOPICALd01312DICHLOROACETIC ACID TOPICALd01313TRICHLOROACETIC ACID TOPICALd01313TRICHLOROACETIC ACID TOPICALd01313COLLAGENASE		
d01288CLOBETASOL TOPICALd01289CLOCORTOLONE TOPICALd01290DESONIDE TOPICALd01291DESOXIMETASONE TOPICALd01292DIFLORASONE TOPICALd01293FLUOCINOLONE TOPICALd01294FLUOCINONIDE TOPICALd01295FLURANDRENOLIDE TOPICALd01298HALOBETASOL TOPICALd01301DIBUCAINE TOPICALd01303PRAMOXINE TOPICALd01304DYCLONINE TOPICALd01305DYCLONINE TOPICALd01306COCAINE TOPICALd01307SALICYLIC ACID TOPICALd01308PODOPHYLLUM RESIN TOPICALd01309PODOFILOX TOPICALd01312DICHLOROACETIC ACID TOPICALd01313TRICHLOROACETIC ACID TOPICALd01315COLLAGENASE	d01283	
TOPICAL d01289 CLOCORTOLONE TOPICAL d01290 DESONIDE TOPICAL d01291 DESOXIMETASONE TOPICAL d01292 DIFLORASONE TOPICAL d01293 FLUOCINOLONE TOPICAL d01294 FLUOCINONIDE TOPICAL d01295 FLURANDRENOLIDE TOPICAL d01298 HALOBETASOL TOPICAL d01301 DIBUCAINE TOPICAL d01303 PRAMOXINE TOPICAL d01305 DYCLONINE TOPICAL d01306 COCAINE TOPICAL d01307 SALICYLIC ACID TOPICAL d01308 PODOPHYLLUM RESIN TOPICAL d01309 PODOFILOX TOPICAL d01310 TRICHLOROACETIC ACID TOPICAL d01313 TRICHLOROACETIC ACID TOPICAL d01315 COLLAGENASE	d01288	
TOPICAL d01290 DESONIDE TOPICAL d01291 DESOXIMETASONE TOPICAL d01292 DIFLORASONE TOPICAL d01293 FLUOCINOLONE TOPICAL d01294 FLUOCINONIDE TOPICAL d01295 FLURANDRENOLIDE TOPICAL d01298 HALOBETASOL TOPICAL d01301 DIBUCAINE TOPICAL d01303 PRAMOXINE TOPICAL d01305 DYCLONINE TOPICAL d01305 DYCLONINE TOPICAL d01306 COCAINE TOPICAL d01307 SALICYLIC ACID TOPICAL d01308 PODOPHYLLUM RESIN TOPICAL d01309 PODOFILOX TOPICAL d01310 TRICHLOROACETIC ACID TOPICAL d01313 TRICHLOROACETIC ACID TOPICAL d01315 COLLAGENASE		TOPICAL
d01290DESONIDE TOPICALd01291DESOXIMETASONE TOPICALd01292DIFLORASONE TOPICALd01293FLUOCINOLONE TOPICALd01294FLUOCINONIDE TOPICALd01295FLURANDRENOLIDE TOPICALd01298HALOBETASOL TOPICALd01301DIBUCAINE TOPICALd01303PRAMOXINE TOPICALd01305DYCLONINE TOPICALd01306COCAINE TOPICALd01307SALICYLIC ACID TOPICALd01308PODOPHYLLUM RESIN TOPICALd01309PODOFILOX TOPICALd01312DICHLOROACETIC ACID TOPICALd01313TRICHLOROACETIC ACID TOPICALd01315COLLAGENASE	d01289	
d01291DESOXIMETASONE TOPICALd01292DIFLORASONE TOPICALd01293FLUOCINOLONE TOPICALd01294FLUOCINONIDE TOPICALd01295FLURANDRENOLIDE TOPICALd01298HALOBETASOL TOPICALd01301DIBUCAINE TOPICALd01303PRAMOXINE TOPICALd01305DYCLONINE TOPICALd01306COCAINE TOPICALd01307SALICYLIC ACID TOPICALd01308PODOPHYLLUM RESIN TOPICALd01309PODOFILOX TOPICALd01312DICHLOROACETIC ACID TOPICALd01313TRICHLOROACETIC ACID TOPICALd01315COLLAGENASE	d01290	
d01292DIFLORASONE TOPICALd01293FLUOCINOLONE TOPICALd01294FLUOCINONIDE TOPICALd01295FLURANDRENOLIDE TOPICALd01298HALOBETASOL TOPICALd01301DIBUCAINE TOPICALd01303PRAMOXINE TOPICALd01305DYCLONINE TOPICALd01306COCAINE TOPICALd01307SALICYLIC ACID TOPICALd01308PODOPHYLLUM RESIN TOPICALd01309PODOFILOX TOPICALd01312DICHLOROACETIC ACID TOPICALd01313TRICHLOROACETIC ACID TOPICALd01315COLLAGENASE		
TOPICAL d01293 FLUOCINOLONE TOPICAL d01294 FLUOCINONIDE TOPICAL d01295 FLURANDRENOLIDE TOPICAL d01298 HALOBETASOL TOPICAL d01301 DIBUCAINE TOPICAL d01303 PRAMOXINE TOPICAL d01305 DYCLONINE TOPICAL d01305 DYCLONINE TOPICAL d01306 COCAINE TOPICAL d01307 SALICYLIC ACID TOPICAL d01308 PODOPHYLLUM RESIN TOPICAL d01309 PODOFILOX TOPICAL d01312 DICHLOROACETIC ACID TOPICAL d01313 TRICHLOROACETIC ACID TOPICAL d01315 COLLAGENASE	-104000	
d01293FLUOCINOLONE TOPICALd01294FLUOCINONIDE TOPICALd01295FLURANDRENOLIDE TOPICALd01298HALOBETASOL TOPICALd01301DIBUCAINE TOPICALd01303PRAMOXINE TOPICALd01305DYCLONINE TOPICALd01306COCAINE TOPICALd01307SALICYLIC ACID TOPICALd01308PODOPHYLLUM RESIN TOPICALd01309PODOFILOX TOPICALd01312DICHLOROACETIC ACID TOPICALd01313TRICHLOROACETIC ACID TOPICALd01315COLLAGENASE	001292	
d01294 FLUOCINONIDE TOPICAL d01295 FLURANDRENOLIDE TOPICAL d01298 HALOBETASOL TOPICAL d01301 DIBUCAINE TOPICAL d01303 PRAMOXINE TOPICAL d01305 DYCLONINE TOPICAL d01305 DYCLONINE TOPICAL d01306 COCAINE TOPICAL d01307 SALICYLIC ACID TOPICAL d01308 PODOPHYLLUM RESIN TOPICAL d01309 PODOFILOX TOPICAL d01312 DICHLOROACETIC ACID TOPICAL d01313 TRICHLOROACETIC ACID TOPICAL d01315 COLLAGENASE	d01293	
TOPICAL d01295 FLURANDRENOLIDE TOPICAL d01298 HALOBETASOL TOPICAL d01301 DIBUCAINE TOPICAL d01303 PRAMOXINE TOPICAL d01305 DYCLONINE TOPICAL d01306 COCAINE TOPICAL d01307 SALICYLIC ACID TOPICAL d01308 PODOPHYLLUM RESIN TOPICAL d01309 PODOFILOX TOPICAL d01312 DICHLOROACETIC ACID TOPICAL d01313 TRICHLOROACETIC ACID TOPICAL d01315 COLLAGENASE	104004	
d01295 FLURANDRENOLIDE TOPICAL d01298 HALOBETASOL TOPICAL d01301 DIBUCAINE TOPICAL d01303 PRAMOXINE TOPICAL d01305 DYCLONINE TOPICAL d01306 COCAINE TOPICAL d01307 SALICYLIC ACID TOPICAL d01308 PODOPHYLLUM RESIN TOPICAL d01309 PODOFILOX TOPICAL d01312 DICHLOROACETIC ACID TOPICAL d01313 TRICHLOROACETIC ACID TOPICAL d01315 COLLAGENASE	d01294	
d01298 HALOBETASOL TOPICAL d01301 DIBUCAINE TOPICAL d01303 PRAMOXINE TOPICAL d01305 DYCLONINE TOPICAL d01306 COCAINE TOPICAL d01307 SALICYLIC ACID TOPICAL d01308 PODOPHYLLUM RESIN TOPICAL d01309 PODOFILOX TOPICAL d01312 DICHLOROACETIC ACID TOPICAL d01313 TRICHLOROACETIC ACID TOPICAL d01315 COLLAGENASE	d01295	
TOPICAL d01301 DIBUCAINE TOPICAL d01303 PRAMOXINE TOPICAL d01305 DYCLONINE TOPICAL d01306 COCAINE TOPICAL d01307 SALICYLIC ACID TOPICAL d01308 PODOPHYLLUM RESIN TOPICAL d01309 PODOFILOX TOPICAL d01312 DICHLOROACETIC ACID TOPICAL d01313 TRICHLOROACETIC ACID TOPICAL d01315 COLLAGENASE	104000	
d01301DIBUCAINE TOPICALd01303PRAMOXINE TOPICALd01305DYCLONINE TOPICALd01306COCAINE TOPICALd01307SALICYLIC ACID TOPICALd01308PODOPHYLLUM RESIN TOPICALd01309PODOFILOX TOPICALd01312DICHLOROACETIC ACID TOPICALd01313TRICHLOROACETIC ACID TOPICALd01315COLLAGENASE	001298	
TOPICAL d01305 DYCLONINE TOPICAL d01306 COCAINE TOPICAL d01307 SALICYLIC ACID TOPICAL d01308 PODOPHYLLUM RESIN TOPICAL d01309 PODOFILOX TOPICAL d01312 DICHLOROACETIC ACID TOPICAL d01313 TRICHLOROACETIC ACID TOPICAL d01315 COLLAGENASE	d01301	DIBUCAINE TOPICAL
d01305 DYCLONINE TOPICAL d01306 COCAINE TOPICAL d01307 SALICYLIC ACID TOPICAL d01308 PODOPHYLLUM RESIN TOPICAL d01309 PODOFILOX TOPICAL d01312 DICHLOROACETIC ACID TOPICAL d01313 TRICHLOROACETIC ACID TOPICAL d01315 COLLAGENASE	d01303	
d01306 COCAINE TOPICAL d01307 SALICYLIC ACID TOPICAL d01308 PODOPHYLLUM RESIN TOPICAL d01309 PODOFILOX TOPICAL d01312 DICHLOROACETIC ACID TOPICAL d01313 TRICHLOROACETIC ACID TOPICAL d01315 COLLAGENASE	d01305	
d01307 SALICYLIC ACID TOPICAL d01308 PODOPHYLLUM RESIN TOPICAL d01309 PODOFILOX TOPICAL d01312 DICHLOROACETIC ACID TOPICAL d01313 TRICHLOROACETIC ACID TOPICAL d01315 COLLAGENASE		
d01308 PODOPHYLLUM RESIN TOPICAL d01309 PODOFILOX TOPICAL d01312 DICHLOROACETIC ACID TOPICAL d01313 TRICHLOROACETIC ACID TOPICAL d01315 COLLAGENASE		SALICYLIC ACID
RESIN TOPICAL d01309 PODOFILOX TOPICAL d01312 DICHLOROACETIC ACID TOPICAL d01313 TRICHLOROACETIC ACID TOPICAL d01315 COLLAGENASE	401200	
d01309 PODOFILOX TOPICAL d01312 DICHLOROACETIC ACID TOPICAL d01313 TRICHLOROACETIC ACID TOPICAL d01315 COLLAGENASE	001306	
ACID TOPICAL d01313 TRICHLOROACETIC ACID TOPICAL d01315 COLLAGENASE		PODOFILOX TOPICAL
d01313 TRICHLOROACETIC ACID TOPICAL d01315 COLLAGENASE	d01312	
ACID TOPICAL d01315 COLLAGENASE	d01313	
	20.010	ACID TOPICAL
TOPICAL	d01315	
		IUPICAL

d01319	HYDROQUINONE
104004	
d01321	CAPSAICIN TOPICAL
d01322	ALUMINUM CHLORIDE
	HEXAHYDRATE
	TOPICAL
d01325	ARNICA TOPICAL
d01332	HEXACHLOROPHENE
	TOPICAL
d01333	BENZALKONIUM
	CHLORIDE TOPICAL
d01335	SODIUM
	HYPOCHLORITE
10 1 0 0 0	TOPICAL
d01339	MECHLORETHAMINE
d01342	
d01344 d01345	FLOXURIDINE THIOGUANINE
d01345 d01346	FLUDARABINE
d01348	MEGESTROL
d01353	LEUPROLIDE
d01354	GOSERELIN
d01369	INTERFERON
	ALFA-2B
d01372	ALTRETAMINE
d01373	HYDROXYUREA
d01375	ALDESLEUKIN
d01376	PACLITAXEL
d01379	ASPARAGINASE
d01382	ETHANOLAMINE
401202	OLEATE
d01383	SODIUM TETRADECYL
	SULFATE
d01384	MORRHUATE
	SODIUM
d01385	BETA; CAROTENE
d01387	ALPROSTADIL
d01388	CHYMOPAPAIN
d01389	DISULFIRAM
d01394	PROCAINE
d01395	CHLOROPROCAINE
d01398	MEPIVACAINE
d01406	NALTREXONE FLUMAZENIL
d01407 d01409	PRALIDOXIME
d01409	MESNA
d01416	TRIENTINE
d01417	SUCCIMER
d01423	POTASSIUM CITRATE
d01425	FLAVOXATE
d01427	BETHANECHOL
d01433	ACETOHYDROXAMIC
	ACID
d01445	BARIUM SULFATE
d01456	IOHEXOL
d01461	IOPAMIDOL

#### 2006 NHAMCS MICRO-DATA FILE DOCUMENTATION, APPENDIX III - GENERIC LIST

d01473 DIATRIZOATE d02374 DESFLURANE d02375 PLASMA PROTEIN FRACTION d02376 ALBUMIN HUMAN d02377 DEXTRAN 1 d03001 CLADRIBINE d03007 MEASLES; MUMPS; **RUBELLA VIRUS** VACCINE d03008 INTERFERON GAMMA-1B d03041 ENOXAPARIN d03050 LORATADINE d03052 HYDROCHLORO-THIAZIDE; TRIAMTERENE d03054 AMYLASE d03061 BUTALBITAL d03071 DIPHENOXYLATE d03075 HYDROCODONE d03078 KAOLIN d03080 LIPASE d03081 MALT SOUP EXTRACT d03085 PEPSIN d03096 SODIUM BENZOATE d03098 SODIUM CITRATE d03110 DIPHTH; PERTUSSIS, ACEL; TETANUS (OBSOLETE) d03112 NEDOCROMÍL d03126 CALCITRIOL d03128 ERGOCALCIFEROL d03129 CHOLECALCIFEROL d03130 THIAMINE d03133 HYDROXO-COBALAMIN d03135 PHYTONADIONE d03137 CALCIUM; VITAMIN D d03140 MULTIVITAMIN d03148 MULTIVITAMIN, PRENATAL d03154 DOXYLAMINE d03157 PAROXETINE d03158 RIMANTADINE d03160 SUMATRIPTAN d03162 ETHANOL d03165 PIPERACILLIN; TAZOBACTAM d03166 CISAPRIDE d03169 TRIMETREXATE d03170 FELBAMATE d03171 GRANISETRON d03180 RISPERIDONE d03181 VENLAFAXINE d03182 GABAPENTIN d03183 FLUVASTATIN d03189 TORSEMIDE

d03190	OXICONAZOLE TOPICAL
d03191	TERBINAFINE
402402	
d03192	ZINC OXIDE TOPICAL
d03193	AMILORIDE;
	HYDROCHLORO-
	THIAZIDE
d03195	MICONAZOLE
	TOPICAL
d03196	GENTAMICIN
	TOPICAL
d03197	BETAMETHASONE
	TOPICAL
d03200	ERYTHROMYCIN
000200	TOPICAL
d03203	MINOXIDIL TOPICAL
d03204	
005204	
d03205	TOPICAL
003205	HYDROCORTISONE
100000	TOPICAL
d03206	TRIAMCINOLONE
	TOPICAL
d03208	METRONIDAZOLE
	TOPICAL
d03210	SELENIUM SULFIDE
	TOPICAL
d03211	CIPROFLOXACIN
	OPHTHALMIC
d03220	FLURBIPROFEN
	OPHTHALMIC
d03221	PREDNISOLONE
	OPHTHALMIC
d03222	TOBRAMYCIN
	OPHTHALMIC
d03225	PREDNICARBATE
	TOPICAL
d03227	FLUOROMETHOLONE
	OPHTHALMIC
d03228	LODOXAMIDE
	OPHTHALMIC
d03229	LEVOCABASTINE
	OPHTHALMIC
d03231	TRIPLE SULFA
	TOPICAL
d03233	VITAMIN E TOPICAL
d03238	ETHINYL ESTRADIOL;
400200	NORETHINDRONE
d03241	ETHINYL ESTRADIOL;
000271	NORGESTREL
d03242	ETHINYL ESTRADIOL;
003242	LEVONORGESTREL
d03244	CONJUGATED
005244	ESTROGENS;
	METHYLTES-
100015	TOSTERONE
d03245	ESTERIFIED
	ESTROGENS;
	METHYLTES-
	TOSTERONE

d03247	HYDROCHLORO- THIAZIDE; SPIRO-
d03250	NOLACTONE CHLOROTHIAZIDE; RESERPINE
d03253	METHYCLOTHIAZIDE; RESERPINE
d03256	HYDRALAZINE; HYDROCHLOROTHIA
d03257	ZIDE; RESERPINE HYDRALAZINE; HYDROCHLORO- THIAZIDE
d03258	ATENOLOL; CHLORTHALIDONE
d03259	BENDRO- FLUMETHIAZIDE;
d03263	NADOLOL HYDROCHLORO- THIAZIDE;
d03265	METHYLDOPA BENAZEPRIL; HYDRO-
d03266	CHLOROTHIAZIDE HYDROCHLORO- THIAZIDE;
d03280	LISINOPRIL EPHEDRINE; PHENOBARBITAL;
d03287	Theophylline Ephedrine; PB; K Iodide;
d03289	THEOPHYLLINE ACETAMINOPHEN; PSEUDOEPHEDRINE
d03292	IBUPROFEN; PSEUDOEPHEDRINE
d03293	APAP; ASA; PPA
d03296	ACETAMINOPHEN; CHLORPHEN-
d03297	IRAMINE ACETAMINOPHEN; PHENYLTOLOX- AMINE
d03298	CHLORPHEN- IRAMINE;
d03299	PSEUDOEPHEDRINE CHLORPHEN- IRAMINE; PHENYLPRO-
d03300	PANOLAMINE CHLORPHEN- IRAMINE;
d03301	PHENYLEPHRINE BROMPHENIRAMINE; PSEUDOEPHEDRINE
d03302	BROMPHENIRAMINE; PHENYLPROPANOL- AMINE

2006 NHAMCS MICRO-DATA FILE DOCUMENTATION, APPENDIX III – GENERIC LIST

PAGE 203

d03306	CHLORPHEN-	d03349	APAP;
	IRAMINE; PE;		DEXTROMETHOR-
	PHENYLTOLOX-		PHAN; DOXYLAMINE;
	AMINE		PSE
d03309	BROMPHENIRAMINE;	d03352	HYDROCODONE;
000000	PHENYLEPHRINE;	000002	PSEUDOEPHEDRINE
	PPA	403353	HYDROCODONE;
400040		005555	
003310	CHLOR-		PHENYLPROPANO-
	PHENIRAMINE; PE;	100054	LAMINE
	PPA;	d03354	DEXTROMETHOR-
	PHENYLTOLOX-		PHAN;
	AMINE		PSEUDOEPHEDRINE
d03311	BROMPHENIRAMINE;	d03357	CODEINE;
	PHENYLEPHRINE		PROMETHAZINE
d03313	CHLORPHEN-	d03359	CHLORPHEN-
	IRAMINE;		IRAMINE;
	PHENYLEPHRINE;		DEXTRO-
	PYRILAMINE		METHORPHAN
d03314		d03360	DEXTRO-
40001-	IRAMINE:	000000	METHORPHAN;
	PHENYLEPHRINE;		PROMETHAZINE
		400004	
100045	PPA	d03361	
d03315	CHLORPHEN-		IRAMINE;
	IRAMINE;		HYDROCODONE;
	PHENYLEPHRINE;		PHENYLEPHRINE
	PPA; PYRILAMINE	d03364	CODEINE;
d03316	PSEUDOEPHEDRINE;		PHENYLEPHRINE;
	TRIPROLIDINE		PROMETHAZINE
d03317	PHENYLEPHRINE;	d03368	BROMPHENIRAMINE;
	PROMETHAZINE		DEXTROMETHOR-
d03318	PHENIRAMINE; PPA;		PHAN; PSE
	PYRILAMINE	d03369	
d03319		400000	IRAMINE;
400010	CHLORPHEN-		DEXTROMETHORP;
	IRAMINE;		PHENYLEPHRINE
	PHENYLPRO-	402270	
		d03370	
-100000	PANOLAMINE		IRAMINE;
d03320	-		DEXTROMETHOR-
	CHLORPHEN-		PHAN; PSE
	IRAMINE;	d03372	BROMPHENIRAMINE;
	PSEUDOEPHEDRINE		DEXTROMETHOR-
d03331	APAP;		PHAN; PPA
	CHLORPHEN-	d03379	GUAIFENESIN;
	IRAMINE;		PSEUDOEPHEDRINE
	PHENYLEPHRINE	d03381	GUAIFENESIN;
d03338	CHLORPHEN-		PHENYLEPHRINE
	IRAMINE;	d03382	GUAIFENESIN;
	METHSCOPOL-		PHENYLPROPANOL-
	AMINE; PE		AMINE
d03340	HOMATROPINE;	403383	GUAIFENESIN;
000040	HYDROCODONE	000000	PHENYLEPHRINE;
402247			
d03347		400000	
	CHLORPHEN-	d03388	
	IRAMINE;	100000	ETHYNODIOL
	DEXTROMETHOR-	d03389	,
	PHAN; PSE		TESTOSTERONE

d03392	CHLORPHENI-
	RAMINE;
	GUAIFENESIN; PHENYLEPHRINE
d03393	CODEINE;
000000	GUAIFENESIN
d03394	CODEINE;
	IODINATED
100000	GLYCEROL
d03396	GUAIFENESIN; HYDROCODONE
d03398	CODEINE;
	GUAIFENESIN; PSE
d03400	DEXTROMETHOR-
100 100	PHAN; GUAIFENESIN
d03403	GUAIFENESIN; HYDROCODONE;
	PHENYLEPHRINE
d03404	GUAIFENESIN;
	HYDROCODONE;
100 100	PSEUDOEPHEDRINE
d03408	DEXTROMETHOR- PHAN:
	GUAIFENESIN;
	PHENYLEPHRINE
d03409	DEXTROMETHOR-
	PHAN;
	GUAIFENESIN; PSEUDOEPHEDRINE
d03411	DEXTROMETHOR-
	PHAN;
100 4 4 0	GUAIFENESIN; PPA
d03416	CHLORPHEN- IRAMINE;
	HYDROCODONE;
	PSE
d03419	CHLORPHEN-
	IRAMINE; DM;
	GUAIFENESIN; PHENYLEPHRINE
d03423	ACETAMINOPHEN;
	CODEINE
d03424	ASPIRIN; CODEINE
d03425	APAP; BUTALBITAL; CAFFEINE; CODEINE
d03426	ASA; BUTALBITAL;
400.20	CAFFEINE; CODEINE
d03428	ACETAMINOPHEN;
-100400	HYDROCODONE
d03429	ASPIRIN; HYDROCODONE
d03431	ACETAMINOPHEN;
	OXYCODONE
d03432	ASPIRIN;
d03433	OXYCODONE MEPERIDINE;
000400	PROMETHAZINE

# 2006 NHAMCS MICRO-DATA FILE DOCUMENTATION, APPENDIX III - GENERIC LIST

100404					
au3434	ACETAMINOPHEN;	d03509	ERYTHROMYCIN;	d03644	LACTOBACILLUS
	PROPOXYPHENE		SULFISOXAZOLÉ		ACIDOPHILUS
d03437	APAP; ASA;	d03510	OXYTETRACYCLINE;	d03646	LACTOBACILLUS
	CAFFEINE;		PHENAZOPYRIDINE;		ACIDOPHILUS AND
	SALICYLAMIDE		SULFAMETHIZOL		BULGARICUS
403430	APAP; ASA;	d03521	CYCLOPENTOLATE;	d03647	ISOPROPYL
000-00	CAFFEINE	000021	PHENYLEPHRINE	u000+1	ALCOHOL TOPICAL
403445	ACETAMINOPHEN;		OPHTHALMIC	403640	BENZOIN TOPICAL
003445	DIPHENHYDRAMINE	402525	GRAMICIDIN;		COLCHICINE;
402440	ASPIRIN; CAFFEINE	003525	-	003032	
				400050	
003455	APAP; BUTALBITAL;		POLYMYXIN B		CALAMINE TOPICAL
100 150	CAFFEINE	100500	OPHTHALMIC	003655	LIDOCAINE;
003456	ACETAMINOPHEN;	003536	DEXAMETHASONE;		PRILOCAINE
100 157	BUTALBITAL		TOBRAMYCIN	100050	
d03457	ASA; BUTALBITAL;		OPHTHALMIC	d03656	ETHYL CHLORIDE
	CAFFEINE	d03541	PREDNISOLONE;		TOPICAL
d03458	ASPIRIN;		SULFACETAMIDE		LECITHIN
	BUTALBITAL		SODIUM		PHENOL TOPICAL
d03459	,		OPHTHALMIC		MENTHOL TOPICAL
	DICHLORALPHEN-	d03546	HYDROCORTISONE;		METHACHOLINE
	AZONE;		PRAMOXINE	d03669	METHYL
	ISOMETHEPTENE		TOPICAL		SALICYLATE;
d03462	AMITRIPTYLINE;	d03555	HYDROCORTISONE;		MENTHOL TOPICAL
	CHLORDIAZEP-		NEOMYCIN TOPICAL	d03676	NALOXONE;
	OXIDE	d03561	BETAMETHASONE;		PENTAZOCINE
d03463	AMITRIPTYLINE;		CLOTRIMAZOLE	d03680	ASA; CITRIC ACID;
	PERPHENAZINE		TOPICAL		NA BICARB
d03468	ASPIRIN;	d03566	CAPTOPRIL;	d03682	ACETAMINOPHEN;
	METHOCARBAMOL		HYDROCHLORO-		PENTAZOCINE
d03469	ASPIRIN;		THIAZIDE	d03684	THROMBIN TOPICAL
	CARISOPRODOL	d03569	CARBINOXAMINE		ALUMINUM ACETATE
d03472	ASA; CAFFEINE;		CARBINOXAMINE;		TOPICAL
	ORPHENADRINE		PSEUDO-	d03689	CALCIUM ACETATE
d03473	CARBIDOPA;		EPHEDRINE		ALUMINUM SULFATE;
400110	LEVODOPA	d03572	CARAMIPHEN;	400000	CALCIUM ACETATE
d03474					
	ΔΙΙΙΜΙΝΙΙΜ	000072	ΡΗΕΝΎΙ ΡΡΟΡΔΝΟΙ -		ΤΟΡΙΟΑΙ
000474		000072	PHENYLPROPANOL-	403602	
000474	HYDROXIDE;		AMINE	d03692	BENZYLPENI-
000474	HYDROXIDE; MAGNESIUM		AMINE CARBETAPENTANE;	d03692	BENZYLPENI- CILLOYL;
	HYDROXIDE; MAGNESIUM HYDROXIDE		AMINE CARBETAPENTANE; CPM; EPHEDRINE;		BENZYLPENI- CILLOYL; POLYLYSINE
	HYDROXIDE; MAGNESIUM HYDROXIDE AL HYDROXIDE; MG	d03574	AMINE CARBETAPENTANE; CPM; EPHEDRINE; PHENYLEPHRINE	d03703	BENZYLPENI- CILLOYL; POLYLYSINE COAL TAR TOPICAL
	HYDROXIDE; MAGNESIUM HYDROXIDE AL HYDROXIDE; MG HYDROXIDE;	d03574	AMINE CARBETAPENTANE; CPM; EPHEDRINE; PHENYLEPHRINE CARBINOXAMINE;	d03703 d03707	BENZYLPENI- CILLOYL; POLYLYSINE COAL TAR TOPICAL ALOE VERA TOPICAL
d03478	HYDROXIDE; MAGNESIUM HYDROXIDE AL HYDROXIDE; MG HYDROXIDE; SIMETHICONE	d03574	AMINE CARBETAPENTANE; CPM; EPHEDRINE; PHENYLEPHRINE CARBINOXAMINE; DEXTROMETHOR-	d03703 d03707	BENZYLPENI- CILLOYL; POLYLYSINE COAL TAR TOPICAL ALOE VERA TOPICAL LANOLIN; MINERAL
d03478	HYDROXIDE; MAGNESIUM HYDROXIDE AL HYDROXIDE; MG HYDROXIDE; SIMETHICONE ATROPINE;	d03574 d03577	AMINE CARBETAPENTANE; CPM; EPHEDRINE; PHENYLEPHRINE CARBINOXAMINE; DEXTROMETHOR- PHAN; PSE	d03703 d03707 d03708	BENZYLPENI- CILLOYL; POLYLYSINE COAL TAR TOPICAL ALOE VERA TOPICAL LANOLIN; MINERAL OIL TOPICAL
d03478	HYDROXIDE; MAGNESIUM HYDROXIDE AL HYDROXIDE; MG HYDROXIDE; SIMETHICONE ATROPINE; HYOSCYAMINE; PB;	d03574 d03577 d03613	AMINE CARBETAPENTANE; CPM; EPHEDRINE; PHENYLEPHRINE CARBINOXAMINE; DEXTROMETHOR- PHAN; PSE PSYLLIUM; SENNA	d03703 d03707 d03708	BENZYLPENI- CILLOYL; POLYLYSINE COAL TAR TOPICAL ALOE VERA TOPICAL LANOLIN; MINERAL OIL TOPICAL TRIETHANOLAMINE
d03478 d03485	HYDROXIDE; MAGNESIUM HYDROXIDE AL HYDROXIDE; MG HYDROXIDE; SIMETHICONE ATROPINE; HYOSCYAMINE; PB; SCOPOLAMINE	d03574 d03577 d03613	AMINE CARBETAPENTANE; CPM; EPHEDRINE; PHENYLEPHRINE CARBINOXAMINE; DEXTROMETHOR- PHAN; PSE PSYLLIUM; SENNA HYOSCYAMINE;	d03703 d03707 d03708	BENZYLPENI- CILLOYL; POLYLYSINE COAL TAR TOPICAL ALOE VERA TOPICAL LANOLIN; MINERAL OIL TOPICAL TRIETHANOLAMINE POLYPEPTIDE
d03478 d03485	HYDROXIDE; MAGNESIUM HYDROXIDE AL HYDROXIDE; MG HYDROXIDE; SIMETHICONE ATROPINE; HYOSCYAMINE; PB; SCOPOLAMINE ATROPINE;	d03574 d03577 d03613	AMINE CARBETAPENTANE; CPM; EPHEDRINE; PHENYLEPHRINE CARBINOXAMINE; DEXTROMETHOR- PHAN; PSE PSYLLIUM; SENNA HYOSCYAMINE; METHENAM; M;	d03703 d03707 d03708 d03735	BENZYLPENI- CILLOYL; POLYLYSINE COAL TAR TOPICAL ALOE VERA TOPICAL LANOLIN; MINERAL OIL TOPICAL TRIETHANOLAMINE POLYPEPTIDE OLEATE OTIC
d03478 d03485 d03490	HYDROXIDE; MAGNESIUM HYDROXIDE AL HYDROXIDE; MG HYDROXIDE; SIMETHICONE ATROPINE; HYOSCYAMINE; PB; SCOPOLAMINE ATROPINE; PHENOBARBITAL	d03574 d03577 d03613	AMINE CARBETAPENTANE; CPM; EPHEDRINE; PHENYLEPHRINE CARBINOXAMINE; DEXTROMETHOR- PHAN; PSE PSYLLIUM; SENNA HYOSCYAMINE; METHENAM; M; BLUE; PHENYL	d03703 d03707 d03708 d03735	BENZYLPENI- CILLOYL; POLYLYSINE COAL TAR TOPICAL ALOE VERA TOPICAL LANOLIN; MINERAL OIL TOPICAL TRIETHANOLAMINE POLYPEPTIDE OLEATE OTIC ENALAPRIL;
d03478 d03485 d03490	HYDROXIDE; MAGNESIUM HYDROXIDE AL HYDROXIDE; MG HYDROXIDE; SIMETHICONE ATROPINE; HYOSCYAMINE; PB; SCOPOLAMINE ATROPINE; PHENOBARBITAL CHLORDIAZEPOXIDE;	d03574 d03577 d03613 d03618	AMINE CARBETAPENTANE; CPM; EPHEDRINE; PHENYLEPHRINE CARBINOXAMINE; DEXTROMETHOR- PHAN; PSE PSYLLIUM; SENNA HYOSCYAMINE; METHENAM; M; BLUE; PHENYL SALICYL	d03703 d03707 d03708 d03735	BENZYLPENI- CILLOYL; POLYLYSINE COAL TAR TOPICAL ALOE VERA TOPICAL LANOLIN; MINERAL OIL TOPICAL TRIETHANOLAMINE POLYPEPTIDE OLEATE OTIC ENALAPRIL; HYDROCHLORO-
d03478 d03485 d03490 d03492	HYDROXIDE; MAGNESIUM HYDROXIDE AL HYDROXIDE; MG HYDROXIDE; SIMETHICONE ATROPINE; HYOSCYAMINE; PB; SCOPOLAMINE ATROPINE; PHENOBARBITAL CHLORDIAZEPOXIDE; CLIDINIUM	d03574 d03577 d03613 d03618	AMINE CARBETAPENTANE; CPM; EPHEDRINE; PHENYLEPHRINE CARBINOXAMINE; DEXTROMETHOR- PHAN; PSE PSYLLIUM; SENNA HYOSCYAMINE; METHENAM; M; BLUE; PHENYL SALICYL ANTAZOLINE;	d03703 d03707 d03708 d03735 d03740	BENZYLPENI- CILLOYL; POLYLYSINE COAL TAR TOPICAL ALOE VERA TOPICAL LANOLIN; MINERAL OIL TOPICAL TRIETHANOLAMINE POLYPEPTIDE OLEATE OTIC ENALAPRIL; HYDROCHLORO- THIAZIDE
d03478 d03485 d03490 d03492	HYDROXIDE; MAGNESIUM HYDROXIDE AL HYDROXIDE; MG HYDROXIDE; SIMETHICONE ATROPINE; HYOSCYAMINE; PB; SCOPOLAMINE ATROPINE; PHENOBARBITAL CHLORDIAZEPOXIDE; CLIDINIUM BELLADONNA;	d03574 d03577 d03613 d03618	AMINE CARBETAPENTANE; CPM; EPHEDRINE; PHENYLEPHRINE CARBINOXAMINE; DEXTROMETHOR- PHAN; PSE PSYLLIUM; SENNA HYOSCYAMINE; METHENAM; M; BLUE; PHENYL SALICYL ANTAZOLINE; NAPHAZOLINE	d03703 d03707 d03708 d03735 d03740	BENZYLPENI- CILLOYL; POLYLYSINE COAL TAR TOPICAL ALOE VERA TOPICAL LANOLIN; MINERAL OIL TOPICAL TRIETHANOLAMINE POLYPEPTIDE OLEATE OTIC ENALAPRIL; HYDROCHLORO- THIAZIDE BISOPROLOL;
d03478 d03485 d03490 d03492	HYDROXIDE; MAGNESIUM HYDROXIDE AL HYDROXIDE; MG HYDROXIDE; SIMETHICONE ATROPINE; HYOSCYAMINE; PB; SCOPOLAMINE ATROPINE; PHENOBARBITAL CHLORDIAZEPOXIDE; CLIDINIUM BELLADONNA; ERGOTAMINE;	d03574 d03577 d03613 d03618 d03620	AMINE CARBETAPENTANE; CPM; EPHEDRINE; PHENYLEPHRINE CARBINOXAMINE; DEXTROMETHOR- PHAN; PSE PSYLLIUM; SENNA HYOSCYAMINE; METHENAM; M; BLUE; PHENYL SALICYL ANTAZOLINE; NAPHAZOLINE OPHTHALMIC	d03703 d03707 d03708 d03735 d03740	BENZYLPENI- CILLOYL; POLYLYSINE COAL TAR TOPICAL ALOE VERA TOPICAL LANOLIN; MINERAL OIL TOPICAL TRIETHANOLAMINE POLYPEPTIDE OLEATE OTIC ENALAPRIL; HYDROCHLORO- THIAZIDE BISOPROLOL; HYDROCHLORO-
d03478 d03485 d03490 d03492 d03495	HYDROXIDE; MAGNESIUM HYDROXIDE AL HYDROXIDE; MG HYDROXIDE; SIMETHICONE ATROPINE; HYOSCYAMINE; PB; SCOPOLAMINE ATROPINE; PHENOBARBITAL CHLORDIAZEPOXIDE; CLIDINIUM BELLADONNA; ERGOTAMINE; PHENOBARBITAL	d03574 d03577 d03613 d03618 d03620	AMINE CARBETAPENTANE; CPM; EPHEDRINE; PHENYLEPHRINE CARBINOXAMINE; DEXTROMETHOR- PHAN; PSE PSYLLIUM; SENNA HYOSCYAMINE; METHENAM; M; BLUE; PHENYL SALICYL ANTAZOLINE; NAPHAZOLINE OPHTHALMIC ACETIC ACID	d03703 d03707 d03708 d03735 d03740 d03744	BENZYLPENI- CILLOYL; POLYLYSINE COAL TAR TOPICAL ALOE VERA TOPICAL LANOLIN; MINERAL OIL TOPICAL TRIETHANOLAMINE POLYPEPTIDE OLEATE OTIC ENALAPRIL; HYDROCHLORO- THIAZIDE BISOPROLOL; HYDROCHLORO- THIAZIDE
d03478 d03485 d03490 d03492 d03495 d03496	HYDROXIDE; MAGNESIUM HYDROXIDE AL HYDROXIDE; MG HYDROXIDE; SIMETHICONE ATROPINE; HYOSCYAMINE; PB; SCOPOLAMINE ATROPINE; PHENOBARBITAL CHLORDIAZEPOXIDE; CLIDINIUM BELLADONNA; ERGOTAMINE; PHENOBARBITAL DOCUSATE; SENNA	d03574 d03577 d03613 d03618 d03620 d03623	AMINE CARBETAPENTANE; CPM; EPHEDRINE; PHENYLEPHRINE CARBINOXAMINE; DEXTROMETHOR- PHAN; PSE PSYLLIUM; SENNA HYOSCYAMINE; METHENAM; M; BLUE; PHENYL SALICYL ANTAZOLINE; NAPHAZOLINE OPHTHALMIC ACETIC ACID TOPICAL	d03703 d03707 d03708 d03735 d03740	BENZYLPENI- CILLOYL; POLYLYSINE COAL TAR TOPICAL ALOE VERA TOPICAL LANOLIN; MINERAL OIL TOPICAL TRIETHANOLAMINE POLYPEPTIDE OLEATE OTIC ENALAPRIL; HYDROCHLORO- THIAZIDE BISOPROLOL; HYDROCHLORO- THIAZIDE DEXBROM-
d03478 d03485 d03490 d03492 d03495 d03496	HYDROXIDE; MAGNESIUM HYDROXIDE AL HYDROXIDE; MG HYDROXIDE; SIMETHICONE ATROPINE; HYOSCYAMINE; PB; SCOPOLAMINE ATROPINE; PHENOBARBITAL CHLORDIAZEPOXIDE; CLIDINIUM BELLADONNA; ERGOTAMINE; PHENOBARBITAL DOCUSATE; SENNA CASANTHRANOL;	d03574 d03577 d03613 d03618 d03620 d03623 d03624	AMINE CARBETAPENTANE; CPM; EPHEDRINE; PHENYLEPHRINE CARBINOXAMINE; DEXTROMETHOR- PHAN; PSE PSYLLIUM; SENNA HYOSCYAMINE; METHENAM; M; BLUE; PHENYL SALICYL ANTAZOLINE; NAPHAZOLINE OPHTHALMIC ACETIC ACID TOPICAL ANTIPYRINE OTIC	d03703 d03707 d03708 d03735 d03740 d03744	BENZYLPENI- CILLOYL; POLYLYSINE COAL TAR TOPICAL ALOE VERA TOPICAL LANOLIN; MINERAL OIL TOPICAL TRIETHANOLAMINE POLYPEPTIDE OLEATE OTIC ENALAPRIL; HYDROCHLORO- THIAZIDE BISOPROLOL; HYDROCHLORO- THIAZIDE DEXBROM- PHENIRAMINE;
d03478 d03485 d03490 d03492 d03495 d03496 d03498	HYDROXIDE; MAGNESIUM HYDROXIDE AL HYDROXIDE; MG HYDROXIDE; SIMETHICONE ATROPINE; HYOSCYAMINE; PB; SCOPOLAMINE ATROPINE; PHENOBARBITAL CHLORDIAZEPOXIDE; CLIDINIUM BELLADONNA; ERGOTAMINE; PHENOBARBITAL DOCUSATE; SENNA CASANTHRANOL; DOCUSATE	d03574 d03577 d03613 d03618 d03620 d03623 d03624	AMINE CARBETAPENTANE; CPM; EPHEDRINE; PHENYLEPHRINE CARBINOXAMINE; DEXTROMETHOR- PHAN; PSE PSYLLIUM; SENNA HYOSCYAMINE; METHENAM; M; BLUE; PHENYL SALICYL ANTAZOLINE; NAPHAZOLINE; OPHTHALMIC ACETIC ACID TOPICAL ANTIPYRINE OTIC BENZOCAINE;	d03703 d03707 d03708 d03735 d03740 d03744 d03751	BENZYLPENI- CILLOYL; POLYLYSINE COAL TAR TOPICAL ALOE VERA TOPICAL LANOLIN; MINERAL OIL TOPICAL TRIETHANOLAMINE POLYPEPTIDE OLEATE OTIC ENALAPRIL; HYDROCHLORO- THIAZIDE BISOPROLOL; HYDROCHLORO- THIAZIDE DEXBROM- PHENIRAMINE; PSEUDOEPHEDRINE
d03478 d03485 d03490 d03492 d03495 d03496 d03498	HYDROXIDE; MAGNESIUM HYDROXIDE AL HYDROXIDE; MG HYDROXIDE; SIMETHICONE ATROPINE; HYOSCYAMINE; PB; SCOPOLAMINE ATROPINE; PHENOBARBITAL CHLORDIAZEPOXIDE; CLIDINIUM BELLADONNA; ERGOTAMINE; PHENOBARBITAL DOCUSATE; SENNA CASANTHRANOL; DOCUSATE ATROPINE;	d03574 d03577 d03613 d03618 d03620 d03623 d03624	AMINE CARBETAPENTANE; CPM; EPHEDRINE; PHENYLEPHRINE CARBINOXAMINE; DEXTROMETHOR- PHAN; PSE PSYLLIUM; SENNA HYOSCYAMINE; METHENAM; M; BLUE; PHENYL SALICYL ANTAZOLINE; NAPHAZOLINE; OPHTHALMIC ACETIC ACID TOPICAL ANTIPYRINE OTIC BENZOCAINE; CETYLPYRIDINIUM	d03703 d03707 d03708 d03735 d03740 d03744 d03751 d03752	BENZYLPENI- CILLOYL; POLYLYSINE COAL TAR TOPICAL ALOE VERA TOPICAL LANOLIN; MINERAL OIL TOPICAL TRIETHANOLAMINE POLYPEPTIDE OLEATE OTIC ENALAPRIL; HYDROCHLORO- THIAZIDE BISOPROLOL; HYDROCHLORO- THIAZIDE DEXBROM- PHENIRAMINE; PSEUDOEPHEDRINE TACROLIMUS
d03478 d03485 d03490 d03492 d03495 d03496 d03498 d03505	HYDROXIDE; MAGNESIUM HYDROXIDE AL HYDROXIDE; MG HYDROXIDE; SIMETHICONE ATROPINE; HYOSCYAMINE; PB; SCOPOLAMINE ATROPINE; PHENOBARBITAL CHLORDIAZEPOXIDE; CLIDINIUM BELLADONNA; ERGOTAMINE; PHENOBARBITAL DOCUSATE; SENNA CASANTHRANOL; DOCUSATE ATROPINE; DIFENOXIN	d03574 d03577 d03613 d03618 d03620 d03623 d03624 d03634	AMINE CARBETAPENTANE; CPM; EPHEDRINE; PHENYLEPHRINE CARBINOXAMINE; DEXTROMETHOR- PHAN; PSE PSYLLIUM; SENNA HYOSCYAMINE; METHENAM; M; BLUE; PHENYL SALICYL ANTAZOLINE; NAPHAZOLINE; OPHTHALMIC ACETIC ACID TOPICAL ANTIPYRINE OTIC BENZOCAINE; CETYLPYRIDINIUM TOPICAL	d03703 d03707 d03708 d03735 d03740 d03744 d03751 d03752	BENZYLPENI- CILLOYL; POLYLYSINE COAL TAR TOPICAL ALOE VERA TOPICAL LANOLIN; MINERAL OIL TOPICAL TRIETHANOLAMINE POLYPEPTIDE OLEATE OTIC ENALAPRIL; HYDROCHLORO- THIAZIDE BISOPROLOL; HYDROCHLORO- THIAZIDE DEXBROM- PHENIRAMINE; PSEUDOEPHEDRINE TACROLIMUS ACRIVASTINE;
d03478 d03485 d03490 d03492 d03495 d03496 d03498 d03505	HYDROXIDE; MAGNESIUM HYDROXIDE AL HYDROXIDE; MG HYDROXIDE; SIMETHICONE ATROPINE; HYOSCYAMINE; PB; SCOPOLAMINE ATROPINE; PHENOBARBITAL CHLORDIAZEPOXIDE; CLIDINIUM BELLADONNA; ERGOTAMINE; PHENOBARBITAL DOCUSATE; SENNA CASANTHRANOL; DOCUSATE ATROPINE;	d03574 d03577 d03613 d03618 d03620 d03620 d03623 d03624 d03634	AMINE CARBETAPENTANE; CPM; EPHEDRINE; PHENYLEPHRINE CARBINOXAMINE; DEXTROMETHOR- PHAN; PSE PSYLLIUM; SENNA HYOSCYAMINE; METHENAM; M; BLUE; PHENYL SALICYL ANTAZOLINE; NAPHAZOLINE OPHTHALMIC ACETIC ACID TOPICAL ANTIPYRINE OTIC BENZOCAINE; CETYLPYRIDINIUM TOPICAL BUDESONIDE NASAL	d03703 d03707 d03708 d03735 d03740 d03744 d03751 d03752 d03754	BENZYLPENI- CILLOYL; POLYLYSINE COAL TAR TOPICAL ALOE VERA TOPICAL LANOLIN; MINERAL OIL TOPICAL TRIETHANOLAMINE POLYPEPTIDE OLEATE OTIC ENALAPRIL; HYDROCHLORO- THIAZIDE BISOPROLOL; HYDROCHLORO- THIAZIDE DEXBROM- PHENIRAMINE; PSEUDOEPHEDRINE TACROLIMUS ACRIVASTINE; PSEUDOEPHEDRINE
d03478 d03485 d03490 d03492 d03495 d03496 d03498 d03505 d03506	HYDROXIDE; MAGNESIUM HYDROXIDE AL HYDROXIDE; MG HYDROXIDE; SIMETHICONE ATROPINE; HYOSCYAMINE; PB; SCOPOLAMINE ATROPINE; PHENOBARBITAL CHLORDIAZEPOXIDE; CLIDINIUM BELLADONNA; ERGOTAMINE; PHENOBARBITAL DOCUSATE; SENNA CASANTHRANOL; DOCUSATE ATROPINE; DIFENOXIN ATROPINE; DIPHENOXYLATE	d03574 d03577 d03613 d03618 d03620 d03620 d03623 d03624 d03634	AMINE CARBETAPENTANE; CPM; EPHEDRINE; PHENYLEPHRINE CARBINOXAMINE; DEXTROMETHOR- PHAN; PSE PSYLLIUM; SENNA HYOSCYAMINE; METHENAM; M; BLUE; PHENYL SALICYL ANTAZOLINE; NAPHAZOLINE OPHTHALMIC ACETIC ACID TOPICAL ANTIPYRINE OTIC BENZOCAINE; CETYLPYRIDINIUM TOPICAL BUDESONIDE NASAL PETROLATUM	d03703 d03707 d03708 d03735 d03740 d03744 d03751 d03752 d03754	BENZYLPENI- CILLOYL; POLYLYSINE COAL TAR TOPICAL ALOE VERA TOPICAL LANOLIN; MINERAL OIL TOPICAL TRIETHANOLAMINE POLYPEPTIDE OLEATE OTIC ENALAPRIL; HYDROCHLORO- THIAZIDE BISOPROLOL; HYDROCHLORO- THIAZIDE DEXBROM- PHENIRAMINE; PSEUDOEPHEDRINE TACROLIMUS ACRIVASTINE; PSEUDOEPHEDRINE BACITRACIN
d03478 d03485 d03490 d03492 d03495 d03496 d03498 d03505 d03506	HYDROXIDE; MAGNESIUM HYDROXIDE AL HYDROXIDE; MG HYDROXIDE; SIMETHICONE ATROPINE; HYOSCYAMINE; PB; SCOPOLAMINE ATROPINE; PHENOBARBITAL CHLORDIAZEPOXIDE; CLIDINIUM BELLADONNA; ERGOTAMINE; PHENOBARBITAL DOCUSATE; SENNA CASANTHRANOL; DOCUSATE ATROPINE; DIFENOXIN ATROPINE;	d03574 d03577 d03613 d03618 d03620 d03620 d03623 d03624 d03634	AMINE CARBETAPENTANE; CPM; EPHEDRINE; PHENYLEPHRINE CARBINOXAMINE; DEXTROMETHOR- PHAN; PSE PSYLLIUM; SENNA HYOSCYAMINE; METHENAM; M; BLUE; PHENYL SALICYL ANTAZOLINE; NAPHAZOLINE OPHTHALMIC ACETIC ACID TOPICAL ANTIPYRINE OTIC BENZOCAINE; CETYLPYRIDINIUM TOPICAL BUDESONIDE NASAL	d03703 d03707 d03708 d03735 d03740 d03744 d03751 d03752 d03754	BENZYLPENI- CILLOYL; POLYLYSINE COAL TAR TOPICAL ALOE VERA TOPICAL LANOLIN; MINERAL OIL TOPICAL TRIETHANOLAMINE POLYPEPTIDE OLEATE OTIC ENALAPRIL; HYDROCHLORO- THIAZIDE BISOPROLOL; HYDROCHLORO- THIAZIDE DEXBROM- PHENIRAMINE; PSEUDOEPHEDRINE TACROLIMUS ACRIVASTINE; PSEUDOEPHEDRINE

d03759	SALMETEROL	d03827	CETIRIZINE	d03908	APAP; CHLORPHEN-
d03761	LANOLIN TOPICAL	d03828	LANSOPRAZOLE		IRAMINE;
d03766	ROCURONIUM	d03829	AMLODIPINE;		DEXTROMETHOR-
d03768	OCULAR LUBRICANT		BENAZEPRIL		PHAN; PPA
d03770	EMOLLIENTS,	d03830	HYDROCHLORO-	d03911	CHLORPHEN-
	TOPICAL		THIAZIDE;		IRAMINE;
d03773	STAVUDINE		LOSARTAN		METHSCOPO-
	DOXEPIN TOPICAL	d03832	VARICELLA VIRUS		LAMINE; PSE
	FAMCICLOVIR		VACCINE	d03915	
	CHLOROTHIAZIDE;	d03833	DIVALPROEX		POTASSIUM
	METHYLDOPA		SODIUM		GUAIACOL-
d03780	DESOGESTREL	d03835	MOEXIPRIL		SULFONATE
	ETHINYL ESTRADIOL;		ACITRETIN	d03922	ACETAMINOPHEN;
000701	NORGESTIMATE		VALACYCLOVIR	000022	CAFFEINE
d03782	DESOGESTREL;		MYCOPHENOLATE	403027	BACITRACIN
000702	ETHINYL	000000	MOFETIL	000027	OPHTHALMIC
	ESTRADIOL	403841	DEXRAZOXANE	403030	AMINOPHYLLINE;
403783	BUPIVACAINE;		SEVOFLURANE	000929	AMOBARBITAL;
000700	EPINEPHRINE		ACARBOSE		EPHEDRINE
403784	EPINEPHRINE;		CARVEDILOL	403053	CITRIC ACID;
003764	LIDOCAINE		AZELAIC ACID	003952	SODIUM CITRATE
402700	CALCIPOTRIENE	u03040	TOPICAL	402060	
003700		402040		002900	DEXAMETHASONE OPHTHALMIC
400700	TOPICAL		ALENDRONATE	402074	EPINEPHRINE
003790	POTASSIUM		BICALUTAMIDE	003971	
100700	PHOSPHATE	003857	BENZOYL PEROXIDE;	-100070	OPHTHALMIC
003796	MAGNESIUM		ERYTHROMYCIN	au3973	ERYTHROMYCIN
	CHLORIDE	100050	TOPICAL	100074	OPHTHALMIC
	MAGNESIUM OXIDE		LAMIVUDINE	d03974	GENTAMICIN
d03798	MAGNESIUM		SAQUINAVIR		OPHTHALMIC
	GLUCONATE	d03861	MAGNESIUM	d03977	OFLOXACIN
	FLUVOXAMINE		LACTATE		OPHTHALMIC
d03805	DORZOLAMIDE	d03862	MAGNESIUM AMINO	d03979	SCOPOLAMINE
	OPHTHALMIC		ACIDS CHELATE		OPHTHALMIC
	ALBENDAZOLE		GLIMEPIRIDE	d03982	TETRACAINE
	METFORMIN		CALCIUM CITRATE		TOPICAL
	NEFAZODONE		AMIFOSTINE		RITONAVIR
	LAMOTRIGINE		RILUZOLE		INDINAVIR
	VINORELBINE		ANASTROZOLE	d03990	CARBAMIDE
d03811	ABCIXIMAB	d03874	CEFTIBUTEN		PEROXIDE OTIC
	DALTEPARIN		CISATRACURIUM	d03994	COLLOIDAL
d03814	RIMEXOLONE	d03879	CANNABIS		OATMEAL TOPICAL
	OPHTHALMIC		(SCHEDULE I	d03996	DIENESTROL
d03818	LORATADINE;		SUBSTANCE)		TOPICAL
	PSEUDOEPHEDRINE	d03882	CEFEPIME	d03997	EPINEPHRINE;
d03819	CONJUGATED	d03884	TROLAMINE		ETIDOCAINE
	ESTROGENS;		SALICYLATE	d03998	STERILE WATER
	MEDROXYPROGES-		TOPICAL	d04000	PIPERONYL
	TERONE	d03894	KAOLIN; PECTIN		BUTOXIDE TOPICAL
d03820	HEPATITIS A		AMYLAŚE;	d04001	PYRETHRINS
	VACCINE		CELLULASE; LIPASE;		TOPICAL
	(OBSOLETE)		PROTEASE	d04002	PIPERONYL
d03821	LOSARTAN	d03897	LACTASE		BUTOXIDE;
	FERROUS		BALSAM PERU;		PYRETHRINS
	GLUCONATE		CASTOR OIL;		TOPICAL
d03823			TRYPSIN TOPICAL	d04003	HYDROGEN
400020	POLYSACCHARIDE				PEROXIDE TOPICAL
d03825	NISOLDIPINE			d04006	DEXFENFLURAMINE
	TRAMADOL				TRANDOLAPRIL
400020				40-000	

1A d04012 TERBINAFINE d04014 TOPOTECAN d04015 ADAPALENE TOPICAL d04017 LATANOPROST OPHTHALMIC d04022 PENTAGASTRIN d04025 MIRTAZAPINE d04026 IRINOTECAN d04027 MEROPENEM d04029 NEVIRAPINE d04032 SULFACETAMIDE SODIUM; SULFUR TOPICAL d04035 AMPHETAMINE;	
d04014TOPOTECANd04015ADAPALENE TOPICALd04017LATANOPROST OPHTHALMICd04022PENTAGASTRINd04025MIRTAZAPINEd04026IRINOTECANd04027MEROPENEMd04029NEVIRAPINEd04032SULFACETAMIDE SODIUM; SULFUR TOPICAL	
d04015ADAPALENE TOPICALd04017LATANOPROST OPHTHALMICd04022PENTAGASTRINd04025MIRTAZAPINEd04026IRINOTECANd04027MEROPENEMd04029NEVIRAPINEd04032SULFACETAMIDE SODIUM; SULFUR TOPICAL	
TOPICAL d04017 LATANOPROST OPHTHALMIC d04022 PENTAGASTRIN d04025 MIRTAZAPINE d04026 IRINOTECAN d04027 MEROPENEM d04029 NEVIRAPINE d04032 SULFACETAMIDE SODIUM; SULFUR TOPICAL	
d04017 LATANOPROST OPHTHALMIC d04022 PENTAGASTRIN d04025 MIRTAZAPINE d04026 IRINOTECAN d04027 MEROPENEM d04029 NEVIRAPINE d04032 SULFACETAMIDE SODIUM; SULFUR TOPICAL	
OPHTHALMIC d04022 PENTAGASTRIN d04025 MIRTAZAPINE d04026 IRINOTECAN d04027 MEROPENEM d04029 NEVIRAPINE d04032 SULFACETAMIDE SODIUM; SULFUR TOPICAL	
d04025 MIRTAZAPINE d04026 IRINOTECAN d04027 MEROPENEM d04029 NEVIRAPINE d04032 SULFACETAMIDE SODIUM; SULFUR TOPICAL	
d04026 IRINOTECAN d04027 MEROPENEM d04029 NEVIRAPINE d04032 SULFACETAMIDE SODIUM; SULFUR TOPICAL	
d04027 MEROPENEM d04029 NEVIRAPINE d04032 SULFACETAMIDE SODIUM; SULFUR TOPICAL	
d04029 NEVIRAPINE d04032 SULFACETAMIDE SODIUM; SULFUR TOPICAL	
d04032 SULFACETAMIDE SODIUM; SULFUR TOPICAL	
SODIUM; SULFUR TOPICAL	
TOPICAL	
DEXTROAMPHET-	
AMINE	
d04037 TIMOLOL	
OPHTHALMIC	
d04038 BETAXOLOL	
OPHTHALMIC	
d04039 CARTEOLOL	
OPHTHALMIC	
d04040 FEXOFENADINE	
d04041 FOSPHENYTOIN	
d04047 MIDODRINE	
d04048 BRIMONIDINE	
OPHTHALMIC	
d04049 AMMONIUM LACTAT	E
d04050 OLANZAPINE d04051 ROPIVACAINE	
d04051 ROFIVACAINE d04052 PENTOSAN	
POLYSULFATE	
SODIUM	
d04054 PENCICLOVIR	
TOPICAL	
d04056 ZINC GLUCONATE	
d04057 ZINC SULFATE	
d04058 MELATONIN	
d04063 BUTENAFINE	
TOPICAL	
d04065 TRANDOLAPRIL;	
d04066 ALBUTEROL; IPRATROPIUM	
d04067 RETEPLASE	
d04068 AZELASTINE NASAL	
d04079 CHLORPHENIRAMIN	F
; EPINEPHRINE	_
d04090 LACTIC ACID	
TOPICAL	
d04093 HYDROCORTISONE;	
IODOQUINOL	
TOPICAL	
d04096 IMIGLUCERASE	

d04099	-
d04101	IVERMECTIN
d04102	TIZANIDINE
d04103	ZILEUTON
d04105	
d04107	AMLEXANOX
	TOPICAL
d04109	LEVOFLOXACIN
d04110	MIGLITOL
d04111	GLATIRAMER
d04112	CABERGOLINE
d04113	VALSARTAN
d04115	TOPIRAMATE
d04117	OLOPATADINE
	OPHTHALMIC
d04118	
d04120	CAFFEINE;
	ERGOTAMINE
d04121	TAMSULOSIN
d04125	IMIQUIMOD TOPICAL
d04126	ANAGRELIDE
d04134	POLYMYXIN B
	OPHTHALMIC
d04138	TAZAROTENE
	TOPICAL
d04141	HYDROCHLORO-
	THIAZIDE;
	MOEXIPRIL
d04145	PRAMIPEXOLE
d04150	BROMFENAC
d04153	PHENAZOPYRIDINE;
10 4 4 5 0	SULFISOXAZOLE
d04156	LETROZOLE
d04159	SORBITOL
d04160	SODIUM
	BIPHOSPHATE;
	SODIUM PHOSPHATE
404465	
d04165	DEXTROMETHOR-
	PHAN:
	DIPHENHYDRAMINE;
	PSE
d04168	APAP:
001100	DIPHENHYDRAMINE;
	PSEUDOEPHEDRINE
d04172	CALAMINE:
	PRAMOXINE
	TOPICAL
d04178	CALCIUM
	HYDROXIDE
	TOPICAL
d04186	PHENYLEPHRINE
	NASAL
d04190	PAPAIN TOPICAL
d04191	PAPAIN; UREA
	TOPICAL
d04200	CALCIUM
	GLYCEROPHOS-
	PHATE

d04207	UREA
d04208	SILVER NITRATE
	TOPICAL
d04209	METHOXSALEN
d04212	TOPICAL GLYCERIN TOPICAL
d04212	DOLASETRON
d04215	ROPINIROLE
d04219	LAMIVUDINE;
d04220	ZIDOVUDINE QUETIAPINE
d04220 d04221	TIAGABINE
d04222	IRBESARTAN
d04223	MOMETASONE NASAL
d04225	HYDROCODONE;
004220	IBUPROFEN
d04233	TRIAMCINOLONE
	NASAL
d04242	SODIUM CHLORIDE
	NASAL
d04244	CHARCOAL;
	SIMETHICONE
d04245	HYDROCHLORO-
	THIAZIDE;
	IRBESARTAN
d04246	GREPAFLOXACIN
d04248	METHYLCELLULOSE
d04253	ZOLMITRIPTAN
d04255	RITUXIMAB
d04256	CEFDINIR
d04257	FENOLDOPAM
d04258	CLOPIDOGREL
d04260	SIBUTRAMINE
d04261	RALOXIFENE
d04262	DACLIZUMAB
d04264	BECAPLERMIN
	TOPICAL
d04266	EPROSARTAN
d04267	REPAGLINIDE
d04269	APAP; CAFFEINE;
	DIHYDROCODEINE
d04270	FEXOFENADINE;
	PSEUDOEPHEDRINE
d04271	DICLOFENAC;
	MISOPROSTOL
d04272	AMOXICILLIN;
	CLARITHROMYCIN;
	LANSOPRAZOLE
d04274	FOMEPIZOLE
d04275	BECLOMETHASONE
	NASAL
d04276	BUDESONIDE
d04279	FLUNISOLIDE NASAL
d04282	TOLCAPONE
d04283	FLUTICASONE
	NASAL
d04284	FLUTICASONE
	TOPICAL
d04285	NARATRIPTAN

d04286	FENOFIBRATE	d
d04289		d
d04289 d04292		d
004292		-
10 4000	OPHTHALMIC	d
d04293		d
	THIAZIDE;	
	VALSARTAN	d
d04294	TOLTERODINE	d
d04295	OXYMETHOLONE	d
d04299	SILDENAFIL	
d04300	RISEDRONATE	d
d04301	BRINZOLAMIDE	d
401001	OPHTHALMIC	d
404311	CAPECITABINE	d
	PARICALCITOL	d
d04315	-	d
d04316	EPTIFIBATIDE	d
d04317		
	CANDESARTAN	d
d04323		
d04328	RIZATRIPTAN	d
d04329	SODIUM	d
	HYALURONATE	d
d04331		
d04332		
	PRAMOXINE OTIC	d
d04342		u
d04342		d
u04344		
-10.40.40	VACCINE	d
d04349		d
d04355		d
d04357		d
d04363	SEVELAMER	d
d04364	TELMISARTAN	d
d04365	ETANERCEPT	d
d04368	TANNIC ACID	d
	TOPICAL	d
d04370	INSULIN ISOPHANE	d
d04375		d
	NORETHINDRONE	d
d04376	ABACAVIR	d
	MODAFINIL	ŭ
	CELECOXIB	d
	CILOSTAZOL	d
d04387		d
	GLUCONATE	
	COMPLEX	d
d04395	CLOTRIMAZOLE	d
	TOPICAL	
d04399		d
d04400	DIMETHYL	d
	SULFOXIDE	
	TOPICAL	
d04404		d
d04405	CLAVULANATE	d
d04403 d04411	GARLIC	d
		u
d04412		4
d04412 d04413	GINSENG	d

d04416	VALERIAN
d04417	CREATINE
d04418	GLUCOSAMINE
d04419	CHONDROITIN
d04420	CHONDROITIN;
001120	GLUCOSAMINE
104400	
d04422	KAVA
d04423	GOLDENSEAL
d04425	DEHYDROEPI-
	ANDROSTERONE
d04427	LEVALBUTEROL
d04428	AMPRENAVIR
d04429	ORLISTAT
d04432	CARBONYL IRON
d04433	ROFECOXIB
d04434	ROSIGLITAZONE
d04435	DOXERCALCIFEROL
d04436	MALATHION TOPICAL
d04441	KETOTIFEN
	OPHTHALMIC
d04442	PIOGLITAZONE
d04443	
d04445	CARBETAPENTANE;
	CHLORPHENIRAMINE;
	PHENYLEPHRINE
d04446	PHENYLEPHRINE;
001110	PYRILAMINE
-104447	
d04447	GANIRELIX
d04448	RABEPRAZOLE
d04451	TEMOZOLOMIDE
d04452	ZALEPLON
d04453	SIROLIMUS
d04459	DOFETILIDE
d04460	ENTACAPONE
d04461	EXEMESTANE
d04462	OSELTAMIVIR
d04468	CLOVE
d04472	BLACK COHOSH
d04476	BILBERRY
d04483	DANDELION
d04497	ASPIRIN;
	DIPYRIDAMOLE
d04499	LEVETIRACETAM
d04500	MOXIFLOXACIN
d04503	NEDOCROMIL
	OPHTHALMIC
d04504	GATIFLOXACIN
d04506	ESTRADIOL:
	NORGESTIMATE
404507	
d04507	BEXAROTENE
d04509	HYDROCHLORO-
	THIAZIDE;
	QUINAPRIL
d04512	CEVIMELINE
d04512	OXCARBAZEPINE
d04514	PANTOPRAZOLE
d04516	ALOSETRON

d04519	MEQUINOL; TRETINOIN TOPICAL
d04523	UBIQUINONE
d04527	ZONISAMIDE
d04532	MELOXICAM
d04534	LINEZOLID
d04537	RIVASTIGMINE
d04538	INSULIN GLARGINE
d04541	AZELASTINE
	OPHTHALMIC
d04547	ATOVAQUONE;
	PROGUANIL
404570	FORMOTEROL
d04572	
d04611	FLUTICASONE;
	SALMETEROL
d04694	TENECTEPLASE
d04695	COLESEVELAM
d04696	TRIPTORELIN
d04697	INSULIN ASPART
d04700	BALSALAZIDE
d04703	GLYBURIDE;
	METFORMIN
104704	
d04704	EFLORNITHINE
	TOPICAL
d04708	ZOLEDRONIC ACID
d04711	CANDESARTAN;
	HYDROCHLORO-
	THIAZIDE
d04716	LOPINAVIR
d04717	LOPINAVIR;
	RITONAVIR
d04721	ESTRADIOL;
004721	
	MEDROXY-
	PROGESTERONE
d04725	IRON SUCROSE
d04727	ABACAVIR;
	LAMIVUDINE;
	ZIDOVUDINE
10 1707	
d04737	HYDROCHLORO-
	THIAZIDE;
	TELMISARTAN
d04740	TACROLIMUS
	TOPICAL
404742	
d04742	BENZOYL PEROXIDE;
	CLINDAMYCIN
	TOPICAL
d04743	NATEGLINIDE
d04746	PEGINTERFERON
004740	
10 17 17	ALFA-2B
d04747	ZIPRASIDONE
d04749	ESOMEPRAZOLE
d04750	GALANTAMINE
d04752	CARBINOXAMINE;
uu+102	
	HYDROCODONE;
	PSEUDOEPHEDRINE
d04753	TRAVOPROST
	OPHTHALMIC
	*

# 2006 NHAMCS MICRO-DATA FILE DOCUMENTATION, APPENDIX III - GENERIC LIST

-104754	
d04754	BIMATOPROST
	OPHTHALMIC
d04755	VALGANCICLOVIR
d04756	ALEMTUZUMAB
d04757	ALMOTRIPTAN
d04758	IMATINIB
d04759	DROSPIRENONE
d04760	DROSPIRENONE;
	ETHINYL
	ESTRADIOL
d04763	NESIRITIDE
d04764	CETIRIZINE;
	PSEUDOEPHEDRINE
d04766	ACETAMINOPHEN;
	TRAMADOL
d04767	CEFDITOREN
d04771	DARBEPOETIN ALFA
d04773	ETHINYL ESTRADIOL;
u04773	
-104774	ETONOGESTREL
d04774	TENOFOVIR
d04775	ANAKINRA
d04776	FROVATRIPTAN
d04777	DEXMETHYL-
	PHENIDATE
d04778	VALDECOXIB
d04779	ETHINYL ESTRADIOL;
	NORELGESTROMIN
d04782	BOSENTAN
d04783	ERTAPENEM
d04784	PIMECROLIMUS
	TOPICAL
d04785	DESLORATADINE
d04787	LOVASTATIN; NIACIN
d04788	DUTASTERIDE
d04790	PEGEII GRASTIM
d04790	PEGFILGRASTIM
d04797	ALFUZOSIN
d04797 d04798	ALFUZOSIN TEGASEROD
d04797 d04798 d04799	ALFUZOSIN TEGASEROD FULVESTRANT
d04797 d04798 d04799 d04801	ALFUZOSIN TEGASEROD FULVESTRANT OLMESARTAN
d04797 d04798 d04799 d04801 d04803	ALFUZOSIN TEGASEROD FULVESTRANT OLMESARTAN VORICONAZOLE
d04797 d04798 d04799 d04801	ALFUZOSIN TEGASEROD FULVESTRANT OLMESARTAN VORICONAZOLE CHARCOAL;
d04797 d04798 d04799 d04801 d04803 d04804	ALFUZOSIN TEGASEROD FULVESTRANT OLMESARTAN VORICONAZOLE CHARCOAL; SORBITOL
d04797 d04798 d04799 d04801 d04803 d04804 d04806	ALFUZOSIN TEGASEROD FULVESTRANT OLMESARTAN VORICONAZOLE CHARCOAL; SORBITOL SODIUM OXYBATE
d04797 d04798 d04799 d04801 d04803 d04804 d04806 d04811	ALFUZOSIN TEGASEROD FULVESTRANT OLMESARTAN VORICONAZOLE CHARCOAL; SORBITOL SODIUM OXYBATE OXALIPLATIN
d04797 d04798 d04799 d04801 d04803 d04804 d04806 d04811 d04812	ALFUZOSIN TEGASEROD FULVESTRANT OLMESARTAN VORICONAZOLE CHARCOAL; SORBITOL SODIUM OXYBATE OXALIPLATIN ESCITALOPRAM
d04797 d04798 d04799 d04801 d04803 d04804 d04806 d04811 d04812 d04814	ALFUZOSIN TEGASEROD FULVESTRANT OLMESARTAN VORICONAZOLE CHARCOAL; SORBITOL SODIUM OXYBATE OXALIPLATIN ESCITALOPRAM ADEFOVIR
d04797 d04798 d04799 d04801 d04803 d04804 d04806 d04811 d04812 d04814 d04815	ALFUZOSIN TEGASEROD FULVESTRANT OLMESARTAN VORICONAZOLE CHARCOAL; SORBITOL SODIUM OXYBATE OXALIPLATIN ESCITALOPRAM ADEFOVIR EPLERENONE
d04797 d04798 d04799 d04801 d04803 d04804 d04806 d04811 d04812 d04814	ALFUZOSIN TEGASEROD FULVESTRANT OLMESARTAN VORICONAZOLE CHARCOAL; SORBITOL SODIUM OXYBATE OXALIPLATIN ESCITALOPRAM ADEFOVIR EPLERENONE DEXCHLOR-
d04797 d04798 d04799 d04801 d04803 d04804 d04806 d04811 d04812 d04814 d04815	ALFUZOSIN TEGASEROD FULVESTRANT OLMESARTAN VORICONAZOLE CHARCOAL; SORBITOL SODIUM OXYBATE OXALIPLATIN ESCITALOPRAM ADEFOVIR EPLERENONE DEXCHLOR- PHENIRAMINE;
d04797 d04798 d04799 d04801 d04803 d04804 d04806 d04811 d04812 d04814 d04815	ALFUZOSIN TEGASEROD FULVESTRANT OLMESARTAN VORICONAZOLE CHARCOAL; SORBITOL SODIUM OXYBATE OXALIPLATIN ESCITALOPRAM ADEFOVIR EPLERENONE DEXCHLOR-
d04797 d04798 d04799 d04801 d04803 d04804 d04806 d04811 d04812 d04814 d04815	ALFUZOSIN TEGASEROD FULVESTRANT OLMESARTAN VORICONAZOLE CHARCOAL; SORBITOL SODIUM OXYBATE OXALIPLATIN ESCITALOPRAM ADEFOVIR EPLERENONE DEXCHLOR- PHENIRAMINE;
d04797 d04798 d04799 d04801 d04803 d04804 d04806 d04811 d04812 d04814 d04815	ALFUZOSIN TEGASEROD FULVESTRANT OLMESARTAN VORICONAZOLE CHARCOAL; SORBITOL SODIUM OXYBATE OXALIPLATIN ESCITALOPRAM ADEFOVIR EPLERENONE DEXCHLOR- PHENIRAMINE; DEXTRO-
d04797 d04798 d04799 d04801 d04803 d04804 d04806 d04811 d04812 d04814 d04815 d04818	ALFUZOSIN TEGASEROD FULVESTRANT OLMESARTAN VORICONAZOLE CHARCOAL; SORBITOL SODIUM OXYBATE OXALIPLATIN ESCITALOPRAM ADEFOVIR EPLERENONE DEXCHLOR- PHENIRAMINE; DEXTRO- METHORPHAN; PSE
d04797 d04798 d04799 d04801 d04803 d04804 d04806 d04811 d04812 d04814 d04815 d04818	ALFUZOSIN TEGASEROD FULVESTRANT OLMESARTAN VORICONAZOLE CHARCOAL; SORBITOL SODIUM OXYBATE OXALIPLATIN ESCITALOPRAM ADEFOVIR EPLERENONE DEXCHLOR- PHENIRAMINE; DEXTRO- METHORPHAN; PSE BUPRENORPHINE; NALOXONE
d04797 d04798 d04799 d04801 d04803 d04804 d04806 d04811 d04812 d04814 d04815 d04818 d04819	ALFUZOSIN TEGASEROD FULVESTRANT OLMESARTAN VORICONAZOLE CHARCOAL; SORBITOL SODIUM OXYBATE OXALIPLATIN ESCITALOPRAM ADEFOVIR EPLERENONE DEXCHLOR- PHENIRAMINE; DEXTRO- METHORPHAN; PSE BUPRENORPHINE; NALOXONE METFORMIN;
d04797 d04798 d04799 d04801 d04803 d04804 d04806 d04811 d04812 d04814 d04815 d04818 d04819 d04820	ALFUZOSIN TEGASEROD FULVESTRANT OLMESARTAN VORICONAZOLE CHARCOAL; SORBITOL SODIUM OXYBATE OXALIPLATIN ESCITALOPRAM ADEFOVIR EPLERENONE DEXCHLOR- PHENIRAMINE; DEXTRO- METHORPHAN; PSE BUPRENORPHINE; NALOXONE METFORMIN; ROSIGLITAZONE
d04797 d04798 d04799 d04801 d04803 d04804 d04806 d04811 d04812 d04814 d04815 d04818 d04819	ALFUZOSIN TEGASEROD FULVESTRANT OLMESARTAN VORICONAZOLE CHARCOAL; SORBITOL SODIUM OXYBATE OXALIPLATIN ESCITALOPRAM ADEFOVIR EPLERENONE DEXCHLOR- PHENIRAMINE; DEXTRO- METHORPHAN; PSE BUPRENORPHINE; NALOXONE METFORMIN; ROSIGLITAZONE GLIPIZIDE;
d04797 d04798 d04799 d04801 d04803 d04804 d04806 d04811 d04812 d04812 d04818 d04819 d04820 d04823	ALFUZOSIN TEGASEROD FULVESTRANT OLMESARTAN VORICONAZOLE CHARCOAL; SORBITOL SODIUM OXYBATE OXALIPLATIN ESCITALOPRAM ADEFOVIR EPLERENONE DEXCHLOR- PHENIRAMINE; DEXTRO- METHORPHAN; PSE BUPRENORPHINE; NALOXONE METFORMIN; ROSIGLITAZONE GLIPIZIDE; METFORMIN
d04797 d04798 d04799 d04801 d04803 d04804 d04806 d04811 d04812 d04812 d04818 d04819 d04820 d04823 d04823	ALFUZOSIN TEGASEROD FULVESTRANT OLMESARTAN VORICONAZOLE CHARCOAL; SORBITOL SODIUM OXYBATE OXALIPLATIN ESCITALOPRAM ADEFOVIR EPLERENONE DEXCHLOR- PHENIRAMINE; DEXTRO- METHORPHAN; PSE BUPRENORPHINE; NALOXONE METFORMIN; ROSIGLITAZONE GLIPIZIDE; METFORMIN EZETIMIBE
d04797 d04798 d04799 d04801 d04803 d04804 d04806 d04811 d04812 d04812 d04818 d04819 d04820 d04823	ALFUZOSIN TEGASEROD FULVESTRANT OLMESARTAN VORICONAZOLE CHARCOAL; SORBITOL SODIUM OXYBATE OXALIPLATIN ESCITALOPRAM ADEFOVIR EPLERENONE DEXCHLOR- PHENIRAMINE; DEXTRO- METHORPHAN; PSE BUPRENORPHINE; NALOXONE METFORMIN; ROSIGLITAZONE GLIPIZIDE; METFORMIN

d04827	ATOMOXETINE
d04828	TERIPARATIDE
d04829	TIOTROPIUM
d04831	SMALLPOX VACCINE
d04835	ADALIMUMAB
d04836	CYCLOSPORINE
004030	OPHTHALMIC
d04839	INSULIN ASPART;
401000	INSULIN ASPART
	PROTAMINE
d04844	CAMPHOR;
401011	MENTHOL TOPICAL
d04849	ELETRIPTAN
d04851	ROSUVASTATIN
d04853	ENFUVIRTIDE
d04855	APREPITANT
d04856	BOTULISM
004000	ANTITOXIN
d04859	GEMIFLOXACIN
d04861	DIPHENHYDRAMINE;
00-001	PHENYLEPHRINE
d04862	BROMPHENIRAMINE:
u04002	DM; GUAIFENESIN;
	PSE
d04864	CARBETAPENTANE;
004004	PSEUDOEPHEDRINE
d04868	GEFITINIB
d04871	BORTEZOMIB
d04871	ATROPINE; CPM;
u04072	HYOSCYAMINE; PE;
	SCOPOLAMINE
d04877	CARBIDOPA;
u04077	ENTACAPONE;
	LEVODOPA
d04878	HYDROCHLORO-
u04070	THIAZIDE;
	OLMESARTAN
d04880	BROMPHENIRAMINE;
u04000	HYDROCODONE;
	PSEUDOEPHEDRINE
d04881	OMALIZUMAB
d04882	ATAZANAVIR
d04882	
	EMTRICITABINE PALONOSETRON
d04888 d04889	MIGLUSTAT
d04893 d04894	VARDENAFIL DAPTOMYCIN
	TADALAFIL
d04896	
d04898	
d04899	OPHTHALMIC MEMANTINE
d04899 d04901	FOSAMPRENAVIR
d04901 d04905	BROMPHENIRAMINE;
u04903	DEXTROMETHORPH
	; PHENYLEPHRINE
d04913	; PHENYLEPHRINE LANSOPRAZOLE;
004913	NAPROXEN
d04915	SERTACONAZOLE
u04910	TOPICAL
	IONOAL

d04917	FLUOXETINE;
d04920	OLANZAPINE PNEUMOCOCCAL 7;
d04933	VALENT VACCINE TELITHROMYCIN
d04986	ACAMPROSATE
d05044	BETAMETHASONE;
	CALCIPOTRIENE
	TOPICAL
d05047	PEMETREXED
d05048	AMLODIPINE;
000040	ATORVASTATIN
405404	CETUXIMAB
d05101	
d05214	BEVACIZUMAB
d05217	MYCOPHENOLIC
	ACID
d05218	CINACALCET
d05227	ALGINIC ACID
d05234	HYALURONAN
d05294	RIFAXIMIN
d05338	DIPHTHERIA:
000000	TETANUS TOXOIDS
10 50 40	
d05348	EZETIMIBE;
	SIMVASTATIN
d05350	POLYETHYLENE
	GLYCOL 3350
d05351	APAP;
	PHENYLTOLOX-
	AMINE;
	SALICYLAMIDE
d05352	EMTRICITABINE:
d05352	EMTRICITABINE; TENOFOVIR
	TENOFOVIR
d05352 d05354	TENOFOVIR ABACAVIR;
d05354	TENOFOVIR ABACAVIR; LAMIVUDINE
d05354 d05355	TENOFOVIR ABACAVIR; LAMIVUDINE DULOXETINE
d05354 d05355 d05357	TENOFOVIR ABACAVIR; LAMIVUDINE DULOXETINE IBANDRONATE
d05354 d05355	TENOFOVIR ABACAVIR; LAMIVUDINE DULOXETINE IBANDRONATE CARBETAPENTANE;
d05354 d05355 d05357 d05361	TENOFOVIR ABACAVIR; LAMIVUDINE DULOXETINE IBANDRONATE CARBETAPENTANE; GUAIFENESIN
d05354 d05355 d05357	TENOFOVIR ABACAVIR; LAMIVUDINE DULOXETINE IBANDRONATE CARBETAPENTANE; GUAIFENESIN LANTHANUM
d05354 d05355 d05357 d05361 d05395	TENOFOVIR ABACAVIR; LAMIVUDINE DULOXETINE IBANDRONATE CARBETAPENTANE; GUAIFENESIN LANTHANUM CARBONATE
d05354 d05355 d05357 d05361	TENOFOVIR ABACAVIR; LAMIVUDINE DULOXETINE IBANDRONATE CARBETAPENTANE; GUAIFENESIN LANTHANUM CARBONATE CHLORPHEN-
d05354 d05355 d05357 d05361 d05395	TENOFOVIR ABACAVIR; LAMIVUDINE DULOXETINE IBANDRONATE CARBETAPENTANE; GUAIFENESIN LANTHANUM CARBONATE CHLORPHEN- IRAMINE:
d05354 d05355 d05357 d05361 d05395	TENOFOVIR ABACAVIR; LAMIVUDINE DULOXETINE IBANDRONATE CARBETAPENTANE; GUAIFENESIN LANTHANUM CARBONATE CHLORPHEN- IRAMINE; METHSCO-
d05354 d05355 d05357 d05361 d05395	TENOFOVIR ABACAVIR; LAMIVUDINE DULOXETINE IBANDRONATE CARBETAPENTANE; GUAIFENESIN LANTHANUM CARBONATE CHLORPHEN- IRAMINE; METHSCO- POLAMINE
d05354 d05355 d05357 d05361 d05395	TENOFOVIR ABACAVIR; LAMIVUDINE DULOXETINE IBANDRONATE CARBETAPENTANE; GUAIFENESIN LANTHANUM CARBONATE CHLORPHEN- IRAMINE; METHSCO- POLAMINE ERLOTINIB
d05354 d05355 d05357 d05361 d05395 d05411	TENOFOVIR ABACAVIR; LAMIVUDINE DULOXETINE IBANDRONATE CARBETAPENTANE; GUAIFENESIN LANTHANUM CARBONATE CHLORPHEN- IRAMINE; METHSCO- POLAMINE
d05354 d05355 d05357 d05361 d05395 d05411 d05412	TENOFOVIR ABACAVIR; LAMIVUDINE DULOXETINE IBANDRONATE CARBETAPENTANE; GUAIFENESIN LANTHANUM CARBONATE CHLORPHEN- IRAMINE; METHSCO- POLAMINE ERLOTINIB
d05354 d05355 d05357 d05361 d05395 d05411 d05412 d05413 d05414	TENOFOVIR ABACAVIR; LAMIVUDINE DULOXETINE IBANDRONATE CARBETAPENTANE; GUAIFENESIN LANTHANUM CARBONATE CHLORPHEN- IRAMINE; METHSCO- POLAMINE ERLOTINIB SOLIFENACIN NATALIZUMAB
d05354 d05355 d05357 d05361 d05395 d05411 d05412 d05413	TENOFOVIR ABACAVIR; LAMIVUDINE DULOXETINE IBANDRONATE CARBETAPENTANE; GUAIFENESIN LANTHANUM CARBONATE CHLORPHEN- IRAMINE; METHSCO- POLAMINE ERLOTINIB SOLIFENACIN NATALIZUMAB IBUPROFEN;
d05354 d05355 d05361 d05395 d05411 d05412 d05413 d05414 d05415	TENOFOVIR ABACAVIR; LAMIVUDINE DULOXETINE IBANDRONATE CARBETAPENTANE; GUAIFENESIN LANTHANUM CARBONATE CHLORPHEN- IRAMINE; METHSCO- POLAMINE ERLOTINIB SOLIFENACIN NATALIZUMAB IBUPROFEN; OXYCODONE
d05354 d05355 d05357 d05361 d05395 d05411 d05412 d05413 d05414	TENOFOVIR ABACAVIR; LAMIVUDINE DULOXETINE IBANDRONATE CARBETAPENTANE; GUAIFENESIN LANTHANUM CARBONATE CHLORPHEN- IRAMINE; METHSCO- POLAMINE ERLOTINIB SOLIFENACIN NATALIZUMAB IBUPROFEN; OXYCODONE CARBINOXAMINE;
d05354 d05355 d05361 d05395 d05411 d05412 d05413 d05413 d05415 d05419	TENOFOVIR ABACAVIR; LAMIVUDINE DULOXETINE IBANDRONATE CARBETAPENTANE; GUAIFENESIN LANTHANUM CARBONATE CHLORPHEN- IRAMINE; METHSCO- POLAMINE ERLOTINIB SOLIFENACIN NATALIZUMAB IBUPROFEN; OXYCODONE CARBINOXAMINE; PHENYLEPHRINE
d05354 d05355 d05357 d05395 d05411 d05411 d05412 d05413 d05413 d05419 d05421	TENOFOVIR ABACAVIR; LAMIVUDINE DULOXETINE IBANDRONATE CARBETAPENTANE; GUAIFENESIN LANTHANUM CARBONATE CHLORPHEN- IRAMINE; METHSCO- POLAMINE ERLOTINIB SOLIFENACIN NATALIZUMAB IBUPROFEN; OXYCODONE CARBINOXAMINE; PHENYLEPHRINE ESZOPICLONE
d05354 d05355 d05357 d05361 d05395 d05411 d05412 d05413 d05413 d05415 d05419 d05421	TENOFOVIR ABACAVIR; LAMIVUDINE DULOXETINE IBANDRONATE CARBETAPENTANE; GUAIFENESIN LANTHANUM CARBONATE CHLORPHEN- IRAMINE; METHSCO- POLAMINE ERLOTINIB SOLIFENACIN NATALIZUMAB IBUPROFEN; OXYCODONE CARBINOXAMINE; PHENYLEPHRINE ESZOPICLONE DARIFENACIN
d05354 d05355 d05357 d05395 d05411 d05411 d05412 d05413 d05413 d05419 d05421	TENOFOVIR ABACAVIR; LAMIVUDINE DULOXETINE IBANDRONATE CARBETAPENTANE; GUAIFENESIN LANTHANUM CARBONATE CHLORPHEN- IRAMINE; METHSCO- POLAMINE ERLOTINIB SOLIFENACIN NATALIZUMAB IBUPROFEN; OXYCODONE CARBINOXAMINE; PHENYLEPHRINE ESZOPICLONE DARIFENACIN LOTEPREDNOL;
d05354 d05355 d05357 d05361 d05395 d05411 d05412 d05413 d05413 d05415 d05419 d05421	TENOFOVIR ABACAVIR; LAMIVUDINE DULOXETINE IBANDRONATE CARBETAPENTANE; GUAIFENESIN LANTHANUM CARBONATE CHLORPHEN- IRAMINE; METHSCO- POLAMINE ERLOTINIB SOLIFENACIN NATALIZUMAB IBUPROFEN; OXYCODONE CARBINOXAMINE; PHENYLEPHRINE ESZOPICLONE DARIFENACIN LOTEPREDNOL; TOBRAMYCIN
d05354 d05355 d05357 d05361 d05395 d05411 d05412 d05413 d05413 d05415 d05419 d05421 d05422 d05425	TENOFOVIR ABACAVIR; LAMIVUDINE DULOXETINE IBANDRONATE CARBETAPENTANE; GUAIFENESIN LANTHANUM CARBONATE CHLORPHEN- IRAMINE; METHSCO- POLAMINE ERLOTINIB SOLIFENACIN NATALIZUMAB IBUPROFEN; OXYCODONE CARBINOXAMINE; PHENYLEPHRINE ESZOPICLONE DARIFENACIN LOTEPREDNOL; TOBRAMYCIN OPHTHALMIC
d05354 d05355 d05357 d05361 d05395 d05411 d05412 d05413 d05413 d05419 d05421 d05422 d05425 d05436	TENOFOVIR ABACAVIR; LAMIVUDINE DULOXETINE IBANDRONATE CARBETAPENTANE; GUAIFENESIN LANTHANUM CARBONATE CHLORPHEN- IRAMINE; METHSCO- POLAMINE ERLOTINIB SOLIFENACIN NATALIZUMAB IBUPROFEN; OXYCODONE CARBINOXAMINE; PHENYLEPHRINE ESZOPICLONE DARIFENACIN LOTEPREDNOL; TOBRAMYCIN OPHTHALMIC INSULIN DETEMIR
d05354 d05355 d05357 d05361 d05395 d05411 d05412 d05413 d05413 d05415 d05419 d05421 d05422 d05425	TENOFOVIR ABACAVIR; LAMIVUDINE DULOXETINE IBANDRONATE CARBETAPENTANE; GUAIFENESIN LANTHANUM CARBONATE CHLORPHEN- IRAMINE; METHSCO- POLAMINE ERLOTINIB SOLIFENACIN NATALIZUMAB IBUPROFEN; OXYCODONE CARBINOXAMINE; PHENYLEPHRINE ESZOPICLONE DARIFENACIN LOTEPREDNOL; TOBRAMYCIN OPHTHALMIC INSULIN DETEMIR DESLORATADINE;
d05354 d05355 d05357 d05361 d05395 d05411 d05412 d05413 d05413 d05419 d05421 d05422 d05425 d05436	TENOFOVIR ABACAVIR; LAMIVUDINE DULOXETINE IBANDRONATE CARBETAPENTANE; GUAIFENESIN LANTHANUM CARBONATE CHLORPHEN- IRAMINE; METHSCO- POLAMINE ERLOTINIB SOLIFENACIN NATALIZUMAB IBUPROFEN; OXYCODONE CARBINOXAMINE; PHENYLEPHRINE ESZOPICLONE DARIFENACIN LOTEPREDNOL; TOBRAMYCIN OPHTHALMIC INSULIN DETEMIR DESLORATADINE; PSEUDOEPHEDRINE
d05354 d05355 d05357 d05361 d05395 d05411 d05412 d05413 d05413 d05419 d05421 d05422 d05425 d05436	TENOFOVIR ABACAVIR; LAMIVUDINE DULOXETINE IBANDRONATE CARBETAPENTANE; GUAIFENESIN LANTHANUM CARBONATE CHLORPHEN- IRAMINE; METHSCO- POLAMINE ERLOTINIB SOLIFENACIN NATALIZUMAB IBUPROFEN; OXYCODONE CARBINOXAMINE; PHENYLEPHRINE ESZOPICLONE DARIFENACIN LOTEPREDNOL; TOBRAMYCIN OPHTHALMIC INSULIN DETEMIR DESLORATADINE;

d05508 d05529 d05537 d05538 d05540	PREGABALIN EXENATIDE TIGECYCLINE TIPRANAVIR HYDRALAZINE; ISOSORBIDE	d05646 d05647 d05657	SACCHAROMYCES BOULARDII LYO FERRIC SUBSULFATE TOPICAL M; CRESYL ACETATE	d05719 d05736 d05748 d05776 d05813	RANOLAZINE LUBIPROSTONE BREWER'S YEAST IODINE ZOSTER VACCINE LIVE
	DINITRATE	400001	OTIC	d05817	HUMAN
d05578	RAMELTEON	d05659	DEFERASIROX		PAPILLOMAVIRUS
d05612	RASAGILINE	d05668	CARBINOXAMINE;		VACCINE
d05633	NEPAFENAC		HYDROCODONE;	d05847	EFAVIRENZ;
	OPHTHALMIC		PHENYLEPHRINE		EMTRICITABINE;
d05635	METFORMIN;	d05674	GLIMEPIRIDE;		TENOFOVIR
	PIOGLITAZONE		ROSIGLITAZONE	d05866	GUAR GUM
d05645	MEASLES; MUMPS;	d05691	SORAFENIB	d05896	SITAGLIPTIN
	RUBELLA;	d05696	LENALIDOMIDE	d05963	COAGULATION
	VARICELLA VIRUS	d05702	METHYLSULFONYL-		FACTOR IX
	VACCINE		METHANE	d06848	LUTEIN
		d05717	SUNITINIB		

#### B. DRUG ENTRY CODES AND NAMES IN NUMERIC ORDER

 Proce 210
 2006 NFMINDS MICRO-DATAFILE DUCUMENTATION, APPENDIA III - GENERAC LIST

 B. DRUG ENTRY CODES AND NAMES IN NUMERIC ORDER
 00200
 MEPERIDINE HCL
 00200

 00000 TAMIFLU
 00100 A.S.A.
 00100 A.S.A.
 00200 MEPERIDINE HCL
 00203 SALINEX

 00000 NEPHROLAS
 00100 A.S.A.
 00100 A.S.A.
 00200 MEPERIDINE HCL
 00203 SALINEX

 00000 NEPHROLAS
 00100 A.S.A.
 00100 A.S.A.
 00200 MEPERIDINE HCL
 00203 SALINEX

 00000 NEPHROLAS
 00106 A.S.A. & CODEINE
 00208 GELEVAB
 00208 GELEVAB
 002018 GELEVAB

 00013 MYCOPHENOLATE
 00107 ROBIGLITAZONE
 00211 DECONINE HCL
 00221 ACCTARE
 INFARLENDAR

 00022 ACCTINALS
 00113 ANDROGEL
 00211 DECONINE HCL
 00221 DECONINE HCL
 00223 ACCTINE
 00223 ACCTARE
 INFARLENDAR

 00022 EXCERNI MIGRAINE
 00122 GATORADE
 00133 CONTRE
 00233 CONCERTA
 00233 CONCERTA

 00023 EXCERNI MIGRAINE
 00130 ACAINE
 00230 CONTREX
 00230 CONCERTA
 00230 CONCERTA

<page-header>2000 NUMBERS DECONCIDENT CONCIDENT CONCIDENT CONCIDENT CONCIDENT CONCIDENT0000 CONCIDENT

W/HYDROCORTISONE

01211 PULMICORT RESPULES01295 AMARIL D01212 ESTROVAN01296 PAPAIN

 PAGE 212
 2009 NHAMINGS MICRO-DATA FILE DOCUMENTATION – APPENDIX III, DRUG ENTRY LIST

 01211
 FULINICORT RESPULES
 01295
 AMARIL D
 0239
 EXTRA STRENGT

 01212
 ESTROVAN
 01295
 PARAIN
 0239
 EXTRA STRENGT

 01212
 ESTROVAN
 01295
 PARAIN
 0239
 EXTRA STRENGT

 01222
 ESTROVAN
 01295
 PARAIN
 0239
 EXTRA STRENGT

 01224
 EDECOMETROPIN
 01305
 PARAIN
 0230
 EXTRA STRENGT

 01233
 RAPANUNE
 01305
 MALEATE
 0230
 EXTRA STRENGT

 01233
 RAPANUNE
 01305
 MARCATE
 0230
 EXTRA STRENGT

 01234
 RALAINSR
 01310
 FAGE ALINE
 0230
 EXTRA STRENGT

 01234
 RETAINNSR
 01310
 FAGE ALINE
 0230
 EXTER STRENGT

 01235
 ALUMINUM MAGNESUM
 01316
 FAMEANNE
 0230
 EXTER STRENGT

 01234
 RATAINSR
 01305
 AMARINGENVA
 0200
 EXTER STRENGT

02036 EXTRA STRENGTH

<page-header>2000 NUMBER SUBJOACTION CONCENTION APPENDIX II - DRUGTING03317 XLC MARK03318 INFANING03319 INFANING03319 INFANING03319 INFANING03319 INFANING03319 INFANING03319 INFANING03310 INFANING03310 INFANING03311 INFANING03311 INFANING03311 INFANING03311 INFANING03311 INFANING03311 INFANING03311 INFANING03311 INFANING03312 INFANING03312 INFANING03313 INFANING03314 INFANING03315 INFANING03315 INFANING03316 INFANING03317 INFANING03318 INFANING03318 INFANING03319 INFANING03310 INFANING03310 INFANING03310 INFANING03311 INFANING03311 INFANING03311 INFANING03312 INFANING03312 INFANING03313 INFANING03313 INFANING03314 INFANING03315 INFANING03

 2000 HUMANC SURCE CALCULATE LOCULATION APPENDIX I - DURING I
 5231
 LEVEL N

 04085
 SANCURA
 0519
 ALEX
 5231
 LEVEL N

 04095
 SANCURA
 0519
 ALEX
 5231
 LEVEL N

 04095
 SANCURA
 0519
 ALEX
 523
 LEVEL N
 523
 LEVEL N
 524
 LAUEX NO

 05101
 PLEFERIN
 0513
 LAUEX NO
 513
 LAUEX NO
 524
 LAUEX NO
 524

<page-header>202021202044000 CARACTERISTIC CONCENTRATION - APPOINT I, DURATION OF A DESCRIPTION OF A DESCRIPTION

<page-header>2000 NHAME'S MICRO-DATA FILE DOCUMENTATION APPENDIX II - DRUG CHIRD STATE0142CALONING0142CALONING0143CALONING0144FICURIDOUST0145CALONING0146CALONING0147CALONING0148CALONING0149CALONING</t

 2004 NHAMES MICRO-DATA FILE DOCUMENTATION, APPENDIX III - DRUGTERY III
 11845
 ESTADIX

 09865
 DIPHENNYDRAMINE HCL SYRUP
 10800
 DURICEF
 11845
 ESTADIX

 09870
 DIPHENNYDRAMINE HCL ZCA
 10805
 EVRENUM
 11845
 ESTADIX

 09870
 DIPHENNYDRAMINE HCL ZCA
 10905
 EVRENUM
 11845
 ESTADIX

 09800
 DIPHENNYDRAMINE HCL ZCA
 10905
 EVRENUM
 11845
 ESTADIX

 09800
 DIPHENNYDRAMINE HCL ZCA
 10905
 EVRENUM
 11845
 ESTADIX

 09800
 DIPHENNYDRAMINE HCL ZCA
 10905
 EVRENUM
 11915
 EURADIX

 09800
 DIPHENNYDRAMINE HCL ZCA
 10905
 EVRENUM
 11915
 EURADIX

 09900
 DIPHENDX
 11905
 ECATIN
 11915
 EURADIX

 09900
 DIPHENDX
 11905
 EURADIX
 11915
 EURADIX

 09900
 DIPHENDX
 11915
 EURADIX
 11915
 EURADIX

 09900
 DIPHENDX
 11915
 EURADIX
 11915
 EU

13835GUAIFENESIN15025HYDROPHILIC OINTMENT16268K-TAB13838GUAIFENESIN W/CODEINE15040HYDROQUINONE16270K-Y STERILE13858GUIAPHED15060HYDROXOCOBALAMIN16335KAOLIN13875GUIATUSS15070HYDROXYCHLOROQUINE16335KAOLIN13880GUIATUSS A.C. SYRUP15090HYDROXYUREA16365KAOPECTATE13885GUIATUSSIN15100HYDROXYZINE16440KAY CIEL13930GYNE-LOTRIMIN15155HYPAQUE16455KAYEXALATE13990HALCION15190HYPER-TET16475KEFLEX14000HALOPERIDOL15305HYTONE16495KEMADRIN

 PAGE 222
 2006 NHAMCS MICRO-DATA FILE DOCUMENTATION – APPENDIX III, DRUG ENTRY LI

 12763
 FLUOROUTACIL
 14080
 HC
 15307
 HYTRIN

 12770
 FLUOROUTACIL
 14091
 HEALON
 15320
 HYTRIN

 12780
 FLUPA-DROPS
 14191
 HEALON
 15320
 HYTRIN

 12780
 FLUPA-DROPS
 14191
 HEP-LOCK
 15345
 H-RON

 12815
 FLURESS
 14217
 HEP-LOCK
 15495
 ILOTYCIN

 12830
 FLUZONE
 14224
 HEPARIN
 15525
 IMMURE SERUM

 12835
 FORMULA #81
 HETAR
 1000K
 SOLITON
 15535
 IMMURE SERUM

 12845
 FORMULA #81
 HETAR
 14440
 HIPREX
 15545
 IMMUNE SERUM

 12895
 FORMULA #81
 HETAR
 15545
 IMMUNE SERUM
 GLOBULIN

 12895
 FORMULA #81
 HETAR
 15555
 IMMUNE SERUM

 12805
 FORTAZ
 H4440
 HIPREX
 15556
 IMMUNE SERUM

 12805
 <td

LUBRICATING JELLY

<page-header>2000 MARCY CARACTER DECOUNTERTION APPENDIX DECOUNT OF CONSTRUCT2000 2000111

<page-header>1702 2000 MARCACOUNCACULACIONACIONAL OPENCINAL DURADA CUENTRAL DE CONCENTRAL DE CON

<page-header>2000 MARCES CONCENTRATION2000 MARCES2000 MARCES</th

<page-header>

 2000 NUMALINON CARCONE
 2002 SULFAMENTION CONCURSIONS
 2003 TEALSON

 2005 SULL ADDITION SULFACTOR
 2003 SULFAMENTION CONCURSIONS
 2003 TEALSON

 2005 SULL ADDITION SULFACTOR
 2003 SULFAMENTION CONCURSIONS
 2003 TEALSON

 2005 SULL ADDITION SULFACTOR
 2003 SULFAMENTION CONCURSIONS
 2003 TEALSON

 2005 SULL ADDITION SULFACTOR
 2003 SULFAMENTION
 2003 TEALSON

 2005 SULFAMENTION CARCONATE
 2003 SULFAMENTION
 2003 TEALSON

 2005 SULFAMENTION CARCONATE
 2005 SULFAMENTION
 2005 SULFAMENTION

 2005 SULMA ELEVANDE
 2005 SULFAMENTION
 2005 SULFAMENTION

 2005 SULMA SULFACETAR
 2005 SULFAMENTION
 2005 SULFAMENTION

 2005 SULMA SULFACETAR
 2005 SULFAMENTION
 2005 SULFAMENTION

 2005 SULMA SULFACETAR
 2005 SULFAMENTION
 2005 SULFAMENTION

 2005 SULMA SULF

<page-header>1002 2000 MARCE CONCENTION CONCENTION

 2000 NUMBERS DIRCIPCIENCE
 11880
 TRI-VI-FLOR WIRDON
 5000 SUBJECT

 35500
 DRIATINE
 11880
 TRI-VI-FLOR WIRDON
 5000 SUBJECT

 35500
 TRI-VI-FLOR WIRDON
 11880
 TRI-VI-FLOR WIRDON
 5000 SUBJECT

 35500
 TRI-VI-FLOR WIRDON
 11880
 TRI-VI-FLOR WIRDON
 5000 SUBJECT

 35500
 TRI-VI-FLOR WIRDON
 11800
 TRI-VI-FLOR WIRDON
 5000 SUBJECT

 35500
 TRI-VI-FLOR WIRDON
 11800
 TRI-VI-FLOR WIRDON
 5000 SUBJECT

 35500
 TRI-VI-FLOR WIRDON
 11800
 TRI-VI-FLOR WIRDON
 5000 SUBJECT

 35500
 TRI-VI-FLOR WIRDON
 11800 SUBJECT
 5000 SUBJECT
 5000 SUBJECT

 36500
 TRI-VI-FLOR WIRDON
 11800 SUBJECT
 5000 SUBJECT
 5000 SUBJECT

 36500
 TRI-VI-FLOR WIRDON
 11800 SUBJECT
 5000 SUBJECT
 5000 SUBJECT

 36500
 TRI-VI-FLOR WIRDON
 11800 SUBJECT
 5000 SUBJECT
 5000 SUBJECT

 36500
 TRI-VI-FLOR WIRDON
 11800 SUBJECT
 5000 SUBJECT
 5000 SUBJECT

 36500
 TRI-VI-FLOR

<page-header>PAGE 2302006 NHAMECS MICRO-DATA FILE DOCUMENTATION - APPENDIX II, DRUG ENTRY LIST1150PERIPHERAL, NUTRITION<br/>WEL-DIOW89068PROCHLORPERAZINE<br/>EDISIDATE<br/>BODOLLORPERAZINE<br/>EDISIDATE<br/>BODOLLORPERAZINE<br/>EDISIDATE<br/>BODOLLORPERAZINE<br/>EDISIDATE<br/>BODOLLORPERAZINE<br/>EDISIDATE<br/>BODOLLORPERAZINE<br/>BODOLLORPERAZINE<br/>BODOLLORPERAZINE<br/>BODOLLORPERAZINE<br/>BODOLLORPERAZINE<br/>BODOLLORPERAZINE<br/>BODOLLORPERAZINE<br/>BODOLLORPERAZINE<br/>BODOLLORPERAZINE<br/>BODOLLORPERAZINE<br/>BODOLLORPERAZINE<br/>BODOLLORPERAZINE<br/>BODOLLORPERAZINE<br/>BODOLLORPERAZINE<br/>BODOLLORPERAZINE<br/>BODOLLORPERAZINE<br/>BODOLLORPERAZINE<br/>BODOLLORPERAZINE<br/>BODOLLORPERAZINE<br/>BODOLLORPERAZINE<br/>BODOLLORPERAZINE<br/>BODOLLORPERAZINE<br/>BODOLLORPERAZINE<br/>BODOLLORPERAZINE<br/>BODOLLORPERAZINE<br/>BODOLLORPERAZINE<br/>BODOLLORPERAZINE<br/>BODOLLORPERAZINE<br/>BODOLLORPERAZINE<br/>BODOLLORPERAZINE<br/>BODOLLORPERAZINE<br/>BODOLLORPERAZINE<br/>BODOLLORPERAZINE<br/>BODOLLORPERAZINE<br/>BODOLLORPERAZINE<br/>BODOLLORPERAZINE<br/>BODOLLORPERAZINE<br/>BODOLLORPERAZINE<br/>BODOLLORPERAZINE<br/>BODOLLORPERAZINE<br/>BODOLLORPERAZINE<br/>BODOLLORPERAZINE<br/>BODOLLORPERAZINE<br/>BODOLLORPERAZINE<br/>BODOLLORPERAZINE<br/>BODOLLORPERAZINE<br/>BODOLLORPERAZINE<br/>BODOLLORPERAZINE<br/>BODOLLORPERAZINE<br/>BODOLLORPERAZINE<br/>BODOLLORPERAZINE<br/>BODOLLORPERAZINE<br/>BODOLLORPERAZINE<br/>BODOLLORPERAZINE<br/>BODOLLORPERAZINE<br/>BODOLLORPERAZINE<br/>BODOLLORPERAZINE<br/>BODOLLORPERAZINE<br/>BODOLLORPERAZINE<br/>BODOLLORPERAZINE<br/>BODOLLORPERAZINE<br/>BODOLLORPERAZINE<br/>BODOLLORPERAZINE<br/>BODOLLORPERAZINE<br/>BODOLLORPERAZINE<br/>BODOLLORPERAZINE<br/>BODOLLORPERAZINE<br/>BODOLLORPERAZINE<br/>BODOLLORPERAZINE<br/>BODOLLORPERAZINE<br/>BODOLLORPERAZINE<br/>BODOLLORPERAZINE<br/>BODOLLORPERAZINE<br/>BODOLLORPERAZINE<br/>BODOLLORPERAZINE<br/>BODOLLORPERAZINE<br/>BODOLLORPERAZINE<br/>BODOLLORPERAZINE<br/>BODOLLORPERAZINE<br/>BODOLLORPERAZINE< 61165 PERIPHERAL NUTRITION 89068 PROCHLORPERAZINE 91085 KETOCONAZOLE

 2000 NUMBER SUBJECT
 2159 MINITRAN (ALMERS)
 9077 HISTUSSIN (ALMERS)
 9078 HISTUSSIN (ALMERS)

 9000 PROSINUSSIN (ALMERS)
 9159 MINITRAN (ALMERS)
 9078 HISTUSSIN (ALMERS)
 9078 HISTUSSIN (ALMERS)

 9000 PROSINUSSIN (ALMERS)
 9159 MINITRAN (ALMERS)
 9078 HISTUSSIN (ALMERS)
 9078 HISTUSSIN (ALMERS)

 9000 FROM (ALMERS)
 9169 FINALIDE (ALMERS)
 9161 TADAOLI (ALMERS)
 9078 HISTUSSIN (ALMERS)

 9000 FROM (ALMERS)
 9161 TADAOLI (ALMERS)
 9161 TADAOLI (ALMERS)
 9078 HISTUSSIN (ALMERS)

 9000 FROM (ALMERS)
 9161 TADAOLI (ALMERS)
 9161 TADAOLI (ALMERS)
 9078 HISTUSSIN (ALMERS)

 9000 FROM (ALMERS)
 9161 TADAOLI (ALMERS)
 9161 TADAOLI (ALMERS)
 9000 HISTUS

 9000 FROM (ALMERS)
 9179 FINALIDE (ALMERS)
 9170 FINALIDE (ALMERS)
 9000 HISTUS

 9100 FROM (ALMERS)
 9171 FINALIDE (ALMERS)
 9171 FINALIDE (ALMERS)
 9000 HISTUS

 9101 FINALIDE (ALMERS)
 9171 FINALIDE (ALMERS)
 9171 FINALIDE (ALMERS)
 9171 HISTUS

 9101 FINALIDE (ALMERS)
 9171 FINALIDE (ALMERS)
 9171 FINALIDE (ALMERS)
 9000 HISTUS

 9111 FINALIDE (ALMERS)
 9171 FINALIDE (ALMERS)
 9171 FINALIDE (ALMERS)
 9171 FIN

<page-header>2000 MURANCE NURVEY ALL DECOMPONENT ALL DECOM

<page-header>DATEDescription

<page-header>2000 MINIMUM CONTRACT7142CONTRACT8000 FUNCTION8700 MINIMUM CONTRACT97142CONTRACT9000 FUNCTION8700 MINIMUM CONTRACT97142CONTRACT9000 FUNCTION8700 FUNCTION97142CONTRACT9000 FUNCTION8700 FUNCTION97142CONTRACT9000 FUNCTION8700 FUNCTION97142CONTRACT9000 FUNCTION8700 FUNCTION97150FUNCTION9000 FUNCTION8700 FUNCTION97151FUNDTION9000 FUNCTION8700 FUNCTION97151FUNDTION9000 FUNCTION8700 FUNCTION97151FUNDTION9000 FUNCTION8700 FUNCTION97151FUNDTION9000 FUNCTION8700 FUNCTION97151FUNDTION9000 FUNCTION8700 FUNCTION97161FUNDTION9000 FUNCTION</t

# Appendix III Multum Lexicon End-User License Agreement

### 1. Introduction

A. This License Agreement (the "License") applies to the Multum Lexicon database (the "Database"). This License does not apply to any other products or services of Cerner Multum, Inc. ("Multum"). A "work based on the Database" means either the Database or any derivative work under copyright law; i.e., a work containing the Database or a substantial portion of it, either verbatim or with modifications. A translation of the Database is included without limitation in the term "modification". Each end-user/licensee is addressed herein as "you".

B. Your use of the Database acknowledges acceptance of these restrictions, disclaimers, and limitations. You expressly acknowledge and agree that Multum is not responsible for the results of your decisions resulting from the use of the Database, including, but not limited to, your choosing to seek or not to seek professional medical care, or from choosing or not choosing specific treatment based on the Database.

C. Every effort has been made to ensure that the information provided in the Database is accurate, up-to-date, and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive.

D. Multum does not assume any responsibility for any aspect of healthcare administered or not administered with the aid of information the Database provides.

2. Terms and Conditions for Copying, Distribution and Modification

A. You may copy and distribute verbatim copies of the Database as you receive it, in any medium, provided that you conspicuously and appropriately publish on each copy an appropriate copyright notice and disclaimer of warranty; keep intact all the notices that refer to this License and to the absence of any warranty; and give any other recipients of the Database a copy of this License (the readme.txt file) along with the Database and anything else that is part of the package, which should be identified.

B. You may modify your copy or copies of the Database or any portion of it to form a derivative work, and copy and distribute such modifications or work under the terms of Section 2.A. above, provided that you also meet all of these conditions:

i) You must cause the modified files to carry prominent notices stating that they are derived from the Multum Lexicon database from Cerner Multum, Inc. and that you changed the files and the date of any change(s).

ii) If you incorporate modified files into a computer program, you must cause it, when started running for interactive use in the most ordinary way, to print or display an announcement including an appropriate copyright notice, a notice that you have modified the Multum Lexicon database from Cerner Multum, Inc., and a notice that there is no warranty (or that you provide the warranty) and telling the user how to view a copy of this License.

C. It is not the intent of this section to claim rights or contest your rights to work written entirely by you; rather, the intent is to exercise the right to control the distribution of derivative or collective works based on the Database.

D. You may copy and distribute the Database (or a work based on it, under Section 2.B.) in an encoded form under the terms of Sections 2.A. and 2.B. above provided that you also do one of the following:

i) Accompany it with the complete corresponding machine-readable plain text, which must be distributed under the terms of Sections 2.A and 2.B. above on a medium customarily used for software interchange; or,

ii) Accompany it with a written offer to give any third party, for no charge, a complete machine-readable copy of the Database (and the entirety of your derivative work based on it, under Section 2.B.), to be distributed under the terms of Sections 2.A. and 2.B. above on a medium customarily used for software interchange.

E. You may not copy, modify, sublicense, or distribute the Database except as expressly provided under this License. Any attempt otherwise to copy, modify, sublicense or distribute the Database will automatically terminate your rights under this License. However, parties who have received copies, or rights, from you under this License will not have their licenses terminated so long as such parties remain in full compliance.

F. You are not required to accept this License. However, nothing else grants you permission to copy, modify or distribute the Database or its derivative works. These actions are prohibited by law if you do not accept this License. Therefore, by copying, modifying or distributing the Database (or any work based on the Database), you indicate your acceptance of this License to do so, and all its terms and conditions for copying, distributing or modifying the Database or works based on it.

G. Each time you redistribute the Database (or any work based on the Database), the recipient automatically receives a license from Multum to copy, distribute or modify the Database subject to these terms and conditions. You may not impose any further restrictions on the recipients' exercise of the rights granted herein. You are not responsible for enforcing compliance by third parties to this License.

3. Disclaimer of Warranties; Limitation of Damages

A. BECAUSE THE DATABASE IS LICENSED FREE OF CHARGE, THERE IS NO WARRANTY FOR THE PROGRAM OR DATA, TO THE EXTENT PERMITTED BY APPLICABLE LAW. EXCEPT WHEN OTHERWISE STATED IN WRITING. MULTUM AND/OR OTHER PARTIES PROVIDE THE DATABASE "AS IS" WITHOUT WARRANTY OF ANY KIND, EITHER EXPRESSED, STATUTORY OR IMPLIED, INCLUDING, BUT NOT LIMITED TO, THE IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE. THE ENTIRE RISK AS TO THE QUALITY AND PERFORMANCE OF THE DATABASE IS WITH YOU. SHOULD THE DATABASE PROVE DEFECTIVE, INCOMPLETE, OR INACCURATE, YOU ASSUME THE RESPONSIBILITY AND COST OF ALL NECESSARY SERVICING, REPAIR OR CORRECTION.

B. IN NO EVENT (UNLESS REQUIRED BY APPLICABLE LAW OR AGREED TO IN WRITING) WILL MULTUM, OR ANY OTHER PARTY WHO MAY MODIFY AND/OR REDISTRIBUTE THE DATABASE AS PERMITTED ABOVE, BE LIABLE FOR ANY SPECIAL, INCIDENTAL, CONSEQUENTIAL, OR INDIRECT DAMAGES, INCLUDING DAMAGES FOR LOSS OF PROFITS, LOSS OF BUSINESS, OR DOWN TIME, EVEN IF MULTUM OR ANY OTHER PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.

C. IN ADDITION, WITHOUT LIMITING THE FOREGOING, THE DATABASE HAS BEEN DESIGNED FOR USE IN THE UNITED STATES ONLY AND COVERS THE DRUG PRODUCTS USED IN PRACTICE IN THE UNITED STATES. MULTUM PROVIDES NO CLINICAL INFORMATION OR CHECKS FOR DRUGS NOT AVAILABLE FOR SALE IN THE UNITED STATES AND CLINICAL PRACTICE PATTERNS OUTSIDE THE UNITED STATES MAY DIFFER SUBSTANTIALLY FROM INFORMATION SUPPLIED BY THE DATABASE. MULTUM DOES NOT WARRANT THAT USES OUTSIDE THE UNITED STATES ARE APPROPRIATE.

D. You acknowledge that updates to the Database are at the sole discretion of Multum. Multum makes no representations or warranties whatsoever, express or implied, with respect to the compatibility of the Database, or future releases thereof, with any computer hardware or software, nor does Multum represent or warrant the continuity of the features or the facilities provided by or through the Database as between various releases thereof.

E. Any warranties expressly provided herein do not apply if: (i) the end-user alters, mishandles or improperly uses, stores or installs all, or any part, of the Database, (ii) the end-user uses, stores or installs the Database

on a computer system which fails to meet the specifications provided by Multum, or (iii) the breach of warranty arises out of or in connection with acts or omissions of persons other than Multum.

4. Assumption of Risk, Disclaimer of Liability, Indemnity

A. THE END-USER ASSUMES ALL RISK FOR SELECTION AND USE OF THE DATABASE AND CONTENT PROVIDED THEREON. MULTUM SHALL NOT BE RESPONSIBLE FOR ANY ERRORS, MISSTATEMENTS, INACCURACIES OR OMISSIONS REGARDING CONTENT DELIVERED THROUGH THE DATABASE OR ANY DELAYS IN OR INTERRUPTIONS OF SUCH DELIVERY.

B. THE END-USER ACKNOWLEDGES THAT MULTUM: (A) HAS NO CONTROL OF OR RESPONSIBILITY FOR THE END-USER'S USE OF THE DATABASE OR CONTENT PROVIDED THEREON, (B) HAS NO KNOWLEDGE OF THE SPECIFIC OR UNIQUE CIRCUMSTANCES UNDER WHICH THE DATABASE OR CONTENT PROVIDED THEREON MAY BE USED BY THE END-USER, (C) UNDERTAKES NO OBLIGATION TO SUPPLEMENT OR UPDATE CONTENT OF THE DATABASE, AND (D) HAS NO LIABILITY TO ANY PERSON FOR ANY DATA OR INFORMATION INPUT ON THE DATABASE BY PERSONS OTHER THAN MULTUM.

C. MULTUM SHALL NOT BE LIABLE TO ANY PERSON (INCLUDING BUT NOT LIMITED TO THE END-USER AND PERSONS TREATED BY OR ON BEHALF OF THE END-USER) FOR, AND THE END-USER AGREES TO INDEMNIFY AND HOLD MULTUM HARMLESS FROM ANY CLAIMS, LAWSUITS, PROCEEDINGS, COSTS, ATTORNEYS' FEES, DAMAGES OR OTHER LOSSES (COLLECTIVELY, "LOSSES") ARISING OUT OF OR RELATING TO (A) THE END-USER'S USE OF THE DATABASE OR CONTENT PROVIDED THEREON OR ANY EQUIPMENT FURNISHED IN CONNECTION THEREWITH AND (B) ANY DATA OR INFORMATION INPUT ON THE DATABASE BY END-USER, IN ALL CASES INCLUDING BUT NOT LIMITED TO LOSSES FOR TORT, PERSONAL INJURY, MEDICAL MALPRACTICE OR PRODUCT LIABILITY.

## 5. Miscellaneous

A. You warrant that you have authority within the organization you identified during registration for the Database to enter into license agreements with other organizations including Multum.

B. You agree that Multum may identify you and/or your organization by name as a "licensee", "licensed user", or "licensing organization" of the Database or a "client" of Multum in Multum's external market communications. You also agree that Multum may issue, if it desires, a press release stating that you and/or your organization have licensed the Database.

C. If conditions are imposed on you (whether by court order, agreement or otherwise) that contradict the conditions of this License, they do not excuse you from the conditions of this License. If you cannot distribute so as to satisfy simultaneously your obligations under this License and any other obligations, then as a consequence you may not distribute the Database at all.

D. If any portion of this License is held invalid or unenforceable under any particular circumstance, the balance of this License is intended to apply and the License as a whole is intended to apply in other circumstances.

E. If the distribution and/or use of the Database is or becomes restricted in certain countries either by patents or by copyrighted interfaces, Multum may add an explicit geographical distribution limitation excluding those countries, so that distribution is permitted only in or among countries not thus excluded. In such case, this License incorporates the limitation as if written in the body of this License.

Multum Lexicon Copyright (c) 1997, 1998, 1999, 2000, 2001, 2002, 2003, 2004, 2005, 2006, 2007 Cerner Multum, Inc. 2000 South Colorado Blvd, Suite 11000 Denver, Colorado 8022

# APPENDIX III. MULTUM CLASSIFICATION OF THERAPEUTIC CLASSES (DRUG CATEGORIES)

	Level 1		Level 2		Level 3
CAT ID	CATEGORY NAME	CAT ID	CATEGORY NAME	CAT ID	CATEGORY NAME
001	anti-infectives	002	amebicides		
001	anti-infectives	003	anthelmintics		
001	anti-infectives	004	antifungals	235	Polyenes
001	anti-infectives	004	antifungals	236	azole antifungals
001	anti-infectives	004	antifungals	237	miscellaneous antifungals
001	anti-infectives	004	antifungals	310	echinocandins
001	anti-infectives	005	antimalarial agents	238	antimalarial quinolines
001	anti-infectives	005	antimalarial agents	239	miscellaneous antimalarials
001	anti-infectives	005	antimalarial agents	328	antimalarial combinations
001	anti-infectives	006	antituberculosis agents	230	aminosalicylates
001	anti-infectives	006	antituberculosis agents	231	nicotinic acid derivatives
001	anti-infectives	006	antituberculosis agents	232	rifamycin derivatives
001	anti-infectives	006	antituberculosis agents	233	streptomyces derivatives
001	anti-infectives	006	antituberculosis agents	234	miscellaneous antituberculosis agents
001	anti-infectives	006	antituberculosis agents	329	antituberculosis combinations
001	anti-infectives	007	antiviral agents	175	protease inhibitors
001	anti-infectives	007	antiviral agents	176	NRTIS
001	anti-infectives	007	antiviral agents	177	miscellaneous antivirals
001	anti-infectives	007	antiviral agents	227	NNRTIS
001	anti-infectives	007	antiviral agents	228	adamantane antivirals
001	anti-infectives	007	antiviral agents	229	purine nucleosides
001	anti-infectives	007	antiviral agents	281	neuraminidase inhibitors
001	anti-infectives	007	antiviral agents	327	antiviral combinations
001	anti-infectives	007	antiviral agents	330	antiviral interferons
001	anti-infectives	007	antiviral agents	364	chemokine receptor antagonist

#### PAGE 242

# 2006 NHAMCS MICRO-DATA FILE DOCUMENTATION

	Level 1		Level 2		Level 3
CAT ID	CATEGORY NAME	CAT ID	CATEGORY NAME	CAT ID	CATEGORY NAME
001	anti-infectives	007	antiviral agents	366	integrase strand transfer inhibitor
001	anti-infectives	008	carbapenems		
001	anti-infectives	009	cephalosporins	159	first generation cephalosporins
001	anti-infectives	009	cephalosporins	160	Second generation cephalosporins
001	anti-infectives	009	cephalosporins	161	third generation cephalosporins
001	anti-infectives	009	cephalosporins	162	fourth generation cephalosporins
001	anti-infectives	010	leprostatics		
001	anti-infectives	011	macrolide derivatives	304	macrolides
001	anti-infectives	011	macrolide derivatives	305	ketolides
001	anti-infectives	012	miscellaneous antibiotics		
001	anti-infectives	013	penicillins	222	penicillinase resistant penicillins
001	anti-infectives	013	penicillins	223	antipseudomonal penicillins
001	anti-infectives	013	penicillins	224	aminopenicillins
001	anti-infectives	013	penicillins	225	beta-lactamase inhibitors
001	anti-infectives	013	penicillins	226	natural penicillins
001	anti-infectives	014	quinolones		
001	anti-infectives	015	sulfonamides		
001	anti-infectives	016	tetracyclines		
001	anti-infectives	017	urinary anti-infectives		
001	anti-infectives	018	aminoglycosides		
001	anti-infectives	240	lincomycin derivatives		
001	anti-infectives	315	glycylcyclines		
020	antineoplastics	021	alkylating agents		
020	antineoplastics	022	antibiotics/antineoplastics		
020	antineoplastics	023	antimetabolites		
020	antineoplastics	024	hormones/antineoplastics		
020	antineoplastics	025	miscellaneous antineoplastics		
020	antineoplastics	026	mitotic inhibitors		
020	antineoplastics	323	antineoplastic monoclonal antibodies		

# 2006 NHAMCS MICRO-DATA FILE DOCUMENTATION

PAGE 243

	Level 1		Level 2		Level 3
CAT ID	CATEGORY NAME	CAT ID	CATEGORY NAME	CAT ID	CATEGORY NAME
020	antineoplastics	324	antineoplastic interferons		
020	antineoplastics	343	tyrosine kinase inhibitors		
028	biologicals	030	antitoxins and antivenins		
028	biologicals	032	colony stimulating factors		
028	biologicals	034	in vivo diagnostic biologicals		
028	biologicals	036	recombinant human erythropoietins		
040	cardiovascular agents	041	agents for hypertensive emergencies		
040	cardiovascular agents	042	angiotensin converting enzyme inhibitors		
040	cardiovascular agents	043	antiadrenergic agents, peripherally acting		
040	cardiovascular agents	044	antiadrenergic agents, centrally acting		
040	cardiovascular agents	045	antianginal agents		
040	cardiovascular agents	046	antiarrhythmic agents		
040	cardiovascular agents	047	beta-adrenergic blocking agents	274	cardioselective beta blockers
040	cardiovascular agents	047	beta-adrenergic blocking agents	275	non-cardioselective beta blockers
040	cardiovascular agents	048	calcium channel blocking agents		
040	cardiovascular agents	049	diuretics	154	loop diuretics
040	cardiovascular agents	049	diuretics	155	potassium-sparing diuretics
040	cardiovascular agents	049	diuretics	156	thiazide diuretics
040	cardiovascular agents	049	diuretics	157	carbonic anhydrase inhibitors
040	cardiovascular agents	049	diuretics	158	miscellaneous diuretics
040	cardiovascular agents	050	inotropic agents		
040	cardiovascular agents	051	miscellaneous cardiovascular agents		
040	cardiovascular agents	052	peripheral vasodilators		
040	cardiovascular agents	053	vasodilators		
040	cardiovascular agents	054	vasopressors		
040	cardiovascular agents	055	antihypertensive combinations		
040	cardiovascular agents	056	angiotensin II inhibitors		
040	cardiovascular agents	303	agents for pulmonary hypertension		

#### PAGE 244

# 2006 NHAMCS MICRO-DATA FILE DOCUMENTATION

	Level 1		Level 2		Level 3
CAT ID	CATEGORY NAME	CAT ID	CATEGORY NAME	CAT ID	CATEGORY NAME
040	cardiovascular agents	319	vasopressin antagonists		
040	cardiovascular agents	325	sclerosing agents		
040	cardiovascular agents	340	aldosterone receptor agonists		
040	cardiovascular agents	342	renin inhibitors		
057	central nervous system agents	058	analgesics	060	narcotic analgesics
057	central nervous system agents	058	analgesics	061	nonsteroidal anti-inflammatory agents
057	central nervous system agents	058	analgesics	062	Salicylates
057	central nervous system agents	058	analgesics	063	analgesic combinations
057	central nervous system agents	058	analgesics	191	narcotic analgesic combinations
057	central nervous system agents	058	analgesics	193	antimigraine agents
057	central nervous system agents	058	analgesics	278	cox-2 inhibitors
057	central nervous system agents	064	anticonvulsants	199	hydantoin anticonvulsants
057	central nervous system agents	064	anticonvulsants	200	succinimide anticonvulsants
057	central nervous system agents	064	anticonvulsants	201	barbiturate anticonvulsants
057	central nervous system agents	064	anticonvulsants	202	oxazolidinedione anticonvulsants
057	central nervous system agents	064	anticonvulsants	203	benzodiazepine anticonvulsants
057	central nervous system agents	064	anticonvulsants	204	miscellaneous anticonvulsants
057	central nervous system agents	064	anticonvulsants	311	dibenzazepine anticonvulsants
057	central nervous system agents	064	anticonvulsants	345	fatty acid derivative anticonvulsants
057	central nervous system agents	064	anticonvulsants	346	gamma-aminobutyric acid reuptake inhibitors
057	central nervous system agents	064	anticonvulsants	347	gamma-aminobutyric acid analogs
057	central nervous system agents	064	anticonvulsants	348	triazine anticonvulsants
057	central nervous system agents	064	anticonvulsants	349	carbamate anticonvulsants
057	central nervous system agents	064	anticonvulsants	350	pyrrolidine anticonvulsants
057	central nervous system agents	064	anticonvulsants	351	carbonic anhydrase inhibitor anticonvulsants
057	central nervous system agents	064	anticonvulsants	352	urea anticonvulsants
057	central nervous system agents	065	antiemetic/antivertigo agents	195	5HT3 receptor antagonists

# 2006 NHAMCS MICRO-DATA FILE DOCUMENTATION

PAGE 245

	Level 1		Level 2		Level 3
CAT ID	CATEGORY NAME	CAT ID	CATEGORY NAME	CAT ID	CATEGORY NAME
057	central nervous system agents	065	antiemetic/antivertigo agents	196	phenothiazine antiemetics
057	central nervous system agents	065	antiemetic/antivertigo agents	197	anticholinergic antiemetics
057	central nervous system agents	065	antiemetic/antivertigo agents	198	miscellaneous antiemetics
057	central nervous system agents	066	antiparkinson agents	205	anticholinergic antiparkinson agents
057	central nervous system agents	066	antiparkinson agents	206	miscellaneous antiparkinson agents
057	central nervous system agents	066	antiparkinson agents	276	dopaminergic antiparkinsonism agents
057	central nervous system agents	067	anxiolytics, sedatives, and hypnotics	068	barbiturates
057	central nervous system agents	067	anxiolytics, sedatives, and hypnotics	069	benzodiazepines
057	central nervous system agents	067	anxiolytics, sedatives, and hypnotics	070	miscellaneous anxiolytics, sedatives and hypnotics
057	central nervous system agents	071	CNS stimulants		
057	central nervous system agents	072	general anesthetics		
057	central nervous system agents	073	muscle relaxants	074	neuromuscular blocking agents
057	central nervous system agents	073	muscle relaxants	178	skeletal muscle relaxants
057	central nervous system agents	073	muscle relaxants miscellaneous central nervous system	179	skeletal muscle relaxant combinations
057	central nervous system agents	080	agents		
057	central nervous system agents	253	anorexiants		
057	central nervous system agents	312	cholinergic agonists		
057	central nervous system agents	313	cholinesterase inhibitors		
081	coagulation modifiers	082	anticoagulants	261	heparins
081	coagulation modifiers	082	anticoagulants	262	coumarins and indandiones
081	coagulation modifiers	082	anticoagulants	283	thrombin inhibitors
081	coagulation modifiers	082	anticoagulants	285	factor Xa inhibitors
081	coagulation modifiers	083	antiplatelet agents	211	platelet aggregation inhibitors
081	coagulation modifiers	083	antiplatelet agents	212	glycoprotein platelet inhibitors
081	coagulation modifiers	084	heparin antagonists		
081	coagulation modifiers	085	miscellaneous coagulation modifiers		

#### PAGE 246

## 2006 NHAMCS MICRO-DATA FILE DOCUMENTATION

	Level 1		Level 2		Level 3
CAT ID	CATEGORY NAME	CAT ID	CATEGORY NAME	CAT ID	CATEGORY NAME
081	coagulation modifiers	086	thrombolytics		
087	gastrointestinal agents	088	antacids		
087	gastrointestinal agents	090	antidiarrheals		
087	gastrointestinal agents	091	digestive enzymes		
087	gastrointestinal agents	092	gallstone solubilizing agents		
087	gastrointestinal agents	093	GI stimulants		
087	gastrointestinal agents	094	H2 antagonists		
087	gastrointestinal agents	095	laxatives		
087	gastrointestinal agents	096	miscellaneous GI agents		
087	gastrointestinal agents	272	proton pump inhibitors		
087	gastrointestinal agents	277	5-aminosalicylates		
087	gastrointestinal agents	354	H. pylori eradication agents		
087	gastrointestinal agents	355	functional bowel disorder agents	89	anticholinergics/antispasmodics
087	gastrointestinal agents	355	functional bowel disorder agents	356	serotoninergic neuroenteric modulators
087	gastrointestinal agents	355	functional bowel disorder agents	362	chloride channel activators
097	hormones	098	adrenal cortical steroids	300	corticotropin
097	hormones	098	adrenal cortical steroids	301	glucocorticoids
097	hormones	098	adrenal cortical steroids	302	mineralocorticoids
097	hormones	100	miscellaneous hormones		
097	hormones	101	sex hormones	102	contraceptives
097	hormones	101	sex hormones	182	androgens and anabolic steroids
097	hormones	101	sex hormones	183	estrogens
097	hormones	101	sex hormones	184	gonadotropins
097	hormones	101	sex hormones	185	progestins
097	hormones	101	sex hormones	186	sex hormone combinations
097	hormones	101	sex hormones	187	miscellaneous sex hormones
097	hormones	101	sex hormones	279	gonadotropin releasing hormones
097	hormones	101	sex hormones	288	5-alpha-reductase inhibitors

# 2006 NHAMCS MICRO-DATA FILE DOCUMENTATION

PAGE 247

	Level 1		Level 2		Level 3
CAT ID	CATEGORY NAME	CAT ID	CATEGORY NAME	CAT ID	CATEGORY NAME
097	hormones	103	thyroid drugs		
097	hormones	217	bisphosphonates		
097	hormones	295	growth hormones		
097	hormones	318	insulin-like growth factor		
097	hormones	357	growth hormone receptor blockers		
105	miscellaneous agents	106	antidotes		
105	miscellaneous agents	107	chelating agents		
105	miscellaneous agents	108	cholinergic muscle stimulatns		
105	miscellaneous agents	109	local injectable anesthetics		
105	miscellaneous agents	110	miscellaneous uncategorized agents		
105	miscellaneous agents	111	psoralens		
105	miscellaneous agents	113	genitourinary tract agents	263	impotence agents
105	miscellaneous agents	113	genitourinary tract agents	264	urinary antispasmodics
105	miscellaneous agents	113	genitourinary tract agents	265	urinary pH modifiers
105	miscellaneous agents	113	genitourinary tract agents	266	miscellaneous genitourinary tract agents
105	miscellaneous agents	114	illicit (street) drugs		
105	miscellaneous agents	192	antirheumatics		
105	miscellaneous agents	270	antipsoriatics		
105	miscellaneous agents	284	viscosupplementation agents		
105	miscellaneous agents	320	smoking cessation agents		
115	nutritional products	116	iron products		
115	nutritional products	117	minerals and electrolytes		
115	nutritional products	118	oral nutritional supplements		
115	nutritional products	119	vitamins		
115	nutritional products	120	vitamin and mineral combinations		
115	nutritional products	121	intravenous nutritional products		
122	respiratory agents	123	antihistamines		

#### PAGE 248

# 2006 NHAMCS MICRO-DATA FILE DOCUMENTATION

	Level 1		Level 2		Level 3
CAT ID	CATEGORY NAME	CATID	CATEGORY NAME	CAT ID	CATEGORY NAME
122	respiratory agents	124	antitussives		
122	respiratory agents	125	bronchodilators	126	methylxanthines
122	respiratory agents	125	bronchodilators	180	adrenergic bronchodilators
122	respiratory agents	125	bronchodilators	181	bronchodilator combinations
122	respiratory agents	125	bronchodilators	299	anticholinergic bronchodilators
122	respiratory agents	127	decongestants		Ť
122	respiratory agents	128	expectorants		
122	respiratory agents	129	miscellaneous respiratory agents		
122	respiratory agents	130	respiratory inhalant products	296	inhaled corticosteroids
122	respiratory agents	130	respiratory inhalant products	297	mucolytics
122	respiratory agents	130	respiratory inhalant products	298	mast cell stabilizers
122	respiratory agents	131	antiasthmatic combinations		
122	respiratory agents	132	upper respiratory combinations		
122	respiratory agents	243	leukotriene modifiers		
122	respiratory agents	273	lung surfactants		
133	topical agents	134	anorectal preparations		
133	topical agents	135	antiseptic and germicides		
133	topical agents	136	dermatological agents	137	topical anti-infectives
133	topical agents	136	dermatological agents	138	topical steroids
133	topical agents	136	dermatological agents	139	topical anesthetics
133	topical agents	136	dermatological agents	140	miscellaneous topical agents
133	topical agents	136	dermatological agents	141	topical steroids with anti-infectives
133	topical agents	136	dermatological agents	143	topical acne agents
133	topical agents	136	dermatological agents	144	topical antipsoriatics
133	topical agents	136	dermatological agents	248	topical emollients
133	topical agents	136	dermatological agents	290	topical antibiotics
133	topical agents	136	dermatological agents	291	topical antivirals
133	topical agents	136	dermatological agents	292	topical antifungals
133	topical agents	146	mouth and throat products		

# 2006 NHAMCS MICRO-DATA FILE DOCUMENTATION

PAGE 249

	Level 1		Level 2		Level 3
CAT ID	CATEGORY NAME	CATID	CATEGORY NAME	CAT ID	CATEGORY NAME
133	topical agents	147	ophthalmic preparations	163	ophthalmic anti-infectives
133	topical agents	147	ophthalmic preparations	164	ophthalmic glaucoma agents
133	topical agents	147	ophthalmic preparations	165	ophthalmic steroids
133	topical agents	147	ophthalmic preparations	166	ophthalmic steroids with anti- infectives
133	topical agents	147	ophthalmic preparations	167	ophthalmic anti-inflammatory agents
133	topical agents	147	ophthalmic preparations	168	ophthalmic lubricants and irrigations
133	topical agents	147	ophthalmic preparations	169	miscellaneous ophthalmic agents
133	topical agents	147	ophthalmic preparations	267	ophthalmic antihistamines and decongestants
133	topical agents	147	ophthalmic preparations	286	mydriatics
133	topical agents	147	ophthalmic preparations	287	ophthalmic anesthetics
133	topical agents	147	ophthalmic preparations	321	ophthalmic diagnostic agents
133	topical agents	147	ophthalmic preparations	322	ophthalmic surgical agents
133	topical agents	147	ophthalmic preparations	353	anti-angiogenic ophthalmic agents
133	topical agents	148	otic preparations	170	otic anti-infectives
133	topical agents	148	otic preparations	171	otic steroids with anti-infectives
133	topical agents	148	otic preparations	172	miscellaneous otic agents
133	topical agents	150	sterile irrigating solutions		
133	topical agents	151	vaginal preparations	149	Spermicides
133	topical agents	151	vaginal preparations	268	vaginal anti-infectives
133	topical agents	151	vaginal preparations	269	miscellaneous vaginal agents
133	topical agents	247	nasal preparations	244	nasal lubricants and irrigations
133	topical agents	247	nasal preparations	245	nasal steroids
133	topical agents	247	nasal preparations	246	nasal antihistamines and decongestants
133	topical agents	247	nasal preparations	344	nasal anti-infectives
218	alternative medicines	219	nutraceutical products		
218	alternative medicines	220	herbal products		

#### PAGE 250

## 2006 NHAMCS MICRO-DATA FILE DOCUMENTATION

	Level 1		Level 2		Level 3
CAT ID	CATEGORY NAME	CATID	CATEGORY NAME	CAT ID	CATEGORY NAME
218	alternative medicines	363	probiotics		
242	psychotherapeutic agents	249	antidepressants	76	miscellaneous antidepressants
242	psychotherapeutic agents	249	antidepressants	208	SSRI antidepressants
242	psychotherapeutic agents	249	antidepressants	209	tricyclic antidepressants
242	psychotherapeutic agents	249	antidepressants	250	monoamine oxidase inhibitors
242	psychotherapeutic agents	249	antidepressants	306	phenylpiperazine antidepressants
242	psychotherapeutic agents	249	antidepressants	307	tetracyclic antidepressants
242	psychotherapeutic agents	249	antidepressants	308	SSNRI antidepressants
242	psychotherapeutic agents	251	antipsychotics	77	miscellaneous antipsychotic agents
242	psychotherapeutic agents	251	antipsychotics	79	psychotherapeutic combinations
242	psychotherapeutic agents	251	antipsychotics	210	phenothiazine antipsychotics
242	psychotherapeutic agents	251	antipsychotics	280	thioxanthenes
242	psychotherapeutic agents	251	antipsychotics	341	atypical antipsychotics
254	immunologic agents	031	bacterial vaccines		
254	immunologic agents	037	toxoids		
254	immunologic agents	038	viral vaccines		
254	immunologic agents	039	miscellaneous biologicals		
254	immunologic agents	104	immunosuppressive agents		
254	immunologic agents	256	interferons		
254	immunologic agents	257	monoclonal antibodies		
331	radiologic agents	027	radiopharmaceuticals	338	diagnostic radiopharmaceuticals
331	radiologic agents	027	radiopharmaceuticals	339	therapeutic radiopharmaceuticals
331	radiologic agents	112	radiocontrast agents	333	iodinated contrast media
331	radiologic agents	112	radiocontrast agents	334	lymphatic staining agents
331	radiologic agents	112	radiocontrast agents	335	magnetic resonance imaging contrast media
331	radiologic agents	112	radiocontrast agents	336	non-iodinated contrast media
331	radiologic agents	112	radiocontrast agents	337	ultrasound contrast media
331	radiologic agents	332	radiologic adjuncts		

# 2006 NHAMCS MICRO-DATA FILE DOCUMENTATION

PAGE 251

	Level 1		Level 2		Level 3
CAT ID	CATEGORY NAME	CAT ID	CATEGORY NAME	CAT ID	CATEGORY NAME
358	metabolic agents	019	antihyperlipidemic agents	173	HMG-CoA reductase inhibitors
358	metabolic agents	019	antihyperlipidemic agents	174	miscellaneous antihyperlipidemic agents
358	metabolic agents	019	antihyperlipidemic agents	241	fibric acid derivatives
358	metabolic agents	019	antihyperlipidemic agents	252	bile acid sequestrants
358	metabolic agents	019	antihyperlipidemic agents	316	cholesterol absorption inhibitors
358	metabolic agents	019	antihyperlipidemic agents	317	antihyperlipidemic combinations
358	metabolic agents	099	antidiabetic agents	213	sulfonylureas
358	metabolic agents	099	antidiabetic agents	214	non-sulfonylureas
358	metabolic agents	099	antidiabetic agents	215	insulin
358	metabolic agents	099	antidiabetic agents	216	alpha-glucosidase inhibitors
358	metabolic agents	099	antidiabetic agents	271	thiazolidinediones
358	metabolic agents	099	antidiabetic agents	282	meglitinides
358	metabolic agents	099	antidiabetic agents	309	miscellaneous antidiabetic agents
358	metabolic agents	099	antidiabetic agents	314	antidiabetic combinations
358	metabolic agents	289	antihyperuricemic agents		
358	metabolic agents	293	glucose elevating agents		
358	metabolic agents	359	peripherally acting antiobesity agents		
358	metabolic agents	360	lysosomal enzymes		
358	metabolic agents	361	miscellaneous metabolic agents		
153	plasma expanders				
365	medical gas				